

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request: cder_mpl2r_wp020, Report 1

Request ID: cder_mpl2r_wp020

Request Description: In this request, we assessed the risk of angioedema following initiation of treatment with angiotensin converting enzyme inhibitors (ACEi) or beta blockers (BB) using data from 2018 to 2022. To estimate changes in healthcare utilization throughout the pandemic, we selected three time periods to study, resulting in three reports: Report 1: pre-pandemic (2018 and 2019 years) which is this report, Report 2: mix of pre-pandemic and pandemic (2019 and 2020), and Report 3: pandemic (2020 to 2022).

<u>Sentinel Routine Querying Module</u>: Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2, with Propensity Score Analysis (PSA) module

Data Source: We ran this query against Merative[™] MarketScan[®] Research Databases on September 13, 2023. The study period included data from May 22, 2018 through April 1, 2022. Please see Appendix A for dates of available data.

<u>Study Design</u>: We identified individuals newly initiating treatment with ACEi or BB with no history of use of other antihypertensive medications or angioedema and evaluated the occurrence of angioedema during the first qualifying (index) exposure episode. We used propensity score methods to control for confounding. We selected three time periods to study: pre-pandemic (2018 and 2019 years), mix (2019 and 2020), and pandemic (2020 to 2022). We also used two lookback periods, which are represented in each report.

Exposure of Interest: New use of ACEi or BB was defined as no prior use of either study drug in the baseline period. We defined exposures of interest using NDCs. Please see Appendix B for a list of generic names of medical products used to define exposures of interest.

Outcome of Interest: We defined our outcome of interest, angioedema, as an angioedema diagnosis code recorded in any diagnostic position of an inpatient, emergency department, or outpatient encounter. Please see Appendix C for a list of ICD-10-CM diagnosis codes used to define the outcome of interest.

Follow-up Time: We followed individuals in an as-treated fashion up to a maximum of 90 days and therefore, the follow-up time was based on the length of the exposure episode. We created exposure episodes using days supply recorded in the outpatient pharmacy dispensing data. We bridged together dispensings less than 14 days apart in covered days and added 14 days at the end of each exposure episode to create continuous treatment episodes. Follow-up began on the day after treatment initiation and continued until the earliest of any of the following: 1) outcome occurrence; 2) treatment discontinuation or crossover; 3) initiation of treatment with aliskiren or ARBs; 4) disenrollment; 5) recorded death; or 5) 90 days since treatment initiation. Only the first valid exposure episode that occurred during the study period was included per patient.

Baseline Characteristics: We measured demographic characteristics such as age, sex, race, ethnicity, and year of treatment initiation for all individuals who entered the study cohorts on the day of cohort entry. Additionally, we measured the following clinical characteristics at baseline: allergic reaction, diabetes, heart failure, ischemic heart disease, NSAID use, acquired hypothyroidism, acute myocardial infarction, Alzheimer's disease and related disorders or senile dementia, anemia, asthma, atrial fibrillation, benign prostatic hyperplasia, cataract, chronic kidney disease, chronic obstructive pulmonary disease and bronchiectasis, depression, glaucoma, hip or pelvic fracture, hyperlipidemia, hypertension, osteoporosis, rheumatoid arthritis or osteoarthritis, stroke or transient ischemic attack, breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, urologic cancer, and the Charlson-Elixhauser Combined Comorbidity Index. We defined NSAID use using NDCs. Please see Appendix F for a list of generic names of medical products and Appendix G for a list of ICD-10-CM diagnosis codes used to define baseline characteristics.

Propensity Score Estimation: We estimated the probability of initiating treatment with ACEi using logistic regression models run at each data partner site. These models included the following characteristics: age, sex, history of diabetes, allergic reactions, heart failure, ischemic heart disease, NSAID use, Charlson-Elixhauser Combined Comorbidity Index, and health care utilization (number of inpatient hospital stays, non-acute institutional stays, emergency department visits, ambulatory visits, and other ambulatory visits) and drug utilization measures (number of dispensings, unique generics dispensed, and unique drug classes dispensed). We used propensity scores to perform matching and stratification separately in order to control for confounding.



Overview for Request: cder_mpl2r_wp020, Report 1

<u>Matching</u>: We matched ACEi new users to BB new users at each data partner site on their estimated propensity scores. We conducted 1:1 nearest neighbor matching without replacement using a caliper of 0.025 on the propensity score scale.

<u>Stratification</u>: We created five strata based on quintiles of the overall propensity score distribution among ACEi and BB new users. The overall propensity score distribution was trimmed to exclude regions of non-overlap between ACEi and BB new users.

<u>Statistical Analysis</u>: We used a risk set-based approach (case centered logistic regression) to estimate the hazard ratio and 95% confidence intervals for the site-adjusted, unconditional (matched), and conditional analyses.

<u>Subgroup analysis</u>: We estimated the risk of angioedema following initiation of ACEi relative to BB in subgroups created by year of cohort entry. In the propensity score matched analysis, subgroups were created from the overall matched population, and individuals were re-matched within the subgroup based on their overall propensity score. In the propensity score stratified analysis, subgroups were created from the overall from the overall from the overall population.

Please see Appendices H and I for the specifications of parameters used in this request and a design diagram. <u>Limitations:</u> Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and covariates are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse).



<u>Glossary (CIDA)</u> List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report <u>Glossary (PSA)</u> List of Terms to Define the Propensity Score Analysis (PSA) Found in this Report

- Table 1aUnadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,2018 to December 11, 2019
- Table 1bAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1c Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1dAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1eUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2019
- Table 1fAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1gUnadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019
- Table 1hAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1iUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2018
- Table 1jAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1kUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2019
- Table 11Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1mUnadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019
- Table 1nAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 10Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2018



- Table 1pAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- <u>Table 1q</u> Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1rAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- <u>Table 1s</u> Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Table 1tAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1uUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2018
- Table 1vAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1wUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2019
- Table 1xAdjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025), in the
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1y Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1zUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2018
- Table 1aaWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1abUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22,
2018 to December 11, 2019, Year: 2019
- Table 1acWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1adWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1aeUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018
to December 11, 2019, Year: 2018



Table of	Contents
----------	----------

- Table 1afWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1agUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018to December 11, 2019, Year: 2019
- Table 1ahWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1aiWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1ajUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22,2018 to December 11, 2019, Year: 2018
- Table 1akWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1alUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22,2018 to December 11, 2019, Year: 2019
- Table 1amWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 1anWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Table 1aoUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018to December 11, 2019, Year: 2018
- Table 1apWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Table 1aqUnadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018to December 11, 2019, Year: 2019
- Table 1arWeighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,
Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5), in the Merative™
MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Table 2aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short
Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, by Analysis Type
- <u>Table 2b</u> Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 3aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, ShortLookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases fromMay 22, 2018 to December 11, 2019, by Analysis Type



- Table 3bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, ShortLookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases fromMay 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 4aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, by Analysis Type
- Table 4bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 5aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type
- Table 5bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 6aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, ShortLookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases fromMay 22, 2018 to December 11, 2019, by Analysis Type
- Table 6b Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 7aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short
Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type
- Table 7bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short
Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 8aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type
- Table 8bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 9aEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type
- Table 9bEffect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long
Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from
May 22, 2018 to December 11, 2019, by Analysis Type and Year
- Table 10Summary of Patient Level Cohort Attrition in the Merative™ MarketScan® Research Databases from May 22,2018 to December 11, 2019
- Figure 1a Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Figure 1b Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018



Figure 1c Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in th
Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
Figure 2a Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019
Figure 2b Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
Figure 2c Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
Figure 3a Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019
Figure 3b Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
Figure 3c Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
Figure 4a Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019
Figure 4b Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
Figure 4c Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE
Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the
Merative™ MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
Figure 5a Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019
Figure 5b Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
Figure 5c Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
Figure 6a Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019
Figure 6b Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
Figure 6c Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs.
Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™
MarketScan [®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019



- **Figure 7a** Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- <u>Figure 7b</u> Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 7c Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- **Figure 8a** Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- **Figure 8b** Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- **Figure 8c** Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 9a Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- **Figure 9b** Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Matched Conditional Analyses in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- **Figure 9c** Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Matched Unconditional Analyses in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Figure 9d Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Stratified Analyses in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Figure 10aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 10bAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019
- Figure 10c Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019
- Figure 10dUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018



- Figure 10eAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 10fAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 10gUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2019
- Figure 10h Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 10iAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 11aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 11bAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019
- Figure 11c Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Figure 11dUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 11eAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, Year: 2018



- Figure 11f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 11gUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2019
- Figure 11hAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 11i Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 12aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 12bAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019
- Figure 12cAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019
- Figure 12dUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 12e Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 12fAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2018



- Figure 12gUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2019
- Figure 12hAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 12iAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research
Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 13aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 13b Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Figure 13cAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM)
from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019
- Figure 13dUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 13e Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 13f Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- Figure 13gUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year
(PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2019



- Figure 13hAdjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users
of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM)
from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic,
Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases
from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 13i Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Figure 14aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year
(PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 14bUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year
(PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 14c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- <u>Figure 15a</u> Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Figure 15b Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018
- <u>Figure 15c</u> Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- <u>Figure 16a</u> Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019
- Figure 16bUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year
(PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 16c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019



- Figure 17aUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year
(PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019
- Figure 17bUnadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New
Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year
(PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to
December 11, 2019, Year: 2018
- Figure 17c Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019
- Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (October 6, 2023)
- Appendix B List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
- Appendix C List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request
- <u>Appendix D</u> List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Exposure Incidence Criteria in this Request
- <u>Appendix E</u> List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request
- Appendix F List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request
- <u>Appendix G</u> List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Covariates in this Request
- Appendix H Specifications Defining Parameters for this Request

Appendix I Diagrams Detailing the Design of this Request



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other sameday ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requesterdefined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
 Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
 Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report



Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Covariate - requester defined binary variable to include in the propensity score estimation model (e.g., diabetes, heart failure, etc.) during requester-defined lookback period. Requester may also choose to add any of the following categorical, continuous, or count metrics to the propensity score estimation model:

- 1. Age (continuous)
- 2. Sex
- 3. Time period (i.e., monitoring period for sequential analyses)
- 4. Year of exposure
- 5. Comorbidity score
- 6. Medical utilization number of inpatient stays
- 7. Medical utilization number of institutional stays
- 8. Medical utilization number of emergency department visits
- 9. Medical utilization number of outpatient visits
- 10. Health care utilization number of other ambulatory encounters (e.g., telemedicine, email consults)
- 11. Drug utilization number of dispensings
- 12. Drug utilization number of unique generics dispensed
- 13. Drug Utilization number of unique drug classes dispensed

Covariate Evaluation Window - specified number of days relative to index date to evaluate the occurrence of covariates of interest. Note: members are required to have continuous enrollment during the covariate evaluation window, regardless of the value included in the "Continuous enrollment before exposure" field.

Individual Level Data Return - program may return individual-level, de-identified datasets to the Sentinel Operations Center (SOC). While the datasets contain a single row per patient for each specified analysis, patient identifiers such as a patient ID are not included in the output. Individual-level datasets are returned to the SOC, aggregated, and used to calculate effect estimates via Cox (proportional hazards) regression.

Mahalanobis Distance - provides a measure of balance across all variables while accounting for their correlation.

Matching Caliper - maximum allowed difference in propensity scores between treatment and control patients. Requester may select any caliper (e.g., 0.01, 0.025, and 0.05).

Matching Ratio - patients in exposed and comparator groups are nearest neighbor matched by a 1:1 or 1:n (up to 10) matching Matched Conditional and Unconditional Analysis - in a conditional matched analysis, a Cox model, stratified by Data Partner site and matched set, is run on the matched population. This can be done for both the both 1:1 and 1:n matched cohorts. In an unconditional analysis, a Cox model, stratified by Data Partner site only, is run on the matched population. This can be done for the 1:1 matched cohort only.

Propensity Score Stratification - option to stratify propensity scores based on requester-defined percentiles in the unmatched population. In a stratified analysis, a Cox model, stratified by Data Partner site, is run on the stratified population. Note that all patients identified in exposure and comparator cohorts are used in the analysis.

PSM Tool - performs effect estimation by comparing exposure propensity-score matched parallel new user cohorts. Propensity score estimation and matching are conducted within each Sentinel Data Partner site via distributed programming code; data are returned to the SOC, aggregated, and used to calculate effect estimates.



Glossary of Terms for Analyses Using Propensity Score Analysis (PSA) Module*

Risk-set Level Data Return - alternative to the patient-level data return approach. In this approach, the PSM tool will produce de-identified, risk-set level datasets instead of or in addition to individual-level output. Whereas each observation in the patient-level datasets represents one patient in the cohort, each observation in the risk set dataset represents one event. Risk sets are created at the Data Partner site, returned to the SOC, aggregated, and used to calculate effect estimates via case-centered logistic regression.

Subgroup Analysis -may be conducted using any requester-defined covariates. Subgroup analyses may be performed in the **Zero Cell Correction** - indicator for whether to screen variables with a zero correction added to each cell in the confounder/outcome 2x2 table. Recommended when the number of exposed outcomes is fewer than 150.

*all terms may not be used in this report



Table 1a. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance				
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Unique patients	253,313	100.0%	235,735	100.0%	N/A	N/A	
Demographic Characteristics							
Age (years)	50.4	11.5	45.6	15.1	4.787	0.357	
Age							
18-44 years	76,952	30.4%	113,754	48.3%	-17.877	-0.372	
45-64 years	162,417	64.1%	105,686	44.8%	19.285	0.395	
≥ 65 years	13,944	5.5%	16,295	6.9%	-1.408	-0.058	
Sex							
Female	109,094	43.1%	144,628	61.4%	-18.285	-0.372	
Male	144,219	56.9%	91,107	38.6%	18.285	0.372	
Race ³							
American Indian or Alaska Native	-	-	-	-	-	-	
Asian	-	-	-	-	-	-	
Black or African American	-	-	-	-	-	-	
Multi-racial	-	-	-	-	-	-	
Unknown	253,313	100.0%	235,735	100.0%	0.000	NaN	
White	-	-	-	-	-	-	
Hispanic origin							
Yes	-	-	-	-	-	-	
No	-	-	-	-	-	-	
Unknown	253,313	100.0%	235,735	100.0%	0.000	NaN	
Year							
2018	99,808	39.4%	93,967	39.9%	-0.460	-0.009	
2019	153,505	60.6%	141,768	60.1%	0.460	0.009	
Health Characteristics							
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.1	0.8	1.7	-0.657	-0.446	
Allergic Reaction	14,616	5.8%	20,368	8.6%	-2.870	-0.111	
Diabetes	41,334	16.3%	18,265	7.7%	8.569	0.266	
Heart Failure	2,367	0.9%	9,239	3.9%	-2.985	-0.195	
Ischemic Heart Disease	6,290	2.5%	22,092	9.4%	-6.888	-0.295	
NSAID Use	38,907	15.4%	38,292	16.2%	-0.884	-0.024	



Table 1a. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	16,880	6.7%	20,357	8.6%	-1.972	-0.074
Acute Myocardial Infarction ⁵	1,225	0.5%	8,869	3.8%	-3.279	-0.229
Alzheimers Disease and Related Disorders ⁵	769	0.3%	1,660	0.7%	-0.401	-0.057
Anemia ⁵	10,981	4.3%	21,349	9.1%	-4.721	-0.190
Asthma ⁵	9,229	3.6%	12,528	5.3%	-1.671	-0.081
Atrial Fibrillation ⁵	2,033	0.8%	13,225	5.6%	-4.808	-0.275
Benign Prostatic Hyperplasia ⁵	4,788	1.9%	4,617	2.0%	-0.068	-0.005
Cataract ⁵	9,133	3.6%	7,893	3.3%	0.257	0.014
Chronic Kidney Disease ⁵	21,429	8.5%	16,956	7.2%	1.267	0.047
Bronchiectasis⁵	6,685	2.6%	9,524	4.0%	-1.401	-0.078
Depression ⁵	19,563	7.7%	39,090	16.6%	-8.859	-0.274
Glaucoma ⁵	6,413	2.5%	5,687	2.4%	0.119	0.008
Hip or Pelvic Fracture ⁵	241	0.1%	478	0.2%	-0.108	-0.028
Hyperlipidemia⁵	60,658	23.9%	50,862	21.6%	2.370	0.057
Hypertension ⁵	96,582	38.1%	66,791	28.3%	9.794	0.209
Osteoporosis ⁵	1,980	0.8%	2,846	1.2%	-0.426	-0.043
Rheumatoid Arthritis or Osteoarthritis ⁵	24,800	9.8%	24,404	10.4%	-0.562	-0.019
Stroke or Transient Ischemic Attack ⁵	3,917	1.5%	5,106	2.2%	-0.620	-0.046
Breast Cancer ⁵	2,310	0.9%	3,110	1.3%	-0.407	-0.039
Colorectal Cancer ⁵	809	0.3%	921	0.4%	-0.071	-0.012
Prostate Cancer ⁵	1,458	0.6%	1,392	0.6%	-0.015	-0.002
Lung Cancer ⁵	284	0.1%	969	0.4%	-0.299	-0.059
Endometrial Cancer ⁵	309	0.1%	310	0.1%	-0.010	-0.003
Urologic Cancer ⁵	363	0.1%	487	0.2%	-0.063	-0.015
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	4.7	6.5	7.6	9.3	-2.941	-0.366
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.180	-0.210
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.166	-0.368
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.023
Mean number of other ambulatory encounters	1.0	2.7	1.7	4.4	-0.709	-0.194
Mean number of filled prescriptions	6.2	8.2	8.4	10.2	-2.252	-0.243



Table 1a. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
	/	Percent/	,	Percent/		~
Patient Characteristics ¹	Number/ Mean	Standard Deviation ²	Number/ Mean	Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.1	3.3	4.2	4.1	-1.042	-0.280
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.7	-0.993	-0.291

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1b. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	146,561	57.9%	146,561	62.2%	N/A	N/A
Demographic Characteristics						
Age (years)	48.2	12.0	48.9	13.9	-0.674	-0.052
Age						
18-44 years	55,851	38.1%	55,269	37.7%	0.397	0.008
45-64 years	84,113	57.4%	79,784	54.4%	2.954	0.060
≥ 65 years	6,597	4.5%	11,508	7.9%	-3.351	-0.140
Sex						
Female	79,282	54.1%	76,213	52.0%	2.094	0.042
Male	67,279	45.9%	70,348	48.0%	-2.094	-0.042
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	146,561	100.0%	146,561	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	146,561	100.0%	146,561	100.0%	0.000	NaN
Year						
2018	57,825	39.5%	58,665	40.0%	-0.573	-0.012
2019	88,736	60.5%	87,896	60.0%	0.573	0.012
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.051	-0.040
Allergic Reaction	10,095	6.9%	10,079	6.9%	0.011	0.000
Diabetes	15,054	10.3%	13,832	9.4%	0.834	0.028
Heart Failure	2,212	1.5%	2,778	1.9%	-0.386	-0.030
Ischemic Heart Disease	5,995	4.1%	6,419	4.4%	-0.289	-0.014
NSAID Use	23,024	15.7%	22,927	15.6%	0.066	0.002



Table 1b. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	10,951	7.5%	11,444	7.8%	-0.336	-0.013
Acute Myocardial Infarction ⁵	1,189	0.8%	2,243	1.5%	-0.719	-0.067
Alzheimers Disease and Related Disorders ⁵	604	0.4%	599	0.4%	0.003	0.001
Anemia ⁵	8,495	5.8%	7,841	5.3%	0.446	0.019
Asthma ⁵	7,282	5.0%	5,073	3.5%	1.507	0.075
Atrial Fibrillation ⁵	1,536	1.0%	7,423	5.1%	-4.017	-0.235
Benign Prostatic Hyperplasia ⁵	2,130	1.5%	3,285	2.2%	-0.788	-0.059
Cataract ⁵	4,595	3.1%	5,566	3.8%	-0.663	-0.036
Chronic Kidney Disease ⁵	11,186	7.6%	8,659	5.9%	1.724	0.069
Bronchiectasis ⁵	5,040	3.4%	4,062	2.8%	0.667	0.038
Depression ⁵	15,670	10.7%	15,443	10.5%	0.155	0.005
Glaucoma ⁵	3,345	2.3%	3,876	2.6%	-0.362	-0.023
Hip or Pelvic Fracture ⁵	204	0.1%	196	0.1%	0.005	0.001
Hyperlipidemia ⁵	31,373	21.4%	33,019	22.5%	-1.123	-0.027
Hypertension ⁵	53,144	36.3%	44,918	30.6%	5.613	0.119
Osteoporosis ⁵	1,297	0.9%	1,701	1.2%	-0.276	-0.027
Rheumatoid Arthritis or Osteoarthritis ⁵	15,491	10.6%	14,735	10.1%	0.516	0.017
Stroke or Transient Ischemic Attack ⁵	2,733	1.9%	2,497	1.7%	0.161	0.012
Breast Cancer ⁵	1,859	1.3%	1,495	1.0%	0.248	0.023
Colorectal Cancer ⁵	615	0.4%	372	0.3%	0.166	0.029
Prostate Cancer ⁵	746	0.5%	907	0.6%	-0.110	-0.015
Lung Cancer ⁵	248	0.2%	241	0.2%	0.005	0.001
Endometrial Cancer ⁵	251	0.2%	144	0.1%	0.073	0.020
Urologic Cancer ⁵	265	0.2%	220	0.2%	0.031	0.008
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	5.6	7.7	5.6	6.7	-0.044	-0.006
Mean number of emergency room encounters	0.3	0.8	0.3	0.8	-0.010	-0.013
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.011	-0.030
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.003
Mean number of other ambulatory encounters	1.1	3.2	1.2	3.2	-0.053	-0.017
Mean number of filled prescriptions	7.0	9.0	7.0	8.7	0.011	0.001



Table 1b. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Chanadanistica ¹	Number/	Percent/ Standard Deviation ²	Number/	Percent/ Standard Deviation ²	Absolute	Standardized
Patient Characteristics ¹	Mean		Mean			Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.5	0.005	0.001
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.2	0.007	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1c. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	57,825	100.0%	58,665	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.3	11.9	49.0	13.8	-0.756	-0.059
Age						
18-44 years	21,805	37.7%	21,793	37.1%	0.560	0.012
45-64 years	33,488	57.9%	32,286	55.0%	2.878	0.058
≥ 65 years	2,532	4.4%	4,586	7.8%	-3.439	-0.144
Sex						
Female	31,453	54.4%	30,660	52.3%	2.131	0.043
Male	26,372	45.6%	28,005	47.7%	-2.131	-0.043
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	57,825	100.0%	58,665	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	-	-	-	-	-	-
Year						
2018	57,825	100.0%	58,665	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.039	-0.030
Allergic Reaction	3,829	6.6%	3,895	6.6%	-0.018	-0.001
Diabetes	6,092	10.5%	5,411	9.2%	1.312	0.044
Heart Failure	891	1.5%	1,096	1.9%	-0.327	-0.025
	051		,			
Ischemic Heart Disease	2,348	4.1%	2,558	4.4%	-0.300	-0.015



Table 1c. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,290	7.4%	4,515	7.7%	-0.277	-0.010
Acute Myocardial Infarction ⁵	484	0.8%	865	1.5%	-0.637	-0.060
Alzheimers Disease and Related Disorders ⁵	243	0.4%	244	0.4%	0.004	0.001
Anemia ⁵	3,335	5.8%	3,119	5.3%	0.451	0.020
Asthma ⁵	2,871	5.0%	2,013	3.4%	1.534	0.077
Atrial Fibrillation ⁵	593	1.0%	2,932	5.0%	-3.972	-0.234
Benign Prostatic Hyperplasia ⁵	819	1.4%	1,256	2.1%	-0.725	-0.055
Cataract ⁵	1,750	3.0%	2,111	3.6%	-0.572	-0.032
Chronic Kidney Disease ⁵	4,477	7.7%	3,362	5.7%	2.011	0.080
Bronchiectasis⁵	1,943	3.4%	1,604	2.7%	0.626	0.036
Depression ⁵	5,986	10.4%	5,988	10.2%	0.145	0.005
Glaucoma ⁵	1,235	2.1%	1,527	2.6%	-0.467	-0.031
Hip or Pelvic Fracture ⁵	80	0.1%	89	0.2%	-0.013	-0.004
Hyperlipidemia ⁵	12,318	21.3%	13,091	22.3%	-1.013	-0.025
Hypertension ⁵	20,982	36.3%	17,865	30.5%	5.833	0.124
Osteoporosis ⁵	519	0.9%	671	1.1%	-0.246	-0.025
Rheumatoid Arthritis or Osteoarthritis ⁵	6,083	10.5%	5,872	10.0%	0.510	0.017
Stroke or Transient Ischemic Attack ⁵	1,083	1.9%	1,018	1.7%	0.138	0.010
Breast Cancer ⁵	765	1.3%	575	1.0%	0.343	0.032
Colorectal Cancer ⁵	233	0.4%	165	0.3%	0.122	0.021
Prostate Cancer ⁵	271	0.5%	377	0.6%	-0.174	-0.023
Lung Cancer ⁵	109	0.2%	87	0.1%	0.040	0.010
Endometrial Cancer ⁵	96	0.2%	49	0.1%	0.082	0.023
Urologic Cancer ⁵	117	0.2%	80	0.1%	0.066	0.016
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	5.6	7.7	5.6	6.8	0.004	0.001
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.007	-0.009
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.008	-0.021
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.003
Mean number of other ambulatory encounters	1.1	3.1	1.1	2.9	-0.029	-0.010
Mean number of filled prescriptions	7.1	9.2	7.2	8.9	-0.044	-0.005



Table 1c. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.6	-0.024	-0.007
Mean number of unique drug classes dispensed	3.3	3.3	3.3	3.3	-0.024	-0.007

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1d. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	57,713	99.8%	57,713	98.4%	N/A	N/A
Demographic Characteristics						
Age (years)	48.3	11.9	49.0	13.8	-0.758	-0.059
Age						
18-44 years	21,782	37.7%	21,461	37.2%	0.556	0.011
45-64 years	33,423	57.9%	31,759	55.0%	2.883	0.058
≥ 65 years	2,508	4.3%	4,493	7.8%	-3.439	-0.144
Sex						
Female	31,394	54.4%	30,187	52.3%	2.091	0.042
Male	26,319	45.6%	27,526	47.7%	-2.091	-0.042
Race ³						
American Indian or Alaska Native						
Asian						
Black or African American	•			•		
Multi-racial	•			•		
Unknown	57,713	100.0%	57,713	100.0%	0.000	NaN
White						
Hispanic origin						
Yes						
No						
Unknown	57,713	100.0%	57,713	100.0%	0.000	NaN
Year						
2018	57,713	100.0%	57,713	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.043	-0.034
Allergic Reaction	3,817	6.6%	3,832	6.6%	-0.026	-0.001
Diabetes	6,054	10.5%	5,317	9.2%	1.277	0.043
Heart Failure	874	1.5%	1,077	1.9%	-0.352	-0.027
Ischemic Heart Disease	2,319	4.0%	2,517	4.4%	-0.343	-0.017
NSAID Use	9,136	15.8%	9,321	16.2%	-0.321	-0.009



Table 1d. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

	Medical Product				Covariate Balance		
	ACE Inhibitors		Beta B	Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	4,276	7.4%	4,451	7.7%	-0.303	-0.011	
Acute Myocardial Infarction ⁵	472	0.8%	851	1.5%	-0.657	-0.062	
Alzheimers Disease and Related Disorders ⁵	240	0.4%	239	0.4%	0.002	0.000	
Anemia ⁵	3,312	5.7%	3,078	5.3%	0.405	0.018	
Asthma ⁵	2,863	5.0%	1,974	3.4%	1.540	0.077	
Atrial Fibrillation ⁵	586	1.0%	2,885	5.0%	-3.984	-0.235	
Benign Prostatic Hyperplasia ⁵	817	1.4%	1,233	2.1%	-0.721	-0.055	
Cataract ⁵	1,746	3.0%	2,075	3.6%	-0.570	-0.032	
Chronic Kidney Disease ⁵	4,457	7.7%	3,307	5.7%	1.993	0.080	
Bronchiectasis ⁵	1,928	3.3%	1,587	2.7%	0.591	0.034	
Depression ⁵	5,961	10.3%	5,892	10.2%	0.120	0.004	
Glaucoma ⁵	1,233	2.1%	1,501	2.6%	-0.464	-0.031	
Hip or Pelvic Fracture ⁵	80	0.1%	89	0.2%	-0.016	-0.004	
Hyperlipidemia⁵	12,271	21.3%	12,860	22.3%	-1.021	-0.025	
Hypertension ⁵	20,923	36.3%	17,577	30.5%	5.798	0.123	
Osteoporosis ⁵	518	0.9%	663	1.1%	-0.251	-0.025	
Rheumatoid Arthritis or Osteoarthritis ⁵	6,067	10.5%	5,781	10.0%	0.496	0.016	
Stroke or Transient Ischemic Attack ⁵	1,072	1.9%	1,004	1.7%	0.118	0.009	
Breast Cancer ⁵	760	1.3%	564	1.0%	0.340	0.032	
Colorectal Cancer ⁵	227	0.4%	163	0.3%	0.111	0.019	
Prostate Cancer ⁵	270	0.5%	371	0.6%	-0.175	-0.024	
Lung Cancer ⁵	105	0.2%	86	0.1%	0.033	0.008	
Endometrial Cancer ⁵	94	0.2%	49	0.1%	0.078	0.022	
Urologic Cancer ⁵	116	0.2%	78	0.1%	0.066	0.016	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	5.5	7.7	5.6	6.8	-0.012	-0.002	
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.007	-0.010	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.009	-0.024	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.003	
Mean number of other ambulatory encounters	1.1	3.1	1.1	2.9	-0.035	-0.012	
Mean number of filled prescriptions	7.1	9.2	7.2	8.9	-0.057	-0.006	
Mean number of inpatient hospital encounters Mean number of non-acute institutional encounters Mean number of other ambulatory encounters	0.1 0.0 1.1	0.4 0.0 3.1	0.1 0.0 1.1	0.4 0.0 2.9	-0.009 -0.000 -0.035	-0. -0. -0.	



Table 1d. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.6	-0.030	-0.008
Mean number of unique drug classes dispensed	3.3	3.3	3.3	3.3	-0.029	-0.009

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1e. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

	Medical Product				Covariate Balance	
	ACE In	ACE Inhibitors Beta Block		lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	88,736	100.0%	87,896	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.2	12.0	48.8	13.9	-0.619	-0.048
Age						
18-44 years	34,046	38.4%	33,476	38.1%	0.282	0.006
45-64 years	50,625	57.1%	47,498	54.0%	3.012	0.061
≥ 65 years	4,065	4.6%	6,922	7.9%	-3.294	-0.137
Sex						
Female	47,829	53.9%	45,553	51.8%	2.074	0.042
Male	40,907	46.1%	42,343	48.2%	-2.074	-0.042
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	88,736	100.0%	87,896	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	88,736	100.0%	87,896	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	88,736	100.0%	87,896	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.060	-0.046
Allergic Reaction	6,266	7.1%	6,184	7.0%	0.026	0.001
Diabetes	8,962	10.1%	8,421	9.6%	0.519	0.017
Heart Failure	1,321	1.5%	1,682	1.9%	-0.425	-0.033
Ischemic Heart Disease	3,647	4.1%	3,861	4.4%	-0.283	-0.014



Table 1e. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

	Medical Product				Covariate Balance	
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	6,661	7.5%	6,929	7.9%	-0.377	-0.014
Acute Myocardial Infarction ⁵	705	0.8%	1,378	1.6%	-0.773	-0.072
Alzheimers Disease and Related Disorders ⁵	361	0.4%	355	0.4%	0.003	0.000
Anemia ⁵	5,160	5.8%	4,722	5.4%	0.443	0.019
Asthma ⁵	4,411	5.0%	3,060	3.5%	1.490	0.074
Atrial Fibrillation ⁵	943	1.1%	4,491	5.1%	-4.047	-0.236
Benign Prostatic Hyperplasia ⁵	1,311	1.5%	2,029	2.3%	-0.831	-0.061
Cataract ⁵	2,845	3.2%	3,455	3.9%	-0.725	-0.039
Chronic Kidney Disease ⁵	6,709	7.6%	5,297	6.0%	1.534	0.061
Bronchiectasis ⁵	3,097	3.5%	2,458	2.8%	0.694	0.040
Depression ⁵	9,684	10.9%	9,455	10.8%	0.156	0.005
Glaucoma ⁵	2,110	2.4%	2,349	2.7%	-0.295	-0.019
Hip or Pelvic Fracture ⁵	124	0.1%	107	0.1%	0.018	0.005
Hyperlipidemia ⁵	19,055	21.5%	19,928	22.7%	-1.198	-0.029
Hypertension ⁵	32,162	36.2%	27,053	30.8%	5.466	0.116
Osteoporosis ⁵	778	0.9%	1,030	1.2%	-0.295	-0.029
Rheumatoid Arthritis or Osteoarthritis ⁵	9,408	10.6%	8,863	10.1%	0.519	0.017
Stroke or Transient Ischemic Attack ⁵	1,650	1.9%	1,479	1.7%	0.177	0.013
Breast Cancer ⁵	1,094	1.2%	920	1.0%	0.186	0.018
Colorectal Cancer ⁵	382	0.4%	207	0.2%	0.195	0.034
Prostate Cancer ⁵	475	0.5%	530	0.6%	-0.068	-0.009
Lung Cancer ⁵	139	0.2%	154	0.2%	-0.019	-0.005
Endometrial Cancer ⁵	155	0.2%	95	0.1%	0.067	0.018
Urologic Cancer ⁵	148	0.2%	140	0.2%	0.008	0.002
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	5.6	7.6	5.7	6.7	-0.077	-0.011
Mean number of emergency room encounters	0.3	0.8	0.3	0.8	-0.012	-0.015
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.013	-0.036
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.002
Mean number of other ambulatory encounters	1.2	3.2	1.2	3.4	-0.070	-0.021
Mean number of filled prescriptions	6.9	8.9	6.9	8.5	0.049	0.006



Table 1e. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.5	0.025	0.007
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.2	0.028	0.008

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1f. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

	Medical Product				Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Unique patients	87,782	98.9%	87,782	99.9%	N/A	N/A	
Demographic Characteristics							
Age (years)	48.2	12.0	48.8	13.9	-0.624	-0.048	
Age							
18-44 years	33,726	38.4%	33,433	38.1%	0.334	0.007	
45-64 years	50,040	57.0%	47,455	54.1%	2.945	0.059	
≥ 65 years	4,016	4.6%	6,894	7.9%	-3.279	-0.136	
Sex							
Female	47,376	54.0%	45,485	51.8%	2.154	0.043	
Male	40,406	46.0%	42,297	48.2%	-2.154	-0.043	
Race ³							
American Indian or Alaska Native	-	-	-	-	-	-	
Asian	-	-	-	-	-	-	
Black or African American	-	-	-	-	-	-	
Multi-racial	-	-	-	-	-	-	
Unknown	87,782	100.0%	87,782	100.0%	0.000	NaN	
White	-	-	-	-	-	-	
Hispanic origin							
Yes	-	-	-	-	-	-	
No	-	-	-	-	-	-	
Unknown	87,782	100.0%	87,782	100.0%	0.000	NaN	
Year							
2018	0	0.0%	0	0.0%	NaN	NaN	
2019	87,782	100.0%	87,782	100.0%	0.000	NaN	
Health Characteristics							
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.058	-0.045	
Allergic Reaction	6,203	7.1%	6,170	7.0%	0.038	0.001	
Diabetes	8,840	10.1%	8,389	9.6%	0.514	0.017	
Heart Failure	1,310	1.5%	1,672	1.9%	-0.412	-0.032	
Ischemic Heart Disease	3,611	4.1%	3,842	4.4%	-0.263	-0.013	
NSAID Use	13,723	15.6%	13,454	15.3%	0.306	0.008	



Table 1f. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

Patient Characteristics1MeanDeviation2MeanDeviation2 <th colspan="3">Covariate Balance</th>	Covariate Balance		
Number/ Patient Characteristics1Number/ MeanStandard Deviation2Number/ MeanStandard Deviation2AlAcquired Hypothyroidism5 $6,583$ 7.5% $6,914$ 7.9%			
Acquired Hypothyroidism ⁵ 6,583 7.5% 6,914 7.9% - Acute Myocardial Infarction ⁵ 699 0.8% 1,374 1.6% - Alzheimers Disease and Related Disorders ⁵ 358 0.4% 352 0.4% - Anemia ⁵ 5,102 5.8% 4,695 5.3% - Asthma ⁵ 4,345 4.9% 3,046 3.5% Atrial Fibrillation ⁵ 936 1.1% 4,482 5.1% Benign Prostatic Hyperplasia ⁵ 1,289 1.5% 2,025 2.3% Cataract ⁵ 2,813 3.2% 3,443 3.9% -	bsolute fference	Standardized Difference	
Acute Myocardial Infarction ⁵ 699 0.8% 1,374 1.6% Alzheimers Disease and Related Disorders ⁵ 358 0.4% 352 0.4% Anemia ⁵ 5,102 5.8% 4,695 5.3% 4 Asthma ⁵ 4,345 4.9% 3,046 3.5% Atrial Fibrillation ⁵ 936 1.1% 4,482 5.1% Benign Prostatic Hyperplasia ⁵ 1,289 1.5% 2,025 2.3% Cataract ⁵ 2,813 3.2% 3,443 3.9% 4.0%	-0.377	-0.014	
Alzheimers Disease and Related Disorders 358 0.4% 352 0.4% Anemia $5,102$ 5.8% $4,695$ 5.3% Asthma $4,345$ 4.9% $3,046$ 3.5% Atrial Fibrillation 936 1.1% $4,482$ 5.1% Benign Prostatic Hyperplasia $1,289$ 1.5% $2,025$ 2.3% Cataract $2,813$ 3.2% $3,443$ 3.9% Chronic Kidney Disease $6,625$ 7.5% $5,280$ 6.0%	-0.769	-0.071	
Anemia ⁵ 5,102 5.8% 4,695 5.3% Asthma ⁵ 4,345 4.9% 3,046 3.5% Atrial Fibrillation ⁵ 936 1.1% 4,482 5.1% - Benign Prostatic Hyperplasia ⁵ 1,289 1.5% 2,025 2.3% - Cataract ⁵ 2,813 3.2% 3,443 3.9% - Chronic Kidney Disease ⁵ 6,625 7.5% 5,280 6.0%	0.007	0.001	
Atrial Fibrillation ⁵ 936 1.1% 4,482 5.1% - Benign Prostatic Hyperplasia ⁵ 1,289 1.5% 2,025 2.3% - Cataract ⁵ 2,813 3.2% 3,443 3.9% - Chronic Kidney Disease ⁵ 6,625 7.5% 5,280 6.0%	0.464	0.020	
Benign Prostatic Hyperplasia ⁵ 1,289 1.5% 2,025 2.3% - Cataract ⁵ 2,813 3.2% 3,443 3.9% - Chronic Kidney Disease ⁵ 6,625 7.5% 5,280 6.0%	1.480	0.074	
Cataract ⁵ 2,813 3.2% 3,443 3.9% - Chronic Kidney Disease ⁵ 6,625 7.5% 5,280 6.0%	-4.040	-0.235	
Chronic Kidney Disease ⁵ 6,625 7.5% 5,280 6.0%	-0.838	-0.062	
	-0.718	-0.039	
- - - - - - - - - -	1.532	0.061	
Bronchiectasis ⁵ 3,056 3.5% 2,450 2.8%	0.690	0.040	
Depression ⁵ 9,563 10.9% 9,425 10.7%	0.157	0.005	
Glaucoma ⁵ 2,082 2.4% 2,345 2.7% -	-0.300	-0.019	
Hip or Pelvic Fracture ⁵ 122 0.1% 105 0.1%	0.019	0.005	
Hyperlipidemia ⁵ 18,843 21.5% 19,886 22.7% -	-1.188	-0.029	
Hypertension ⁵ 31,811 36.2% 26,997 30.8%	5.484	0.116	
Osteoporosis ⁵ 766 0.9% 1,025 1.2% -	-0.295	-0.029	
Rheumatoid Arthritis or Osteoarthritis9,320 10.6% $8,836$ 10.1%	0.551	0.018	
Stroke or Transient Ischemic Attack ⁵ 1,634 1.9% 1,469 1.7%	0.188	0.014	
Breast Cancer ⁵ 1,084 1.2% 914 1.0%	0.194	0.018	
Colorectal Cancer ⁵ 379 0.4% 206 0.2%	0.197	0.034	
Prostate Cancer ⁵ 468 0.5% 528 0.6% -	-0.068	-0.009	
Lung Cancer ⁵ 137 0.2% 152 0.2% -	-0.017	-0.004	
Endometrial Cancer ⁵ 151 0.2% 95 0.1%	0.064	0.017	
Urologic Cancer ⁵ 144 0.2% 140 0.2%	0.005	0.001	
Health Service Utilization Intensity Metrics			
Mean number of ambulatory encounters 5.6 7.6 5.7 6.7 -	-0.066	-0.009	
Mean number of emergency room encounters 0.3 0.8 0.3 0.8 -	-0.011	-0.015	
Mean number of inpatient hospital encounters 0.1 0.4 0.1 0.4 -	-0.012	-0.034	
Mean number of non-acute institutional encounters 0.0 0.0 0.0 0.0 -	-0.000	-0.002	
Mean number of other ambulatory encounters 1.2 3.2 1.2 3.4 -	-0.067	-0.020	
Mean number of filled prescriptions6.98.96.98.5	0.049	0.006	



Table 1f. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.5	0.025	0.007
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.2	0.027	0.008

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1g. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	253,313	100.0%	235,735	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.4	11.5	45.6	15.1	4.787	0.357
Age						
18-44 years	76,952	30.4%	113,754	48.3%	-17.877	-0.372
45-64 years	162,417	64.1%	105,686	44.8%	19.285	0.395
≥ 65 years	13,944	5.5%	16,295	6.9%	-1.408	-0.058
Sex						
Female	109,094	43.1%	144,628	61.4%	-18.285	-0.372
Male	144,219	56.9%	91,107	38.6%	18.285	0.372
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	253,313	100.0%	235,735	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	253,313	100.0%	235,735	100.0%	0.000	NaN
Year						
2018	99,808	39.4%	93,967	39.9%	-0.460	-0.009
2019	153,505	60.6%	141,768	60.1%	0.460	0.009
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.1	0.8	1.7	-0.657	-0.446
Allergic Reaction	14,616	5.8%	20,368	8.6%	-2.870	-0.111
Diabetes	41,334	16.3%	18,265	7.7%	8.569	0.266
Heart Failure	2,367	0.9%	9,239	3.9%	-2.985	-0.195
Ischemic Heart Disease	6,290	2.5%	22,092	9.4%	-6.888	-0.295
NSAID Use	38,907	15.4%	38,292	16.2%	-0.884	-0.024



Table 1g. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	16,880	6.7%	20,357	8.6%	-1.972	-0.074
Acute Myocardial Infarction ⁵	1,225	0.5%	8,869	3.8%	-3.279	-0.229
Alzheimers Disease and Related Disorders ⁵	769	0.3%	1,660	0.7%	-0.401	-0.057
Anemia ⁵	10,981	4.3%	21,349	9.1%	-4.721	-0.190
Asthma ⁵	9,229	3.6%	12,528	5.3%	-1.671	-0.081
Atrial Fibrillation ⁵	2,033	0.8%	13,225	5.6%	-4.808	-0.275
Benign Prostatic Hyperplasia ⁵	4,788	1.9%	4,617	2.0%	-0.068	-0.005
Cataract ⁵	9,133	3.6%	7,893	3.3%	0.257	0.014
Chronic Kidney Disease ⁵	21,429	8.5%	16,956	7.2%	1.267	0.047
Bronchiectasis ⁵	6,685	2.6%	9,524	4.0%	-1.401	-0.078
Depression ⁵	19,563	7.7%	39,090	16.6%	-8.859	-0.274
Glaucoma ⁵	6,413	2.5%	5,687	2.4%	0.119	0.008
Hip or Pelvic Fracture ⁵	241	0.1%	478	0.2%	-0.108	-0.028
Hyperlipidemia⁵	60,658	23.9%	50,862	21.6%	2.370	0.057
Hypertension ⁵	96,582	38.1%	66,791	28.3%	9.794	0.209
Osteoporosis ⁵	1,980	0.8%	2,846	1.2%	-0.426	-0.043
Rheumatoid Arthritis or Osteoarthritis ⁵	24,800	9.8%	24,404	10.4%	-0.562	-0.019
Stroke or Transient Ischemic Attack ⁵	3,917	1.5%	5,106	2.2%	-0.620	-0.046
Breast Cancer ⁵	2,310	0.9%	3,110	1.3%	-0.407	-0.039
Colorectal Cancer ⁵	809	0.3%	921	0.4%	-0.071	-0.012
Prostate Cancer ⁵	1,458	0.6%	1,392	0.6%	-0.015	-0.002
Lung Cancer ⁵	284	0.1%	969	0.4%	-0.299	-0.059
Endometrial Cancer ⁵	309	0.1%	310	0.1%	-0.010	-0.003
Urologic Cancer ⁵	363	0.1%	487	0.2%	-0.063	-0.015
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	4.7	6.5	7.6	9.3	-2.941	-0.366
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.180	-0.210
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.166	-0.368
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.023
Mean number of other ambulatory encounters	1.0	2.7	1.7	4.4	-0.709	-0.194
Mean number of filled prescriptions	6.2	8.2	8.4	10.2	-2.252	-0.243



Table 1g. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
	Number/	Standard	Number/	Standard	Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.1	3.3	4.2	4.1	-1.042	-0.280
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.7	-0.993	-0.291

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1h. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	146,532	57.8%	146,532	62.2%	N/A	N/A
Demographic Characteristics						
Age (years)	48.2	12.0	48.9	13.9	-0.700	-0.054
Age						
18-44 years	55,729	38.0%	55,229	37.7%	0.341	0.007
45-64 years	84,242	57.5%	79,672	54.4%	3.119	0.063
≥ 65 years	6,561	4.5%	11,631	7.9%	-3.460	-0.144
Sex						
Female	79,343	54.1%	76,039	51.9%	2.255	0.045
Male	67,189	45.9%	70,493	48.1%	-2.255	-0.045
Race ³						
American Indian or Alaska Native	•				•	
Asian				•		•
Black or African American				•		•
Multi-racial				•		•
Unknown	146,532	100.0%	146,532	100.0%	0.000	NaN
White						
Hispanic origin						
Yes						
No						
Unknown	146,532	100.0%	146,532	100.0%	0.000	NaN
Year						
2018	58,037	39.6%	58,197	39.7%	-0.109	-0.002
2019	88,495	60.4%	88,335	60.3%	0.109	0.002
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.055	-0.043
Allergic Reaction	10,153	6.9%	10,121	6.9%	0.022	0.001
Diabetes	15,159	10.3%	13,873	9.5%	0.878	0.029
Heart Failure	2,207	1.5%	2,722	1.9%	-0.351	-0.027
Ischemic Heart Disease	6,002	4.1%	6,496	4.4%	-0.337	-0.017
NSAID Use	23,051	15.7%	22,922	15.6%	0.088	0.002



Table 1h. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta Blockers				
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	10,995	7.5%	11,405	7.8%	-0.280	-0.011	
Acute Myocardial Infarction ⁵	1,191	0.8%	2,300	1.6%	-0.757	-0.070	
Alzheimers Disease and Related Disorders ⁵	619	0.4%	627	0.4%	-0.005	-0.001	
Anemia ⁵	8,539	5.8%	7,917	5.4%	0.424	0.018	
Asthma ⁵	7,275	5.0%	5,107	3.5%	1.480	0.074	
Atrial Fibrillation ⁵	1,564	1.1%	7,413	5.1%	-3.992	-0.233	
Benign Prostatic Hyperplasia ⁵	2,187	1.5%	3,298	2.3%	-0.758	-0.056	
Cataract ⁵	4,580	3.1%	5,565	3.8%	-0.672	-0.037	
Chronic Kidney Disease ⁵	11,250	7.7%	8,705	5.9%	1.737	0.069	
Bronchiectasis ⁵	5,060	3.5%	4,110	2.8%	0.648	0.037	
Depression ⁵	15,723	10.7%	15,415	10.5%	0.210	0.007	
Glaucoma ⁵	3,442	2.3%	3,922	2.7%	-0.328	-0.021	
Hip or Pelvic Fracture ⁵	204	0.1%	197	0.1%	0.005	0.001	
Hyperlipidemia⁵	31,673	21.6%	33,091	22.6%	-0.968	-0.023	
Hypertension ⁵	53,565	36.6%	44,899	30.6%	5.914	0.125	
Osteoporosis ⁵	1,303	0.9%	1,656	1.1%	-0.241	-0.024	
Rheumatoid Arthritis or Osteoarthritis ⁵	15,599	10.6%	14,869	10.1%	0.498	0.016	
Stroke or Transient Ischemic Attack ⁵	2,804	1.9%	2,508	1.7%	0.202	0.015	
Breast Cancer ⁵	1,848	1.3%	1,477	1.0%	0.253	0.024	
Colorectal Cancer ⁵	607	0.4%	368	0.3%	0.163	0.028	
Prostate Cancer ⁵	734	0.5%	906	0.6%	-0.117	-0.016	
Lung Cancer ⁵	241	0.2%	264	0.2%	-0.016	-0.004	
Endometrial Cancer ⁵	247	0.2%	130	0.1%	0.080	0.022	
Urologic Cancer ⁵	275	0.2%	213	0.1%	0.042	0.010	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	5.6	7.7	5.7	6.8	-0.041	-0.006	
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.009	-0.012	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.011	-0.029	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	0.000	0.000	
Mean number of other ambulatory encounters	1.2	3.1	1.2	3.2	-0.047	-0.015	
Mean number of filled prescriptions	7.0	9.0	7.0	8.7	0.028	0.003	



Table 1h. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.5	0.016	0.005
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.3	0.017	0.005

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1i. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta E	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Deviation ²	Absolute Difference	Standardized Difference
Unique patients	58,037	100.0%	58,197	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.3	11.9	49.1	13.9	-0.836	-0.065
Age						
18-44 years	21,904	37.7%	21,473	36.9%	0.844	0.017
45-64 years	33,586	57.9%	32,124	55.2%	2.671	0.054
≥ 65 years	2,547	4.4%	4,600	7.9%	-3.516	-0.147
Sex						
Female	31,543	54.3%	30,223	51.9%	2.418	0.048
Male	26,494	45.7%	27,974	48.1%	-2.418	-0.048
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	58,037	100.0%	58,197	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	58,037	100.0%	58,197	100.0%	0.000	NaN
Year						
2018	58,037	100.0%	58,197	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.047	-0.036
Allergic Reaction	3,890	6.7%	3,885	6.7%	0.027	0.001
Diabetes	6,154	10.6%	5,398	9.3%	1.328	0.044
Heart Failure	882	1.5%	1,052	1.8%	-0.288	-0.023
Ischemic Heart Disease	2,351	4.1%	2,572	4.4%	-0.369	-0.018
NSAID Use	9,268	16.0%	9,345	16.1%	-0.088	-0.002



Table 1i. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covaria	Covariate Balance	
	ACE In	hibitors	Beta B	Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	4,307	7.4%	4,454	7.7%	-0.232	-0.009	
Acute Myocardial Infarction ⁵	484	0.8%	905	1.6%	-0.721	-0.066	
Alzheimers Disease and Related Disorders ⁵	246	0.4%	251	0.4%	-0.007	-0.001	
Anemia ⁵	3,365	5.8%	3,121	5.4%	0.435	0.019	
Asthma ⁵	2,842	4.9%	2,025	3.5%	1.417	0.071	
Atrial Fibrillation ⁵	604	1.0%	2,908	5.0%	-3.956	-0.233	
Benign Prostatic Hyperplasia ⁵	884	1.5%	1,257	2.2%	-0.637	-0.047	
Cataract ⁵	1,759	3.0%	2,102	3.6%	-0.581	-0.032	
Chronic Kidney Disease ⁵	4,514	7.8%	3,387	5.8%	1.958	0.078	
Bronchiectasis⁵	1,975	3.4%	1,635	2.8%	0.594	0.034	
Depression ⁵	6,050	10.4%	5,880	10.1%	0.321	0.011	
Glaucoma ⁵	1,290	2.2%	1,534	2.6%	-0.413	-0.027	
Hip or Pelvic Fracture ⁵	84	0.1%	89	0.2%	-0.008	-0.002	
Hyperlipidemia⁵	12,479	21.5%	12,991	22.3%	-0.821	-0.020	
Hypertension ⁵	21,179	36.5%	17,782	30.6%	5.937	0.126	
Osteoporosis ⁵	520	0.9%	660	1.1%	-0.238	-0.024	
Rheumatoid Arthritis or Osteoarthritis ⁵	6,166	10.6%	5,906	10.1%	0.476	0.016	
Stroke or Transient Ischemic Attack ⁵	1,110	1.9%	1,024	1.8%	0.153	0.011	
Breast Cancer ⁵	753	1.3%	561	1.0%	0.333	0.032	
Colorectal Cancer ⁵	232	0.4%	150	0.3%	0.142	0.025	
Prostate Cancer ⁵	267	0.5%	364	0.6%	-0.165	-0.023	
Lung Cancer ⁵	109	0.2%	97	0.2%	0.021	0.005	
Endometrial Cancer ⁵	100	0.2%	44	0.1%	0.097	0.027	
Urologic Cancer ⁵	118	0.2%	83	0.1%	0.061	0.015	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	5.6	7.7	5.6	6.8	0.015	0.002	
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.008	-0.010	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.010	-0.026	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	0.000	0.001	
Mean number of other ambulatory encounters	1.1	3.1	1.1	3.0	-0.031	-0.010	
Mean number of filled prescriptions	7.2	9.2	7.1	8.9	0.032	0.003	



Table 1i. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.6	0.013	0.004
Mean number of unique drug classes dispensed	3.3	3.3	3.3	3.3	0.012	0.004

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1j. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	57,569	99.2%	57,569	98.9%	N/A	N/A
Demographic Characteristics						
Age (years)	48.3	11.9	49.1	13.8	-0.811	-0.063
Age						
18-44 years	21,701	37.7%	21,279	37.0%	0.733	0.015
45-64 years	33,353	57.9%	31,758	55.2%	2.771	0.056
≥ 65 years	2,515	4.4%	4,532	7.9%	-3.504	-0.147
Sex						
Female	31,204	54.2%	29,956	52.0%	2.168	0.043
Male	26,365	45.8%	27,613	48.0%	-2.168	-0.043
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	57,569	100.0%	57,569	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	57,569	100.0%	57,569	100.0%	0.000	NaN
Year						
2018	57,569	100.0%	57,569	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.050	-0.039
Allergic Reaction	3,849	6.7%	3,851	6.7%	-0.003	-0.000
Diabetes	6,095	10.6%	5,333	9.3%	1.324	0.044
Heart Failure	868	1.5%	1,046	1.8%	-0.309	-0.024
Ischemic Heart Disease	2,318	4.0%	2,538	4.4%	-0.382	-0.019
NSAID Use	9,194	16.0%	9,256	16.1%	-0.108	-0.003



Table 1j. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,269	7.4%	4,412	7.7%	-0.248	-0.009
Acute Myocardial Infarction ⁵	480	0.8%	894	1.6%	-0.719	-0.066
Alzheimers Disease and Related Disorders ⁵	237	0.4%	250	0.4%	-0.023	-0.003
Anemia ⁵	3,329	5.8%	3,089	5.4%	0.417	0.018
Asthma ⁵	2,815	4.9%	2,005	3.5%	1.407	0.070
Atrial Fibrillation ⁵	594	1.0%	2,883	5.0%	-3.976	-0.234
Benign Prostatic Hyperplasia ⁵	876	1.5%	1,236	2.1%	-0.625	-0.047
Cataract ⁵	1,742	3.0%	2,068	3.6%	-0.566	-0.032
Chronic Kidney Disease ⁵	4,464	7.8%	3,348	5.8%	1.939	0.077
Bronchiectasis ⁵	1,955	3.4%	1,618	2.8%	0.585	0.034
Depression ⁵	5,978	10.4%	5,808	10.1%	0.295	0.010
Glaucoma ⁵	1,271	2.2%	1,508	2.6%	-0.412	-0.027
Hip or Pelvic Fracture ⁵	81	0.1%	88	0.2%	-0.012	-0.003
Hyperlipidemia ⁵	12,367	21.5%	12,832	22.3%	-0.808	-0.020
Hypertension ⁵	20,999	36.5%	17,572	30.5%	5.953	0.126
Osteoporosis ⁵	514	0.9%	654	1.1%	-0.243	-0.024
Rheumatoid Arthritis or Osteoarthritis ⁵	6,103	10.6%	5,850	10.2%	0.439	0.014
Stroke or Transient Ischemic Attack ⁵	1,100	1.9%	1,016	1.8%	0.146	0.011
Breast Cancer ⁵	747	1.3%	557	1.0%	0.330	0.031
Colorectal Cancer ⁵	229	0.4%	149	0.3%	0.139	0.024
Prostate Cancer ⁵	265	0.5%	360	0.6%	-0.165	-0.022
Lung Cancer ⁵	106	0.2%	97	0.2%	0.016	0.004
Endometrial Cancer ⁵	98	0.2%	44	0.1%	0.094	0.027
Urologic Cancer ⁵	114	0.2%	82	0.1%	0.056	0.013
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	5.6	7.7	5.6	6.7	0.003	0.000
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.009	-0.011
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.010	-0.027
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	0.000	0.001
Mean number of other ambulatory encounters	1.1	3.1	1.1	3.0	-0.033	-0.011
Mean number of filled prescriptions	7.2	9.2	7.1	8.9	0.019	0.002



Table 1j. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.6	0.007	0.002
Mean number of unique drug classes dispensed	3.3	3.3	3.3	3.3	0.006	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1k. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	88,495	100.0%	88,335	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.2	12.0	48.8	13.9	-0.611	-0.047
Age						
18-44 years	33,825	38.2%	33,756	38.2%	0.009	0.000
45-64 years	50,656	57.2%	47,548	53.8%	3.415	0.069
≥ 65 years	4,014	4.5%	7,031	8.0%	-3.424	-0.142
Sex						
Female	47,800	54.0%	45,816	51.9%	2.148	0.043
Male	40,695	46.0%	42,519	48.1%	-2.148	-0.043
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	88,495	100.0%	88,335	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	88,495	100.0%	88,335	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	88,495	100.0%	88,335	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.061	-0.047
Allergic Reaction	6,263	7.1%	6,236	7.1%	0.018	0.001
Diabetes	9,005	10.2%	8,475	9.6%	0.582	0.019
Heart Failure	1,325	1.5%	1,670	1.9%	-0.393	-0.030
Ischemic Heart Disease	3,651	4.1%	3,924	4.4%	-0.317	-0.016
NSAID Use	13,783	15.6%	13,577	15.4%	0.205	0.006



Table 1k. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	6,688	7.6%	6,951	7.9%	-0.311	-0.012
Acute Myocardial Infarction ⁵	707	0.8%	1,395	1.6%	-0.780	-0.072
Alzheimers Disease and Related Disorders ⁵	373	0.4%	376	0.4%	-0.004	-0.001
Anemia ⁵	5,174	5.8%	4,796	5.4%	0.417	0.018
Asthma ⁵	4,433	5.0%	3,082	3.5%	1.520	0.075
Atrial Fibrillation ⁵	960	1.1%	4,505	5.1%	-4.015	-0.234
Benign Prostatic Hyperplasia ⁵	1,303	1.5%	2,041	2.3%	-0.838	-0.062
Cataract ⁵	2,821	3.2%	3,463	3.9%	-0.733	-0.040
Chronic Kidney Disease ⁵	6,736	7.6%	5,318	6.0%	1.591	0.063
Bronchiectasis ⁵	3,085	3.5%	2,475	2.8%	0.684	0.039
Depression ⁵	9,673	10.9%	9,535	10.8%	0.136	0.004
Glaucoma ⁵	2,152	2.4%	2,388	2.7%	-0.272	-0.017
Hip or Pelvic Fracture ⁵	120	0.1%	108	0.1%	0.013	0.004
Hyperlipidemia⁵	19,194	21.7%	20,100	22.8%	-1.065	-0.026
Hypertension ⁵	32,386	36.6%	27,117	30.7%	5.899	0.125
Osteoporosis ⁵	783	0.9%	996	1.1%	-0.243	-0.024
Rheumatoid Arthritis or Osteoarthritis ⁵	9,433	10.7%	8,963	10.1%	0.513	0.017
Stroke or Transient Ischemic Attack ⁵	1,694	1.9%	1,484	1.7%	0.234	0.018
Breast Cancer ⁵	1,095	1.2%	916	1.0%	0.200	0.019
Colorectal Cancer ⁵	375	0.4%	218	0.2%	0.177	0.031
Prostate Cancer ⁵	467	0.5%	542	0.6%	-0.086	-0.011
Lung Cancer ⁵	132	0.1%	167	0.2%	-0.040	-0.010
Endometrial Cancer ⁵	147	0.2%	86	0.1%	0.069	0.019
Urologic Cancer ⁵	157	0.2%	130	0.1%	0.030	0.008
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	5.6	7.6	5.7	6.9	-0.077	-0.011
Mean number of emergency room encounters	0.3	0.8	0.3	0.8	-0.009	-0.012
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.011	-0.032
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.000
Mean number of other ambulatory encounters	1.2	3.1	1.2	3.3	-0.057	-0.018
Mean number of filled prescriptions	6.9	8.9	6.9	8.6	0.026	0.003



Table 1k. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
Patient Characteristics ¹	Number/ Mean	Standard Deviation ²	Number/ Mean	Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.5	3.6	3.5	3.5	0.018	0.005
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.2	0.021	0.006

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1I. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	87,862	99.3%	87,862	99.5%	N/A	N/A
Demographic Characteristics						
Age (years)	48.2	12.0	48.8	13.9	-0.645	-0.050
Age						
18-44 years	33,644	38.3%	33,509	38.1%	0.154	0.003
45-64 years	50,251	57.2%	47,375	53.9%	3.273	0.066
≥ 65 years	3,967	4.5%	6,978	7.9%	-3.427	-0.142
Sex						
Female	47,555	54.1%	45,496	51.8%	2.343	0.047
Male	40,307	45.9%	42,366	48.2%	-2.343	-0.047
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	87,862	100.0%	87,862	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	87,862	100.0%	87,862	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	87,862	100.0%	87,862	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	0.4	1.2	-0.061	-0.047
Allergic Reaction	6,219	7.1%	6,198	7.1%	0.024	0.001
Diabetes	8,912	10.1%	8,423	9.6%	0.557	0.019
Heart Failure	1,314	1.5%	1,656	1.9%	-0.389	-0.030
Ischemic Heart Disease	3,600	4.1%	3,891	4.4%	-0.331	-0.016
NSAID Use	13,675	15.6%	13,507	15.4%	0.191	0.005



Table 1I. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	6,647	7.6%	6,905	7.9%	-0.294	-0.011	
Acute Myocardial Infarction ⁵	699	0.8%	1,382	1.6%	-0.777	-0.072	
Alzheimers Disease and Related Disorders ⁵	370	0.4%	374	0.4%	-0.005	-0.001	
Anemia ⁵	5,119	5.8%	4,753	5.4%	0.417	0.018	
Asthma ⁵	4,401	5.0%	3,056	3.5%	1.531	0.076	
Atrial Fibrillation ⁵	944	1.1%	4,481	5.1%	-4.026	-0.234	
Benign Prostatic Hyperplasia ⁵	1,291	1.5%	2,035	2.3%	-0.847	-0.062	
Cataract ⁵	2,797	3.2%	3,444	3.9%	-0.736	-0.040	
Chronic Kidney Disease ⁵	6,671	7.6%	5,284	6.0%	1.579	0.063	
Bronchiectasis⁵	3,060	3.5%	2,452	2.8%	0.692	0.040	
Depression ⁵	9,594	10.9%	9,460	10.8%	0.153	0.005	
Glaucoma ⁵	2,135	2.4%	2,377	2.7%	-0.275	-0.017	
Hip or Pelvic Fracture ⁵	118	0.1%	106	0.1%	0.014	0.004	
Hyperlipidemia ⁵	19,027	21.7%	20,000	22.8%	-1.107	-0.027	
Hypertension ⁵	32,126	36.6%	26,987	30.7%	5.849	0.124	
Osteoporosis ⁵	776	0.9%	990	1.1%	-0.244	-0.024	
Rheumatoid Arthritis or Osteoarthritis ⁵	9,342	10.6%	8,914	10.1%	0.487	0.016	
Stroke or Transient Ischemic Attack ⁵	1,680	1.9%	1,476	1.7%	0.232	0.017	
Breast Cancer ⁵	1,091	1.2%	909	1.0%	0.207	0.020	
Colorectal Cancer ⁵	370	0.4%	217	0.2%	0.174	0.030	
Prostate Cancer ⁵	462	0.5%	539	0.6%	-0.088	-0.012	
Lung Cancer ⁵	128	0.1%	161	0.2%	-0.038	-0.009	
Endometrial Cancer ⁵	146	0.2%	86	0.1%	0.068	0.019	
Urologic Cancer ⁵	157	0.2%	130	0.1%	0.031	0.008	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	5.6	7.6	5.7	6.8	-0.073	-0.010	
Mean number of emergency room encounters	0.3	0.8	0.3	0.7	-0.009	-0.012	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.011	-0.031	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	0.000	0.000	
Mean number of other ambulatory encounters	1.2	3.1	1.2	3.2	-0.056	-0.018	
Mean number of filled prescriptions	6.9	8.9	6.9	8.6	0.028	0.003	



Table 1I. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute	Standardized
Mean number of generics dispensed	Mean 3.5	3.6	Mean 3.5	3.5	0.021	Difference
Mean number of unique drug classes dispensed	3.3	3.4	3.3	3.2	0.021	0.007

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1m. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	191,799	100.0%	180,617	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.7	11.6	45.8	15.4	4.891	0.359
Age						
18-44 years	57,039	29.7%	86,598	47.9%	-18.207	-0.380
45-64 years	123,162	64.2%	80,316	44.5%	19.747	0.404
≥ 65 years	11,598	6.0%	13,703	7.6%	-1.540	-0.061
Sex						
Female	83,324	43.4%	111,331	61.6%	-18.196	-0.371
Male	108,475	56.6%	69,286	38.4%	18.196	0.371
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	191,799	100.0%	180,617	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	191,799	100.0%	180,617	100.0%	0.000	NaN
Year						
2018	68,205	35.6%	65,471	36.2%	-0.688	-0.014
2019	123,594	64.4%	115,146	63.8%	0.688	0.014
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.753	-0.461
Allergic Reaction	18,335	9.6%	24,543	13.6%	-4.029	-0.126
Diabetes	33,304	17.4%	14,681	8.1%	9.236	0.280
Heart Failure	2,047	1.1%	7,592	4.2%	-3.136	-0.197
Ischemic Heart Disease	5,874	3.1%	18,720	10.4%	-7.302	-0.295
NSAID Use	42,149	22.0%	43,281	24.0%	-1.987	-0.047



Table 1m. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	16,787	8.8%	19,638	10.9%	-2.120	-0.071
Acute Myocardial Infarction ⁵	1,079	0.6%	7,341	4.1%	-3.502	-0.235
Alzheimers Disease and Related Disorders ⁵	764	0.4%	1,605	0.9%	-0.490	-0.061
Anemia ⁵	11,638	6.1%	20,947	11.6%	-5.530	-0.196
Asthma ⁵	10,250	5.3%	13,559	7.5%	-2.163	-0.088
Atrial Fibrillation ⁵	1,783	0.9%	11,155	6.2%	-5.246	-0.286
Benign Prostatic Hyperplasia ⁵	5,630	2.9%	5,290	2.9%	0.007	0.000
Cataract ⁵	11,629	6.1%	10,374	5.7%	0.319	0.014
Chronic Kidney Disease ⁵	18,976	9.9%	14,636	8.1%	1.790	0.063
Bronchiectasis⁵	7,981	4.2%	10,494	5.8%	-1.649	-0.076
Depression ⁵	19,602	10.2%	37,050	20.5%	-10.293	-0.288
Glaucoma ⁵	7,396	3.9%	6,607	3.7%	0.198	0.010
Hip or Pelvic Fracture ⁵	275	0.1%	506	0.3%	-0.137	-0.030
Hyperlipidemia⁵	59,255	30.9%	48,548	26.9%	4.015	0.089
Hypertension ⁵	82,876	43.2%	55,448	30.7%	12.511	0.261
Osteoporosis⁵	2,423	1.3%	3,307	1.8%	-0.568	-0.046
Rheumatoid Arthritis or Osteoarthritis ⁵	26,750	13.9%	26,329	14.6%	-0.630	-0.018
Stroke or Transient Ischemic Attack ⁵	3,622	1.9%	4,796	2.7%	-0.767	-0.051
Breast Cancer ⁵	2,239	1.2%	2,977	1.6%	-0.481	-0.041
Colorectal Cancer ⁵	774	0.4%	904	0.5%	-0.097	-0.014
Prostate Cancer ⁵	1,375	0.7%	1,349	0.7%	-0.030	-0.004
Lung Cancer ⁵	274	0.1%	893	0.5%	-0.352	-0.062
Endometrial Cancer ⁵	308	0.2%	321	0.2%	-0.017	-0.004
Urologic Cancer ⁵	358	0.2%	447	0.2%	-0.061	-0.013
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.8	11.3	13.8	16.0	-5.003	-0.362
Mean number of emergency room encounters	0.3	0.9	0.6	1.4	-0.266	-0.225
Mean number of inpatient hospital encounters	0.1	0.4	0.3	0.7	-0.196	-0.357
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.026
Mean number of other ambulatory encounters	1.7	4.4	2.8	6.8	-1.094	-0.191
Mean number of filled prescriptions	12.1	15.7	16.3	19.4	-4.211	-0.239



Table 1m. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	4.6	4.5	6.2	5.5	-1.595	-0.319
Mean number of unique drug classes dispensed	4.2	4.0	5.7	4.8	-1.459	-0.331

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1n. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	120,456	62.8%	120,456	66.7%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.2	14.3	-0.549	-0.041
Age						
18-44 years	44,208	36.7%	44,827	37.2%	-0.514	-0.011
45-64 years	70,155	58.2%	64,702	53.7%	4.527	0.091
≥ 65 years	6,093	5.1%	10,927	9.1%	-4.013	-0.157
Sex						
Female	65,081	54.0%	62,659	52.0%	2.011	0.040
Male	55,375	46.0%	57,797	48.0%	-2.011	-0.040
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	120,456	100.0%	120,456	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	120,456	100.0%	120,456	100.0%	0.000	NaN
Year						
2018	43,012	35.7%	43,714	36.3%	-0.583	-0.012
2019	77,444	64.3%	76,742	63.7%	0.583	0.012
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.058	-0.040
Allergic Reaction	12,910	10.7%	14,324	11.9%	-1.174	-0.037
Diabetes	22,888	19.0%	9,230	7.7%	11.339	0.338
Heart Failure	1,865	1.5%	3,278	2.7%	-1.173	-0.081
Ischemic Heart Disease	4,149	3.4%	12,738	10.6%	-7.130	-0.282
NSAID Use	29,106	24.2%	26,208	21.8%	2.406	0.057



Table 1n. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	12,126	10.1%	12,133	10.1%	-0.006	-0.000
Acute Myocardial Infarction ⁵	916	0.8%	4,686	3.9%	-3.130	-0.209
Alzheimers Disease and Related Disorders ⁵	658	0.5%	748	0.6%	-0.075	-0.010
Anemia⁵	9,930	8.2%	9,124	7.6%	0.669	0.025
Asthma⁵	8,508	7.1%	6,291	5.2%	1.841	0.077
Atrial Fibrillation ⁵	1,351	1.1%	7,218	6.0%	-4.871	-0.265
Benign Prostatic Hyperplasia ⁵	2,814	2.3%	4,350	3.6%	-1.275	-0.075
Cataract ⁵	6,855	5.7%	7,930	6.6%	-0.892	-0.037
Chronic Kidney Disease ⁵	14,594	12.1%	7,556	6.3%	5.843	0.203
Bronchiectasis ⁵	6,292	5.2%	5,624	4.7%	0.555	0.026
Depression ⁵	16,583	13.8%	17,073	14.2%	-0.407	-0.012
Glaucoma ⁵	4,519	3.8%	4,922	4.1%	-0.335	-0.017
Hip or Pelvic Fracture ⁵	232	0.2%	240	0.2%	-0.007	-0.002
Hyperlipidemia ⁵	36,543	30.3%	36,162	30.0%	0.316	0.007
Hypertension ⁵	50,186	41.7%	40,845	33.9%	7.755	0.160
Osteoporosis ⁵	1,704	1.4%	2,224	1.8%	-0.432	-0.034
Rheumatoid Arthritis or Osteoarthritis ⁵	18,131	15.1%	17,635	14.6%	0.412	0.012
Stroke or Transient Ischemic Attack ⁵	2,776	2.3%	2,587	2.1%	0.157	0.011
Breast Cancer ⁵	1,899	1.6%	1,622	1.3%	0.230	0.019
Colorectal Cancer ⁵	603	0.5%	439	0.4%	0.136	0.021
Prostate Cancer ⁵	739	0.6%	1,024	0.9%	-0.237	-0.028
Lung Cancer ⁵	247	0.2%	292	0.2%	-0.037	-0.008
Endometrial Cancer ⁵	265	0.2%	150	0.1%	0.095	0.023
Urologic Cancer ⁵	292	0.2%	242	0.2%	0.042	0.009
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.5	13.0	10.7	11.9	-0.165	-0.013
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.019	-0.018
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.023	-0.051
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.009
Mean number of other ambulatory encounters	2.0	5.0	2.1	5.5	-0.099	-0.019
Mean number of filled prescriptions	13.9	17.2	14.0	17.2	-0.052	-0.003



Table 1n. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.3	4.8	5.3	4.8	-0.002	-0.001
Mean number of unique drug classes dispensed	4.9	4.3	4.9	4.3	0.004	0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1o. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	43,012	100.0%	43,714	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.1	49.3	14.2	-0.623	-0.047
Age						
18-44 years	15,852	36.9%	16,027	36.7%	0.192	0.004
45-64 years	24,987	58.1%	23,844	54.5%	3.548	0.072
≥ 65 years	2,173	5.1%	3,843	8.8%	-3.739	-0.148
Sex						
Female	23,391	54.4%	22,845	52.3%	2.122	0.043
Male	19,621	45.6%	20,869	47.7%	-2.122	-0.043
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	43,012	100.0%	43,714	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	43,012	100.0%	43,714	100.0%	0.000	NaN
Year						
2018	43,012	100.0%	43,714	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.045	-0.030
Allergic Reaction	4,492	10.4%	5,080	11.6%	-1.177	-0.038
Diabetes	8,218	19.1%	3,200	7.3%	11.786	0.353
Heart Failure	691	1.6%	1,156	2.6%	-1.038	-0.072
Ischemic Heart Disease	1,479	3.4%	4,597	10.5%	-7.078	-0.281
NSAID Use	10,506	24.4%	9,975	22.8%	1.607	0.038



Table 1o. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,289	10.0%	4,320	9.9%	0.089	0.003
Acute Myocardial Infarction ⁵	336	0.8%	1,695	3.9%	-3.096	-0.206
Alzheimers Disease and Related Disorders ⁵	225	0.5%	290	0.7%	-0.140	-0.018
Anemia ⁵	3,504	8.1%	3,337	7.6%	0.513	0.019
Asthma⁵	3,117	7.2%	2,298	5.3%	1.990	0.082
Atrial Fibrillation ⁵	486	1.1%	2,568	5.9%	-4.745	-0.260
Benign Prostatic Hyperplasia ⁵	1,019	2.4%	1,567	3.6%	-1.216	-0.072
Cataract ⁵	2,442	5.7%	2,847	6.5%	-0.835	-0.035
Chronic Kidney Disease ⁵	5,233	12.2%	2,633	6.0%	6.143	0.215
Bronchiectasis⁵	2,376	5.5%	2,132	4.9%	0.647	0.029
Depression ⁵	5,781	13.4%	6,056	13.9%	-0.413	-0.012
Glaucoma⁵	1,572	3.7%	1,751	4.0%	-0.351	-0.018
Hip or Pelvic Fracture ⁵	84	0.2%	102	0.2%	-0.038	-0.008
Hyperlipidemia⁵	12,936	30.1%	12,975	29.7%	0.394	0.009
Hypertension ⁵	17,827	41.4%	14,782	33.8%	7.631	0.158
Osteoporosis ⁵	620	1.4%	782	1.8%	-0.347	-0.028
Rheumatoid Arthritis or Osteoarthritis ⁵	6,514	15.1%	6,487	14.8%	0.305	0.009
Stroke or Transient Ischemic Attack ⁵	985	2.3%	945	2.2%	0.128	0.009
Breast Cancer ⁵	733	1.7%	575	1.3%	0.389	0.032
Colorectal Cancer ⁵	215	0.5%	165	0.4%	0.122	0.019
Prostate Cancer ⁵	257	0.6%	377	0.9%	-0.265	-0.031
Lung Cancer ⁵	107	0.2%	113	0.3%	-0.010	-0.002
Endometrial Cancer ⁵	90	0.2%	53	0.1%	0.088	0.022
Urologic Cancer ⁵	119	0.3%	84	0.2%	0.085	0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.6	13.0	10.7	11.8	-0.070	-0.006
Mean number of emergency room encounters	0.4	1.1	0.5	1.0	-0.024	-0.023
Mean number of inpatient hospital encounters	0.1	0.5	0.2	0.4	-0.021	-0.044
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.015
Mean number of other ambulatory encounters	2.0	4.6	2.0	4.9	-0.042	-0.009
Mean number of filled prescriptions	14.4	17.6	14.5	17.6	-0.072	-0.004



Table 1o. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.4	4.9	5.4	4.9	-0.011	-0.002
Mean number of unique drug classes dispensed	5.0	4.4	5.0	4.3	-0.005	-0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1p. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	42,854	99.6%	42,854	98.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.3	14.2	-0.591	-0.045
Age						
18-44 years	15,787	36.8%	15,769	36.8%	0.042	0.001
45-64 years	24,915	58.1%	23,336	54.5%	3.685	0.074
≥ 65 years	2,152	5.0%	3,749	8.7%	-3.727	-0.148
Sex						
Female	23,319	54.4%	22,493	52.5%	1.927	0.039
Male	19,535	45.6%	20,361	47.5%	-1.927	-0.039
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	42,854	100.0%	42,854	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	42,854	100.0%	42,854	100.0%	0.000	NaN
Year						
2018	42,854	100.0%	42,854	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.056	-0.038
Allergic Reaction	4,471	10.4%	4,993	11.7%	-1.218	-0.039
Diabetes	8,182	19.1%	3,134	7.3%	11.780	0.353
Heart Failure	682	1.6%	1,141	2.7%	-1.071	-0.074
Ischemic Heart Disease	1,471	3.4%	4,509	10.5%	-7.089	-0.281
NSAID Use	10,466	24.4%	9,778	22.8%	1.605	0.038



Table 1p. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,270	10.0%	4,245	9.9%	0.058	0.002
Acute Myocardial Infarction ⁵	334	0.8%	1,673	3.9%	-3.125	-0.208
Alzheimers Disease and Related Disorders ⁵	222	0.5%	285	0.7%	-0.147	-0.019
Anemia ⁵	3,477	8.1%	3,286	7.7%	0.446	0.017
Asthma ⁵	3,101	7.2%	2,263	5.3%	1.955	0.081
Atrial Fibrillation ⁵	481	1.1%	2,533	5.9%	-4.788	-0.262
Benign Prostatic Hyperplasia ⁵	1,009	2.4%	1,517	3.5%	-1.185	-0.070
Cataract ⁵	2,426	5.7%	2,789	6.5%	-0.847	-0.035
Chronic Kidney Disease ⁵	5,208	12.2%	2,599	6.1%	6.088	0.213
Bronchiectasis ⁵	2,365	5.5%	2,098	4.9%	0.623	0.028
Depression ⁵	5,751	13.4%	5,986	14.0%	-0.548	-0.016
Glaucoma ⁵	1,562	3.6%	1,717	4.0%	-0.362	-0.019
Hip or Pelvic Fracture ⁵	83	0.2%	102	0.2%	-0.044	-0.010
Hyperlipidemia ⁵	12,880	30.1%	12,725	29.7%	0.362	0.008
Hypertension ⁵	17,740	41.4%	14,455	33.7%	7.666	0.159
Osteoporosis ⁵	616	1.4%	773	1.8%	-0.366	-0.029
Rheumatoid Arthritis or Osteoarthritis ⁵	6,485	15.1%	6,351	14.8%	0.313	0.009
Stroke or Transient Ischemic Attack ⁵	974	2.3%	932	2.2%	0.098	0.007
Breast Cancer ⁵	725	1.7%	568	1.3%	0.366	0.030
Colorectal Cancer ⁵	213	0.5%	163	0.4%	0.117	0.018
Prostate Cancer ⁵	256	0.6%	365	0.9%	-0.254	-0.030
Lung Cancer⁵	106	0.2%	112	0.3%	-0.014	-0.003
Endometrial Cancer ⁵	90	0.2%	52	0.1%	0.089	0.022
Urologic Cancer ⁵	119	0.3%	82	0.2%	0.086	0.018
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.6	12.9	10.7	11.9	-0.134	-0.011
Mean number of emergency room encounters	0.4	1.1	0.5	1.0	-0.028	-0.026
Mean number of inpatient hospital encounters	0.1	0.5	0.2	0.5	-0.024	-0.051
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.015
Mean number of other ambulatory encounters	1.9	4.6	2.0	5.0	-0.060	-0.013
Mean number of filled prescriptions	14.4	17.6	14.5	17.6	-0.126	-0.007



Table 1p. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.4	4.9	5.4	4.9	-0.030	-0.006
Mean number of unique drug classes dispensed	5.0	4.4	5.0	4.3	-0.022	-0.005

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1q. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	77,444	100.0%	76,742	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.2	14.4	-0.507	-0.038
Age						
18-44 years	28,356	36.6%	28,800	37.5%	-0.913	-0.019
45-64 years	45,168	58.3%	40,858	53.2%	5.083	0.102
≥ 65 years	3,920	5.1%	7,084	9.2%	-4.169	-0.162
Sex						
Female	41,690	53.8%	39,814	51.9%	1.952	0.039
Male	35,754	46.2%	36,928	48.1%	-1.952	-0.039
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	77,444	100.0%	76,742	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	77,444	100.0%	76,742	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	77,444	100.0%	76,742	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.066	-0.045
Allergic Reaction	8,418	10.9%	9,244	12.0%	-1.176	-0.037
Diabetes	14,670	18.9%	6,030	7.9%	11.085	0.330
Heart Failure	1,174	1.5%	2,122	2.8%	-1.249	-0.086
Ischemic Heart Disease	2,670	3.4%	8,141	10.6%	-7.161	-0.283
NSAID Use	18,600	24.0%	16,233	21.2%	2.865	0.069



Table 1q. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	7,837	10.1%	7,813	10.2%	-0.061	-0.002
Acute Myocardial Infarction ⁵	580	0.7%	2,991	3.9%	-3.149	-0.210
Alzheimers Disease and Related Disorders ⁵	433	0.6%	458	0.6%	-0.038	-0.005
Anemia ⁵	6,426	8.3%	5,787	7.5%	0.757	0.028
Asthma ⁵	5,391	7.0%	3,993	5.2%	1.758	0.074
Atrial Fibrillation ⁵	865	1.1%	4,650	6.1%	-4.942	-0.268
Benign Prostatic Hyperplasia ⁵	1,795	2.3%	2,783	3.6%	-1.309	-0.077
Cataract ⁵	4,413	5.7%	5,083	6.6%	-0.925	-0.038
Chronic Kidney Disease ⁵	9,361	12.1%	4,923	6.4%	5.672	0.197
Bronchiectasis ⁵	3,916	5.1%	3,492	4.6%	0.506	0.024
Depression ⁵	10,802	13.9%	11,017	14.4%	-0.408	-0.012
Glaucoma ⁵	2,947	3.8%	3,171	4.1%	-0.327	-0.017
Hip or Pelvic Fracture ⁵	148	0.2%	138	0.2%	0.011	0.003
Hyperlipidemia⁵	23,607	30.5%	23,187	30.2%	0.268	0.006
Hypertension ⁵	32,359	41.8%	26,063	34.0%	7.822	0.162
Osteoporosis ⁵	1,084	1.4%	1,442	1.9%	-0.479	-0.038
Rheumatoid Arthritis or Osteoarthritis ⁵	11,617	15.0%	11,148	14.5%	0.474	0.013
Stroke or Transient Ischemic Attack ⁵	1,791	2.3%	1,642	2.1%	0.173	0.012
Breast Cancer ⁵	1,166	1.5%	1,047	1.4%	0.141	0.012
Colorectal Cancer ⁵	388	0.5%	274	0.4%	0.144	0.022
Prostate Cancer ⁵	482	0.6%	647	0.8%	-0.221	-0.026
Lung Cancer ⁵	140	0.2%	179	0.2%	-0.052	-0.012
Endometrial Cancer ⁵	175	0.2%	97	0.1%	0.100	0.024
Urologic Cancer ⁵	173	0.2%	158	0.2%	0.018	0.004
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.5	13.1	10.7	11.9	-0.217	-0.017
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.016	-0.016
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.024	-0.055
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.004
Mean number of other ambulatory encounters	2.0	5.1	2.2	5.8	-0.132	-0.024
Mean number of filled prescriptions	13.7	17.0	13.7	17.0	-0.034	-0.002



Table 1q. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.2	4.8	5.2	4.8	0.004	0.001
Mean number of unique drug classes dispensed	4.8	4.3	4.8	4.2	0.010	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1r. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	76,583	98.9%	76,583	99.8%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.2	14.4	-0.522	-0.039
Age						
18-44 years	28,126	36.7%	28,739	37.5%	-0.800	-0.017
45-64 years	44,580	58.2%	40,792	53.3%	4.946	0.100
≥ 65 years	3,877	5.1%	7,052	9.2%	-4.146	-0.162
Sex						
Female	41,349	54.0%	39,735	51.9%	2.108	0.042
Male	35,234	46.0%	36,848	48.1%	-2.108	-0.042
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	76,583	100.0%	76,583	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	76,583	100.0%	76,583	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	76,583	100.0%	76,583	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.060	-0.042
Allergic Reaction	8,349	10.9%	9,221	12.0%	-1.139	-0.036
Diabetes	14,529	19.0%	6,010	7.8%	11.124	0.331
Heart Failure	1,164	1.5%	2,113	2.8%	-1.239	-0.086
Ischemic Heart Disease	2,640	3.4%	8,117	10.6%	-7.152	-0.283
NSAID Use	18,421	24.1%	16,196	21.1%	2.905	0.070



Table 1r. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covaria	te Balance		
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	7,772	10.1%	7,787	10.2%	-0.020	-0.001
Acute Myocardial Infarction ⁵	575	0.8%	2,984	3.9%	-3.146	-0.210
Alzheimers Disease and Related Disorders ⁵	427	0.6%	456	0.6%	-0.038	-0.005
Anemia ⁵	6,377	8.3%	5,759	7.5%	0.807	0.030
Asthma⁵	5,342	7.0%	3,984	5.2%	1.773	0.074
Atrial Fibrillation ⁵	858	1.1%	4,636	6.1%	-4.933	-0.268
Benign Prostatic Hyperplasia ⁵	1,767	2.3%	2,778	3.6%	-1.320	-0.078
Cataract ⁵	4,362	5.7%	5,068	6.6%	-0.922	-0.038
Chronic Kidney Disease ⁵	9,283	12.1%	4,901	6.4%	5.722	0.198
Bronchiectasis ⁵	3,887	5.1%	3,484	4.5%	0.526	0.025
Depression ⁵	10,706	14.0%	10,982	14.3%	-0.360	-0.010
Glaucoma ⁵	2,914	3.8%	3,163	4.1%	-0.325	-0.017
Hip or Pelvic Fracture ⁵	148	0.2%	137	0.2%	0.014	0.003
Hyperlipidemia ⁵	23,357	30.5%	23,130	30.2%	0.296	0.006
Hypertension ⁵	31,998	41.8%	25,989	33.9%	7.846	0.162
Osteoporosis⁵	1,077	1.4%	1,439	1.9%	-0.473	-0.037
Rheumatoid Arthritis or Osteoarthritis ⁵	11,499	15.0%	11,127	14.5%	0.486	0.014
Stroke or Transient Ischemic Attack ⁵	1,778	2.3%	1,632	2.1%	0.191	0.013
Breast Cancer ⁵	1,155	1.5%	1,042	1.4%	0.148	0.012
Colorectal Cancer ⁵	384	0.5%	273	0.4%	0.145	0.022
Prostate Cancer ⁵	477	0.6%	646	0.8%	-0.221	-0.026
Lung Cancer ⁵	140	0.2%	178	0.2%	-0.050	-0.011
Endometrial Cancer ⁵	174	0.2%	96	0.1%	0.102	0.024
Urologic Cancer ⁵	171	0.2%	157	0.2%	0.018	0.004
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.5	13.1	10.7	11.9	-0.184	-0.015
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.014	-0.014
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.022	-0.051
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.004
Mean number of other ambulatory encounters	2.1	5.1	2.2	5.8	-0.122	-0.022
Mean number of filled prescriptions	13.7	17.0	13.7	17.0	-0.007	-0.000



Table 1r. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.2	4.8	5.2	4.8	0.016	0.003
Mean number of unique drug classes dispensed	4.8	4.3	4.8	4.2	0.020	0.005

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1s. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	191,799	100.0%	180,617	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.7	11.6	45.8	15.4	4.891	0.359
Age						
18-44 years	57,039	29.7%	86,598	47.9%	-18.207	-0.380
45-64 years	123,162	64.2%	80,316	44.5%	19.747	0.404
≥ 65 years	11,598	6.0%	13,703	7.6%	-1.540	-0.061
Sex						
Female	83,324	43.4%	111,331	61.6%	-18.196	-0.371
Male	108,475	56.6%	69,286	38.4%	18.196	0.371
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	191,799	100.0%	180,617	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	191,799	100.0%	180,617	100.0%	0.000	NaN
Year						
2018	68,205	35.6%	65,471	36.2%	-0.688	-0.014
2019	123,594	64.4%	115,146	63.8%	0.688	0.014
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.753	-0.461
Allergic Reaction	18,335	9.6%	24,543	13.6%	-4.029	-0.126
Diabetes	33,304	17.4%	14,681	8.1%	9.236	0.280
Heart Failure	2,047	1.1%	7,592	4.2%	-3.136	-0.197
Ischemic Heart Disease	5,874	3.1%	18,720	10.4%	-7.302	-0.295
NSAID Use	42,149	22.0%	43,281	24.0%	-1.987	-0.047



Table 1s. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	16,787	8.8%	19,638	10.9%	-2.120	-0.071	
Acute Myocardial Infarction ⁵	1,079	0.6%	7,341	4.1%	-3.502	-0.235	
Alzheimers Disease and Related Disorders ⁵	764	0.4%	1,605	0.9%	-0.490	-0.061	
Anemia ⁵	11,638	6.1%	20,947	11.6%	-5.530	-0.196	
Asthma ⁵	10,250	5.3%	13,559	7.5%	-2.163	-0.088	
Atrial Fibrillation ⁵	1,783	0.9%	11,155	6.2%	-5.246	-0.286	
Benign Prostatic Hyperplasia ⁵	5,630	2.9%	5,290	2.9%	0.007	0.000	
Cataract ⁵	11,629	6.1%	10,374	5.7%	0.319	0.014	
Chronic Kidney Disease ⁵	18,976	9.9%	14,636	8.1%	1.790	0.063	
Bronchiectasis ⁵	7,981	4.2%	10,494	5.8%	-1.649	-0.076	
Depression ⁵	19,602	10.2%	37,050	20.5%	-10.293	-0.288	
Glaucoma ⁵	7,396	3.9%	6,607	3.7%	0.198	0.010	
Hip or Pelvic Fracture ⁵	275	0.1%	506	0.3%	-0.137	-0.030	
Hyperlipidemia ⁵	59,255	30.9%	48,548	26.9%	4.015	0.089	
Hypertension ⁵	82,876	43.2%	55,448	30.7%	12.511	0.261	
Osteoporosis ⁵	2,423	1.3%	3,307	1.8%	-0.568	-0.046	
Rheumatoid Arthritis or Osteoarthritis ⁵	26,750	13.9%	26,329	14.6%	-0.630	-0.018	
Stroke or Transient Ischemic Attack ⁵	3,622	1.9%	4,796	2.7%	-0.767	-0.051	
Breast Cancer ⁵	2,239	1.2%	2,977	1.6%	-0.481	-0.041	
Colorectal Cancer ⁵	774	0.4%	904	0.5%	-0.097	-0.014	
Prostate Cancer ⁵	1,375	0.7%	1,349	0.7%	-0.030	-0.004	
Lung Cancer ⁵	274	0.1%	893	0.5%	-0.352	-0.062	
Endometrial Cancer ⁵	308	0.2%	321	0.2%	-0.017	-0.004	
Urologic Cancer ⁵	358	0.2%	447	0.2%	-0.061	-0.013	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	8.8	11.3	13.8	16.0	-5.003	-0.362	
Mean number of emergency room encounters	0.3	0.9	0.6	1.4	-0.266	-0.225	
Mean number of inpatient hospital encounters	0.1	0.4	0.3	0.7	-0.196	-0.357	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.026	
Mean number of other ambulatory encounters	1.7	4.4	2.8	6.8	-1.094	-0.191	
Mean number of filled prescriptions	12.1	15.7	16.3	19.4	-4.211	-0.239	



Table 1s. Unadjusted Characteristics of New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	4.6	4.5	6.2	5.5	-1.595	-0.319
Mean number of unique drug classes dispensed	4.2	4.0	5.7	4.8	-1.459	-0.331

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1t. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	120,459	62.8%	120,459	66.7%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.1	49.2	14.3	-0.533	-0.040
Age						
18-44 years	44,190	36.7%	44,733	37.1%	-0.451	-0.009
45-64 years	70,129	58.2%	64,876	53.9%	4.361	0.088
≥ 65 years	6,140	5.1%	10,850	9.0%	-3.910	-0.153
Sex						
Female	65,146	54.1%	62,708	52.1%	2.024	0.041
Male	55,313	45.9%	57,751	47.9%	-2.024	-0.041
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	120,459	100.0%	120,459	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	120,459	100.0%	120,459	100.0%	0.000	NaN
Year						
2018	43,399	36.0%	43,417	36.0%	-0.015	-0.000
2019	77,060	64.0%	77,042	64.0%	0.015	0.000
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.057	-0.039
Allergic Reaction	12,922	10.7%	14,358	11.9%	-1.192	-0.038
Diabetes	22,876	19.0%	9,239	7.7%	11.321	0.338
Heart Failure	1,863	1.5%	3,322	2.8%	-1.211	-0.084
Ischemic Heart Disease	4,155	3.4%	12,754	10.6%	-7.139	-0.282
NSAID Use	29,079	24.1%	26,111	21.7%	2.464	0.059



Table 1t. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta Blockers				
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	12,127	10.1%	12,164	10.1%	-0.031	-0.001	
Acute Myocardial Infarction ⁵	912	0.8%	4,688	3.9%	-3.135	-0.209	
Alzheimers Disease and Related Disorders ⁵	653	0.5%	695	0.6%	-0.035	-0.005	
Anemia ⁵	9,963	8.3%	9,023	7.5%	0.780	0.029	
Asthma ⁵	8,499	7.1%	6,313	5.2%	1.815	0.076	
Atrial Fibrillation ⁵	1,388	1.2%	7,205	6.0%	-4.829	-0.263	
Benign Prostatic Hyperplasia ⁵	2,726	2.3%	4,304	3.6%	-1.310	-0.078	
Cataract ⁵	6,932	5.8%	7,902	6.6%	-0.805	-0.034	
Chronic Kidney Disease ⁵	14,628	12.1%	7,601	6.3%	5.834	0.203	
Bronchiectasis⁵	6,286	5.2%	5,579	4.6%	0.587	0.027	
Depression ⁵	16,573	13.8%	17,097	14.2%	-0.435	-0.013	
Glaucoma ⁵	4,580	3.8%	4,948	4.1%	-0.305	-0.016	
Hip or Pelvic Fracture ⁵	237	0.2%	219	0.2%	0.015	0.003	
Hyperlipidemia⁵	36,499	30.3%	36,264	30.1%	0.195	0.004	
Hypertension ⁵	50,331	41.8%	40,843	33.9%	7.877	0.163	
Osteoporosis ⁵	1,681	1.4%	2,213	1.8%	-0.442	-0.035	
Rheumatoid Arthritis or Osteoarthritis ⁵	18,098	15.0%	17,649	14.7%	0.373	0.010	
Stroke or Transient Ischemic Attack ⁵	2,806	2.3%	2,612	2.2%	0.161	0.011	
Breast Cancer ⁵	1,896	1.6%	1,649	1.4%	0.205	0.017	
Colorectal Cancer ⁵	626	0.5%	432	0.4%	0.161	0.024	
Prostate Cancer ⁵	804	0.7%	1,014	0.8%	-0.174	-0.020	
Lung Cancer ⁵	243	0.2%	296	0.2%	-0.044	-0.009	
Endometrial Cancer ⁵	270	0.2%	152	0.1%	0.098	0.023	
Urologic Cancer ⁵	285	0.2%	230	0.2%	0.046	0.010	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	10.5	13.0	10.6	11.8	-0.131	-0.011	
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.018	-0.017	
Mean number of inpatient hospital encounters	0.1	0.5	0.1	0.4	-0.024	-0.053	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.005	
Mean number of other ambulatory encounters	2.0	4.8	2.1	5.2	-0.093	-0.018	
Mean number of filled prescriptions	13.9	17.2	14.0	17.2	-0.078	-0.005	



Table 1t. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	5.3	4.8	5.3	4.8	-0.003	-0.001
Mean number of unique drug classes dispensed	4.9	4.3	4.9	4.3	0.003	0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1u. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	43,399	100.0%	43,417	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.3	14.2	-0.640	-0.049
Age						
18-44 years	15,957	36.8%	15,855	36.5%	0.250	0.005
45-64 years	25,264	58.2%	23,766	54.7%	3.474	0.070
≥ 65 years	2,178	5.0%	3,796	8.7%	-3.725	-0.148
Sex						
Female	23,547	54.3%	22,647	52.2%	2.095	0.042
Male	19,852	45.7%	20,770	47.8%	-2.095	-0.042
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	43,399	100.0%	43,417	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	43,399	100.0%	43,417	100.0%	0.000	NaN
Year						
2018	43,399	100.0%	43,417	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.051	-0.035
Allergic Reaction	4,520	10.4%	5,062	11.7%	-1.244	-0.040
Diabetes	8,342	19.2%	3,216	7.4%	11.814	0.353
Heart Failure	683	1.6%	1,154	2.7%	-1.084	-0.075
Ischemic Heart Disease	1,489	3.4%	4,544	10.5%	-7.035	-0.279
NSAID Use	10,547	24.3%	9,821	22.6%	1.682	0.040



Table 1u. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,331	10.0%	4,326	10.0%	0.016	0.001
Acute Myocardial Infarction ⁵	336	0.8%	1,675	3.9%	-3.084	-0.206
Alzheimers Disease and Related Disorders ⁵	231	0.5%	259	0.6%	-0.064	-0.009
Anemia ⁵	3,541	8.2%	3,309	7.6%	0.538	0.020
Asthma ⁵	3,109	7.2%	2,319	5.3%	1.823	0.075
Atrial Fibrillation ⁵	500	1.2%	2,554	5.9%	-4.730	-0.259
Benign Prostatic Hyperplasia ⁵	1,001	2.3%	1,537	3.5%	-1.234	-0.073
Cataract ⁵	2,500	5.8%	2,815	6.5%	-0.723	-0.030
Chronic Kidney Disease ⁵	5,262	12.1%	2,667	6.1%	5.982	0.209
Bronchiectasis⁵	2,386	5.5%	2,107	4.9%	0.645	0.029
Depression ⁵	5,831	13.4%	5,956	13.7%	-0.282	-0.008
Glaucoma⁵	1,575	3.6%	1,749	4.0%	-0.399	-0.021
Hip or Pelvic Fracture ⁵	91	0.2%	88	0.2%	0.007	0.002
Hyperlipidemia⁵	13,004	30.0%	12,920	29.8%	0.206	0.004
Hypertension ⁵	18,052	41.6%	14,623	33.7%	7.915	0.164
Osteoporosis ⁵	632	1.5%	780	1.8%	-0.340	-0.027
Rheumatoid Arthritis or Osteoarthritis ⁵	6,591	15.2%	6,431	14.8%	0.375	0.010
Stroke or Transient Ischemic Attack ⁵	1,028	2.4%	947	2.2%	0.188	0.013
Breast Cancer ⁵	741	1.7%	571	1.3%	0.392	0.032
Colorectal Cancer ⁵	220	0.5%	159	0.4%	0.141	0.021
Prostate Cancer ⁵	269	0.6%	366	0.8%	-0.223	-0.026
Lung Cancer ⁵	106	0.2%	118	0.3%	-0.028	-0.005
Endometrial Cancer ⁵	92	0.2%	49	0.1%	0.099	0.025
Urologic Cancer ⁵	118	0.3%	77	0.2%	0.095	0.020
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.6	12.9	10.7	11.9	-0.091	-0.007
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.023	-0.022
Mean number of inpatient hospital encounters	0.1	0.5	0.2	0.5	-0.025	-0.053
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.013
Mean number of other ambulatory encounters	1.9	4.6	2.0	4.7	-0.056	-0.012
Mean number of filled prescriptions	14.3	17.5	14.5	17.7	-0.141	-0.008



Table 1u. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
	Number	Percent/ Standard	Number /	Percent/ Standard	Abaaluta	Standardized
Patient Characteristics ¹	Number/ Mean	Deviation ²	Number/ Mean		Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.4	4.9	5.4	4.9	-0.025	-0.005
Mean number of unique drug classes dispensed	5.0	4.3	5.0	4.3	-0.013	-0.003

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1v. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	43,119	99.4%	43,119	99.3%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.3	14.2	-0.601	-0.046
Age						
18-44 years	15,839	36.7%	15,790	36.6%	0.114	0.002
45-64 years	25,131	58.3%	23,601	54.7%	3.548	0.072
≥ 65 years	2,149	5.0%	3,728	8.6%	-3.662	-0.146
Sex						
Female	23,381	54.2%	22,539	52.3%	1.953	0.039
Male	19,738	45.8%	20,580	47.7%	-1.953	-0.039
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	43,119	100.0%	43,119	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	43,119	100.0%	43,119	100.0%	0.000	NaN
Year						
2018	43,119	100.0%	43,119	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.056	-0.039
Allergic Reaction	4,482	10.4%	5,033	11.7%	-1.278	-0.041
Diabetes	8,274	19.2%	3,185	7.4%	11.802	0.353
Heart Failure	672	1.6%	1,148	2.7%	-1.104	-0.077
Ischemic Heart Disease	1,482	3.4%	4,515	10.5%	-7.034	-0.279
NSAID Use	10,463	24.3%	9,747	22.6%	1.661	0.039



Table 1v. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	4,304	10.0%	4,297	10.0%	0.016	0.001
Acute Myocardial Infarction ⁵	333	0.8%	1,671	3.9%	-3.103	-0.207
Alzheimers Disease and Related Disorders ⁵	226	0.5%	256	0.6%	-0.070	-0.009
Anemia ⁵	3,501	8.1%	3,295	7.6%	0.478	0.018
Asthma ⁵	3,081	7.1%	2,296	5.3%	1.821	0.075
Atrial Fibrillation ⁵	488	1.1%	2,541	5.9%	-4.761	-0.261
Benign Prostatic Hyperplasia ⁵	992	2.3%	1,509	3.5%	-1.199	-0.071
Cataract ⁵	2,475	5.7%	2,783	6.5%	-0.714	-0.030
Chronic Kidney Disease ⁵	5,211	12.1%	2,651	6.1%	5.937	0.207
Bronchiectasis ⁵	2,357	5.5%	2,092	4.9%	0.615	0.028
Depression ⁵	5,780	13.4%	5,918	13.7%	-0.320	-0.009
Glaucoma ⁵	1,558	3.6%	1,733	4.0%	-0.406	-0.021
Hip or Pelvic Fracture⁵	91	0.2%	87	0.2%	0.009	0.002
Hyperlipidemia ⁵	12,905	29.9%	12,808	29.7%	0.225	0.005
Hypertension ⁵	17,930	41.6%	14,499	33.6%	7.957	0.165
Osteoporosis ⁵	624	1.4%	777	1.8%	-0.355	-0.028
Rheumatoid Arthritis or Osteoarthritis ⁵	6,540	15.2%	6,390	14.8%	0.348	0.010
Stroke or Transient Ischemic Attack ⁵	1,015	2.4%	938	2.2%	0.179	0.012
Breast Cancer ⁵	736	1.7%	566	1.3%	0.394	0.032
Colorectal Cancer ⁵	217	0.5%	158	0.4%	0.137	0.021
Prostate Cancer ⁵	268	0.6%	361	0.8%	-0.216	-0.025
Lung Cancer ⁵	105	0.2%	117	0.3%	-0.028	-0.005
Endometrial Cancer ⁵	90	0.2%	49	0.1%	0.095	0.024
Urologic Cancer ⁵	118	0.3%	76	0.2%	0.097	0.021
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.5	12.9	10.7	11.8	-0.131	-0.011
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.024	-0.023
Mean number of inpatient hospital encounters	0.1	0.5	0.2	0.5	-0.026	-0.056
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.013
Mean number of other ambulatory encounters	1.9	4.6	2.0	4.7	-0.060	-0.013
Mean number of filled prescriptions	14.3	17.4	14.5	17.7	-0.174	-0.010



Table 1v. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Petient Channels in 1	Number/		Number/	Percent/ Standard Deviation ²	Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ⁻	Difference	Difference
Mean number of generics dispensed	5.4	4.9	5.4	4.9	-0.035	-0.007
Mean number of unique drug classes dispensed	5.0	4.3	5.0	4.3	-0.022	-0.005

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1w. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	77,060	100.0%	77,042	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.1	49.2	14.4	-0.473	-0.036
Age						
18-44 years	28,233	36.6%	28,878	37.5%	-0.846	-0.018
45-64 years	44,865	58.2%	41,110	53.4%	4.860	0.098
≥ 65 years	3,962	5.1%	7,054	9.2%	-4.015	-0.156
Sex						
Female	41,599	54.0%	40,061	52.0%	1.984	0.040
Male	35,461	46.0%	36,981	48.0%	-1.984	-0.040
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	77,060	100.0%	77,042	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	77,060	100.0%	77,042	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	77,060	100.0%	77,042	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.060	-0.042
Allergic Reaction	8,402	10.9%	9,296	12.1%	-1.163	-0.036
Diabetes	14,534	18.9%	6,023	7.8%	11.043	0.329
Heart Failure	1,180	1.5%	2,168	2.8%	-1.283	-0.088
Ischemic Heart Disease	2,666	3.5%	8,210	10.7%	-7.197	-0.284
NSAID Use	18,532	24.0%	16,290	21.1%	2.904	0.069



Table 1w. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	7,796	10.1%	7,838	10.2%	-0.057	-0.002	
Acute Myocardial Infarction ⁵	576	0.7%	3,013	3.9%	-3.163	-0.211	
Alzheimers Disease and Related Disorders ⁵	422	0.5%	436	0.6%	-0.018	-0.002	
Anemia ⁵	6,422	8.3%	5,714	7.4%	0.917	0.034	
Asthma⁵	5,390	7.0%	3,994	5.2%	1.810	0.076	
Atrial Fibrillation ⁵	888	1.2%	4,651	6.0%	-4.885	-0.265	
Benign Prostatic Hyperplasia ⁵	1,725	2.2%	2,767	3.6%	-1.353	-0.080	
Cataract ⁵	4,432	5.8%	5,087	6.6%	-0.852	-0.035	
Chronic Kidney Disease ⁵	9,366	12.2%	4,934	6.4%	5.750	0.199	
Bronchiectasis ⁵	3,900	5.1%	3,472	4.5%	0.554	0.026	
Depression ⁵	10,742	13.9%	11,141	14.5%	-0.521	-0.015	
Glaucoma ⁵	3,005	3.9%	3,199	4.2%	-0.253	-0.013	
Hip or Pelvic Fracture ⁵	146	0.2%	131	0.2%	0.019	0.005	
Hyperlipidemia ⁵	23,495	30.5%	23,344	30.3%	0.189	0.004	
Hypertension ⁵	32,279	41.9%	26,220	34.0%	7.855	0.162	
Osteoporosis ⁵	1,049	1.4%	1,433	1.9%	-0.499	-0.040	
Rheumatoid Arthritis or Osteoarthritis ⁵	11,507	14.9%	11,218	14.6%	0.372	0.010	
Stroke or Transient Ischemic Attack ⁵	1,778	2.3%	1,665	2.2%	0.146	0.010	
Breast Cancer ⁵	1,155	1.5%	1,078	1.4%	0.100	0.008	
Colorectal Cancer ⁵	406	0.5%	273	0.4%	0.173	0.026	
Prostate Cancer ⁵	535	0.7%	648	0.8%	-0.147	-0.017	
Lung Cancer ⁵	137	0.2%	178	0.2%	-0.053	-0.012	
Endometrial Cancer ⁵	178	0.2%	103	0.1%	0.097	0.023	
Urologic Cancer ⁵	167	0.2%	153	0.2%	0.018	0.004	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	10.5	13.1	10.6	11.8	-0.153	-0.012	
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.015	-0.014	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.024	-0.053	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.001	
Mean number of other ambulatory encounters	2.0	5.0	2.2	5.5	-0.114	-0.022	
Mean number of filled prescriptions	13.7	17.0	13.7	17.0	-0.042	-0.002	



Table 1w. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
Patient Characteristics ¹	Number/ Mean	Standard Deviation ²	Number/ Mean	Standard Deviation ²	Absolute	Standardized Difference
Mean number of generics dispensed	5.2	4.8	5.2	4.8	0.009	0.002
Mean number of unique drug classes dispensed	4.8	4.3	4.8	4.2	0.005	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1x. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	76,734	99.6%	76,734	99.6%	N/A	N/A
Demographic Characteristics						
Age (years)	48.7	12.0	49.2	14.4	-0.505	-0.038
Age						
18-44 years	28,169	36.7%	28,727	37.4%	-0.727	-0.015
45-64 years	44,634	58.2%	40,976	53.4%	4.767	0.096
≥ 65 years	3,931	5.1%	7,031	9.2%	-4.040	-0.157
Sex						
Female	41,490	54.1%	39,863	51.9%	2.120	0.042
Male	35,244	45.9%	36,871	48.1%	-2.120	-0.042
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	76,734	100.0%	76,734	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	76,734	100.0%	76,734	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	76,734	100.0%	76,734	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.5	1.5	0.6	1.4	-0.058	-0.040
Allergic Reaction	8,375	10.9%	9,256	12.1%	-1.148	-0.036
Diabetes	14,470	18.9%	5,991	7.8%	11.050	0.329
Heart Failure	1,174	1.5%	2,158	2.8%	-1.282	-0.088
Ischemic Heart Disease	2,653	3.5%	8,190	10.7%	-7.216	-0.284
NSAID Use	18,471	24.1%	16,227	21.1%	2.924	0.070



Table 1x. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	7,778	10.1%	7,804	10.2%	-0.034	-0.001
Acute Myocardial Infarction ⁵	571	0.7%	3,008	3.9%	-3.176	-0.212
Alzheimers Disease and Related Disorders ⁵	421	0.5%	434	0.6%	-0.017	-0.002
Anemia ⁵	6,400	8.3%	5,680	7.4%	0.938	0.035
Asthma⁵	5,366	7.0%	3,974	5.2%	1.814	0.076
Atrial Fibrillation ⁵	886	1.2%	4,636	6.0%	-4.887	-0.265
Benign Prostatic Hyperplasia ⁵	1,713	2.2%	2,758	3.6%	-1.362	-0.081
Cataract ⁵	4,410	5.7%	5,066	6.6%	-0.855	-0.036
Chronic Kidney Disease ⁵	9,333	12.2%	4,914	6.4%	5.759	0.199
Bronchiectasis ⁵	3,891	5.1%	3,453	4.5%	0.571	0.027
Depression ⁵	10,709	14.0%	11,083	14.4%	-0.487	-0.014
Glaucoma ⁵	2,994	3.9%	3,182	4.1%	-0.245	-0.012
Hip or Pelvic Fracture ⁵	146	0.2%	130	0.2%	0.021	0.005
Hyperlipidemia ⁵	23,392	30.5%	23,257	30.3%	0.176	0.004
Hypertension ⁵	32,135	41.9%	26,132	34.1%	7.823	0.162
Osteoporosis ⁵	1,049	1.4%	1,423	1.9%	-0.487	-0.039
Rheumatoid Arthritis or Osteoarthritis ⁵	11,464	14.9%	11,172	14.6%	0.381	0.011
Stroke or Transient Ischemic Attack ⁵	1,769	2.3%	1,653	2.2%	0.151	0.010
Breast Cancer ⁵	1,153	1.5%	1,073	1.4%	0.104	0.009
Colorectal Cancer ⁵	401	0.5%	273	0.4%	0.167	0.025
Prostate Cancer ⁵	532	0.7%	647	0.8%	-0.150	-0.017
Lung Cancer ⁵	137	0.2%	177	0.2%	-0.052	-0.012
Endometrial Cancer ⁵	178	0.2%	103	0.1%	0.098	0.023
Urologic Cancer ⁵	167	0.2%	153	0.2%	0.018	0.004
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	10.5	13.1	10.6	11.7	-0.137	-0.011
Mean number of emergency room encounters	0.4	1.1	0.4	1.0	-0.014	-0.013
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.4	-0.023	-0.053
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.001
Mean number of other ambulatory encounters	2.0	5.0	2.2	5.5	-0.112	-0.021
Mean number of filled prescriptions	13.7	17.0	13.7	17.0	-0.024	-0.001



Table 1x. Adjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) (Propensity Score Matched, Fixed Ratio 1:1, Caliper: 0.025) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
1	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	5.2	4.8	5.2	4.8	0.016	0.003
Mean number of unique drug classes dispensed	4.8	4.3	4.8	4.2	0.019	0.004

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1y. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	253,311	100.0%	235,734	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.9	12.4	48.9	14.6	0.024	0.002
Age						
18-44 years	91,632	36.2%	89,570	38.0%	-1.822	-0.038
45-64 years	148,021	58.4%	125,519	53.2%	5.188	0.105
≥ 65 years	13,658	5.4%	20,645	8.8%	-3.366	-0.132
Sex						
Female	130,952	51.7%	121,622	51.6%	0.104	0.002
Male	122,359	48.3%	114,112	48.4%	-0.104	-0.002
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	253,311	100.0%	235,734	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	253,311	100.0%	235,734	100.0%	0.000	NaN
Year						
2018	99,570	39.3%	94,345	40.0%	-0.715	-0.015
2019	153,741	60.7%	141,389	60.0%	0.715	0.015
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.032	-0.021
Allergic Reaction	18,587	7.3%	17,324	7.3%	-0.011	-0.000
Diabetes	33,536	13.2%	25,084	10.6%	2.598	0.080
Heart Failure	5,737	2.3%	6,218	2.6%	-0.373	-0.024
Ischemic Heart Disease	15,218	6.0%	14,502	6.2%	-0.144	-0.006
NSAID Use	41,084	16.2%	37,610	16.0%	0.264	0.007



Table 1y. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁶	20,086	7.9%	18,833	8.0%	-0.060	-0.002	
Acute Myocardial Infarction ⁶	3,316	1.3%	5,602	2.4%	-1.067	-0.079	
Alzheimers Disease and Related Disorders ⁶	1,475	0.6%	1,251	0.5%	0.052	0.007	
Anemia ⁶	17,860	7.1%	15,932	6.8%	0.293	0.012	
Asthma ⁶	14,047	5.5%	9,397	4.0%	1.559	0.073	
Atrial Fibrillation ⁶	3,518	1.4%	12,480	5.3%	-3.905	-0.219	
Benign Prostatic Hyperplasia ⁶	4,526	1.8%	5,790	2.5%	-0.669	-0.046	
Cataract ⁶	8,961	3.5%	9,317	4.0%	-0.415	-0.022	
Chronic Kidney Disease ⁶	23,636	9.3%	16,149	6.9%	2.480	0.091	
Bronchiectasis ⁶	10,263	4.1%	7,607	3.2%	0.825	0.044	
Depression ⁶	30,768	12.1%	28,848	12.2%	-0.091	-0.003	
Glaucoma ⁶	6,396	2.5%	6,458	2.7%	-0.214	-0.013	
Hip or Pelvic Fracture ⁶	450	0.2%	380	0.2%	0.016	0.004	
Hyperlipidemia ⁶	60,572	23.9%	55,545	23.6%	0.350	0.008	
Hypertension ⁶	98,374	38.8%	74,750	31.7%	7.126	0.150	
Osteoporosis ⁶	2,492	1.0%	2,722	1.2%	-0.171	-0.017	
Rheumatoid Arthritis or Osteoarthritis ⁶	28,657	11.3%	24,483	10.4%	0.927	0.030	
Stroke or Transient Ischemic Attack ⁶	5,751	2.3%	4,543	1.9%	0.343	0.024	
Breast Cancer ⁶	3,721	1.5%	2,562	1.1%	0.382	0.034	
Colorectal Cancer ⁶	1,418	0.6%	726	0.3%	0.252	0.038	
Prostate Cancer ⁶	1,554	0.6%	1,574	0.7%	-0.054	-0.007	
Lung Cancer ⁶	655	0.3%	628	0.3%	-0.008	-0.002	
Endometrial Cancer ⁶	524	0.2%	247	0.1%	0.102	0.026	
Urologic Cancer ⁶	628	0.2%	412	0.2%	0.073	0.016	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	6.3	8.7	6.3	7.9	-0.041	-0.005	
Mean number of emergency room encounters	0.3	0.9	0.3	0.9	-0.006	-0.007	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.022	-0.049	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.007	
Mean number of other ambulatory encounters	1.4	3.7	1.4	3.7	-0.043	-0.011	
Mean number of filled prescriptions	7.6	9.8	7.4	9.3	0.190	0.020	



Table 1y. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.8	0.075	0.019
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.5	0.067	0.019

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1z. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	99,808	100.0%	93,967	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.4	11.5	45.7	15.0	4.683	0.350
Age						
18-44 years	30,053	30.1%	44,829	47.7%	-17.596	-0.367
45-64 years	64,338	64.5%	42,732	45.5%	18.986	0.389
≥ 65 years	5,417	5.4%	6,406	6.8%	-1.390	-0.058
Sex						
Female	43,160	43.2%	57,663	61.4%	-18.122	-0.369
Male	56,648	56.8%	36,304	38.6%	18.122	0.369
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	99,808	100.0%	93,967	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	99,808	100.0%	93,967	100.0%	0.000	NaN
Year						
2018	99,808	100.0%	93,967	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.2	0.8	1.7	-0.651	-0.440
Allergic Reaction	5,624	5.6%	7,892	8.4%	-2.764	-0.108
Diabetes	16,534	16.6%	7,146	7.6%	8.961	0.278
Heart Failure	958	1.0%	3,646	3.9%	-2.920	-0.191
Ischemic Heart Disease	2,459	2.5%	8,789	9.4%	-6.890	-0.295
NSAID Use	15,542	15.6%	15,600	16.6%	-1.030	-0.028



Table 1z. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	6,590	6.6%	8,005	8.5%	-1.916	-0.073
Acute Myocardial Infarction ⁵	496	0.5%	3,490	3.7%	-3.217	-0.226
Alzheimers Disease and Related Disorders ⁵	313	0.3%	671	0.7%	-0.400	-0.056
Anemia ⁵	4,270	4.3%	8,580	9.1%	-4.853	-0.195
Asthma ⁵	3,607	3.6%	4,961	5.3%	-1.666	-0.081
Atrial Fibrillation ⁵	801	0.8%	5,267	5.6%	-4.803	-0.275
Benign Prostatic Hyperplasia ⁵	1,884	1.9%	1,801	1.9%	-0.029	-0.002
Cataract ⁵	3,505	3.5%	3,021	3.2%	0.297	0.016
Chronic Kidney Disease ⁵	8,500	8.5%	6,758	7.2%	1.324	0.049
Bronchiectasis⁵	2,548	2.6%	3,784	4.0%	-1.474	-0.083
Depression ⁵	7,525	7.5%	14,948	15.9%	-8.368	-0.262
Glaucoma⁵	2,422	2.4%	2,259	2.4%	0.023	0.001
Hip or Pelvic Fracture ⁵	93	0.1%	215	0.2%	-0.136	-0.034
Hyperlipidemia⁵	23,730	23.8%	20,107	21.4%	2.378	0.057
Hypertension ⁵	38,052	38.1%	26,566	28.3%	9.854	0.210
Osteoporosis ⁵	788	0.8%	1,112	1.2%	-0.394	-0.040
Rheumatoid Arthritis or Osteoarthritis ⁵	9,791	9.8%	9,673	10.3%	-0.484	-0.016
Stroke or Transient Ischemic Attack ⁵	1,536	1.5%	2,061	2.2%	-0.654	-0.048
Breast Cancer ⁵	941	0.9%	1,183	1.3%	-0.316	-0.030
Colorectal Cancer ⁵	317	0.3%	387	0.4%	-0.094	-0.016
Prostate Cancer ⁵	546	0.5%	562	0.6%	-0.051	-0.007
Lung Cancer ⁵	126	0.1%	389	0.4%	-0.288	-0.055
Endometrial Cancer ⁵	122	0.1%	119	0.1%	-0.004	-0.001
Urologic Cancer ⁵	159	0.2%	198	0.2%	-0.051	-0.012
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	4.7	6.5	7.6	9.5	-2.908	-0.357
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.182	-0.214
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.167	-0.366
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.021
Mean number of other ambulatory encounters	1.0	2.7	1.6	4.2	-0.678	-0.193
Mean number of filled prescriptions	6.3	8.4	8.6	10.4	-2.263	-0.239



Table 1z. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
	Number/		Number/	Standard	Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.1	3.3	4.2	4.1	-1.048	-0.280
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.8	-1.001	-0.292

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1aa. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	99,806	100.0%	93,965	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.0	12.3	49.0	14.6	-0.024	-0.002
Age						
18-44 years	35,730	35.8%	35,267	37.5%	-1.733	-0.036
45-64 years	58,780	58.9%	50,529	53.8%	5.120	0.103
≥ 65 years	5,296	5.3%	8,169	8.7%	-3.387	-0.133
Sex						
Female	51,672	51.8%	48,617	51.7%	0.033	0.001
Male	48,134	48.2%	45,348	48.3%	-0.033	-0.001
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	99,806	100.0%	93,965	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	99,806	100.0%	93,965	100.0%	0.000	NaN
Year						
2018	99,806	100.0%	93,965	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.019	-0.012
Allergic Reaction	7,087	7.1%	6,695	7.1%	-0.024	-0.001
Diabetes	13,451	13.5%	9,697	10.3%	3.158	0.098
Heart Failure	2,354	2.4%	2,450	2.6%	-0.248	-0.016
Ischemic Heart Disease	5,995	6.0%	5,782	6.2%	-0.147	-0.006
NSAID Use	16,403	16.4%	15,382	16.4%	0.065	0.002



Table 1aa. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	7,926	7.9%	7,382	7.9%	0.085	0.003
Acute Myocardial Infarction ⁶	1,336	1.3%	2,210	2.4%	-1.013	-0.075
Alzheimers Disease and Related Disorders ⁶	607	0.6%	497	0.5%	0.080	0.011
Anemia ⁶	7,078	7.1%	6,392	6.8%	0.289	0.011
Asthma ⁶	5,515	5.5%	3,708	3.9%	1.579	0.074
Atrial Fibrillation ⁶	1,410	1.4%	4,908	5.2%	-3.810	-0.214
Benign Prostatic Hyperplasia ⁶	1,770	1.8%	2,230	2.4%	-0.599	-0.042
Cataract ⁶	3,427	3.4%	3,499	3.7%	-0.290	-0.016
Chronic Kidney Disease ⁶	9,413	9.4%	6,328	6.7%	2.697	0.099
Bronchiectasis ⁶	3,971	4.0%	3,022	3.2%	0.762	0.041
Depression ⁶	11,859	11.9%	11,035	11.7%	0.138	0.004
Glaucoma ⁶	2,402	2.4%	2,510	2.7%	-0.265	-0.017
Hip or Pelvic Fracture ⁶	188	0.2%	166	0.2%	0.011	0.003
Hyperlipidemia ⁶	23,839	23.9%	21,723	23.1%	0.766	0.018
Hypertension ⁶	38,949	39.0%	29,441	31.3%	7.692	0.162
Osteoporosis ⁶	1,002	1.0%	1,063	1.1%	-0.128	-0.012
Rheumatoid Arthritis or Osteoarthritis ⁶	11,360	11.4%	9,712	10.3%	1.047	0.034
Stroke or Transient Ischemic Attack ⁶	2,256	2.3%	1,801	1.9%	0.344	0.024
Breast Cancer ⁶	1,573	1.6%	971	1.0%	0.543	0.048
Colorectal Cancer ⁶	543	0.5%	310	0.3%	0.215	0.033
Prostate Cancer ⁶	583	0.6%	644	0.7%	-0.101	-0.013
Lung Cancer ⁶	291	0.3%	250	0.3%	0.025	0.005
Endometrial Cancer ⁶	197	0.2%	92	0.1%	0.100	0.026
Urologic Cancer ⁶	289	0.3%	166	0.2%	0.113	0.023
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	6.2	8.8	6.2	8.1	0.020	0.002
Mean number of emergency room encounters	0.3	0.9	0.3	0.8	-0.003	-0.004
Mean number of inpatient hospital encounters	0.1	0.4	0.2	0.5	-0.017	-0.037
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.008
Mean number of other ambulatory encounters	1.3	3.7	1.3	3.5	-0.014	-0.004



Table 1aa. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
5 ··· · · 1 ²	Number/		Number/		Absolute	Standardized
Patient Characteristics ^{1,2}	Mean	Deviation ³	Mean	Deviation ³	Difference	Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.8	0.068	0.018
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.5	0.058	0.016

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ab. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	153,505	100.0%	141,768	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.4	11.6	45.5	15.1	4.857	0.361
Age						
18-44 years	46,899	30.6%	68,925	48.6%	-18.066	-0.376
45-64 years	98,079	63.9%	62,954	44.4%	19.487	0.399
≥ 65 years	8,527	5.6%	9,889	7.0%	-1.421	-0.059
Sex						
Female	65,934	43.0%	86,965	61.3%	-18.391	-0.375
Male	87,571	57.0%	54,803	38.7%	18.391	0.375
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	153,505	100.0%	141,768	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	153,505	100.0%	141,768	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	153,505	100.0%	141,768	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.1	0.8	1.7	-0.662	-0.450
Allergic Reaction	8,992	5.9%	12,476	8.8%	-2.943	-0.113
Diabetes	24,800	16.2%	11,119	7.8%	8.313	0.258
Heart Failure	1,409	0.9%	5,593	3.9%	-3.027	-0.197
Ischemic Heart Disease	3,831	2.5%	13,303	9.4%	-6.888	-0.295
NSAID Use	23,365	15.2%	22,692	16.0%	-0.785	-0.022



Table 1ab. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	10,290	6.7%	12,352	8.7%	-2.009	-0.075
Acute Myocardial Infarction ⁵	729	0.5%	5,379	3.8%	-3.319	-0.231
Alzheimers Disease and Related Disorders ⁵	456	0.3%	989	0.7%	-0.401	-0.057
Anemia ⁵	6,711	4.4%	12,769	9.0%	-4.635	-0.186
Asthma⁵	5,622	3.7%	7,567	5.3%	-1.675	-0.081
Atrial Fibrillation ⁵	1,232	0.8%	7,958	5.6%	-4.811	-0.276
Benign Prostatic Hyperplasia ⁵	2,904	1.9%	2,816	2.0%	-0.095	-0.007
Cataract ⁵	5,628	3.7%	4,872	3.4%	0.230	0.012
Chronic Kidney Disease ⁵	12,929	8.4%	10,198	7.2%	1.229	0.046
Bronchiectasis ⁵	4,137	2.7%	5,740	4.0%	-1.354	-0.075
Depression ⁵	12,038	7.8%	24,142	17.0%	-9.187	-0.281
Glaucoma⁵	3,991	2.6%	3,428	2.4%	0.182	0.012
Hip or Pelvic Fracture ⁵	148	0.1%	263	0.2%	-0.089	-0.024
Hyperlipidemia⁵	36,928	24.1%	30,755	21.7%	2.363	0.056
Hypertension ⁵	58,530	38.1%	40,225	28.4%	9.755	0.208
Osteoporosis ⁵	1,192	0.8%	1,734	1.2%	-0.447	-0.045
Rheumatoid Arthritis or Osteoarthritis ⁵	15,009	9.8%	14,731	10.4%	-0.613	-0.020
Stroke or Transient Ischemic Attack ⁵	2,381	1.6%	3,045	2.1%	-0.597	-0.044
Breast Cancer ⁵	1,369	0.9%	1,927	1.4%	-0.467	-0.044
Colorectal Cancer ⁵	492	0.3%	534	0.4%	-0.056	-0.010
Prostate Cancer ⁵	912	0.6%	830	0.6%	0.009	0.001
Lung Cancer ⁵	158	0.1%	580	0.4%	-0.306	-0.061
Endometrial Cancer ⁵	187	0.1%	191	0.1%	-0.013	-0.004
Urologic Cancer ⁵	204	0.1%	289	0.2%	-0.071	-0.017
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	4.7	6.5	7.7	9.2	-2.963	-0.372
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.179	-0.207
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.165	-0.369
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.025
Mean number of other ambulatory encounters	1.0	2.8	1.7	4.5	-0.730	-0.195
Mean number of filled prescriptions	6.1	8.1	8.3	10.1	-2.244	-0.246



Table 1ab. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

	Medical Product				Covariate Balance	
	ACE In	hibitors	Beta B	Blockers		
		Percent/		Percent/		
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.1	3.3	4.1	4.1	-1.037	-0.279
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.7	-0.988	-0.290

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ac. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	153,503	100.0%	141,762	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.9	12.4	48.8	14.6	0.054	0.004
Age						
18-44 years	55,906	36.4%	54,296	38.3%	-1.880	-0.039
45-64 years	89,243	58.1%	74,996	52.9%	5.235	0.105
≥ 65 years	8,354	5.4%	12,471	8.8%	-3.355	-0.131
Sex						
Female	79,277	51.6%	72,994	51.5%	0.155	0.003
Male	74,226	48.4%	68,768	48.5%	-0.155	-0.003
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	153,503	100.0%	141,762	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	153,503	100.0%	141,762	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	153,503	100.0%	141,762	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.041	-0.027
Allergic Reaction	11,490	7.5%	10,624	7.5%	-0.009	-0.000
Diabetes	20,081	13.1%	15,393	10.9%	2.224	0.069
Heart Failure	3,382	2.2%	3,767	2.7%	-0.454	-0.029
Ischemic Heart Disease	9,224	6.0%	8,718	6.1%	-0.141	-0.006
NSAID Use	24,680	16.1%	22,219	15.7%	0.405	0.011



Table 1ac. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	12,164	7.9%	11,456	8.1%	-0.157	-0.006
Acute Myocardial Infarction ⁶	1,981	1.3%	3,392	2.4%	-1.102	-0.082
Alzheimers Disease and Related Disorders ⁶	868	0.6%	754	0.5%	0.034	0.005
Anemia ⁶	10,775	7.0%	9,534	6.7%	0.294	0.012
Asthma ⁶	8,530	5.6%	5,689	4.0%	1.544	0.072
Atrial Fibrillation ⁶	2,108	1.4%	7,571	5.3%	-3.967	-0.222
Benign Prostatic Hyperplasia ⁶	2,756	1.8%	3,563	2.5%	-0.718	-0.049
Cataract ⁶	5,528	3.6%	5,823	4.1%	-0.506	-0.026
Chronic Kidney Disease ⁶	14,221	9.3%	9,823	6.9%	2.335	0.086
Bronchiectasis ⁶	6,288	4.1%	4,586	3.2%	0.861	0.046
Depression ⁶	18,901	12.3%	17,808	12.6%	-0.248	-0.008
Glaucoma ⁶	3,994	2.6%	3,950	2.8%	-0.185	-0.011
Hip or Pelvic Fracture ⁶	263	0.2%	215	0.2%	0.020	0.005
Hyperlipidemia ⁶	36,734	23.9%	33,829	23.9%	0.067	0.002
Hypertension ⁶	59,420	38.7%	45,329	32.0%	6.734	0.141
Osteoporosis ⁶	1,490	1.0%	1,659	1.2%	-0.200	-0.019
Rheumatoid Arthritis or Osteoarthritis ⁶	17,293	11.3%	14,771	10.4%	0.846	0.027
Stroke or Transient Ischemic Attack ⁶	3,496	2.3%	2,742	1.9%	0.343	0.024
Breast Cancer ⁶	2,146	1.4%	1,593	1.1%	0.275	0.025
Colorectal Cancer ⁶	875	0.6%	417	0.3%	0.276	0.042
Prostate Cancer ⁶	970	0.6%	930	0.7%	-0.024	-0.003
Lung Cancer ⁶	365	0.2%	378	0.3%	-0.029	-0.006
Endometrial Cancer ⁶	327	0.2%	155	0.1%	0.103	0.026
Urologic Cancer ⁶	340	0.2%	246	0.2%	0.048	0.011
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	6.3	8.7	6.3	7.9	-0.083	-0.010
Mean number of emergency room encounters	0.3	0.9	0.3	0.9	-0.008	-0.010
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.025	-0.056
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.006
Mean number of other ambulatory encounters	1.4	3.7	1.4	3.9	-0.063	-0.017
Mean number of filled prescriptions	7.5	9.7	7.3	9.2	0.189	0.020



Table 1ac. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

	Medical Product				Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³		Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.7	0.080	0.021
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.4	0.073	0.021

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ad. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

Variant Characteristics 1,2 MeanDeviation 3MeanDeviation 3DifferenceDifferenceDifferenceUnique patients253,311100.0%235,734100.0%N/AN/ADemographic CharacteristicsAge (years)48.912.448.914.60.0210.002Age18-44 years91,64236.2%89,56838.0%-1.818-0.0345-64 years148,02458.4%125,52553.2%5.1870.109≥ 65 years13,6455.4%20,6408.8%-3.369-0.13exFemale130,95451.7%121,59451.6%0.1160.002			Medical	Covariate Balance			
Number/ MeanStandard DeviationNumber/ MeanStandard DeviationAbsolute DifferenceStandard DifferenceInique patients253,311100.0%235,734100.0%N/AN/ADemographic Characteristics253,311100.0%235,734100.0%N/AN/ADemographic Characteristics48.912.448.914.60.0210.003Nge91,64236.2%89,56838.0%-1.818-0.0345-64 years91,64236.2%89,56838.0%-1.818-0.0345-64 years148,02458.4%125,52553.2%5.1870.109 \geq 65 years13,6455.4%20,6408.8%-3.369-0.13ex130,95451.7%121,59451.6%0.1160.002Male122,35748.3%114,14048.4%-0.116-0.00ace ⁴		ACE In	hibitors	Beta B	lockers		
Demographic Characteristics xge (years) 48.9 12.4 48.9 14.6 0.021 0.002 xge 18-44 years 91,642 36.2% 89,568 38.0% -1.818 -0.03 45-64 years 148,024 58.4% 125,525 53.2% 5.187 0.105 ≥ 65 years 13,645 5.4% 20,640 8.8% -3.369 -0.13 ex 130,954 51.7% 121,594 51.6% 0.116 0.002 Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 American Indian or Alaska Native - - - - - -	Characteristics ^{1,2}	-	Standard		Standard		Standardized Difference
Age (years) 48.9 12.4 48.9 14.6 0.021 0.0021 Nge $18-44$ years $91,642$ 36.2% $89,568$ 38.0% -1.818 -0.03 $45-64$ years $148,024$ 58.4% $125,525$ 53.2% 5.187 0.102 ≥ 65 years $13,645$ 5.4% $20,640$ 8.8% -3.369 -0.13 exFemale $130,954$ 51.7% $121,594$ 51.6% 0.116 0.002 Male $122,357$ 48.3% $114,140$ 48.4% -0.116 -0.00 tace ⁴ American Indian or Alaska Native $ -$	patients	253,311	100.0%	235,734	100.0%	N/A	N/A
Age 18-44 years 91,642 36.2% 89,568 38.0% -1.818 -0.03 45-64 years 148,024 58.4% 125,525 53.2% 5.187 0.109 ≥ 65 years 13,645 5.4% 20,640 8.8% -3.369 -0.13 ex Female 130,954 51.7% 121,594 51.6% 0.116 0.002 Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 Mace ⁴ American Indian or Alaska Native	raphic Characteristics						
18-44 years91,642 36.2% $89,568$ 38.0% -1.818 -0.03 45-64 years148,024 58.4% $125,525$ 53.2% 5.187 0.105 ≥ 65 years13,645 5.4% $20,640$ 8.8% -3.369 -0.13 exremaleFemale130,954 51.7% $121,594$ 51.6% 0.116 0.002 Male122,357 48.3% $114,140$ 48.4% -0.116 -0.00 tace4	ars)	48.9	12.4	48.9	14.6	0.021	0.002
45-64 years148,02458.4%125,52553.2%5.1870.109 \geq 65 years13,6455.4%20,6408.8%-3.369-0.13ex130,95451.7%121,59451.6%0.1160.002Male122,35748.3%114,14048.4%-0.116-0.00tace4							
≥ 65 years 13,645 5.4% 20,640 8.8% -3.369 -0.13 ex Female 130,954 51.7% 121,594 51.6% 0.116 0.002 Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 tace ⁴ American Indian or Alaska Native	years	91,642	36.2%	89,568	38.0%	-1.818	-0.038
Female 130,954 51.7% 121,594 51.6% 0.116 0.002 Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 Bace ⁴ - -<	years	148,024	58.4%	125,525	53.2%	5.187	0.105
Female 130,954 51.7% 121,594 51.6% 0.116 0.002 Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 tace ⁴ American Indian or Alaska Native - <td>ears</td> <td>13,645</td> <td>5.4%</td> <td>20,640</td> <td>8.8%</td> <td>-3.369</td> <td>-0.132</td>	ears	13,645	5.4%	20,640	8.8%	-3.369	-0.132
Male 122,357 48.3% 114,140 48.4% -0.116 -0.00 tace ⁴ - - </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Race ⁴ American Indian or Alaska Native	e	130,954	51.7%	121,594	51.6%	0.116	0.002
American Indian or Alaska Native		122,357	48.3%	114,140	48.4%	-0.116	-0.002
Asian	can Indian or Alaska Native	-	-	-	-	-	-
		-	-	-	-	-	-
Black or African American	or African American	-	-	-	-	-	-
Multi-racial	racial	-	-	-	-	-	-
Unknown 253,311 100.0% 235,734 100.0% 0.000 NaN	ywn	253,311	100.0%	235,734	100.0%	0.000	NaN
White		-	-	-	-	-	-
lispanic origin	c origin						
Yes		-	-	-	-	-	-
No		-	-	-	-	-	-
Unknown 253,311 100.0% 235,734 100.0% 0.000 NaN	own	253,311	100.0%	235,734	100.0%	0.000	NaN
'ear							
2018 100,358 39.6% 93,653 39.7% -0.110 -0.00		100,358	39.6%	93,653	39.7%	-0.110	-0.002
2019 152,953 60.4% 142,081 60.3% 0.110 0.002		152,953	60.4%	142,081	60.3%	0.110	0.002
lealth Characteristics	Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵ 0.5 1.6 0.5 1.5 -0.032 -0.02	n/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.032	-0.021
Illergic Reaction 18,595 7.3% 17,319 7.3% -0.006 -0.00	Reaction	18,595	7.3%	17,319	7.3%	-0.006	-0.000
Diabetes 33,527 13.2% 25,080 10.6% 2.596 0.080	S	33,527	13.2%	25,080	10.6%	2.596	0.080
leart Failure 5,747 2.3% 6,218 2.6% -0.369 -0.02	ailure	5,747	2.3%	6,218	2.6%	-0.369	-0.024
schemic Heart Disease 15,208 6.0% 14,511 6.2% -0.152 -0.00	c Heart Disease	15,208	6.0%	14,511	6.2%	-0.152	-0.006
ISAID Use 41,082 16.2% 37,609 16.0% 0.264 0.007	Jse	41,082	16.2%	37,609	16.0%	0.264	0.007



Table 1ad. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	20,079	7.9%	18,831	8.0%	-0.062	-0.002
Acute Myocardial Infarction ⁶	3,316	1.3%	5,603	2.4%	-1.068	-0.079
Alzheimers Disease and Related Disorders ⁶	1,474	0.6%	1,251	0.5%	0.051	0.007
Anemia ⁶	17,859	7.1%	15,933	6.8%	0.291	0.011
Asthma ⁶	14,043	5.5%	9,398	4.0%	1.557	0.073
Atrial Fibrillation ⁶	3,516	1.4%	12,485	5.3%	-3.908	-0.219
Benign Prostatic Hyperplasia ⁶	4,516	1.8%	5,793	2.5%	-0.675	-0.047
Cataract ⁶	8,954	3.5%	9,316	4.0%	-0.417	-0.022
Chronic Kidney Disease ⁶	23,630	9.3%	16,150	6.9%	2.477	0.091
Bronchiectasis ⁶	10,258	4.0%	7,599	3.2%	0.826	0.044
Depression ⁶	30,732	12.1%	28,843	12.2%	-0.103	-0.003
Glaucoma ⁶	6,392	2.5%	6,452	2.7%	-0.214	-0.013
Hip or Pelvic Fracture ⁶	449	0.2%	380	0.2%	0.016	0.004
Hyperlipidemia ⁶	60,571	23.9%	55,536	23.6%	0.353	0.008
Hypertension ⁶	98,383	38.8%	74,774	31.7%	7.119	0.149
Osteoporosis ⁶	2,493	1.0%	2,718	1.2%	-0.169	-0.016
Rheumatoid Arthritis or Osteoarthritis ⁶	28,644	11.3%	24,486	10.4%	0.921	0.030
Stroke or Transient Ischemic Attack ⁶	5,746	2.3%	4,543	1.9%	0.341	0.024
Breast Cancer ⁶	3,722	1.5%	2,560	1.1%	0.383	0.034
Colorectal Cancer ⁶	1,418	0.6%	725	0.3%	0.252	0.038
Prostate Cancer ⁶	1,558	0.6%	1,576	0.7%	-0.053	-0.007
Lung Cancer ⁶	650	0.3%	627	0.3%	-0.009	-0.002
Endometrial Cancer ⁶	523	0.2%	248	0.1%	0.101	0.026
Urologic Cancer ⁶	630	0.2%	411	0.2%	0.074	0.016
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	6.2	8.7	6.3	7.9	-0.042	-0.005
Mean number of emergency room encounters	0.3	0.9	0.3	0.9	-0.007	-0.008
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.022	-0.049
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.007
Mean number of other ambulatory encounters	1.4	3.7	1.4	3.7	-0.044	-0.012
Mean number of filled prescriptions	7.6	9.8	7.4	9.3	0.186	0.019



Table 1ad. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³		Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.8	0.074	0.019
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.5	0.066	0.019

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CNI. Med Care. 2017;55(1)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



 Table 1ae. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,

 Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December

 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	99,808	100.0%	93,967	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.4	11.5	45.7	15.0	4.683	0.350
Age						
18-44 years	30,053	30.1%	44,829	47.7%	-17.596	-0.367
45-64 years	64,338	64.5%	42,732	45.5%	18.986	0.389
≥ 65 years	5,417	5.4%	6,406	6.8%	-1.390	-0.058
Sex						
Female	43,160	43.2%	57,663	61.4%	-18.122	-0.369
Male	56,648	56.8%	36,304	38.6%	18.122	0.369
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	99,808	100.0%	93,967	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	99,808	100.0%	93,967	100.0%	0.000	NaN
Year						
2018	99,808	100.0%	93,967	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.2	0.8	1.7	-0.651	-0.440
Allergic Reaction	5,624	5.6%	7,892	8.4%	-2.764	-0.108
Diabetes	16,534	16.6%	7,146	7.6%	8.961	0.278
Heart Failure	958	1.0%	3,646	3.9%	-2.920	-0.191
Ischemic Heart Disease	2,459	2.5%	8,789	9.4%	-6.890	-0.295
NSAID Use	15,542	15.6%	15,600	16.6%	-1.030	-0.028



Table 1ae. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	6,590	6.6%	8,005	8.5%	-1.916	-0.073
Acute Myocardial Infarction ⁵	496	0.5%	3,490	3.7%	-3.217	-0.226
Alzheimers Disease and Related Disorders ⁵	313	0.3%	671	0.7%	-0.400	-0.056
Anemia ⁵	4,270	4.3%	8,580	9.1%	-4.853	-0.195
Asthma ⁵	3,607	3.6%	4,961	5.3%	-1.666	-0.081
Atrial Fibrillation ⁵	801	0.8%	5,267	5.6%	-4.803	-0.275
Benign Prostatic Hyperplasia ⁵	1,884	1.9%	1,801	1.9%	-0.029	-0.002
Cataract ⁵	3,505	3.5%	3,021	3.2%	0.297	0.016
Chronic Kidney Disease ⁵	8,500	8.5%	6,758	7.2%	1.324	0.049
Bronchiectasis ⁵	2,548	2.6%	3,784	4.0%	-1.474	-0.083
Depression ⁵	7,525	7.5%	14,948	15.9%	-8.368	-0.262
Glaucoma⁵	2,422	2.4%	2,259	2.4%	0.023	0.001
Hip or Pelvic Fracture ⁵	93	0.1%	215	0.2%	-0.136	-0.034
Hyperlipidemia ⁵	23,730	23.8%	20,107	21.4%	2.378	0.057
Hypertension ⁵	38,052	38.1%	26,566	28.3%	9.854	0.210
Osteoporosis ⁵	788	0.8%	1,112	1.2%	-0.394	-0.040
Rheumatoid Arthritis or Osteoarthritis ⁵	9,791	9.8%	9,673	10.3%	-0.484	-0.016
Stroke or Transient Ischemic Attack ⁵	1,536	1.5%	2,061	2.2%	-0.654	-0.048
Breast Cancer ⁵	941	0.9%	1,183	1.3%	-0.316	-0.030
Colorectal Cancer ⁵	317	0.3%	387	0.4%	-0.094	-0.016
Prostate Cancer ⁵	546	0.5%	562	0.6%	-0.051	-0.007
Lung Cancer ⁵	126	0.1%	389	0.4%	-0.288	-0.055
Endometrial Cancer ⁵	122	0.1%	119	0.1%	-0.004	-0.001
Urologic Cancer⁵	159	0.2%	198	0.2%	-0.051	-0.012
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	4.7	6.5	7.6	9.5	-2.908	-0.357
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.182	-0.214
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.167	-0.366
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.021
Mean number of other ambulatory encounters	1.0	2.7	1.6	4.2	-0.678	-0.193
Mean number of filled prescriptions	6.3	8.4	8.6	10.4	-2.263	-0.239



Table 1ae. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/	,	Percent/		
Patient Characteristics ¹	Number/ Mean	Standard Deviation ²	Number/ Mean	Standard Deviation ²	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.1	3.3	4.2	4.1	-1.048	-0.280
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.8	-1.001	-0.292

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1af. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	99,806	100.0%	93,965	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.0	12.3	49.0	14.6	-0.024	-0.002
Age						
18-44 years	35,731	35.8%	35,268	37.5%	-1.733	-0.036
45-64 years	58,778	58.9%	50,526	53.8%	5.121	0.103
≥ 65 years	5,297	5.3%	8,171	8.7%	-3.388	-0.133
Sex						
Female	51,671	51.8%	48,618	51.7%	0.031	0.001
Male	48,135	48.2%	45,347	48.3%	-0.031	-0.001
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	99,806	100.0%	93,965	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	99,806	100.0%	93,965	100.0%	0.000	NaN
Year						
2018	99,806	100.0%	93,965	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.019	-0.012
Allergic Reaction	7,092	7.1%	6,695	7.1%	-0.019	-0.001
Diabetes	13,451	13.5%	9,699	10.3%	3.154	0.098
Heart Failure	2,352	2.4%	2,450	2.6%	-0.251	-0.016
Ischemic Heart Disease	5,995	6.0%	5,783	6.2%	-0.148	-0.006
NSAID Use	16,402	16.4%	15,384	16.4%	0.062	0.002



Table 1af. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	7,927	7.9%	7,383	7.9%	0.085	0.003
Acute Myocardial Infarction ⁶	1,334	1.3%	2,210	2.4%	-1.015	-0.076
Alzheimers Disease and Related Disorders ⁶	607	0.6%	497	0.5%	0.079	0.011
Anemia ⁶	7,078	7.1%	6,392	6.8%	0.289	0.011
Asthma ⁶	5,514	5.5%	3,708	3.9%	1.579	0.074
Atrial Fibrillation ⁶	1,410	1.4%	4,908	5.2%	-3.810	-0.214
Benign Prostatic Hyperplasia ⁶	1,770	1.8%	2,230	2.4%	-0.600	-0.042
Cataract ⁶	3,427	3.4%	3,499	3.7%	-0.290	-0.016
Chronic Kidney Disease ⁶	9,413	9.4%	6,329	6.7%	2.696	0.099
Bronchiectasis ⁶	3,970	4.0%	3,022	3.2%	0.762	0.041
Depression ⁶	11,858	11.9%	11,036	11.7%	0.136	0.004
Glaucoma ⁶	2,402	2.4%	2,511	2.7%	-0.265	-0.017
Hip or Pelvic Fracture ⁶	188	0.2%	166	0.2%	0.011	0.003
Hyperlipidemia ⁶	23,837	23.9%	21,725	23.1%	0.763	0.018
Hypertension ⁶	38,947	39.0%	29,442	31.3%	7.690	0.162
Osteoporosis ⁶	1,002	1.0%	1,063	1.1%	-0.128	-0.012
Rheumatoid Arthritis or Osteoarthritis ⁶	11,360	11.4%	9,713	10.3%	1.046	0.034
Stroke or Transient Ischemic Attack ⁶	2,255	2.3%	1,801	1.9%	0.342	0.024
Breast Cancer ⁶	1,573	1.6%	971	1.0%	0.542	0.048
Colorectal Cancer ⁶	543	0.5%	310	0.3%	0.215	0.033
Prostate Cancer ⁶	585	0.6%	644	0.7%	-0.100	-0.013
Lung Cancer ⁶	291	0.3%	250	0.3%	0.025	0.005
Endometrial Cancer ⁶	197	0.2%	92	0.1%	0.100	0.026
Urologic Cancer ⁶	289	0.3%	166	0.2%	0.113	0.023
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	6.2	8.8	6.2	8.1	0.020	0.002
Mean number of emergency room encounters	0.3	0.9	0.3	0.8	-0.003	-0.004
Mean number of inpatient hospital encounters	0.1	0.4	0.2	0.5	-0.017	-0.037
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.008
Mean number of other ambulatory encounters	1.3	3.7	1.3	3.5	-0.014	-0.004
Mean number of filled prescriptions	7.8	10.0	7.6	9.5	0.196	0.020



Table 1af. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	•	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.8	0.068	0.018
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.5	0.058	0.016

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ag. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Deviation ²	Absolute Difference	Standardized Difference
Unique patients	153,505	100.0%	141,768	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.4	11.6	45.5	15.1	4.857	0.361
Age						
18-44 years	46,899	30.6%	68,925	48.6%	-18.066	-0.376
45-64 years	98,079	63.9%	62,954	44.4%	19.487	0.399
≥ 65 years	8,527	5.6%	9,889	7.0%	-1.421	-0.059
Sex						
Female	65,934	43.0%	86,965	61.3%	-18.391	-0.375
Male	87,571	57.0%	54,803	38.7%	18.391	0.375
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	153,505	100.0%	141,768	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	153,505	100.0%	141,768	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	153,505	100.0%	141,768	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.2	1.1	0.8	1.7	-0.662	-0.450
Allergic Reaction	8,992	5.9%	12,476	8.8%	-2.943	-0.113
Diabetes	24,800	16.2%	11,119	7.8%	8.313	0.258
Heart Failure	1,409	0.9%	5,593	3.9%	-3.027	-0.197
Ischemic Heart Disease	3,831	2.5%	13,303	9.4%	-6.888	-0.295
NSAID Use	23,365	15.2%	22,692	16.0%	-0.785	-0.022



 Table 1ag. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback,

 Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December

 11, 2019, Year: 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	10,290	6.7%	12,352	8.7%	-2.009	-0.075	
Acute Myocardial Infarction ⁵	729	0.5%	5,379	3.8%	-3.319	-0.231	
Alzheimers Disease and Related Disorders ⁵	456	0.3%	989	0.7%	-0.401	-0.057	
Anemia ⁵	6,711	4.4%	12,769	9.0%	-4.635	-0.186	
Asthma ⁵	5,622	3.7%	7,567	5.3%	-1.675	-0.081	
Atrial Fibrillation ⁵	1,232	0.8%	7,958	5.6%	-4.811	-0.276	
Benign Prostatic Hyperplasia ⁵	2,904	1.9%	2,816	2.0%	-0.095	-0.007	
Cataract ⁵	5,628	3.7%	4,872	3.4%	0.230	0.012	
Chronic Kidney Disease ⁵	12,929	8.4%	10,198	7.2%	1.229	0.046	
Bronchiectasis ⁵	4,137	2.7%	5,740	4.0%	-1.354	-0.075	
Depression ⁵	12,038	7.8%	24,142	17.0%	-9.187	-0.281	
Glaucoma ⁵	3,991	2.6%	3,428	2.4%	0.182	0.012	
Hip or Pelvic Fracture ⁵	148	0.1%	263	0.2%	-0.089	-0.024	
Hyperlipidemia ⁵	36,928	24.1%	30,755	21.7%	2.363	0.056	
Hypertension ⁵	58,530	38.1%	40,225	28.4%	9.755	0.208	
Osteoporosis⁵	1,192	0.8%	1,734	1.2%	-0.447	-0.045	
Rheumatoid Arthritis or Osteoarthritis ⁵	15,009	9.8%	14,731	10.4%	-0.613	-0.020	
Stroke or Transient Ischemic Attack ⁵	2,381	1.6%	3,045	2.1%	-0.597	-0.044	
Breast Cancer ⁵	1,369	0.9%	1,927	1.4%	-0.467	-0.044	
Colorectal Cancer ⁵	492	0.3%	534	0.4%	-0.056	-0.010	
Prostate Cancer ⁵	912	0.6%	830	0.6%	0.009	0.001	
Lung Cancer ⁵	158	0.1%	580	0.4%	-0.306	-0.061	
Endometrial Cancer ⁵	187	0.1%	191	0.1%	-0.013	-0.004	
Urologic Cancer⁵	204	0.1%	289	0.2%	-0.071	-0.017	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	4.7	6.5	7.7	9.2	-2.963	-0.372	
Mean number of emergency room encounters	0.2	0.7	0.4	1.0	-0.179	-0.207	
Mean number of inpatient hospital encounters	0.1	0.3	0.2	0.6	-0.165	-0.369	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.025	
Mean number of other ambulatory encounters	1.0	2.8	1.7	4.5	-0.730	-0.195	
Mean number of filled prescriptions	6.1	8.1	8.3	10.1	-2.244	-0.246	



Table 1ag. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	3.1	3.3	4.1	4.1	-1.037	-0.279
Mean number of unique drug classes dispensed	2.9	3.1	3.9	3.7	-0.988	-0.290

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ah. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	153,504	100.0%	141,762	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	48.9	12.4	48.8	14.6	0.054	0.004
Age						
18-44 years	55,910	36.4%	54,296	38.3%	-1.878	-0.039
45-64 years	89,236	58.1%	74,996	52.9%	5.230	0.105
≥ 65 years	8,358	5.4%	12,470	8.8%	-3.352	-0.131
Sex						
Female	79,277	51.6%	72,997	51.5%	0.153	0.003
Male	74,227	48.4%	68,765	48.5%	-0.153	-0.003
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	153,504	100.0%	141,762	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	153,504	100.0%	141,762	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	153,504	100.0%	141,762	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.5	1.6	0.5	1.5	-0.040	-0.026
Allergic Reaction	11,495	7.5%	10,620	7.5%	-0.003	-0.000
Diabetes	20,083	13.1%	15,391	10.9%	2.226	0.069
Heart Failure	3,386	2.2%	3,767	2.7%	-0.452	-0.029
Ischemic Heart Disease	9,225	6.0%	8,718	6.1%	-0.140	-0.006
NSAID Use	24,678	16.1%	22,220	15.7%	0.402	0.011



Table 1ah. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁶	12,162	7.9%	11,457	8.1%	-0.159	-0.006	
Acute Myocardial Infarction ⁶	1,981	1.3%	3,392	2.4%	-1.102	-0.082	
Alzheimers Disease and Related Disorders ⁶	868	0.6%	754	0.5%	0.034	0.005	
Anemia ⁶	10,785	7.0%	9,534	6.7%	0.300	0.012	
Asthma ⁶	8,531	5.6%	5,689	4.0%	1.544	0.072	
Atrial Fibrillation ⁶	2,109	1.4%	7,571	5.3%	-3.967	-0.222	
Benign Prostatic Hyperplasia ⁶	2,756	1.8%	3,563	2.5%	-0.718	-0.049	
Cataract ⁶	5,531	3.6%	5,823	4.1%	-0.504	-0.026	
Chronic Kidney Disease ⁶	14,224	9.3%	9,822	6.9%	2.337	0.086	
Bronchiectasis ⁶	6,292	4.1%	4,586	3.2%	0.864	0.046	
Depression ⁶	18,904	12.3%	17,807	12.6%	-0.246	-0.007	
Glaucoma ⁶	3,994	2.6%	3,951	2.8%	-0.185	-0.011	
Hip or Pelvic Fracture ⁶	263	0.2%	215	0.2%	0.020	0.005	
Hyperlipidemia ⁶	36,734	23.9%	33,827	23.9%	0.068	0.002	
Hypertension ⁶	59,425	38.7%	45,329	32.0%	6.737	0.141	
Osteoporosis ⁶	1,490	1.0%	1,659	1.2%	-0.199	-0.019	
Rheumatoid Arthritis or Osteoarthritis ⁶	17,295	11.3%	14,770	10.4%	0.848	0.027	
Stroke or Transient Ischemic Attack ⁶	3,494	2.3%	2,741	1.9%	0.342	0.024	
Breast Cancer ⁶	2,150	1.4%	1,592	1.1%	0.277	0.025	
Colorectal Cancer ⁶	875	0.6%	417	0.3%	0.276	0.042	
Prostate Cancer ⁶	971	0.6%	930	0.7%	-0.023	-0.003	
Lung Cancer ⁶	365	0.2%	378	0.3%	-0.029	-0.006	
Endometrial Cancer ⁶	327	0.2%	155	0.1%	0.103	0.026	
Urologic Cancer ⁶	340	0.2%	246	0.2%	0.048	0.011	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	6.3	8.7	6.3	7.9	-0.081	-0.010	
Mean number of emergency room encounters	0.3	0.9	0.3	0.9	-0.008	-0.010	
Mean number of inpatient hospital encounters	0.1	0.4	0.1	0.5	-0.025	-0.056	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.006	
Mean number of other ambulatory encounters	1.4	3.7	1.4	3.9	-0.062	-0.016	
Mean number of filled prescriptions	7.5	9.7	7.3	9.2	0.188	0.020	



Table 1ah. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³		Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	3.8	3.9	3.7	3.7	0.080	0.021
Mean number of unique drug classes dispensed	3.6	3.6	3.5	3.4	0.073	0.021

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ai. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

Patient Characteristics ¹⁴ MeanDeviation ³ DifferenceDifferenceUnique patients191,796100.0%180.617100.0%N/AN/ADemographic Characteristics49.11.2.349.015.00.1340.010Age (years)49.11.2.349.015.00.1340.01518-44 years68.07335.5%68.89838.1%-2.6530.05545-64 years113.02858.9%94.35752.2%6.6900.135≥ 65 years10.0595.6%17,3629.6%4.037-0.153Sex52.2%93.8052.0%0.2810.006Male100,20852.2%93.8052.0%0.2810.006Race ⁴ American Indian or Alaska NativeAsianMulti-racial100.0%180.617100.0%0.000NaNWhiteUnknown191,796100.0%180.617100.0%0.000NaNWhiteUnknown191,796100.0%180.617100.0%0.000NaNWhiteUnknown191,796100.0%180.617100.0%0.000NaN <th></th> <th></th> <th colspan="4">Medical Product</th> <th colspan="3">Covariate Balance</th>			Medical Product				Covariate Balance		
Number/ Patient Characteristics ¹² Number/ ManStandard DeviationAbsolue Difference DifferenceUnique patients191,7960.00.0%10.0010.00N/AN/ADemographic Characteristics49.012.349.05.00.1340.010Age (vears)49.112.349.05.2.2%6.6900.13518-44 years68.07335.5%68.89838.1%-2.6530.05545-64 years113.02858.9%94.35752.2%6.6900.135≥ 65 years10.0595.6%94.3572.65%0.2810.006Male100.20852.2%93.86052.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2810.006Male91,58847.8%86.75748.0%0.2011.00Male91,58847.8%86.75748.0%0.2011.00Male91,58847.8%86.75748.0%1.00.00 </th <th></th> <th>ACE In</th> <th>hibitors</th> <th>Beta E</th> <th>Blockers</th> <th></th> <th></th>		ACE In	hibitors	Beta E	Blockers				
Demographic Characteristics Age (years) 49.1 12.3 49.0 15.0 0.134 0.010 Age 18-44 years 68,073 35.5% 68,898 38.1% -2.653 -0.055 45-64 years 113,028 58.9% 94,357 52.2% 6.690 0.135 ≥ 65 years 10,695 5.6% 17,362 9.6% -4.037 -0.153 Sex - - 17,362 9.6% -0.051 -0.056 Female 100,208 52.2% 93,860 52.0% 0.281 0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - - - - - - - Alsian - - - - - - - Multi-acial - - - - - - - Muknown 191,796 100.0% 180,617 100.0%	Patient Characteristics ^{1,2}	-	Standard	-	Standard		Standardized Difference		
Age (vears) 49.1 12.3 49.0 15.0 0.134 0.010 Age 18-44 years 68,073 35.5% 68,898 38.1% -2.653 -0.055 45-64 years 113,028 58.9% 94,357 52.2% 6.690 0.135 ≥ 65 years 10,695 5.6% 17,362 9.6% -4.037 -0.153 Sex 100,208 52.2% 93,860 52.0% 0.281 0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - -	Unique patients	191,796	100.0%	180,617	100.0%	N/A	N/A		
Age 18-44 years 68,073 35.5% 68,898 38.1% -2.653 -0.055 45-64 years 113,028 58.9% 94,357 52.2% 6.690 0.135 ≥ 65 years 10,695 5.6% 17,362 9.6% -4.037 -0.153 Sex 100,208 52.2% 93,860 52.0% 0.281 0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - - - - - - -0.006 Asian -	Demographic Characteristics								
18-44 years68,07335.5%68,89838.1%-2.653-0.05545-64 years113,02858.9%94,35752.2%6.6900.13≥ 65 years10,6955.6%17,3629.6%4.037-0.153Sex91,58847.8%86,75748.0%-0.281-0.006Male91,58847.8%86,75748.0%-0.281-0.006Race ⁴ American Indian or Alaska NativeAsianBlack or African AmericanMulti-racialUnknown191,796100.0%180,617100.0%0.000NaNWhiteNoNoNoNoNoNoNoNoNo<	Age (years)	49.1	12.3	49.0	15.0	0.134	0.010		
45-64 years 113,028 58.9% 94,357 52.2% 6.690 0.135 ≥ 65 years 10,695 5.6% 17,362 9.6% 4.037 -0.153 Sex	Age								
È 65 years 10,695 5.6% 17,362 9.6% 4.037 -0.153 Sex Female 100,208 52.2% 93,860 52.0% 0.281 0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - - <td< td=""><td>18-44 years</td><td>68,073</td><td>35.5%</td><td>68,898</td><td>38.1%</td><td>-2.653</td><td>-0.055</td></td<>	18-44 years	68,073	35.5%	68,898	38.1%	-2.653	-0.055		
Sex Sex Sex 93,860 52.0% 0.281 0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - - - - - - - Asian - - - - - - - - Black or African American - <td>45-64 years</td> <td>113,028</td> <td>58.9%</td> <td>94,357</td> <td>52.2%</td> <td>6.690</td> <td>0.135</td>	45-64 years	113,028	58.9%	94,357	52.2%	6.690	0.135		
Female100,20852.2%93,86052.0%0.2810.006Male91,58847.8%86,75748.0%-0.281-0.006Race ⁴ American Indian or Alaska NativeAsianBlack or African AmericanMulti-racialUnknown191,796100.0%180,617100.0%0.000NaNWhiteNoNoUnknown191,796100.0%180,617100.0%0.000NaNYesNoUnknown191,796100.0%180,617100.0%0.000NaNYea201868,46835.7%65,43336.2%-0.529-0.0112019123,2864.3%15.18%63.8%0.5290.012Heart Selfuction21,50611.2%22,23112.3%-0.045-0.026Allergic Reaction37,58619.6%14,3618.0%11.640.343 <t< td=""><td>≥ 65 years</td><td>10,695</td><td>5.6%</td><td>17,362</td><td>9.6%</td><td>-4.037</td><td>-0.153</td></t<>	≥ 65 years	10,695	5.6%	17,362	9.6%	-4.037	-0.153		
Male 91,588 47.8% 86,757 48.0% -0.281 -0.006 Race ⁴ - -	Sex								
American Indian or Alaska Native - - - - Asian - - - - - Black or African American - - - - - Multi-racial - - - - - - Multi-racial - - - - - - Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN White - - - - - - - - Hispanic origin - <t< td=""><td>Female</td><td>100,208</td><td>52.2%</td><td>93,860</td><td>52.0%</td><td>0.281</td><td>0.006</td></t<>	Female	100,208	52.2%	93,860	52.0%	0.281	0.006		
American Indian or Alaska Native - - - - - Asian - - - - - - Black or African American - - - - - - Multi-racial - - - - - - - Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN White - - - - - - - - Hspanic origin -	Male	91,588	47.8%	86,757	48.0%	-0.281	-0.006		
Asian - - - - - - Black or African American - - - - - - - Multi-racial - - - - - - - - Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN White - - - - - - - - Hispanic origin -	Race ⁴								
Black or African American - <td>American Indian or Alaska Native</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td>	American Indian or Alaska Native	-	-	-	-	-	-		
Multi-racial - No 100.0% 180,617 100.0% 0.000 NaN Multi-racial -<	Asian	-	-	-	-	-	-		
Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN White -	Black or African American	-	-	-	-	-	-		
White - - - - - - Hispanic origin Yes - - - - - Yes - - - - - - - No - - - - - - - - Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN Year -	Multi-racial	-	-	-	-	-	-		
Hispanic origin Yes - - - - - No - - - - - - Unknown 191,796 100.0% 180,617 100.0% 0.000 NaN Year 2018 68,468 35.7% 65,433 36.2% -0.529 -0.011 2019 123,328 64.3% 115,184 63.8% 0.529 0.011 Health Characteristics Charlson/Elixhauser combined comorbidity score ⁵ 0.7 1.7 0.7 1.6 -0.045 -0.026 Allergic Reaction 21,506 11.2% 22,231 12.3% -1.095 -0.034 Diabetes 37,586 19.6% 14,361 8.0% 11.646 0.343 Heart Failure 3,833 2.0% 5,703 3.2% -1.159 -0.073	Unknown	191,796	100.0%	180,617	100.0%	0.000	NaN		
YesNoUnknown191,796100.0%180,617100.0%0.000NaNYear201868,46835.7%65,43336.2%-0.529-0.0112019123,32864.3%115,18463.8%0.5290.011Health CharacteristicsCharlson/Elixhauser combined comorbidity score ⁵ 0.71.70.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073	White	-	-	-	-	-	-		
No I	Hispanic origin								
Unknown191,796100.0%180,617100.0%0.000NaNYear201868,46835.7%65,43336.2%-0.529-0.0112019123,32864.3%115,18463.8%0.5290.011Health Characteristics50.71.70.71.6-0.045-0.026Charlson/Elixhauser combined comorbidity score50.71.7%0.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073	Yes	-	-	-	-	-	-		
Year201868,46835.7%65,43336.2%-0.529-0.0112019123,32864.3%115,18463.8%0.5290.011Health CharacteristicsCharlson/Elixhauser combined comorbidity score ⁵ 0.71.70.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	No	-	-	-	-	-	-		
201868,46835.7%65,43336.2%-0.529-0.0112019123,32864.3%115,18463.8%0.5290.011Health CharacteristicsCharlson/Elixhauser combined comorbidity score ⁵ 0.71.70.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	Unknown	191,796	100.0%	180,617	100.0%	0.000	NaN		
2019123,32864.3%115,18463.8%0.5290.011Health CharacteristicsCharlson/Elixhauser combined comorbidity score50.71.70.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	Year								
Health Characteristics Charlson/Elixhauser combined comorbidity score ⁵ 0.7 1.7 0.7 1.6 -0.045 -0.026 Allergic Reaction 21,506 11.2% 22,231 12.3% -1.095 -0.034 Diabetes 37,586 19.6% 14,361 8.0% 11.646 0.343 Heart Failure 3,833 2.0% 5,703 3.2% -1.159 -0.073 Ischemic Heart Disease 7,352 3.8% 19,320 10.7% -6.864 -0.267	2018	68,468	35.7%	65,433	36.2%	-0.529	-0.011		
Charlson/Elixhauser combined comorbidity score50.71.70.71.6-0.045-0.026Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	2019	123,328	64.3%	115,184	63.8%	0.529	0.011		
Allergic Reaction21,50611.2%22,23112.3%-1.095-0.034Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	Health Characteristics								
Diabetes37,58619.6%14,3618.0%11.6460.343Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.6	-0.045	-0.026		
Heart Failure3,8332.0%5,7033.2%-1.159-0.073Ischemic Heart Disease7,3523.8%19,32010.7%-6.864-0.267	Allergic Reaction	21,506	11.2%	22,231	12.3%	-1.095	-0.034		
Ischemic Heart Disease 7,352 3.8% 19,320 10.7% -6.864 -0.267	Diabetes	37,586	19.6%	14,361	8.0%	11.646	0.343		
	Heart Failure	3,833	2.0%	5,703	3.2%	-1.159	-0.073		
NSAID Use 46,800 24.4% 40,073 22.2% 2.214 0.052	Ischemic Heart Disease	7,352	3.8%	19,320	10.7%	-6.864	-0.267		
	NSAID Use	46,800	24.4%	40,073	22.2%	2.214	0.052		



Table 1ai. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covaria	Covariate Balance	
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁶	19,715	10.3%	18,222	10.1%	0.190	0.006	
Acute Myocardial Infarction ⁶	1,699	0.9%	6,871	3.8%	-2.918	-0.194	
Alzheimers Disease and Related Disorders ⁶	1,296	0.7%	1,261	0.7%	-0.022	-0.003	
Anemia ⁶	17,985	9.4%	15,887	8.8%	0.581	0.020	
Asthma ⁶	14,492	7.6%	10,550	5.8%	1.715	0.069	
Atrial Fibrillation ⁶	2,555	1.3%	10,982	6.1%	-4.748	-0.253	
Benign Prostatic Hyperplasia ⁶	4,951	2.6%	6,836	3.8%	-1.203	-0.069	
Cataract ⁶	11,470	6.0%	12,073	6.7%	-0.704	-0.029	
Chronic Kidney Disease ⁶	25,189	13.1%	12,447	6.9%	6.242	0.209	
Bronchiectasis ⁶	10,918	5.7%	8,903	4.9%	0.763	0.034	
Depression ⁶	28,756	15.0%	28,426	15.7%	-0.745	-0.021	
Glaucoma ⁶	7,381	3.8%	7,395	4.1%	-0.246	-0.013	
Hip or Pelvic Fracture ⁶	452	0.2%	397	0.2%	0.016	0.003	
Hyperlipidemia ⁶	59,539	31.0%	53,958	29.9%	1.169	0.025	
Hypertension ⁶	82,438	43.0%	61,694	34.2%	8.825	0.182	
Osteoporosis ⁶	2,853	1.5%	3,269	1.8%	-0.322	-0.025	
Rheumatoid Arthritis or Osteoarthritis ⁶	29,980	15.6%	26,542	14.7%	0.936	0.026	
Stroke or Transient Ischemic Attack ⁶	5,072	2.6%	4,248	2.4%	0.292	0.019	
Breast Cancer ⁶	3,390	1.8%	2,516	1.4%	0.374	0.030	
Colorectal Cancer ⁶	1,236	0.6%	753	0.4%	0.228	0.031	
Prostate Cancer ⁶	1,351	0.7%	1,607	0.9%	-0.186	-0.021	
Lung Cancer ⁶	534	0.3%	620	0.3%	-0.065	-0.012	
Endometrial Cancer ⁶	507	0.3%	255	0.1%	0.123	0.027	
Urologic Cancer ⁶	544	0.3%	394	0.2%	0.065	0.013	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	11.3	14.6	11.6	13.8	-0.300	-0.021	
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.028	-0.023	
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.031	-0.057	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.010	
Mean number of other ambulatory encounters	2.2	5.4	2.4	6.2	-0.132	-0.023	
Mean number of filled prescriptions	14.6	18.2	14.5	17.9	0.068	0.004	



Table 1ai. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.5	5.1	5.5	5.1	0.001	0.000
Mean number of unique drug classes dispensed	5.1	4.6	5.1	4.5	0.004	0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative™ MarketScan® Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1aj. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	68,205	100.0%	65,471	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.6	11.6	45.9	15.3	4.793	0.353
Age						
18-44 years	20,281	29.7%	31,040	47.4%	-17.675	-0.369
45-64 years	43,843	64.3%	29,573	45.2%	19.112	0.391
≥ 65 years	4,081	6.0%	4,858	7.4%	-1.437	-0.057
Sex						
Female	29,819	43.7%	40,483	61.8%	-18.114	-0.369
Male	38,386	56.3%	24,988	38.2%	18.114	0.369
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	68,205	100.0%	65,471	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	68,205	100.0%	65,471	100.0%	0.000	NaN
Year						
2018	68,205	100.0%	65,471	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.740	-0.452
Allergic Reaction	6,395	9.4%	8,679	13.3%	-3.880	-0.123
Diabetes	11,932	17.5%	5,106	7.8%	9.695	0.295
Heart Failure	749	1.1%	2,687	4.1%	-3.006	-0.190
Ischemic Heart Disease	2,067	3.0%	6,751	10.3%	-7.281	-0.295
NSAID Use	15,175	22.2%	16,235	24.8%	-2.548	-0.060



Table 1aj. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁵	5,892	8.6%	7,014	10.7%	-2.074	-0.070
Acute Myocardial Infarction ⁵	395	0.6%	2,632	4.0%	-3.441	-0.231
Alzheimers Disease and Related Disorders ⁵	265	0.4%	597	0.9%	-0.523	-0.065
Anemia ⁵	4,064	6.0%	7,686	11.7%	-5.781	-0.205
Asthma ⁵	3,736	5.5%	5,025	7.7%	-2.198	-0.089
Atrial Fibrillation ⁵	640	0.9%	4,043	6.2%	-5.237	-0.286
Benign Prostatic Hyperplasia ⁵	2,040	3.0%	1,914	2.9%	0.068	0.004
Cataract ⁵	4,137	6.1%	3,736	5.7%	0.359	0.015
Chronic Kidney Disease ⁵	6,748	9.9%	5,220	8.0%	1.921	0.067
Bronchiectasis ⁵	2,979	4.4%	3,954	6.0%	-1.672	-0.075
Depression ⁵	6,875	10.1%	13,002	19.9%	-9.779	-0.277
Glaucoma ⁵	2,568	3.8%	2,350	3.6%	0.176	0.009
Hip or Pelvic Fracture ⁵	103	0.2%	211	0.3%	-0.171	-0.035
Hyperlipidemia ⁵	20,938	30.7%	17,418	26.6%	4.094	0.091
Hypertension ⁵	29,289	42.9%	20,004	30.6%	12.389	0.259
Osteoporosis ⁵	895	1.3%	1,174	1.8%	-0.481	-0.039
Rheumatoid Arthritis or Osteoarthritis ⁵	9,592	14.1%	9,596	14.7%	-0.593	-0.017
Stroke or Transient Ischemic Attack ⁵	1,292	1.9%	1,775	2.7%	-0.817	-0.054
Breast Cancer ⁵	854	1.3%	1,040	1.6%	-0.336	-0.028
Colorectal Cancer ⁵	274	0.4%	350	0.5%	-0.133	-0.019
Prostate Cancer ⁵	479	0.7%	499	0.8%	-0.060	-0.007
Lung Cancer ⁵	119	0.2%	334	0.5%	-0.336	-0.057
Endometrial Cancer ⁵	107	0.2%	116	0.2%	-0.020	-0.005
Urologic Cancer ⁵	144	0.2%	156	0.2%	-0.027	-0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	8.9	11.3	13.8	16.1	-4.906	-0.353
Mean number of emergency room encounters	0.3	0.9	0.6	1.4	-0.270	-0.230
Mean number of inpatient hospital encounters	0.1	0.4	0.3	0.7	-0.196	-0.355
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.030
Mean number of other ambulatory encounters	1.7	4.2	2.7	6.4	-1.024	-0.189
Mean number of filled prescriptions	12.6	16.2	16.8	19.6	-4.214	-0.234



Table 1aj. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
	Number/	Percent/ Standard	Number/	Percent/ Standard	Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²		Difference
Mean number of generics dispensed	4.7	4.5	6.3	5.5	-1.602	-0.317
Mean number of unique drug classes dispensed	4.4	4.0	5.8	4.8	-1.464	-0.329

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ak. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	68,203	100.0%	65,470	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.1	12.3	48.9	14.9	0.145	0.011
Age						
18-44 years	24,195	35.5%	24,733	37.8%	-2.303	-0.048
45-64 years	40,202	58.9%	34,653	52.9%	6.014	0.121
≥ 65 years	3,807	5.6%	6,084	9.3%	-3.711	-0.142
Sex						
Female	35,878	52.6%	34,260	52.3%	0.276	0.006
Male	32,325	47.4%	31,210	47.7%	-0.276	-0.006
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	68,203	100.0%	65,470	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	68,203	100.0%	65,470	100.0%	0.000	NaN
Year						
2018	68,203	100.0%	65,470	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.7	-0.031	-0.019
Allergic Reaction	7,487	11.0%	7,896	12.1%	-1.084	-0.034
Diabetes	13,475	19.8%	4,974	7.6%	12.159	0.360
Heart Failure	1,405	2.1%	2,018	3.1%	-1.022	-0.065
Ischemic Heart Disease	2,621	3.8%	6,918	10.6%	-6.724	-0.262
NSAID Use	16,809	24.6%	15,156	23.1%	1.496	0.035



Table 1ak. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covaria	Covariate Balance	
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁶	6,971	10.2%	6,507	9.9%	0.283	0.009	
Acute Myocardial Infarction ⁶	632	0.9%	2,473	3.8%	-2.851	-0.189	
Alzheimers Disease and Related Disorders ⁶	438	0.6%	461	0.7%	-0.062	-0.008	
Anemia ⁶	6,367	9.3%	5,850	8.9%	0.400	0.014	
Asthma ⁶	5,260	7.7%	3,911	6.0%	1.739	0.069	
Atrial Fibrillation ⁶	917	1.3%	3,926	6.0%	-4.652	-0.249	
Benign Prostatic Hyperplasia ⁶	1,802	2.6%	2,438	3.7%	-1.081	-0.062	
Cataract ⁶	4,052	5.9%	4,306	6.6%	-0.636	-0.026	
Chronic Kidney Disease ⁶	8,982	13.2%	4,382	6.7%	6.475	0.218	
Bronchiectasis ⁶	4,087	6.0%	3,379	5.2%	0.830	0.036	
Depression ⁶	10,008	14.7%	10,039	15.3%	-0.660	-0.018	
Glaucoma ⁶	2,526	3.7%	2,610	4.0%	-0.283	-0.015	
Hip or Pelvic Fracture ⁶	178	0.3%	165	0.3%	0.008	0.002	
Hyperlipidemia ⁶	21,056	30.9%	19,276	29.4%	1.430	0.031	
Hypertension ⁶	29,180	42.8%	22,095	33.7%	9.034	0.187	
Osteoporosis ⁶	1,063	1.6%	1,150	1.8%	-0.199	-0.016	
Rheumatoid Arthritis or Osteoarthritis ⁶	10,836	15.9%	9,678	14.8%	1.106	0.031	
Stroke or Transient Ischemic Attack ⁶	1,808	2.7%	1,548	2.4%	0.286	0.018	
Breast Cancer ⁶	1,330	2.0%	872	1.3%	0.619	0.049	
Colorectal Cancer ⁶	436	0.6%	287	0.4%	0.201	0.027	
Prostate Cancer ⁶	462	0.7%	589	0.9%	-0.221	-0.025	
Lung Cancer ⁶	226	0.3%	232	0.4%	-0.023	-0.004	
Endometrial Cancer ⁶	174	0.3%	91	0.1%	0.117	0.026	
Urologic Cancer ⁶	228	0.3%	132	0.2%	0.132	0.026	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	11.4	14.4	11.7	13.9	-0.231	-0.016	
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.030	-0.025	
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.028	-0.050	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.019	
Mean number of other ambulatory encounters	2.2	5.3	2.2	5.7	-0.060	-0.011	
Mean number of filled prescriptions	15.1	18.7	15.1	18.3	0.043	0.002	



Table 1ak. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.6	5.2	5.7	5.1	-0.005	-0.001
Mean number of unique drug classes dispensed	5.2	4.6	5.2	4.5	-0.005	-0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1al. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	123,594	100.0%	115,146	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.7	11.6	45.7	15.4	4.946	0.363
Age						
18-44 years	36,758	29.7%	55,558	48.3%	-18.509	-0.387
45-64 years	79,319	64.2%	50,743	44.1%	20.109	0.412
≥ 65 years	7,517	6.1%	8,845	7.7%	-1.600	-0.063
Sex						
Female	53,505	43.3%	70,848	61.5%	-18.238	-0.371
Male	70,089	56.7%	44,298	38.5%	18.238	0.371
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	123,594	100.0%	115,146	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	123,594	100.0%	115,146	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	123,594	100.0%	115,146	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.760	-0.466
Allergic Reaction	11,940	9.7%	15,864	13.8%	-4.117	-0.128
Diabetes	21,372	17.3%	9,575	8.3%	8.977	0.271
Heart Failure	1,298	1.1%	4,905	4.3%	-3.210	-0.201
Ischemic Heart Disease	3,807	3.1%	11,969	10.4%	-7.314	-0.295
NSAID Use	26,974	21.8%	27,046	23.5%	-1.664	-0.040



Table 1al. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

Patient Characteristics ¹ Number/ Mean Percent/ Standard Deviation ² Num Mean Acquired Hypothyroidism ⁵ 10,895 8.8% 12 Acute Myocardial Infarction ⁵ 684 0.6% 4, Alzheimers Disease and Related Disorders ⁵ 499 0.4% 1, Anemia ⁵ 7,574 6.1% 13 Asthma ⁵ 6,514 5.3% 8, Atrial Fibrillation ⁵ 1,143 0.9% 7, Benign Prostatic Hyperplasia ⁵ 3,590 2.9% 3, Cataract ⁵ 7,492 6.1% 6, Chronic Kidney Disease ⁵ 12,228 9.9% 9, Bronchiectasis ⁵ 5,002 4.0% 6, Depression ⁵ 12,727 10.3% 24 Glaucoma ⁵ 4,828 3.9% 4, Hip or Pelvic Fracture ⁵ 172 0.1% 2 Hyperlipidemia ⁵ 53,587 43.4% 35 Osteoporosis ⁵ 1,528 1.2% 2, Rheumatoid Arthritis or	Beta Blockers Percent/ Standard Deviation ² ,624 11.0% 709 4.1% 008 0.9% ,261 11.5% 534 7.4% 112 6.2% 376 2.9% 638 5.8%	Absolute Difference -2.148 -3.536 -0.472 -5.389 -2.141 -5.252 -0.027	Standardized Difference -0.072 -0.236 -0.059 -0.191 -0.088 -0.287 2.002
Patient Characteristics1Number/MeanStandard Deviation2Num MAcquired Hypothyroidism510,895 8.8% 12Acute Myocardial Infarction5684 0.6% 4,Alzheimers Disease and Related Disorders5499 0.4% 1,Anemia57,574 6.1% 13Asthma5 $6,514$ 5.3% 8,Atrial Fibrillation51,143 0.9% 7,Benign Prostatic Hyperplasia53,5902.9%3,Cataract57,492 6.1% 6,Chronic Kidney Disease512,228 9.9% 9,Bronchiectasis55,002 4.0% 6,Depression5122,727 10.3% 24Glaucoma54,828 3.9% 4,Hip or Pelvic Fracture5172 0.1% 21Hyperlipidemia53,587 43.4% 35Osteoporosis51,528 1.2% 2,72%Rheumatoid Arthritis or Osteoarthritis517,158 13.9% 16	Standard Jean Standard 0.624 11.0% 709 4.1% 008 0.9% 0,261 11.5% 534 7.4% 112 6.2% 376 2.9%	 Difference -2.148 -3.536 -0.472 -5.389 -2.141 -5.252 	Difference -0.072 -0.236 -0.059 -0.191 -0.088 -0.287
Acute Myocardial Infarction ⁵ 684 0.6% 4, Alzheimers Disease and Related Disorders ⁵ 499 0.4% 1, Anemia ⁵ 7,574 6.1% 13 Asthma ⁵ 6,514 5.3% 8, Atrial Fibrillation ⁵ 1,143 0.9% 7, Benign Prostatic Hyperplasia ⁵ 3,590 2.9% 3, Cataract ⁵ 7,492 6.1% 6, Chronic Kidney Disease ⁵ 12,228 9.9% 9, Bronchiectasis ⁵ 5,002 4.0% 6, Depression ⁵ 12,727 10.3% 24 Glaucoma ⁵ 4,828 3.9% 4, Hip or Pelvic Fracture ⁵ 172 0.1% 2 Hyperlipidemia ⁵ 38,317 31.0% 31 Hypertension ⁵ 1,528 1.2% 2, Rheumatoid Arthritis or Osteoarthritis ⁵ 17,158 13.9% 16	709 4.1% 008 0.9% 0,261 11.5% 534 7.4% 112 6.2% 376 2.9%	-3.536 -0.472 -5.389 -2.141 -5.252	-0.236 -0.059 -0.191 -0.088 -0.287
Alzheimers Disease and Related Disorders ⁵ 499 0.4% 1, Anemia ⁵ 7,574 6.1% 13 Asthma ⁵ 6,514 5.3% 8, Atrial Fibrillation ⁵ 1,143 0.9% 7, Benign Prostatic Hyperplasia ⁵ 3,590 2.9% 3, Cataract ⁵ 7,492 6.1% 6, Chronic Kidney Disease ⁵ 12,228 9.9% 9, Bronchiectasis ⁵ 5,002 4.0% 6, Depression ⁵ 12,727 10.3% 24 Glaucoma ⁵ 4,828 3.9% 4, Hip or Pelvic Fracture ⁵ 172 0.1% 2 Hyperlipidemia ⁵ 38,317 31.0% 31 Hypertension ⁵ 1,528 1.2% 2, Rheumatoid Arthritis or Osteoarthritis ⁵ 17,158 13.9% 16	008 0.9% ,261 11.5% 534 7.4% 112 6.2% 376 2.9%	-0.472 -5.389 -2.141 -5.252	-0.059 -0.191 -0.088 -0.287
Anemia ⁵ 7,574 6.1% 13 Asthma ⁵ 6,514 5.3% 8, Atrial Fibrillation ⁵ 1,143 0.9% 7, Benign Prostatic Hyperplasia ⁵ 3,590 2.9% 3, Cataract ⁵ 7,492 6.1% 6, Chronic Kidney Disease ⁵ 12,228 9.9% 9, Bronchiectasis ⁵ 5,002 4.0% 6, Depression ⁵ 12,727 10.3% 24 Glaucoma ⁵ 4,828 3.9% 4, Hip or Pelvic Fracture ⁵ 172 0.1% 2 Hyperlipidemia ⁵ 38,317 31.0% 31 Hypertension ⁵ 1,528 1.2% 2, Rheumatoid Arthritis or Osteoarthritis ⁵ 17,158 13.9% 16	,26111.5%5347.4%1126.2%3762.9%	-5.389 -2.141 -5.252	-0.191 -0.088 -0.287
Asthma $6,514$ 5.3% $8,$ Atrial Fibrillation $1,143$ 0.9% $7,$ Benign Prostatic Hyperplasia $3,590$ 2.9% $3,$ Cataract $7,492$ 6.1% $6,$ Chronic Kidney Disease $12,228$ 9.9% $9,$ Bronchiectasis $5,002$ 4.0% $6,$ Depression $12,727$ 10.3% 24 Glaucoma $4,828$ 3.9% $4,$ Hip or Pelvic Fracture 172 0.1% 2 Hyperlipidemia $38,317$ 31.0% 31 Hypertension $53,587$ 43.4% 35 Osteoporosis $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis $17,158$ 13.9% 16	5347.4%1126.2%3762.9%	-2.141 -5.252	-0.088 -0.287
Atrial Fibrillation $1,143$ 0.9% $7,$ Benign Prostatic Hyperplasia $3,590$ 2.9% $3,$ Cataract $7,492$ 6.1% $6,$ Chronic Kidney Disease $12,228$ 9.9% $9,$ Bronchiectasis $5,002$ 4.0% $6,$ Depression $5,002$ 4.0% $6,$ Depression $12,727$ 10.3% 24 Glaucoma $4,828$ 3.9% $4,$ Hip or Pelvic Fracture 172 0.1% 2 Hyperlipidemia $38,317$ 31.0% 31 Hypertension $53,587$ 43.4% 35 Osteoporosis $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis $17,158$ 13.9% 16	1126.2%3762.9%	-5.252	-0.287
Benign Prostatic Hyperplasia5 $3,590$ 2.9% $3,$ Cataract5 $7,492$ 6.1% $6,$ Chronic Kidney Disease5 $12,228$ 9.9% $9,$ Bronchiectasis5 $5,002$ 4.0% $6,$ Depression5 $12,727$ 10.3% 24 Glaucoma5 $4,828$ 3.9% $4,$ Hip or Pelvic Fracture5 172 0.1% 2 Hyperlipidemia5 $38,317$ 31.0% 31 Hypertension5 $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis5 $17,158$ 13.9% 16	376 2.9%		
Cataract5 $7,492$ 6.1% $6,$ Chronic Kidney Disease5 $12,228$ 9.9% $9,$ Bronchiectasis5 $5,002$ 4.0% $6,$ Depression5 $12,727$ 10.3% 24 Glaucoma5 $4,828$ 3.9% $4,$ Hip or Pelvic Fracture5 172 0.1% 2 Hyperlipidemia5 $38,317$ 31.0% 31 Hypertension5 $53,587$ 43.4% 35 Osteoporosis5 $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis5 $17,158$ 13.9% 16		-0.027	0.000
Chronic Kidney Disease $12,228$ 9.9% $9,$ Bronchiectasis $5,002$ 4.0% $6,$ Depression $12,727$ 10.3% 24 Glaucoma $4,828$ 3.9% $4,$ Hip or Pelvic Fracture 172 0.1% 2 Hyperlipidemia $38,317$ 31.0% 31 Hypertension $53,587$ 43.4% 35 Osteoporosis $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis $17,158$ 13.9% 16	638 5.8%		-0.002
Bronchiectasis5 $5,002$ 4.0% $6,$ Depression5 $12,727$ 10.3% 24 Glaucoma5 $4,828$ 3.9% $4,$ Hip or Pelvic Fracture5 172 0.1% 2 Hyperlipidemia5 $38,317$ 31.0% 31 Hypertension5 $53,587$ 43.4% 35 Osteoporosis5 $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis5 $17,158$ 13.9% 16		0.297	0.013
Depression 5 12,72710.3%24Glaucoma 5 4,8283.9%4,Hip or Pelvic Fracture 5 1720.1%2Hyperlipidemia 5 38,31731.0%31Hypertension 5 53,58743.4%35Osteoporosis 5 1,5281.2%2,Rheumatoid Arthritis or Osteoarthritis 5 17,15813.9%16	416 8.2%	1.716	0.060
Glaucoma5 $4,828$ 3.9% $4,$ Hip or Pelvic Fracture5 172 0.1% 2 Hyperlipidemia5 $38,317$ 31.0% 31.0% Hypertension5 $53,587$ 43.4% 35.0% Osteoporosis5 $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis5 $17,158$ 13.9% 16.0%	540 5.7%	-1.633	-0.076
Hip or Pelvic Fracture 172 0.1% 2 Hyperlipidemia $38,317$ 31.0% 31 Hypertension $53,587$ 43.4% 35 Osteoporosis $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis $17,158$ 13.9% 16	,048 20.9%	-10.587	-0.295
Hyperlipidemia $38,317$ 31.0% 31 Hypertension $53,587$ 43.4% 35 Osteoporosis $1,528$ 1.2% $2,$ Rheumatoid Arthritis or Osteoarthritis $17,158$ 13.9% 16	.257 3.7%	0.209	0.011
Hypertension53,58743.4%35Osteoporosis1,5281.2%2,Rheumatoid Arthritis or Osteoarthritis17,15813.9%16	0.3%	-0.117	-0.026
Osteoporosis ⁵ 1,528 1.2% 2, Rheumatoid Arthritis or Osteoarthritis ⁵ 17,158 13.9% 16	,130 27.0%	3.967	0.087
Rheumatoid Arthritis or Osteoarthritis ⁵ 17,158 13.9% 16	,444 30.8%	12.575	0.263
-	133 1.9%	-0.616	-0.050
Stroke or Transient Ischemic Attack ⁵ $2,330$ 1.9% $3,$,733 14.5%	-0.649	-0.019
	.021 2.6%	-0.738	-0.050
Breast Cancer ⁵ 1,385 1.1% 1,	.937 1.7%	-0.562	-0.048
Colorectal Cancer ⁵ 500 0.4% 5	554 0.5%	-0.077	-0.012
Prostate Cancer ⁵ 896 0.7% 8	350 0.7%	-0.013	-0.002
Lung Cancer ⁵ 155 0.1% 5	559 0.5%	-0.360	-0.065
Endometrial Cancer ⁵ 201 0.2% 2	205 0.2%	-0.015	-0.004
Urologic Cancer ⁵ 214 0.2% 2	0.3%	-0.080	-0.017
Health Service Utilization Intensity Metrics			
Mean number of ambulatory encounters 8.8 11.3 1	3.8 15.9	-5.057	-0.367
Mean number of emergency room encounters 0.3 0.9 0	0.6 1.4	-0.264	-0.222
Mean number of inpatient hospital encounters 0.1 0.4 0	0.3 0.7	-0.196	-0.358
Mean number of non-acute institutional encounters 0.0 0.0 0	0.0 0.0	-0.001	-0.024
Mean number of other ambulatory encounters 1.7 4.6 2	2.9 6.9	-1.135	-0.193
Mean number of filled prescriptions 11.9 15.5 1	6.1 19.2	-4.202	-0.241



Table 1al. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Blockers		
		Percent/		Percent/		
	Number/		Number/		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	4.5	4.4	6.1	5.5	-1.588	-0.320
Mean number of unique drug classes dispensed	4.2	3.9	5.6	4.8	-1.454	-0.332

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1am. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	123,592	100.0%	115,141	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.1	12.3	49.0	15.0	0.133	0.010
Age						
18-44 years	43,861	35.5%	44,169	38.4%	-2.872	-0.060
45-64 years	72,848	58.9%	59,693	51.8%	7.099	0.143
≥ 65 years	6,883	5.6%	11,279	9.8%	-4.227	-0.159
Sex						
Female	64,325	52.0%	59,612	51.8%	0.273	0.005
Male	59,267	48.0%	55,529	48.2%	-0.273	-0.005
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	123,592	100.0%	115,141	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	123,592	100.0%	115,141	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	123,592	100.0%	115,141	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.6	-0.052	-0.031
Allergic Reaction	14,013	11.3%	14,331	12.4%	-1.109	-0.034
Diabetes	24,109	19.5%	9,385	8.2%	11.356	0.334
Heart Failure	2,426	2.0%	3,685	3.2%	-1.237	-0.078
Ischemic Heart Disease	4,727	3.8%	12,405	10.8%	-6.949	-0.270
NSAID Use	29,995	24.3%	24,915	21.6%	2.631	0.063



Table 1am. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	12,736	10.3%	11,722	10.2%	0.125	0.004
Acute Myocardial Infarction ⁶	1,062	0.9%	4,401	3.8%	-2.962	-0.197
Alzheimers Disease and Related Disorders ⁶	858	0.7%	800	0.7%	-0.001	-0.000
Anemia ⁶	11,611	9.4%	10,036	8.7%	0.678	0.024
Asthma ⁶	9,240	7.5%	6,642	5.8%	1.707	0.069
Atrial Fibrillation ⁶	1,631	1.3%	7,057	6.1%	-4.809	-0.256
Benign Prostatic Hyperplasia ⁶	3,147	2.5%	4,396	3.8%	-1.271	-0.072
Cataract ⁶	7,415	6.0%	7,763	6.7%	-0.743	-0.030
Chronic Kidney Disease ⁶	16,208	13.1%	8,057	7.0%	6.116	0.204
Bronchiectasis ⁶	6,828	5.5%	5,522	4.8%	0.729	0.033
Depression ⁶	18,742	15.2%	18,384	16.0%	-0.802	-0.022
Glaucoma ⁶	4,856	3.9%	4,786	4.2%	-0.228	-0.012
Hip or Pelvic Fracture ⁶	274	0.2%	232	0.2%	0.020	0.004
Hyperlipidemia ⁶	38,488	31.1%	34,678	30.1%	1.023	0.022
Hypertension ⁶	53,253	43.1%	39,595	34.4%	8.699	0.179
Osteoporosis ⁶	1,783	1.4%	2,122	1.8%	-0.400	-0.032
Rheumatoid Arthritis or Osteoarthritis ⁶	19,147	15.5%	16,862	14.6%	0.848	0.024
Stroke or Transient Ischemic Attack ⁶	3,263	2.6%	2,698	2.3%	0.297	0.019
Breast Cancer ⁶	2,059	1.7%	1,646	1.4%	0.237	0.019
Colorectal Cancer ⁶	797	0.6%	465	0.4%	0.241	0.033
Prostate Cancer ⁶	889	0.7%	1,020	0.9%	-0.167	-0.019
Lung Cancer ⁶	307	0.2%	388	0.3%	-0.088	-0.016
Endometrial Cancer ⁶	332	0.3%	165	0.1%	0.126	0.028
Urologic Cancer ⁶	317	0.3%	262	0.2%	0.029	0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	14.6	11.6	13.7	-0.337	-0.024
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.026	-0.022
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.033	-0.061
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.006
Mean number of other ambulatory encounters	2.3	5.5	2.4	6.4	-0.174	-0.029
Mean number of filled prescriptions	14.3	18.0	14.2	17.7	0.087	0.005



Table 1am. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.4	5.1	5.4	5.1	0.007	0.001
Mean number of unique drug classes dispensed	5.0	4.5	5.0	4.5	0.010	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1an. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta B	Beta Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	191,796	100.0%	180,615	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.1	12.3	49.0	15.0	0.136	0.010
Age						
18-44 years	68,076	35.5%	68,908	38.2%	-2.657	-0.055
45-64 years	113,026	58.9%	94,347	52.2%	6.694	0.135
≥ 65 years	10,694	5.6%	17,360	9.6%	-4.036	-0.153
Sex						
Female	100,205	52.2%	93,837	52.0%	0.292	0.006
Male	91,591	47.8%	86,778	48.0%	-0.292	-0.006
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	191,796	100.0%	180,615	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	191,796	100.0%	180,615	100.0%	0.000	NaN
Year						
2018	68,926	35.9%	65,013	36.0%	-0.058	-0.001
2019	122,870	64.1%	115,602	64.0%	0.058	0.001
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.6	-0.044	-0.026
Allergic Reaction	21,505	11.2%	22,234	12.3%	-1.097	-0.034
Diabetes	37,570	19.6%	14,364	8.0%	11.636	0.343
Heart Failure	3,830	2.0%	5,703	3.2%	-1.161	-0.073
Ischemic Heart Disease	7,350	3.8%	19,318	10.7%	-6.863	-0.267
NSAID Use	46,799	24.4%	40,083	22.2%	2.208	0.052



Table 1an. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019

		Medical	Product		Covariate Balance	
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	19,721	10.3%	18,220	10.1%	0.195	0.006
Acute Myocardial Infarction ⁶	1,699	0.9%	6,876	3.8%	-2.921	-0.194
Alzheimers Disease and Related Disorders ⁶	1,303	0.7%	1,260	0.7%	-0.018	-0.002
Anemia ⁶	18,006	9.4%	15,882	8.8%	0.595	0.021
Asthma ⁶	14,504	7.6%	10,552	5.8%	1.720	0.069
Atrial Fibrillation ⁶	2,559	1.3%	10,977	6.1%	-4.743	-0.253
Benign Prostatic Hyperplasia ⁶	4,950	2.6%	6,835	3.8%	-1.203	-0.069
Cataract ⁶	11,475	6.0%	12,064	6.7%	-0.696	-0.029
Chronic Kidney Disease ⁶	25,195	13.1%	12,448	6.9%	6.244	0.209
Bronchiectasis ⁶	10,931	5.7%	8,892	4.9%	0.776	0.035
Depression ⁶	28,740	15.0%	28,432	15.7%	-0.757	-0.021
Glaucoma ⁶	7,382	3.8%	7,400	4.1%	-0.248	-0.013
Hip or Pelvic Fracture ⁶	452	0.2%	397	0.2%	0.016	0.003
Hyperlipidemia ⁶	59,525	31.0%	53,954	29.9%	1.163	0.025
Hypertension ⁶	82,439	43.0%	61,687	34.2%	8.829	0.182
Osteoporosis ⁶	2,855	1.5%	3,271	1.8%	-0.323	-0.025
Rheumatoid Arthritis or Osteoarthritis ⁶	29,985	15.6%	26,538	14.7%	0.941	0.026
Stroke or Transient Ischemic Attack ⁶	5,077	2.6%	4,251	2.4%	0.294	0.019
Breast Cancer ⁶	3,392	1.8%	2,515	1.4%	0.376	0.030
Colorectal Cancer ⁶	1,230	0.6%	752	0.4%	0.225	0.031
Prostate Cancer ⁶	1,355	0.7%	1,607	0.9%	-0.184	-0.021
Lung Cancer ⁶	535	0.3%	619	0.3%	-0.064	-0.011
Endometrial Cancer ⁶	503	0.3%	255	0.1%	0.121	0.027
Urologic Cancer ⁶	545	0.3%	394	0.2%	0.066	0.013
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	14.6	11.6	13.8	-0.298	-0.021
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.028	-0.023
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.031	-0.057
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.010
Mean number of other ambulatory encounters	2.2	5.4	2.4	6.2	-0.131	-0.023
Mean number of filled prescriptions	14.6	18.2	14.5	17.9	0.069	0.004



Table 1an. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³		Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.5	5.1	5.5	5.1	0.002	0.000
Mean number of unique drug classes dispensed	5.1	4.6	5.1	4.5	0.004	0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ao. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta E	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Deviation ²	Absolute Difference	Standardized Difference
Unique patients	68,205	100.0%	65,471	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.6	11.6	45.9	15.3	4.793	0.353
Age						
18-44 years	20,281	29.7%	31,040	47.4%	-17.675	-0.369
45-64 years	43,843	64.3%	29,573	45.2%	19.112	0.391
≥ 65 years	4,081	6.0%	4,858	7.4%	-1.437	-0.057
Sex						
Female	29,819	43.7%	40,483	61.8%	-18.114	-0.369
Male	38,386	56.3%	24,988	38.2%	18.114	0.369
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	68,205	100.0%	65,471	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	68,205	100.0%	65,471	100.0%	0.000	NaN
Year						
2018	68,205	100.0%	65,471	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.740	-0.452
Allergic Reaction	6,395	9.4%	8,679	13.3%	-3.880	-0.123
Diabetes	11,932	17.5%	5,106	7.8%	9.695	0.295
Heart Failure	749	1.1%	2,687	4.1%	-3.006	-0.190
Ischemic Heart Disease	2,067	3.0%	6,751	10.3%	-7.281	-0.295
NSAID Use	15,175	22.2%	16,235	24.8%	-2.548	-0.060



Table 1ao. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December11, 2019, Year: 2018

		Medical	Product		Covariate Balance		
	ACE In	hibitors	Beta B	lockers			
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference	
Acquired Hypothyroidism ⁵	5,892	8.6%	7,014	10.7%	-2.074	-0.070	
Acute Myocardial Infarction ⁵	395	0.6%	2,632	4.0%	-3.441	-0.231	
Alzheimers Disease and Related Disorders ⁵	265	0.4%	597	0.9%	-0.523	-0.065	
Anemia ⁵	4,064	6.0%	7,686	11.7%	-5.781	-0.205	
Asthma ⁵	3,736	5.5%	5,025	7.7%	-2.198	-0.089	
Atrial Fibrillation ⁵	640	0.9%	4,043	6.2%	-5.237	-0.286	
Benign Prostatic Hyperplasia ⁵	2,040	3.0%	1,914	2.9%	0.068	0.004	
Cataract ⁵	4,137	6.1%	3,736	5.7%	0.359	0.015	
Chronic Kidney Disease ⁵	6,748	9.9%	5,220	8.0%	1.921	0.067	
Bronchiectasis ⁵	2,979	4.4%	3,954	6.0%	-1.672	-0.075	
Depression ⁵	6,875	10.1%	13,002	19.9%	-9.779	-0.277	
Glaucoma ⁵	2,568	3.8%	2,350	3.6%	0.176	0.009	
Hip or Pelvic Fracture ⁵	103	0.2%	211	0.3%	-0.171	-0.035	
Hyperlipidemia ⁵	20,938	30.7%	17,418	26.6%	4.094	0.091	
Hypertension ⁵	29,289	42.9%	20,004	30.6%	12.389	0.259	
Osteoporosis ⁵	895	1.3%	1,174	1.8%	-0.481	-0.039	
Rheumatoid Arthritis or Osteoarthritis ⁵	9,592	14.1%	9,596	14.7%	-0.593	-0.017	
Stroke or Transient Ischemic Attack ⁵	1,292	1.9%	1,775	2.7%	-0.817	-0.054	
Breast Cancer ⁵	854	1.3%	1,040	1.6%	-0.336	-0.028	
Colorectal Cancer ⁵	274	0.4%	350	0.5%	-0.133	-0.019	
Prostate Cancer ⁵	479	0.7%	499	0.8%	-0.060	-0.007	
Lung Cancer ⁵	119	0.2%	334	0.5%	-0.336	-0.057	
Endometrial Cancer ⁵	107	0.2%	116	0.2%	-0.020	-0.005	
Urologic Cancer ⁵	144	0.2%	156	0.2%	-0.027	-0.006	
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	8.9	11.3	13.8	16.1	-4.906	-0.353	
Mean number of emergency room encounters	0.3	0.9	0.6	1.4	-0.270	-0.230	
Mean number of inpatient hospital encounters	0.1	0.4	0.3	0.7	-0.196	-0.355	
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.030	
Mean number of other ambulatory encounters	1.7	4.2	2.7	6.4	-1.024	-0.189	
Mean number of filled prescriptions	12.6	16.2	16.8	19.6	-4.214	-0.234	



Table 1ao. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
		Percent/		Percent/		
1	Number/		•		Absolute	Standardized
Patient Characteristics ¹	Mean	Deviation ²	Mean	Deviation ²	Difference	Difference
Mean number of generics dispensed	4.7	4.5	6.3	5.5	-1.602	-0.317
Mean number of unique drug classes dispensed	4.4	4.0	5.8	4.8	-1.464	-0.329

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.



Table 1ap. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	68,204	100.0%	65,469	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.1	12.3	48.9	14.9	0.143	0.010
Age						
18-44 years	24,199	35.5%	24,730	37.8%	-2.294	-0.048
45-64 years	40,198	58.9%	34,655	52.9%	6.005	0.121
≥ 65 years	3,807	5.6%	6,084	9.3%	-3.710	-0.142
Sex						
Female	35,877	52.6%	34,258	52.3%	0.276	0.006
Male	32,327	47.4%	31,211	47.7%	-0.276	-0.006
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	68,204	100.0%	65,469	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	68,204	100.0%	65,469	100.0%	0.000	NaN
Year						
2018	68,204	100.0%	65,469	100.0%	0.000	NaN
2019	0	0.0%	0	0.0%	NaN	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.7	-0.031	-0.018
Allergic Reaction	7,488	11.0%	7,897	12.1%	-1.083	-0.034
Diabetes	13,473	19.8%	4,975	7.6%	12.156	0.359
Heart Failure	1,406	2.1%	2,018	3.1%	-1.021	-0.065
Ischemic Heart Disease	2,620	3.8%	6,916	10.6%	-6.723	-0.262
NSAID Use	16,810	24.6%	15,157	23.2%	1.494	0.035
	-					



Table 1ap. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	6,972	10.2%	6,507	9.9%	0.284	0.009
Acute Myocardial Infarction ⁶	632	0.9%	2,472	3.8%	-2.849	-0.189
Alzheimers Disease and Related Disorders ⁶	438	0.6%	460	0.7%	-0.061	-0.007
Anemia ⁶	6,367	9.3%	5,849	8.9%	0.401	0.014
Asthma ⁶	5,259	7.7%	3,910	6.0%	1.739	0.069
Atrial Fibrillation ⁶	917	1.3%	3,926	6.0%	-4.652	-0.249
Benign Prostatic Hyperplasia ⁶	1,802	2.6%	2,438	3.7%	-1.081	-0.062
Cataract ⁶	4,051	5.9%	4,307	6.6%	-0.638	-0.026
Chronic Kidney Disease ⁶	8,983	13.2%	4,383	6.7%	6.476	0.218
Bronchiectasis ⁶	4,086	6.0%	3,379	5.2%	0.829	0.036
Depression ⁶	10,011	14.7%	10,037	15.3%	-0.654	-0.018
Glaucoma ⁶	2,525	3.7%	2,610	4.0%	-0.285	-0.015
Hip or Pelvic Fracture ⁶	178	0.3%	165	0.3%	0.008	0.002
Hyperlipidemia ⁶	21,055	30.9%	19,277	29.4%	1.427	0.031
Hypertension ⁶	29,180	42.8%	22,097	33.8%	9.032	0.187
Osteoporosis ⁶	1,062	1.6%	1,150	1.8%	-0.199	-0.016
Rheumatoid Arthritis or Osteoarthritis ⁶	10,836	15.9%	9,678	14.8%	1.105	0.031
Stroke or Transient Ischemic Attack ⁶	1,806	2.6%	1,547	2.4%	0.285	0.018
Breast Cancer ⁶	1,329	1.9%	871	1.3%	0.617	0.049
Colorectal Cancer ⁶	437	0.6%	287	0.4%	0.201	0.027
Prostate Cancer ⁶	462	0.7%	589	0.9%	-0.221	-0.025
Lung Cancer ⁶	226	0.3%	232	0.4%	-0.022	-0.004
Endometrial Cancer ⁶	174	0.3%	91	0.1%	0.117	0.026
Urologic Cancer ⁶	228	0.3%	132	0.2%	0.133	0.026
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.4	14.4	11.7	13.9	-0.230	-0.016
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.030	-0.025
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.028	-0.050
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.001	-0.019
Mean number of other ambulatory encounters	2.2	5.3	2.2	5.7	-0.058	-0.011
Mean number of filled prescriptions	15.1	18.6	15.1	18.3	0.038	0.002



Table 1ap. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018

		Medical	Covariate Balance			
	ACE Inhibitors		Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³		Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.6	5.2	5.7	5.1	-0.006	-0.001
Mean number of unique drug classes dispensed	5.2	4.6	5.2	4.5	-0.006	-0.001

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Determinate not included in the propensity score logistic regressio

Data presented by a dash represents missing information.



Table 1aq. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta E	Blockers		
Patient Characteristics ¹	Number/ Mean	Percent/ Standard Deviation ²	Number/ Mean	Percent/ Standard Deviation ²	Absolute Difference	Standardized Difference
Unique patients	123,594	100.0%	115,146	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	50.7	11.6	45.7	15.4	4.946	0.363
Age						
18-44 years	36,758	29.7%	55,558	48.3%	-18.509	-0.387
45-64 years	79,319	64.2%	50,743	44.1%	20.109	0.412
≥ 65 years	7,517	6.1%	8,845	7.7%	-1.600	-0.063
Sex						
Female	53,505	43.3%	70,848	61.5%	-18.238	-0.371
Male	70,089	56.7%	44,298	38.5%	18.238	0.371
Race ³						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	123,594	100.0%	115,146	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	123,594	100.0%	115,146	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	123,594	100.0%	115,146	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁴	0.3	1.3	1.0	1.9	-0.760	-0.466
Allergic Reaction	11,940	9.7%	15,864	13.8%	-4.117	-0.128
Diabetes	21,372	17.3%	9,575	8.3%	8.977	0.271
Heart Failure	1,298	1.1%	4,905	4.3%	-3.210	-0.201
Ischemic Heart Disease	3,807	3.1%	11,969	10.4%	-7.314	-0.295
NSAID Use	26,974	21.8%	27,046	23.5%	-1.664	-0.040



 Table 1aq. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback,

 Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December

 11, 2019, Year: 2019

Standardized Difference -0.072 -0.236 -0.059 -0.191 -0.287 -0.002 0.013 0.060 -0.076
 Difference -0.072 -0.236 -0.059 -0.191 -0.088 -0.287 -0.002 0.013 0.060
-0.236 -0.059 -0.191 -0.088 -0.287 -0.002 0.013 0.060
-0.059 -0.191 -0.088 -0.287 -0.002 0.013 0.060
-0.191 -0.088 -0.287 -0.002 0.013 0.060
-0.088 -0.287 -0.002 0.013 0.060
-0.287 -0.002 0.013 0.060
-0.002 0.013 0.060
0.013 0.060
0.060
-0.076
-0.295
0.011
-0.026
0.087
0.263
-0.050
-0.019
-0.050
-0.048
-0.012
-0.002
-0.065
-0.004
-0.017
-0.367
-0.222
-0.358
-0.024
-0.193
-0.241



Table 1aq. Unadjusted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

E Inhibitors	Beta B	Blockers		
Percent/		Percent/		
	•		Absolute	Standardized Difference
				-0.320
				-0.320
	er/ Standard	er/ Standard Number/ n Deviation ² Mean 4.4 6.1	er/ Standard Number/ Standard n Deviation ² Mean Deviation ² 4.4 6.1 5.5	Ver/StandardNumber/StandardAbsoluteInDeviation ² MeanDeviation ² Difference4.46.15.5-1.588

¹Covariates in blue show a standardized difference greater than 0.1.

²Value represents standard deviation where no % follows the value.

³Data not available in Merative[™] MarketScan[®] Research Databases

⁴The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁵Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 1ar. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	Blockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Unique patients	123,591	100.0%	115,140	100.0%	N/A	N/A
Demographic Characteristics						
Age (years)	49.1	12.3	49.0	15.0	0.134	0.010
Age						
18-44 years	43,860	35.5%	44,168	38.4%	-2.872	-0.060
45-64 years	72,847	58.9%	59,696	51.8%	7.096	0.143
≥ 65 years	6,884	5.6%	11,277	9.8%	-4.224	-0.159
Sex						
Female	64,326	52.0%	59,613	51.8%	0.273	0.005
Male	59,265	48.0%	55,527	48.2%	-0.273	-0.005
Race ⁴						
American Indian or Alaska Native	-	-	-	-	-	-
Asian	-	-	-	-	-	-
Black or African American	-	-	-	-	-	-
Multi-racial	-	-	-	-	-	-
Unknown	123,591	100.0%	115,140	100.0%	0.000	NaN
White	-	-	-	-	-	-
Hispanic origin						
Yes	-	-	-	-	-	-
No	-	-	-	-	-	-
Unknown	123,591	100.0%	115,140	100.0%	0.000	NaN
Year						
2018	0	0.0%	0	0.0%	NaN	NaN
2019	123,591	100.0%	115,140	100.0%	0.000	NaN
Health Characteristics						
Charlson/Elixhauser combined comorbidity score ⁵	0.7	1.7	0.7	1.6	-0.052	-0.031
Allergic Reaction	14,009	11.3%	14,332	12.4%	-1.113	-0.034
Diabetes	24,109	19.5%	9,386	8.2%	11.356	0.333
Heart Failure	2,424	2.0%	3,684	3.2%	-1.238	-0.078
Ischemic Heart Disease	4,727	3.8%	12,407	10.8%	-6.951	-0.270
NSAID Use	29,994	24.3%	24,916	21.6%	2.629	0.063



Table 1ar. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Product		Covaria	te Balance
	ACE In	hibitors	Beta B	lockers		
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	Number/ Mean	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Acquired Hypothyroidism ⁶	12,733	10.3%	11,722	10.2%	0.122	0.004
Acute Myocardial Infarction ⁶	1,063	0.9%	4,402	3.8%	-2.963	-0.197
Alzheimers Disease and Related Disorders ⁶	859	0.7%	800	0.7%	0.000	0.000
Anemia ⁶	11,611	9.4%	10,036	8.7%	0.678	0.024
Asthma ⁶	9,235	7.5%	6,642	5.8%	1.703	0.069
Atrial Fibrillation ⁶	1,633	1.3%	7,056	6.1%	-4.807	-0.256
Benign Prostatic Hyperplasia ⁶	3,147	2.5%	4,395	3.8%	-1.271	-0.072
Cataract ⁶	7,416	6.0%	7,763	6.7%	-0.742	-0.030
Chronic Kidney Disease ⁶	16,206	13.1%	8,057	7.0%	6.115	0.204
Bronchiectasis ⁶	6,826	5.5%	5,523	4.8%	0.727	0.033
Depression ⁶	18,742	15.2%	18,384	16.0%	-0.802	-0.022
Glaucoma ⁶	4,856	3.9%	4,786	4.2%	-0.228	-0.012
Hip or Pelvic Fracture ⁶	274	0.2%	232	0.2%	0.020	0.004
Hyperlipidemia ⁶	38,489	31.1%	34,679	30.1%	1.023	0.022
Hypertension ⁶	53,252	43.1%	39,597	34.4%	8.697	0.179
Osteoporosis ⁶	1,783	1.4%	2,122	1.8%	-0.400	-0.031
Rheumatoid Arthritis or Osteoarthritis ⁶	19,142	15.5%	16,864	14.6%	0.842	0.024
Stroke or Transient Ischemic Attack ⁶	3,264	2.6%	2,698	2.3%	0.298	0.019
Breast Cancer ⁶	2,059	1.7%	1,646	1.4%	0.237	0.019
Colorectal Cancer ⁶	797	0.6%	465	0.4%	0.241	0.033
Prostate Cancer ⁶	888	0.7%	1,020	0.9%	-0.167	-0.019
Lung Cancer ⁶	307	0.2%	388	0.3%	-0.088	-0.016
Endometrial Cancer ⁶	332	0.3%	165	0.1%	0.126	0.028
Urologic Cancer ⁶	317	0.3%	262	0.2%	0.029	0.006
Health Service Utilization Intensity Metrics						
Mean number of ambulatory encounters	11.3	14.6	11.6	13.7	-0.337	-0.024
Mean number of emergency room encounters	0.5	1.2	0.5	1.2	-0.026	-0.022
Mean number of inpatient hospital encounters	0.2	0.5	0.2	0.6	-0.033	-0.062
Mean number of non-acute institutional encounters	0.0	0.0	0.0	0.0	-0.000	-0.006
Mean number of other ambulatory encounters	2.3	5.5	2.4	6.4	-0.174	-0.029
Mean number of filled prescriptions	14.3	18.0	14.2	17.7	0.081	0.005



Table 1ar. Weighted Characteristics of New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) (Propensity Score Stratified, Percentiles: 5) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019

		Medical	Covariate Balance			
	ACE In	hibitors	Beta Blockers			
Patient Characteristics ^{1,2}	Number/ Mean	Percent/ Standard Deviation ³	•	Percent/ Standard Deviation ³	Absolute Difference	Standardized Difference
Mean number of generics dispensed	5.4	5.1	5.4	5.1	0.006	0.001
Mean number of unique drug classes dispensed	5.0	4.5	5.0	4.5	0.009	0.002

¹Covariates in blue show a standardized difference greater than 0.1.

²Weighted patient characteristics tables facilitate the assessment of covariate balance after propensity score (PS) stratification and should not be interpreted as a description of the unweighted population. Treated/control patients are weighted by the proportion of the total patient population included in their PS stratum divided by the proportion of the total treated/control patient population included in their PS stratum.

³Value represents standard deviation where no % follows the value.

⁴Data not available in Merative[™] MarketScan[®] Research Databases

⁵The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ.

Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

⁶Covariate not included in the propensity score logistic regression model.

Data presented by a dash represents missing information.

Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 2a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
Site-Adjusted Analysis									
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (5.50, 5.26)	\0.001
Fixed Ratio 1:1 Propen	sity Score Matche	ed Conditional A	nalysis; Caliper= 0	0.025					
ACE Inhibitors	146,561	18,339.38	45.70	0.13	221	12.05	1.51	4.60 (3.37, 6.29)	<0.001
Beta Blockers	146,561	18,339.38	45.70	0.13	48	2.62	0.33	4.00 (3.37, 0.23)	\0.001
Fixed Ratio 1:1 Propen	sity Score Matche	ed Unconditional	l Analysis; Caliper	= 0.025					
ACE Inhibitors	146,561	26,519.18	66.09	0.18	277	10.45	1.89	4.87 (3.62, 6.55)	<0.001
Beta Blockers	146,561	23,036.82	57.41	0.16	52	2.26	0.35	4.07 (3.02, 0.33)	<0.001



Table 2b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I	nhibitors vs. Bet	a Blockers, Over	all						
Site-Adjusted Analy	sis								
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 3.20)	(0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	146,561	18,339.38	45.70	0.13	221	12.05	1.51	4.60 (3.37, 6.29)	<0.001
Beta Blockers	146,561	18,339.38	45.70	0.13	48	2.62	0.33	4.00 (3.37, 0.23)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Calip	per= 0.025					
ACE Inhibitors	146,561	26,519.18	66.09	0.18	277	10.45	1.89	4.87 (3.62, 6.55)	<0.001
Beta Blockers	146,561	23,036.82	57.41	0.16	52	2.26	0.35	4.07 (3.02, 0.33)	(0.001
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2018						
Site-Adjusted Analy	sis								
ACE Inhibitors	57,825	11,049.78	69.80	0.19	114	10.32	1.97	4.62 (2.95, 7.23)	<0.001
Beta Blockers	58,665	9,759.66	60.76	0.17	23	2.36	0.39	4.02 (2.55, 7.25)	(0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	57,713	7,922.91	50.14	0.14	96	12.12	1.66	4.80 (2.96, 7.77)	<0.001
Beta Blockers	57,713	7,922.91	50.14	0.14	20	2.52	0.35	4.00 (2.00, 7.77)	\$0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Calip	per= 0.025					
ACE Inhibitors	57,713	11,028.75	69.80	0.19	114	10.34	1.98	4.55 (2.91, 7.13)	<0.001
Beta Blockers	57,713	9,602.15	60.77	0.17	23	2.40	0.40	7.55 (2.51, 7.15)	\0.001



Table 2b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2019						
Site-Adjusted Analy	sis								
ACE Inhibitors	88,736	15,469.40	63.67	0.17	163	10.54	1.84	5.06 (3.41, 7.52)	<0.001
Beta Blockers	87,896	13,277.17	55.17	0.15	29	2.18	0.33	5.00 (5.41, 7.52)	0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	87,782	10,311.37	42.90	0.12	127	12.32	1.45	5.08 (3.31, 7.80)	<0.001
Beta Blockers	87,782	10,311.37	42.90	0.12	25	2.42	0.28	5.00 (5.51, 7.00)	0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unconditio	onal Analysis; Calip	oer= 0.025					
ACE Inhibitors	87,782	15,306.15	63.69	0.17	162	10.58	1.85	5.08 (3.42, 7.54)	<0.001
Beta Blockers	87,782	13,259.75	55.17	0.15	29	2.19	0.33	5.00 (5.42, 7.54)	.0.001



Table 3a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

						Incidence		Hazard Ratio (95%				
	Number of	Person-Years	Average Person	- Average Person-	Number	Rate per 1,000	Risk per 1,000	Confidence	Wald P-			
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	of Events	Person-Years	New Users	Interval)	Value			
Site-Adjusted Analysis												
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001			
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 3.20)	<0.001			
Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper= 0.025												
ACE Inhibitors	146,532	18,296.54	45.61	0.12	210	11.48	1.43	4.37 (3.20, 5.99)	<0.001			
Beta Blockers	146,532	18,296.54	45.61	0.12	48	2.62	0.33	4.57 (5.20, 5.55)	<0.001			
Fixed Ratio 1:1 Propensi	ity Score Match	ed Unconditional	Analysis; Caliper	= 0.025								
ACE Inhibitors	146,532	26,528.00	66.12	0.18	268	10.10	1.83	4.07 (3.07, 5.38)	<0.001			
Beta Blockers	146,532	22,995.47	57.32	0.16	60	2.61	0.41	4.07 (3.07, 3.38)	NO.001			



Table 3b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I	nhibitors vs. Bet	a Blockers, Over	all						
Site-Adjusted Analy	sis								
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	(0.00) 0.20)	0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	146,532	18,296.54	45.61	0.12	210	11.48	1.43	4.37 (3.20, 5.99)	<0.001
Beta Blockers	146,532	18,296.54	45.61	0.12	48	2.62	0.33	4.37 (3.20, 3.33)	(0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Calip	oer= 0.025					
ACE Inhibitors	146,532	26,528.00	66.12	0.18	268	10.10	1.83	4.07 (3.07, 5.38)	<0.001
Beta Blockers	146,532	22,995.47	57.32	0.16	60	2.61	0.41	4.07 (3.07, 5.30)	(0.001
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2018						
Site-Adjusted Analy	sis								
ACE Inhibitors	58,037	11,072.67	69.68	0.19	106	9.57	1.83	3.91 (2.53, 6.05)	<0.001
Beta Blockers	58,197	9,662.12	60.64	0.17	25	2.59	0.43	5.91 (2.55, 0.05)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	57,569	7,891.27	50.07	0.14	82	10.39	1.42	3.90 (2.42, 6.31)	<0.001
Beta Blockers	57,569	7,891.27	50.07	0.14	21	2.66	0.36	5.50 (2.42, 0.31)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Calip	per= 0.025					
ACE Inhibitors	57,569	10,984.10	69.69	0.19	105	9.56	1.82	3.86 (2.50, 5.98)	<0.001
Beta Blockers	57,569	9,561.71	60.66	0.17	25	2.61	0.43	3.00 (2.30, 3.98)	<0.001



Table 3b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2019						
Site-Adjusted Analy	sis								
ACE Inhibitors	88,495	15,455.32	63.79	0.17	162	10.48	1.83	4.18 (2.90, 6.02)	<0.001
Beta Blockers	88,335	13,333.35	55.13	0.15	35	2.62	0.40	4.10 (2.30, 0.02)	0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	87,862	10,317.16	42.89	0.12	124	12.02	1.41	4.77 (3.12, 7.28)	<0.001
Beta Blockers	87,862	10,317.16	42.89	0.12	26	2.52	0.30	4.77 (3.12, 7.20)	<0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unconditio	onal Analysis; Calip	per= 0.025					
ACE Inhibitors	87,862	15,346.61	63.80	0.17	161	10.49	1.83	4.16 (2.88, 5.99)	<0.001
Beta Blockers	87,862	13,261.84	55.13	0.15	35	2.64	0.40	4.10 (2.00, 5.99)	<0.001



Table 4a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

						Incidence		Hazard Ratio (95%	
	Number of	Person-Years	Average Person	- Average Person-	Number	Rate per 1,000	Risk per 1,000	Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	of Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Analysis									
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	\0.001
Fixed Ratio 1:1 Propens	ity Score Match	ed Conditional A	nalysis; Caliper= 0	0.025					
ACE Inhibitors	120,456	15,359.09	46.57	0.13	180	11.72	1.49	5.62 (3.86, 8.19)	<0.001
Beta Blockers	120,456	15,359.09	46.57	0.13	32	2.08	0.27	5.02 (5.00, 0.15)	\0.001
Fixed Ratio 1:1 Propens	ity Score Match	ed Unconditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	120,456	22,052.15	66.87	0.18	236	10.70	1.96	5.65 (4.01, 7.96)	<0.001
Beta Blockers	120,456	19,162.97	58.11	0.16	38	1.98	0.32	5.05 (4.01, 7.90)	\U.UUI



Table 4b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
New Users of ACE I	nhibitors vs. Bet	a Blockers, Over	all						
Site-Adjusted Analy	rsis								
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.10 (1120) 7.27)	101001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	r= 0.025					
ACE Inhibitors	120,456	15,359.09	46.57	0.13	180	11.72	1.49	5.62 (3.86, 8.19)	<0.001
Beta Blockers	120,456	15,359.09	46.57	0.13	32	2.08	0.27	5.02 (5.80, 8.19)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Cali	per= 0.025					
ACE Inhibitors	120,456	22,052.15	66.87	0.18	236	10.70	1.96	5.65 (4.01, 7.96)	<0.001
Beta Blockers	120,456	19,162.97	58.11	0.16	38	1.98	0.32	5.05 (4.01, 7.50)	<0.001
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2018						
Site-Adjusted Analy	rsis								
ACE Inhibitors	43,012	8,360.68	71.00	0.19	79	9.45	1.84	5.28 (2.99, 9.32)	<0.001
Beta Blockers	43,714	7,443.29	62.19	0.17	14	1.88	0.32	5.28 (2.99, 9.52)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	r= 0.025					
ACE Inhibitors	42,854	6,107.52	52.06	0.14	63	10.32	1.47	4.85 (2.67, 8.80)	<0.001
Beta Blockers	42,854	6,107.52	52.06	0.14	13	2.13	0.30	4.05 (2.07, 8.80)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Cali	per= 0.025					
ACE Inhibitors	42,854	8,332.13	71.02	0.19	79	9.48	1.84	E 10 (2 04 0 17)	<0.001
Beta Blockers	42,854	7,292.31	62.15	0.17	14	1.92	0.33	5.19 (2.94, 9.17)	<0.001



Table 4b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P-Value
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2019						
Site-Adjusted Analy	sis								
ACE Inhibitors	77,444	13,691.46	64.57	0.18	157	11.47	2.03	5.85 (3.81, 9.00)	<0.001
Beta Blockers	76,742	11,719.68	55.78	0.15	24	2.05	0.31	5.05 (5.01, 5.00)	0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Conditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	76,583	9,172.86	43.75	0.12	118	12.86	1.54	6.94 (4.17,	<0.001
Beta Blockers	76,583	9,172.86	43.75	0.12	17	1.85	0.22	11.54)	\0.001
Fixed Ratio 1:1 Prop	ensity Score Ma	tched Unconditio	nal Analysis; Cali	per= 0.025					
ACE Inhibitors	76,583	13,536.73	64.56	0.18	154	11.38	2.01	5.80 (3.77, 8.92)	<0.001
Beta Blockers	76,583	11,696.80	55.79	0.15	24	2.05	0.31	5.00 (5.77, 8.92)	<0.001



Table 5a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

						Incidence		Hazard Ratio (95%	
	Number of	Person-Years	Average Person	- Average Person-	Number	Rate per 1,000	Risk per 1,000	Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	of Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Analysis									
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	\$0.001
Fixed Ratio 1:1 Propens	ity Score Match	ed Conditional A	nalysis; Caliper= ().025					
ACE Inhibitors	120,459	15,372.45	46.61	0.13	183	11.90	1.52	5.08 (3.56, 7.27)	<0.001
Beta Blockers	120,459	15,372.45	46.61	0.13	36	2.34	0.30	5.00 (5.50, 7.27)	0.001
Fixed Ratio 1:1 Propens	ity Score Match	ed Unconditiona	l Analysis; Caliper	= 0.025					
ACE Inhibitors	120,459	22,072.24	66.93	0.18	230	10.42	1.91	5.36 (3.81, 7.52)	<0.001
Beta Blockers	120,459	19,173.40	58.14	0.16	39	2.03	0.32	5.50 (5.81, 7.52)	\0.001



Table 5b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	-	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence	Wald P-Value
New Users of ACE			Days at Risk	Tears at Risk	Events	Person-rears	New Users	Interval)	vvalu P-value
Site-Adjusted Analy									
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	r= 0.025					
ACE Inhibitors	120,459	15,372.45	46.61	0.13	183	11.90	1.52	5.08 (3.56, 7.27)	<0.001
Beta Blockers	120,459	15,372.45	46.61	0.13	36	2.34	0.30	5.08 (5.50, 7.27)	<0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Cali	per= 0.025					
ACE Inhibitors	120,459	22,072.24	66.93	0.18	230	10.42	1.91	5.36 (3.81, 7.52)	<0.001
Beta Blockers	120,459	19,173.40	58.14	0.16	39	2.03	0.32	5.50 (5.01, 7.52)	(0.001
New Users of ACE	nhibitors vs. Bet	a Blockers by Ye	ar, 2018						
Site-Adjusted Analy	vsis								
ACE Inhibitors	43,399	8,448.56	71.10	0.19	74	8.76	1.71	4.54 (2.60, 7.91)	<0.001
Beta Blockers	43,417	7,399.23	62.25	0.17	15	2.03	0.35	4.54 (2.00, 7.51)	(0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Caliper	r= 0.025					
ACE Inhibitors	43,119	6,151.67	52.11	0.14	59	9.59	1.37	4.54 (2.49, 8.27)	<0.001
Beta Blockers	43,119	6,151.67	52.11	0.14	13	2.11	0.30	4.54 (2.45, 0.27)	0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	onal Analysis; Cali	per= 0.025					
ACE Inhibitors	43,119	8,395.27	71.11	0.19	74	8.81	1.72	4.53 (2.60, 7.90)	<0.001
Beta Blockers	43,119	7,347.72	62.24	0.17	15	2.04	0.35	7.55 (2.00, 7.50)	N0.001



Table 5b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

	Number of	Person-Years	Average Person	- Average Person-	Number of	Incidence Rate per 1,000	Risk per 1,000	Hazard Ratio (95% Confidence	
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	Events	Person-Years	New Users	Interval)	Wald P-Value
New Users of ACE I	nhibitors vs. Bet	a Blockers by Ye	ar, 2019						
Site-Adjusted Analy	sis								
ACE Inhibitors	77,060	13,623.68	64.57	0.18	156	11.45	2.02	5.86 (3.81, 9.01)	<0.001
Beta Blockers	77,042	11,774.17	55.82	0.15	24	2.04	0.31	5.00 (5.01, 5.01)	(0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Conditiona	l Analysis; Calipei	r= 0.025					
ACE Inhibitors	76,734	9,182.68	43.71	0.12	115	12.52	1.50	5.00 (3.20, 7.82)	<0.001
Beta Blockers	76,734	9,182.68	43.71	0.12	23	2.50	0.30	5.00 (5.20, 7.82)	\0.001
Fixed Ratio 1:1 Prop	pensity Score Ma	tched Unconditio	nal Analysis; Cali	per= 0.025					
ACE Inhibitors	76,734	13,565.37	64.57	0.18	156	11.50	2.03	5.86 (3.81, 9.01)	<0.001
Beta Blockers	76,734	11,726.02	55.82	0.15	24	2.05	0.31	5.00 (5.81, 9.01)	<0.001



Table 6a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

	Number of	Person-Years	Average Person	Average Person-	Number of	Incidence Rate per 1,000	Risk per 1,000	Hazard Ratio (95% Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Ana	lysis								
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 3.28)	<0.001
Propensity Score	Adjusted Stratif	ied Analysis; Per	centiles= 5, Trimr	ned					
ACE Inhibitors	253,311	46,437.64	66.96	0.18	418	9.00	1.65	4.89 (3.79, 6.31)	<0.001
Beta Blockers	235,734	36,648.76	56.78	0.16	84	2.29	0.36	4.05 (5.79, 0.51)	NO.001



Table 6b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person- Davs at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I					LVCIII			intervaly	Value
Site-Adjusted Analys		,							
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4 17 (2 20 E 20)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 5.28)	<0.001
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	253,311	46,437.64	66.96	0.18	418	9.00	1.65	4.89 (3.79, 6.31)	<0.001
Beta Blockers	235,734	36,648.76	56.78	0.16	84	2.29	0.36	4.89 (5.79, 0.51)	<0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2018						
Site-Adjusted Analys	sis								
ACE Inhibitors	99,808	19,340.45	70.78	0.19	165	8.53	1.65	3.89 (2.71, 5.58)	<0.001
Beta Blockers	93,967	15,439.46	60.01	0.16	36	2.33	0.38	5.89 (2.71, 5.58)	<0.001
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	99,806	19,340.21	70.78	0.19	165	8.53	1.65	4.51 (3.04, 6.68)	<0.001
Beta Blockers	93,965	15,439.29	60.01	0.16	36	2.33	0.38	4.51 (5.04, 0.08)	<0.001
New Users of ACE I	nhibitors vs. Beta	Blockers by Yea	ır, 2019						
Site-Adjusted Analys	sis								
ACE Inhibitors	153,505	27,097.55	64.48	0.18	253	9.34	1.65	4.38 (3.22, 5.96)	<0.001
Beta Blockers	141,768	21,209.43	54.64	0.15	48	2.26	0.34	4.30 (3.22, 3.90)	\U.UU1
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	153,503	27,097.30	64.48	0.18	253	9.34	1.65	5.18 (3.71, 7.23)	<0.001
Beta Blockers	141,762	21,208.74	54.64	0.15	48	2.26	0.34	5.10 (5.71, 7.25)	\U.UUI



Table 7a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

	Number of	Person-Years	Average Person	- Average Person-	Number of	Incidence Rate per 1,000	Risk per 1,000	Hazard Ratio (95% Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Ana	lysis								
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65	4.17 (3.30, 5.28)	<0.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 3.28)	\0.001
Propensity Score	Adjusted Stratif	ied Analysis; Per	centiles= 5, Trimr	ned					
ACE Inhibitors	253,311	46,437.64	66.96	0.18	418	9.00	1.65	4.89 (3.79, 6.31)	<0.001
Beta Blockers	235,734	36,648.76	56.78	0.16	84	2.29	0.36	4.09 (3.79, 0.31)	\0.001



Table 7b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence	Wald P- Value
New Users of ACE I			Days at Risk	Tears at Risk	Events	Person-rears	New Osers	Interval)	value
Site-Adjusted Analys									
ACE Inhibitors	253,313	46,438.00	66.96	0.18	418	9.00	1.65		10.001
Beta Blockers	235,735	36,648.88	56.78	0.16	84	2.29	0.36	4.17 (3.30, 5.28)	<0.001
Propensity Score Ad	ljusted Stratified /	Analysis; Percent	iles= 5, Trimmed						
ACE Inhibitors	253,311	46,437.64	66.96	0.18	418	9.00	1.65	4.89 (3.79, 6.31)	<0.001
Beta Blockers	235,734	36,648.76	56.78	0.16	84	2.29	0.36	4.89 (3.79, 0.31)	<0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2018						
Site-Adjusted Analy	sis								
ACE Inhibitors	99,808	19,340.45	70.78	0.19	165	8.53	1.65	3.89 (2.71, 5.58)	<0.001
Beta Blockers	93,967	15,439.46	60.01	0.16	36	2.33	0.38	3.65 (2.71, 3.56)	\0.001
Propensity Score Ad	ljusted Stratified /	Analysis; Percent	iles= 5, Trimmed						
ACE Inhibitors	99,806	19,340.21	70.78	0.19	165	8.53	1.65	4.51 (3.04, 6.68)	<0.001
Beta Blockers	93,965	15,439.29	60.01	0.16	36	2.33	0.38	4.51 (5.64, 6.66)	0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2019						
Site-Adjusted Analy	sis								
ACE Inhibitors	153,505	27,097.55	64.48	0.18	253	9.34	1.65	4.38 (3.22, 5.96)	<0.001
Beta Blockers	141,768	21,209.43	54.64	0.15	48	2.26	0.34		
Propensity Score Ad	ljusted Stratified /	Analysis; Percent	iles= 5, Trimmed						
ACE Inhibitors	153,504	27,097.31	64.48	0.18	253	9.34	1.65	5.18 (3.71, 7.23)	<0.001
Beta Blockers	141,762	21,208.74	54.64	0.15	48	2.26	0.34		



Table 8a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

	Number of	Person-Years	Average Person	Average Person-	Number of	Incidence Rate per 1,000	Risk per 1,000	Hazard Ratio (95% Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Ana	lysis								
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	<0.001
Propensity Score	Adjusted Stratif	ied Analysis; Per	centiles= 5, Trimr	ned					
ACE Inhibitors	191,796	35,490.69	67.59	0.19	346	9.75	1.80	6.22 (4.60, 8.42)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	0.22 (4.00, 8.42)	<0.001



Table 8b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person- Davs at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE II					LVEIIUS	reison-reais	1464 03613	intervalj	value
Site-Adjusted Analys		· · · · · , · · · ·							
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80		<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.46 (4.10, 7.27)	<0.001
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	191,796	35,490.69	67.59	0.19	346	9.75	1.80	6.22 (4.60, 8.42)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	0.22 (4.00, 8.42)	<0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2018						
Site-Adjusted Analys	sis								
ACE Inhibitors	68,205	13,435.36	71.95	0.20	124	9.23	1.82	4.73 (3.03, 7.39)	<0.001
Beta Blockers	65,471	10,974.75	61.23	0.17	23	2.10	0.35	4.73 (3.03, 7.39)	<0.001
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	68,203	13,434.99	71.95	0.20	124	9.23	1.82	5.39 (3.36, 8.63)	<0.001
Beta Blockers	65,470	10,974.50	61.23	0.17	23	2.10	0.35	5.55 (5.56, 8.65)	<0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2019						
Site-Adjusted Analys	sis								
ACE Inhibitors	123,594	22,055.92	65.18	0.18	222	10.07	1.80	5.99 (4.11, 8.72)	<0.001
Beta Blockers	115,146	17,407.80	55.22	0.15	31	1.78	0.27	5.55 (4.11, 0.72)	\U.UU1
Propensity Score Ad	justed Stratified	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	123,592	22,055.45	65.18	0.18	222	10.07	1.80	6.78 (4.57, 10.05)	<0.001
Beta Blockers	115,141	17,407.13	55.22	0.15	31	1.78	0.27	0.70 (4.37, 10.03)	\U.UUI



Table 9a. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type

	Number of	Person-Years	Average Person	- Average Person-	Number of	Incidence Rate per 1,000	Risk per 1,000	Hazard Ratio (95% Confidence	Wald P-
Medical Product	New Users	at Risk	Days at Risk	Years at Risk	Events	Person-Years	New Users	Interval)	Value
Site-Adjusted Ana	lysis								
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	<0.001
Propensity Score	Adjusted Stratif	ied Analysis; Per	centiles= 5, Trimr	ned					
ACE Inhibitors	191,796	35,490.69	67.59	0.19	346	9.75	1.80	6.25 (4.62, 8.45)	<0.001
Beta Blockers	180,615	28,382.18	57.40	0.16	54	1.90	0.30	0.23 (4.02, 8.43)	<0.001



Table 9b. Effect Estimates for New Users of ACE Inhibitors vs. Beta Blockers and Angioedema, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, by Analysis Type and Year

Medical Product	Number of New Users	Person-Years at Risk	Average Person Days at Risk	- Average Person- Years at Risk	Number of Events	Incidence Rate per 1,000 Person-Years	Risk per 1,000 New Users	Hazard Ratio (95% Confidence Interval)	Wald P- Value
New Users of ACE I	nhibitors vs. Beta	a Blockers, Overa							
Site-Adjusted Analys	sis								
ACE Inhibitors	191,799	35,491.28	67.59	0.19	346	9.75	1.80	5.46 (4.10, 7.27)	<0.001
Beta Blockers	180,617	28,382.55	57.40	0.16	54	1.90	0.30	5.40 (4.10, 7.27)	<0.001
Propensity Score Ad	justed Stratified /	Analysis; Percenti	iles= 5, Trimmed						
ACE Inhibitors	191,796	35,490.69	67.59	0.19	346	9.75	1.80	6.25 (4.62, 8.45)	<0.001
Beta Blockers	180,615	28,382.18	57.40	0.16	54	1.90	0.30	0.23 (4.02, 8.43)	<0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2018						
Site-Adjusted Analys	sis								
ACE Inhibitors	68,205	13,435.36	71.95	0.20	124	9.23	1.82	4.73 (3.03, 7.39)	<0.001
Beta Blockers	65,471	10,974.75	61.23	0.17	23	2.10	0.35	4.73 (3.03, 7.39)	<0.001
Propensity Score Ad	justed Stratified	Analysis; Percent	iles= 5, Trimmed						
ACE Inhibitors	68,204	13,435.24	71.95	0.20	124	9.23	1.82	5.39 (3.36, 8.63)	<0.001
Beta Blockers	65,469	10,974.49	61.23	0.17	23	2.10	0.35	5.55 (5.56, 8.65)	\0.001
New Users of ACE I	nhibitors vs. Beta	a Blockers by Yea	ır, 2019						
Site-Adjusted Analys	sis								
ACE Inhibitors	123,594	22,055.92	65.18	0.18	222	10.07	1.80	5.99 (4.11, 8.72)	<0.001
Beta Blockers	115,146	17,407.80	55.22	0.15	31	1.78	0.27	5.55 (4.11, 0.72)	×0.001
Propensity Score Ad	justed Stratified	Analysis; Percent	iles= 5, Trimmed						
ACE Inhibitors	123,591	22,055.31	65.18	0.18	222	10.07	1.80	6.78 (4.57, 10.05)	<0.001
Beta Blockers	115,140	17,406.89	55.22	0.15	31	1.78	0.27	0.76 (4.57, 10.05)	<0.001



	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model without Year (PSM)				New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model with Year (PSM)				
	ACE Inl	ACE Inhibitors		Beta Blockers		ACE Inhibitors		lockers	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Members meeting enrollment and demograp	hic requirement	ts							
Enrolled at any point during the query period	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	
Had required coverage type (medical and/or									
drug coverage)	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	
Enrolled during specified age range	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	
Had requestable medical charts	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Met demographic requirements (sex, race,									
and Hispanic origin)	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Members with a valid index event									
Had any cohort-defining claim during the									
query period	2,007,552	22,239,289	1,878,894	22,367,947	2,007,552	22,239,289	1,878,894	22,367,947	
Claim recorded during specified age range	2,007,095	457	1,876,924	1,970	2,007,095	457	1,876,924	1,970	
Episode defining index claim recorded during									
the query period	594,539	1,412,556	591,955	1,284,969	594,539	1,412,556	591,955	1,284,969	
Members with required pre-index history									
Had sufficient pre-index continuous									
enrollment	328,814	265,725	358,736	233,219	328,814	265,725	358,736	233,219	
Met inclusion and exclusion criteria ¹	265,259	63,555	247,682	111,054	265,259	63,555	247,682	111,054	
Evidence of ACE Inhibitors, Beta Blockers,									
Angiotensin II Receptor Blockers, Aliskiren	N/A	63,401	N/A	110,691	N/A	63,401	N/A	110,691	
Evidence of angioedema (exclusion)	N/A	225	N/A	1,084	N/A	225	N/A	1,084	
Met event incidence criteria	265,259	0	247,682	0	265,259	0	247,682	0	
Members with required post-index follow-up									
Had sufficient post-index continuous									
enrollment	265,259	0	247,682	0	265,259	0	247,682	0	
Had minimum days' supply on index date	265,259	0	247,682	0	265,259	0	247,682	0	
Had index episode of at least required length	265,259	0	247,682	0	265,259	0	247,682	0	
Had index episode longer than blackout									
period	265,259	0	247,682	0	265,259	0	247,682	0	



		rt Lookback, Pr	ors vs. Beta Bloc opensity Score I (PSM)	,	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model with Year (PSM)				
	ACE Inh	ibitors	Beta Bl	ockers	ACE Inh	nibitors	Beta Blockers		
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Did not have an event during blackout period	265,259	0	247,682	0	265,259	0	247,682	0	
Final cohort									
Number of members	265,259	N/A	247,682	N/A	265,259	N/A	247,682	N/A	
Number of episodes	265,259	N/A	247,682	N/A	265,259	N/A	247,682	N/A	
Members meeting comparative cohort eligibi	lity requirement	s							
Excluded due to same-day initition of both									
exposure groups	253,727	11,532	236,150	11,532	253,727	11,532	236,150	11,532	
Excluded due to prior initiation of other									
exposure group	253,313	414	235,735	415	253,313	414	235,735	415	
Excluded due to propensity score trimming	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Included in comparative analysis	146,561	106,752	146,561	89,174	146,532	106,781	146,532	89,203	
Additional information									
Number of events in comparative analysis	277	N/A	52	N/A	268	N/A	60	N/A	

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.



	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model without F Year (PSM)			New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model with Yea (PSM)				
	ACE Inl	ACE Inhibitors		Beta Blockers		ACE Inhibitors		ockers
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demograp	hic requirement	ts						
Enrolled at any point during the query period	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A
Had required coverage type (medical and/or								
drug coverage)	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500
Enrolled during specified age range	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103
Had requestable medical charts	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0
Met demographic requirements (sex, race,								
and Hispanic origin)	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0
Members with a valid index event								
Had any cohort-defining claim during the								
query period	2,007,552	22,239,289	1,878,894	22,367,947	2,007,552	22,239,289	1,878,894	22,367,947
Claim recorded during specified age range	2,007,095	457	1,876,924	1,970	2,007,095	457	1,876,924	1,970
Episode defining index claim recorded during								
the query period	594,539	1,412,556	591,955	1,284,969	594,539	1,412,556	591,955	1,284,969
Members with required pre-index history								
Had sufficient pre-index continuous								
enrollment	256,754	337,785	285,532	306,423	256,754	337,785	285,532	306,423
Met inclusion and exclusion criteria ¹	200,121	56,633	188,926	96,606	200,121	56,633	188,926	96,606
Evidence of ACE Inhibitors, Beta Blockers,								
Angiotensin II Receptor Blockers, Aliskiren	N/A	56,445	N/A	96,166	N/A	56,445	N/A	96,166
Evidence of angioedema (exclusion)	N/A	283	N/A	1,209	N/A	283	N/A	1,209
Met event incidence criteria	200,121	0	188,926	0	200,121	0	188,926	0
Members with required post-index follow-up								
Had sufficient post-index continuous								
enrollment	200,121	0	188,926	0	200,121	0	188,926	0
Had minimum days' supply on index date	200,121	0	188,926	0	200,121	0	188,926	0
Had index episode of at least required length	200,121	0	188,926	0	200,121	0	188,926	0
Had index episode longer than blackout								
period	200,121	0	188,926	0	200,121	0	188,926	0



	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model without P Year (PSM)				New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model with Yea (PSM)				
	ACE Inh	ibitors	Beta Bl	ockers	ACE Inf	nibitors	Beta Blockers		
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Did not have an event during blackout period	200,121	0	188,926	0	200,121	0	188,926	0	
Final cohort									
Number of members	200,121	N/A	188,926	N/A	200,121	N/A	188,926	N/A	
Number of episodes	200,121	N/A	188,926	N/A	200,121	N/A	188,926	N/A	
Members meeting comparative cohort eligibi	lity requirement	S							
Excluded due to same-day initition of both									
exposure groups	191,853	8,268	180,658	8,268	191,853	8,268	180,658	8,268	
Excluded due to prior initiation of other									
exposure group	191,799	54	180,617	41	191,799	54	180,617	41	
Excluded due to propensity score trimming	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Included in comparative analysis	120,456	71,343	120,456	60,161	120,459	71,340	120,459	60,158	
Additional information									
Number of events in comparative analysis	236	N/A	38	N/A	230	N/A	39	N/A	

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.



	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model without Year (PSS)				New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model with Year (PSS)				
	ACE In	ACE Inhibitors		Beta Blockers		ACE Inhibitors		lockers	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Members meeting enrollment and demograp	hic requirement	ts							
Enrolled at any point during the query period	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	
Had required coverage type (medical and/or									
drug coverage)	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	
Enrolled during specified age range	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	
Had requestable medical charts	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Met demographic requirements (sex, race,									
and Hispanic origin)	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Members with a valid index event									
Had any cohort-defining claim during the									
query period	2,007,552	22,239,289	1,878,894	22,367,947	2,007,552	22,239,289	1,878,894	22,367,947	
Claim recorded during specified age range	2,007,095	457	1,876,924	1,970	2,007,095	457	1,876,924	1,970	
Episode defining index claim recorded during									
the query period	594,539	1,412,556	591,955	1,284,969	594,539	1,412,556	591,955	1,284,969	
Members with required pre-index history									
Had sufficient pre-index continuous									
enrollment	328,814	265,725	358,736	233,219	328,814	265,725	358,736	233,219	
Met inclusion and exclusion criteria ¹	265,259	63,555	247,682	111,054	265,259	63,555	247,682	111,054	
Evidence of ACE Inhibitors, Beta Blockers,									
Angiotensin II Receptor Blockers, Aliskiren	N/A	63,401	N/A	110,691	N/A	63,401	N/A	110,691	
Evidence of angioedema (exclusion)	N/A	225	N/A	1,084	N/A	225	N/A	1,084	
Met event incidence criteria	265,259	0	247,682	0	265,259	0	247,682	0	
Members with required post-index follow-up									
Had sufficient post-index continuous									
enrollment	265,259	0	247,682	0	265,259	0	247,682	0	
Had minimum days' supply on index date	265,259	0	247,682	0	265,259	0	247,682	0	
Had index episode of at least required length	265,259	0	247,682	0	265,259	0	247,682	0	
Had index episode longer than blackout									
period	265,259	0	247,682	0	265,259	0	247,682	0	



		rt Lookback, Pr	ors vs. Beta Bloc opensity Score I (PSS)	,	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Short Lookback, Propensity Score Model with Year (PSS)				
	ACE Inh	ibitors	Beta Bl	ockers	ACE Inh	ibitors	Beta Blockers		
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Did not have an event during blackout period	265,259	0	247,682	0	265,259	0	247,682	0	
Final cohort									
Number of members	265,259	N/A	247,682	N/A	265,259	N/A	247,682	N/A	
Number of episodes	265,259	N/A	247,682	N/A	265,259	N/A	247,682	N/A	
Members meeting comparative cohort eligibi	lity requirement	S							
Excluded due to same-day initition of both									
exposure groups	253,727	11,532	236,150	11,532	253,727	11,532	236,150	11,532	
Excluded due to prior initiation of other									
exposure group	253,313	414	235,735	415	253,313	414	235,735	415	
Excluded due to propensity score trimming	253,311	2	235,734	1	253,311	2	235,734	1	
Included in comparative analysis	253,311	0	235,734	0	253,311	0	235,734	0	
Additional information									
Number of events in comparative analysis	418	N/A	84	N/A	418	N/A	84	N/A	

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.



	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model without P Year (PSS)				New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model with Year (PSS)				
	ACE Inl	ACE Inhibitors		Beta Blockers		ACE Inhibitors		ockers	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Members meeting enrollment and demograp	hic requirement	ts							
Enrolled at any point during the query period	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	32,466,444	N/A	
Had required coverage type (medical and/or									
drug coverage)	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	30,652,944	1,813,500	
Enrolled during specified age range	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	24,246,841	6,406,103	
Had requestable medical charts	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Met demographic requirements (sex, race,									
and Hispanic origin)	24,246,841	0	24,246,841	0	24,246,841	0	24,246,841	0	
Members with a valid index event									
Had any cohort-defining claim during the									
query period	2,007,552	22,239,289	1,878,894	22,367,947	2,007,552	22,239,289	1,878,894	22,367,947	
Claim recorded during specified age range	2,007,095	457	1,876,924	1,970	2,007,095	457	1,876,924	1,970	
Episode defining index claim recorded during									
the query period	594,539	1,412,556	591,955	1,284,969	594,539	1,412,556	591,955	1,284,969	
Members with required pre-index history									
Had sufficient pre-index continuous									
enrollment	256,754	337,785	285,532	306,423	256,754	337,785	285,532	306,423	
Met inclusion and exclusion criteria ¹	200,121	56,633	188,926	96,606	200,121	56,633	188,926	96,606	
Evidence of ACE Inhibitors, Beta Blockers,									
Angiotensin II Receptor Blockers, Aliskiren	N/A	56,445	N/A	96,166	N/A	56,445	N/A	96,166	
Evidence of angioedema (exclusion)	N/A	283	N/A	1,209	N/A	283	N/A	1,209	
Met event incidence criteria	200,121	0	188,926	0	200,121	0	188,926	0	
Members with required post-index follow-up									
Had sufficient post-index continuous									
enrollment	200,121	0	188,926	0	200,121	0	188,926	0	
Had minimum days' supply on index date	200,121	0	188,926	0	200,121	0	188,926	0	
Had index episode of at least required length	200,121	0	188,926	0	200,121	0	188,926	0	
Had index episode longer than blackout									
period	200,121	0	188,926	0	200,121	0	188,926	0	




	New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model without P Year (PSS)				New Users of ACE Inhibitors vs. Beta Blockers, Pre- Pandemic, Long Lookback, Propensity Score Model with Yea (PSS)				
	ACE Inh	nibitors	Beta Bl	Beta Blockers		nibitors	Beta Blockers		
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Did not have an event during blackout period	200,121	0	188,926	0	200,121	0	188,926	0	
Final cohort									
Number of members	200,121	N/A	188,926	N/A	200,121	N/A	188,926	N/A	
Number of episodes	200,121	N/A	188,926	N/A	200,121	N/A	188,926	N/A	
Members meeting comparative cohort eligibil	lity requirement	S							
Excluded due to same-day initition of both									
exposure groups	191,853	8,268	180,658	8,268	191,853	8,268	180,658	8,268	
Excluded due to prior initiation of other									
exposure group	191,799	54	180,617	41	191,799	54	180,617	41	
Excluded due to propensity score trimming	191,796	3	180,617	0	191,796	3	180,615	2	
Included in comparative analysis	191,796	0	180,617	0	191,796	0	180,615	0	
Additional information									
Number of events in comparative analysis	346	N/A	54	N/A	346	N/A	54	N/A	

¹Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.



Figure 1a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019












Figure 1b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018











Figure 1c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019














Figure 2a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019








Propensity Score Fixed Ratio 1:1 Adjusted Cohort, Matched Caliper = 0.025



Figure 2b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018








Propensity Score Fixed Ratio 1:1 Adjusted Cohort, Matched Caliper = 0.025



Figure 2c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019











Figure 3a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019



Propensity Score Fixed Ratio 1:1 Adjusted Cohort, Matched Caliper = 0.025







Figure 3b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018



Propensity Score Fixed Ratio 1:1 Adjusted Cohort, Matched Caliper = 0.025







Figure 3c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019











Figure 4a. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019












Figure 4b. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018








Unadjusted Propensity Score Distribution



Figure 4c. Histograms Depicting Propensity Score Distributions Before and After Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019



Propensity Score Fixed Ratio 1:1 Adjusted Cohort, Matched Caliper = 0.025






Figure 5a. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 5b. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 5c. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 6a. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 6b. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 6c. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 7a. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 7b. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 7c. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 8a. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 8b. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 8c. Histograms Depicting Propensity Score Distributions Before Adjustment for New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 9a. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Site-Adjusted Analyses in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

Analysis		
Pre Era, Short Lookback, PS Year- (PSM)		
Overall		4.17 (3.30, 5.28)
Year	-	()
2018		4.62 (2.95, 7.23)
2019		5.06 (3.41, 7.52)
Pre Era, Short Lookback, PS Year+ (PSM)	-	
Overall		4.17 (3.30, 5.28)
Year	-	, , , , , , , , , , , , , , , , , , ,
2018		3.91 (2.53, 6.05)
2019	_	4.18 (2.90, 6.02)
Pre Era, Long Lookback, PS Year- (PSM)	-	(<i>'</i>
Overall		5.46 (4.10, 7.27)
Year	_	
2018	_	5.28 (2.99, 9.32)
2019		5.85 (3.81, 9.00)
Pre Era, Long Lookback, PS Year+ (PSM)		
Overall		5.46 (4.10, 7.27)
Year	_	
2018		4.54 (2.60, 7.91)
2019	_	5.86 (3.81, 9.01)
Pre Era, Short Lookback, PS Year- (PSS)		
Overall	e	4.17 (3.30 <i>,</i> 5.28)
Year		
2018	_	3.89 (2.71, 5.58)
2019	_	4.38 (3.22, 5.96)
Pre Era, Short Lookback, PS Year+ (PSS)		
Overall	_ _	4.17 (3.30, 5.28)
Year		
2018	_	3.89 (2.71, 5.58)
2019	_	4.38 (3.22, 5.96)
Pre Era, Long Lookback, PS Year- (PSS)		
Overall	_	5.46 (4.10, 7.27)
Year		
2018	_	4.73 (3.03, 7.39)
2019	_	5.99 (4.11, 8.72)
Pre Era, Long Lookback, PS Year+ (PSS)		
Overall	_	5.46 (4.10, 7.27)
Year		
2018	_	4.73 (3.03, 7.39)
2019	e	5.99 (4.11, 8.72)
	2 3 4 5 6 7 8 9	
	HR (95% CI)	

Notes:

Pre Era: Pre-Pandemic Era (May 22, 2018 to December 11, 2019)

PS Year-: Propensity Score Model without Year

PS Year+: Propensity Score Model with Year

PSM: Propensity Score Matching



Figure 9b. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Matched Conditional Analyses in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

Analysis		
Pre Era, Short Lookback, PS Year- (PSM) ¹		
Overall	_	4.60 (3.37, 6.29)
Year		
2018	_	4.80 (2.96, 7.77)
2019	_	5.08 (3.31, 7.80)
Pre Era, Short Lookback, PS Year+ (PSM) ¹		
Overall	_	4.37 (3.20, 5.99)
Year		
2018	_	3.90 (2.42, 6.31)
2019	_	4.77 (3.12, 7.28)
Pre Era, Long Lookback, PS Year- (PSM) ¹		
Overall	_	5.62 (3.86, 8.19)
Year		
2018	_	4.85 (2.67, 8.80)
2019	_	<u> </u>
Pre Era, Long Lookback, PS Year+ (PSM) ¹		
Overall	_	5.08 (3.56, 7.27)
Year		
2018	_	4.54 (2.49, 8.27)
2019	e	5.00 (3.20, 7.82)
	2 4 6 8 1	
	HR (95% CI)	

Notes:

¹Fixed Ratio 1:1 Propensity Score Matched Conditional Analysis; Caliper=0.025

Pre Era: Pre-Pandemic Era (May 22, 2018 to December 11, 2019)

PS Year-: Propensity Score Model without Year

PS Year+: Propensity Score Model with Year

PSM: Propensity Score Matching



Figure 9c. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Matched Unconditional Analyses in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

Analysis		
Pre Era, Short Lookback, PS Year- (PSM) ¹		
Overall	_	4.87 (3.62, 6.55
Year		
2018	_	4.55 (2.91, 7.13
2019	e	- 5.08 (3.42, 7.54
Pre Era, Short Lookback, PS Year+ (PSM) ¹		
Overall	_	4.07 (3.07, 5.38
Year		
2018	_	3.86 (2.50, 5.98
2019	_	4.16 (2.88, 5.99
Pre Era, Long Lookback, PS Year- (PSM) ¹		
Overall		 5.65 (4.01, 7.96
Year		
2018	_	5.19 (2.94, 9.17
2019	_	5.80 (3.77, 8.92
Pre Era, Long Lookback, PS Year+ (PSM) ¹		
Overall		- 5.36 (3.81, 7.52
Year		
2018	_	4.53 (2.60, 7.90
2019	_	5.86 (3.81 <i>,</i> 9.02
	2 3 4 5 6 7	
I	2 3 4 5 6 7 HR (95% CI)	0.3

Notes:

¹Fixed Ratio 1:1 Propensity Score Matched Unconditional Analysis; Caliper=0.025

Pre Era: Pre-Pandemic Era (May 22, 2018 to December 11, 2019)

PS Year-: Propensity Score Model without Year

PS Year+: Propensity Score Model with Year

PSM: Propensity Score Matching



Figure 9d. Forest Plot of Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Propensity Score Stratified Analyses in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019

Analysis		
Pre Era, Short Lookback, PS Year- (PSS) ¹		
Overall		4.89 (3.79, 6.31)
Year		
2018	B	4.51 (3.04, 6.68)
2019	_	5.18 (3.71, 7.23)
Pre Era, Short Lookback, PS Year+ (PSS) ¹		
Overall	_	4.89 (3.79, 6.31)
Year		
2018	_	4.51 (3.04, 6.68)
2019	_	5.18 (3.71, 7.23)
Pre Era, Long Lookback, PS Year- (PSS) ¹		
Overall	_	6.22 (4.60, 8.42)
Year		
2018	_	5.39 (3.36, 8.63)
2019	_	6.78 (4.57, 10.05)
Pre Era, Long Lookback, PS Year+ (PSS) ¹		
Overall	_	6.25 (4.62, 8.45)
Year		
2018	_	5.39 (3.36, 8.63)
2019		6.78 (4.57, 10.05)
	2 3 4 5 6 7 8	 10
I I	2 5 4 5 6 7 8 HR (95% CI)	

Notes:

¹Percentiles: 5

Pre Era: Pre-Pandemic Era (May 22, 2018 to December 11, 2019)

PS Year-: Propensity Score Model without Year

PS Year+: Propensity Score Model with Year

PSM: Propensity Score Matching



Figure 10a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 10b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 10c. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 10d. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 10e. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 10f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 10g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 10h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 10i. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 11a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 11b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 11c. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 11d. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 11e. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 11f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 11g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 11h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 11i. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 12a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 12b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 12c. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 12d. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 12e. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 12f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 12g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 12h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 12i. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 13a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 13b. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 13c. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019






Figure 13d. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 13e. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 13f. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 13g. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 13h. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Conditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 13i. Adjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) from the Unconditional Matched Population after New Users of ACE Inhibitors vs Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSM) in the Merative[™] MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 14a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 14b. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 14c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 15a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 15b. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 15c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Short Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan[®] Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 16a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 16b. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018






Figure 16c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model without Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019






Figure 17a. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019






Figure 17b. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2018







Figure 17c. Unadjusted Kaplan-Meier Estimate and 95% Confidence Interval of Angioedema Not Occurring Among New Users of ACE Inhibitors vs. Beta Blockers, Pre-Pandemic, Long Lookback, Propensity Score Model with Year (PSS) from the Whole Population in the Merative™ MarketScan® Research Databases from May 22, 2018 to December 11, 2019, Year: 2019





Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2010	09/30/2022

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.



Generic Name	Brand Name
	ACE Inhibitors
amlodipine besylate/benazepril HCl	Lotrel
amlodipine besylate/benazepril HCl	amlodipine-benazepril
benazepril HCl	Lotensin
benazepril HCl	benazepril
benazepril HCl/hydrochlorothiazide	Lotensin HCT
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
captopril	captopril
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalapril maleate	enalapril maleate
enalapril maleate/hydrochlorothiazide	Vaseretic
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
fosinopril sodium	fosinopril
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
lisinopril	lisinopril
lisinopril/hydrochlorothiazide	Zestoretic
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
moexipril HCl	moexipril
moexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	Aceon
perindopril erbumine	perindopril erbumine
quinapril HCl	Accupril
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
trandolapril	Mavik
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
	Beta Blockers

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request



Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name Brand Name		
acebutolol HCl	Sectral	
acebutolol HCl	acebutolol	
atenolol	Tenormin	
atenolol	atenolol	
atenolol/chlorthalidone	Tenoretic 100	
atenolol/chlorthalidone	Tenoretic 50	
atenolol/chlorthalidone	atenolol-chlorthalidone	
betaxolol HCl	betaxolol	
bisoprolol fumarate	Zebeta	
bisoprolol fumarate	bisoprolol fumarate	
bisoprolol fumarate/hydrochlorothiazide	Ziac	
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide	
carvedilol	Coreg	
carvedilol	carvedilol	
carvedilol phosphate	Coreg CR	
carvedilol phosphate	carvedilol phosphate	
labetalol HCl	labetalol	
metoprolol succinate	Kapspargo Sprinkle	
metoprolol succinate	Toprol XL	
metoprolol succinate	metoprolol succinate	
metoprolol succinate/hydrochlorothiazide	Dutoprol	
metoprolol succinate/hydrochlorothiazide	metoprolol su-hydrochlorothiaz	
metoprolol tartrate	Lopressor	
metoprolol tartrate	metoprolol tartrate	
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz	
nadolol	Corgard	
nadolol	nadolol	
nadolol/bendroflumethiazide	Corzide	
nadolol/bendroflumethiazide	nadolol-bendroflumethiazide	
nebivolol HCl	Bystolic	
nebivolol HCl	nebivolol	
pindolol	pindolol	
propranolol HCl	Inderal LA	
propranolol HCI	Inderal XL	
propranolol HCI	InnoPran XL	
propranolol HCI	propranolol	
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid	
sotalol HCl	Betapace	



	Generic Name	Brand Name
sotalol HCl		Betapace AF
sotalol HCl		Sorine
sotalol HCl		Sotalol AF
sotalol HCl		Sotylize
sotalol HCl		sotalol
timolol maleate		timolol maleate

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request



Code	Description	Code Category	Code Type
Angioedema (Outcome)		
T78.3XXA	Angioneurotic edema, initial encounter	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
Angioedema (Exclusion)		
T78.3XXA	Angioneurotic edema, initial encounter	Diagnosis	ICD-10-CM
T78.3XXD	Angioneurotic edema, subsequent encounter	Diagnosis	ICD-10-CM
T78.3XXS	Angioneurotic edema, sequela	Diagnosis	ICD-10-CM



Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exp	posure Incidence Criteria in this Request

Generic Name	Brand Name
Angiotensin	Receptor Blockers (ARBs)
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
azilsartan medoxomil	Edarbi
zilsartan medoxomil/chlorthalidone	Edarbyclor
andesartan cilexetil	Atacand
andesartan cilexetil	candesartan
andesartan cilexetil/hydrochlorothiazide	Atacand HCT
andesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
eprosartan mesylate	eprosartan
rbesartan	Avapro
rbesartan	irbesartan
rbesartan/hydrochlorothiazide	Avalide
rbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
osartan potassium	Cozaar
osartan potassium	losartan
osartan potassium/hydrochlorothiazide	Hyzaar
osartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
nebivolol HCI/valsartan	Byvalson
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine	
pesylate/hydrochlorothiazide	Tribenzor
olmesartan medoxomil/amlodipine	
pesylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
acubitril/valsartan	Entresto
elmisartan	Micardis
elmisartan	telmisartan
elmisartan/amlodipine besylate	Twynsta
elmisartan/amlodipine besylate	telmisartan-amlodipine
elmisartan/hydrochlorothiazide	Micardis HCT
elmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
valsartan	Diovan
valsartan	valsartan Diaura UCT
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
amlodipine besylate/benazepril HCl	ACE Inhibitors Lotrel
amiodipine besylate/benazepril HCl amiodipine besylate/benazepril HCl	
	amlodipine-benazepril Lotensin
benazepril HCl benazepril HCl	
	benazepril



Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Request

Generic Name	Brand Name
oenazepril HCl/hydrochlorothiazide	Lotensin HCT
enazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
aptopril	captopril
aptopril/hydrochlorothiazide	captopril-hydrochlorothiazide
enalapril maleate	Epaned
enalapril maleate	Vasotec
nalapril maleate	enalapril maleate
nalapril maleate/hydrochlorothiazide	Vaseretic
nalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
osinopril sodium	fosinopril
osinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
sinopril	Prinivil
isinopril	Qbrelis
isinopril	Zestril
isinopril	lisinopril
isinopril/hydrochlorothiazide	Zestoretic
isinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
noexipril HCl	moexipril
noexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
erindopril arginine/amlodipine besylate	Prestalia
erindopril erbumine	Aceon
erindopril erbumine	perindopril erbumine
uinapril HCl	Accupril
uinapril HCl	quinapril
uinapril HCl/hydrochlorothiazide	Accuretic
uinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
amipril	Altace
amipril	ramipril
randolapril	Mavik
randolapril	trandolapril
randolapril/verapamil HCl	Tarka
randolapril/verapamil HCl	trandolapril-verapamil
	Beta Blockers
cebutolol HCl	Sectral
cebutolol HCl	acebutolol
itenolol	Tenormin
itenolol	atenolol
tenolol/chlorthalidone	Tenoretic 100
tenolol/chlorthalidone	Tenoretic 50
tenolol/chlorthalidone	atenolol-chlorthalidone
etaxolol HCl	betaxolol
bisoprolol fumarate	Zebeta
pisoprolol fumarate	bisoprolol fumarate
pisoprolol fumarate/hydrochlorothiazide	Ziac
pisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
carvedilol	Coreg
11.1	

carvedilol

carvedilol



Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Incidence Criteria in this Reques

Generic Name	Brand Name
carvedilol phosphate	Coreg CR
carvedilol phosphate	carvedilol phosphate
labetalol HCl	labetalol
metoprolol succinate	Kapspargo Sprinkle
metoprolol succinate	Toprol XL
metoprolol succinate	metoprolol succinate
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol succinate/hydrochlorothiazide	metoprolol su-hydrochlorothiaz
metoprolol tartrate	Lopressor
metoprolol tartrate	metoprolol tartrate
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
nadolol	Corgard
nadolol	nadolol
nadolol/bendroflumethiazide	Corzide
nadolol/bendroflumethiazide	nadolol-bendroflumethiazide
nebivolol HCl	Bystolic
nebivolol HCl	nebivolol
pindolol	pindolol
propranolol HCl	Inderal LA
propranolol HCl	Inderal XL
propranolol HCl	InnoPran XL
propranolol HCl	propranolol
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
sotalol HCl	Betapace
sotalol HCl	Betapace AF
sotalol HCl	Sorine
sotalol HCl	Sotalol AF
sotalol HCI	Sotylize
sotalol HCl	sotalol
timolol maleate	timolol maleate
	Aliskiren
aliskiren hemifumarate	Tekturna
aliskiren hemifumarate	aliskiren
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT



Generic Name	Brand Name
Non-Sterc	pidal Anti-Inflammatory Drug (NSAID) Use
amlodipine besylate/celecoxib	Consensi
celecoxib	Celebrex
celecoxib	Elyxyb
celecoxib	celecoxib
diclofenac potassium	Cambia
diclofenac potassium	Cataflam
diclofenac potassium	Lofena
diclofenac potassium	Zipsor
diclofenac potassium	diclofenac potassium
diclofenac sodium	Voltaren-XR
diclofenac sodium	diclofenac sodium
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
diclofenac sodium/misoprostol	diclofenac-misoprostol
diclofenac submicronized	Zorvolex
diclofenac submicronized	diclofenac submicronized
etodolac	Lodine
etodolac	etodolac
fenoprofen calcium	Fenortho
fenoprofen calcium	Nalfon
fenoprofen calcium	ProFeno
fenoprofen calcium	fenoprofen
flurbiprofen	flurbiprofen
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Reprexain
hydrocodone/ibuprofen	Vicoprofen
hydrocodone/ibuprofen	Xylon 10
hydrocodone/ibuprofen	hydrocodone-ibuprofen
ibuprofen	IBU
ibuprofen	ibuprofen
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibuprofen/glycerin	Ibupak
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
indomethacin	Indocin
indomethacin	indomethacin

Appendix F. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request



Generic Name	Brand Name
indomethacin, submicronized	Tivorbex
indomethacin, submicronized	indomethacin submicronized
ketoprofen	ketoprofen
ketorolac tromethamine	ketorolac
meclofenamate sodium	meclofenamate
mefenamic acid	Ponstel
mefenamic acid	mefenamic acid
meloxicam	Mobic
meloxicam	Qmiiz ODT
meloxicam	meloxicam
meloxicam, submicronized	Vivlodex
meloxicam, submicronized	meloxicam submicronized
nabumetone	Relafen
nabumetone	Relafen DS
nabumetone	nabumetone
naproxen	EC-Naprosyn
naproxen	EC-Naproxen
naproxen	Naprosyn
naproxen	naproxen
naproxen sodium	Anaprox
naproxen sodium	Anaprox DS
naproxen sodium	Naprelan CR
naproxen sodium	naproxen sodium
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
oxaprozin	Daypro
oxaprozin	oxaprozin
piroxicam	Feldene
piroxicam	piroxicam
sulindac	sulindac
sumatriptan succinate/naproxen sodium	Treximet
sumatriptan succinate/naproxen sodium	sumatriptan-naproxen
tolmetin sodium	tolmetin
tramadol HCl/celecoxib	Seglentis

Appendix F. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request



		Code	
Code	Description	Category	Code Type
	Allergic Reaction	0,	/
B44.81	Allergic bronchopulmonary aspergillosis	Diagnosis	ICD-10-CM
J30.5	Allergic rhinitis due to food	Diagnosis	ICD-10-CM
K52.21	Food protein-induced enterocolitis syndrome	Diagnosis	ICD-10-CM
K52.22	Food protein-induced enteropathy	Diagnosis	ICD-10-CM
K52.29	Other allergic and dietetic gastroenteritis and colitis	Diagnosis	ICD-10-CM
L20.0	Besnier's prurigo	Diagnosis	ICD-10-CM
L20.81	Atopic neurodermatitis	Diagnosis	ICD-10-CM
L20.82	Flexural eczema	Diagnosis	ICD-10-CM
L20.84	Intrinsic (allergic) eczema	Diagnosis	ICD-10-CM
L20.89	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.9	Atopic dermatitis, unspecified	Diagnosis	ICD-10-CM
L23.0	Allergic contact dermatitis due to metals	Diagnosis	ICD-10-CM
L23.1	Allergic contact dermatitis due to adhesives	Diagnosis	ICD-10-CM
L23.2	Allergic contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L23.3	Allergic contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L23.4	Allergic contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L23.5	Allergic contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L23.6	Allergic contact dermatitis due to food in contact with the skin	Diagnosis	ICD-10-CM
L23.7	Allergic contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L23.81	Allergic contact dermatitis due to animal (cat) (dog) dander	Diagnosis	ICD-10-CM
L23.89	Allergic contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L23.9	Allergic contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L24.0	Irritant contact dermatitis due to detergents	Diagnosis	ICD-10-CM
L24.1	Irritant contact dermatitis due to oils and greases	Diagnosis	ICD-10-CM
L24.2	Irritant contact dermatitis due to solvents	Diagnosis	ICD-10-CM
L24.3	Irritant contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L24.4	Irritant contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L24.5	Irritant contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L24.6	Irritant contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L24.7	Irritant contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L24.81	Irritant contact dermatitis due to metals	Diagnosis	ICD-10-CM
L24.89	Irritant contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L24.9	Irritant contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L25.0	Unspecified contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L25.1	Unspecified contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L25.2	Unspecified contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L25.3	Unspecified contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L25.4	Unspecified contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L25.5	Unspecified contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L25.8	Unspecified contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L25.9	Unspecified contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L27.0	Generalized skin eruption due to drugs and medicaments taken internally	Diagnosis	ICD-10-CM
L27.1	Localized skin eruption due to drugs and medicaments taken internally	Diagnosis	ICD-10-CM
L27.2	Dermatitis due to ingested food	Diagnosis	ICD-10-CM
L27.8	Dermatitis due to other substances taken internally	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
L27.9	Dermatitis due to unspecified substance taken internally	Diagnosis	ICD-10-CM
L30.0	Nummular dermatitis	Diagnosis	ICD-10-CM
L30.2	Cutaneous autosensitization	Diagnosis	ICD-10-CM
L30.8	Other specified dermatitis	Diagnosis	ICD-10-CM
L30.9	Dermatitis, unspecified	Diagnosis	ICD-10-CM
L50.0	Allergic urticaria	Diagnosis	ICD-10-CM
L50.1	Idiopathic urticaria	Diagnosis	ICD-10-CM
L50.2	Urticaria due to cold and heat	Diagnosis	ICD-10-CM
L50.3	Dermatographic urticaria	Diagnosis	ICD-10-CM
L50.4	Vibratory urticaria	Diagnosis	ICD-10-CM
L50.5	Cholinergic urticaria	Diagnosis	ICD-10-CM
L50.6	Contact urticaria	Diagnosis	ICD-10-CM
L50.8	Other urticaria	Diagnosis Diagnosis	ICD-10-CM
L50.9	Urticaria, unspecified	Diagnosis	ICD-10-CM
L56.0 L56.1	Drug phototoxic response	Diagnosis	ICD-10-CM
L56.1 L56.2	Drug photoallergic response Photocontact dermatitis [berloque dermatitis]	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
L56.3	Solar urticaria	Diagnosis	ICD-10-CIVI
L56.4	Polymorphous light eruption	Diagnosis	ICD-10-CM
L56.8	Other specified acute skin changes due to ultraviolet radiation	Diagnosis	ICD-10-CM
L56.9	Acute skin change due to ultraviolet radiation, unspecified	Diagnosis	ICD-10-CM
L57.1	Actinic reticuloid	Diagnosis	ICD-10-CM
L57.5	Actinic granuloma	Diagnosis	ICD-10-CM
L57.8	Other skin changes due to chronic exposure to nonionizing radiation	Diagnosis	ICD-10-CM
L57.9	Skin changes due to chronic exposure to nonionizing radiation, unspecified	Diagnosis	ICD-10-CM
L58.0	Acute radiodermatitis	Diagnosis	ICD-10-CM
L58.1	Chronic radiodermatitis	Diagnosis	ICD-10-CM
L58.9	Radiodermatitis, unspecified	Diagnosis	ICD-10-CM
L59.0	Erythema ab igne [dermatitis ab igne]	Diagnosis	ICD-10-CM
L59.8	Other specified disorders of the skin and subcutaneous tissue related to radiation	Diagnosis	ICD-10-CM
L59.9	Disorder of the skin and subcutaneous tissue related to radiation, unspecified	Diagnosis	ICD-10-CM
T78.00XA	Anaphylactic reaction due to unspecified food, initial encounter	Diagnosis	ICD-10-CM
T78.01XA	Anaphylactic reaction due to peanuts, initial encounter	Diagnosis	ICD-10-CM
T78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to other fish, initial encounter	Diagnosis	ICD-10-CM
	Anaphylactic reaction due to fruits and vegetables, initial encounter	Diagnosis	ICD-10-CM
T78.05XA		Diagnosis	ICD-10-CM
T78.06XA	Anaphylactic reaction due to food additives, initial encounter	Diagnosis	ICD-10-CM
T78.07XA		Diagnosis	ICD-10-CM
T78.08XA		Diagnosis Diagnosis	ICD-10-CM
T78.09XA		Diagnosis Diagnosis	ICD-10-CM
T78.1XXA		Diagnosis	ICD-10-CM
T78.2XXA		Diagnosis	ICD-10-CM
	Allergy, unspecified, initial encounter	Diagnosis	ICD-10-CM
T78.49XA	Other allergy, initial encounter	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
	Anaphylactic reaction due to adverse effect of correct drug or medicament properly		
F88.6XXA	administered, initial encounter	Diagnosis	ICD-10-CM
201.82	Encounter for allergy testing	Diagnosis	ICD-10-CM
Z51.6	Encounter for desensitization to allergens	Diagnosis	ICD-10-CM
Z87.892	Personal history of anaphylaxis	Diagnosis	ICD-10-CM
<u>7</u> 88.0	Allergy status to penicillin	Diagnosis	ICD-10-CM
Z88.1	Allergy status to other antibiotic agents	Diagnosis	ICD-10-CM
Z88.2	Allergy status to sulfonamides	Diagnosis	ICD-10-CM
Z88.3	Allergy status to other anti-infective agents	Diagnosis	ICD-10-CM
z88.4	Allergy status to anesthetic agent	Diagnosis	ICD-10-CM
Z88.5	Allergy status to narcotic agent	Diagnosis	ICD-10-CM
Z88.6	Allergy status to analgesic agent	Diagnosis	ICD-10-CM
Z88.7	Allergy status to serum and vaccine	Diagnosis	ICD-10-CM
Z88.8	Allergy status to other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
Z88.9	Allergy status to unspecified drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
Z91.010	Allergy to peanuts	Diagnosis	ICD-10-CM
Z91.011	Allergy to milk products	Diagnosis	ICD-10-CM
291.012	Allergy to eggs	Diagnosis	ICD-10-CN
291.013	Allergy to seafood	Diagnosis	ICD-10-CM
291.018	Allergy to other foods	Diagnosis	ICD-10-CN
Z91.02	Food additives allergy status	Diagnosis	ICD-10-CN
Z91.030	Bee allergy status	Diagnosis	ICD-10-CN
Z91.038	Other insect allergy status	Diagnosis	ICD-10-CN
Z91.040	Latex allergy status	Diagnosis	ICD-10-CN
Z91.041	Radiographic dye allergy status	Diagnosis	ICD-10-CN
Z91.048	Other nonmedicinal substance allergy status	Diagnosis	ICD-10-CN
Z91.09	Other allergy status, other than to drugs and biological substances	Diagnosis	ICD-10-CN
	Acquired Hypothyroidism		
200.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CN
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CN
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CN
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CN
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CN
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CN
03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CN
503.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CN
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CN
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CN
03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CN
03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CN
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CN
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CN
	Acute Myocardial Infarction		
21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CN
	ST elevation (STEMI) myocardial infarction involving left anterior descending		
21.02	coronary artery	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterio		
121.09	wall	Diagnosis	ICD-10-CM
121.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior		
121.19	wall	Diagnosis	ICD-10-CM
121.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
121.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
121.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
121.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
121.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
122.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
122.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
122.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
123.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
	Ventricular septal defect as current complication following acute myocardial		
123.2	infarction	Diagnosis	ICD-10-CM
	Rupture of cardiac wall without hemopericardium as current complication following		
123.3	acute myocardial infarction	Diagnosis	ICD-10-CM
	Rupture of chordae tendineae as current complication following acute myocardial		
123.4	infarction	Diagnosis	ICD-10-CM
	Rupture of papillary muscle as current complication following acute myocardial		
123.5	infarction	Diagnosis	ICD-10-CM
	Thrombosis of atrium, auricular appendage, and ventricle as current complications		
123.6	following acute myocardial infarction	Diagnosis	ICD-10-CM
123.7	Postinfarction angina	Diagnosis	ICD-10-CM
123.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
	Alzheimers Disease & Related Disorders or Senile Dementia		
	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic		
F01.50	disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, unspecified severity, without		
F02.80	behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, unspecified severity, with behaviora	I	
F02.81	disturbance	Diagnosis	ICD-10-CM
	Unspecified dementia, unspecified severity, without behavioral disturbance,		
F03.90	psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
	Systemic atrophy primarily affecting central nervous system in other diseases		
G13.8	classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
	Anemia		
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
046.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CN
046.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CN
046.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CN
046.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CN
046.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CN
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CN
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CN
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CN
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CN
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CN
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CN
047.4	Osteomyelofibrosis	Diagnosis	ICD-10-CN
050.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CN
050.1	Sideropenic dysphagia	Diagnosis	ICD-10-CN
050.8	Other iron deficiency anemias	Diagnosis	ICD-10-CN
050.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CN
051.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CN
	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with		
051.1	proteinuria	Diagnosis	ICD-10-CN
051.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CN
051.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CN
051.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CN
051.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CN
052.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CN
052.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CN
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CN
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CN
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CN
		Diagnosis	
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CN



		Code	
Code	Description	Category	Code Type
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
	Sieke een maassenna seta zero with eerestat vasealar moovement	2.0.8.000.0	
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.438 D57.439			
	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis with other specified complication Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
063.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CN
064.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CN
064.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CN
064.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CN
064.3	Other sideroblastic anemias	Diagnosis	ICD-10-CN
064.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CN
064.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CN
064.89	Other specified anemias	Diagnosis	ICD-10-CN
064.9	Anemia, unspecified	Diagnosis	ICD-10-CN
075.81	Myelofibrosis	Diagnosis	ICD-10-CN
	Asthma		
45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CN
45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CN
45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CN
45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CN
45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CN
45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CN
45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CN
45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CN
45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CN
45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CN
45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CN
45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CN
45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CN
45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CN
45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CN
45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CN
45.991	Cough variant asthma	Diagnosis	ICD-10-CN
45.998	Other asthma	Diagnosis	ICD-10-CN
	Atrial Fibrillation		
48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CN
48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CN
48.11	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CN
48.19	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CN
48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CN
48.20	Chronic atrial fibrillation	Diagnosis	ICD-10-CN
48.21	Other persistent atrial fibrillation	Diagnosis	ICD-10-CN
48.3	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CN
48.4	Atypical atrial flutter	Diagnosis	ICD-10-CN
48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CN
	Benign Prostatic Hyperplasia		
140.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CN
140.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CN
V40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CN
	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CN
V40.3	Nodular prostate with lower annary tract symptoms	2.000.0000	



		Code	
Code	Description	Category	Code Type
	Cataract		
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM



	•	Code	
Code	Description	Category	Code Type
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.221	Cataract with neovascularization, unspecified eye Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
1120.225	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified	Diagnosis	
H26.229	eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
.120.40		510510515	



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Covariates in this Request			
		Code	
Code	Description	Category	Code Type
H26.411	Soemmering's ring, right eye	Diagnosis	ICD-10-CM
H26.412	Soemmering's ring, left eye	Diagnosis	ICD-10-CM
H26.413	Soemmering's ring, bilateral	Diagnosis	ICD-10-CM
H26.419	Soemmering's ring, unspecified eye	Diagnosis	ICD-10-CM

11 ~ 1 1/ div G ... al Clé ifi atid -1:**f**: ati/ - -l ^ fn - • • .

H26.412	Soemmering's ring, left eye	Diagnosis	ICD-10-CM
H26.413	Soemmering's ring, bilateral	Diagnosis	ICD-10-CM
H26.419	Soemmering's ring, unspecified eye	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
Q12.0	Congenital cataract	Diagnosis	ICD-10-CM
Z96.1	Presence of intraocular lens	Diagnosis	ICD-10-CM
	Chronic Kidney Disease		
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
	Diabetes mellitus due to underlying condition with other diabetic kidney		
E08.29	complication	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage		
112.0	renal disease	Diagnosis	ICD-10-CM
	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney		
112.9	disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through		
I13.0	stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease without heart failure, with stage 1		
I13.10	through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease without heart failure, with stage 5		
113.11	chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and with stage 5		
l13.2	chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
170.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
172.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis Rapidly progressive nephritic syndrome with diffuse mesangial proliferative	Diagnosis	ICD-10-CM
N01.3	glomerulonephritis Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative	Diagnosis	ICD-10-CM
N01.4	glomerulonephritis	Diagnosis	ICD-10-CM
	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary		
N01.5	glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis Recurrent and persistent hematuria with diffuse mesangial proliferative	Diagnosis	ICD-10-CM
N02.3	glomerulonephritis	Diagnosis	ICD-10-CM
1102.0	Recurrent and persistent hematuria with diffuse endocapillary proliferative	Diagnosis	
N02.4	glomerulonephritis	Diagnosis	ICD-10-CM
1102.4	Recurrent and persistent hematuria with diffuse mesangiocapillary	Diagnosis	
N02.5	glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with dispective morphologic changes	Diagnosis	ICD-10-CIVI
N02.A	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
1003.0	entone reprinte syndrome with millor glomerular abnormanty	Diagnosis	



		Code	
Code	Description	Category	Code Type
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
	Chronic nephritic syndrome with diffuse endocapillary proliferative		
N03.4	glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis Unspecified nephritic syndrome with diffuse mesangial proliferative	Diagnosis	ICD-10-CM
N05.3	glomerulonephritis	Diagnosis	ICD-10-CM
	Unspecified nephritic syndrome with diffuse endocapillary proliferative	U	
N05.4	glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM



CodeDescriptionCategoryCode TypeN07.0Hereditary nephropathy, not elsewhere classified with minor glomerular abnormalityDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse membranousDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse membranousDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse endocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.5Hereditary nephropathy, not elsewhere classified with other morphologicDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with other morphologicDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with other morphologicDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagn		•	Code	
N07.0 Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse membranous Diagnosis ICD-10-CM N07.1 glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse crescentic Diagnosis ICD-10-CM N07.6 Hereditary nephropathy, not elsewhere classified with other morphologic lesions Diagnosis ICD-10-CM N07.7 glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with other morphologic lesions ICD-10-CM N07.7 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N07.8 Hereditary nep	Code	Description		
Hereditary nephropathy, not elsewhere classified with focal and segmentalDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse membranousDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMN07.2glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with unspecified morphologicICD-10-CMN07.7Hereditary nephropathy, not elsewhere classified with unspecified morphologicICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-1	COUL		category	code rype
Hereditary nephropathy, not elsewhere classified with focal and segmentalDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse membranousDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMN07.2glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with unspecified morphologicICD-10-CMN07.7Hereditary nephropathy, not elsewhere classified with unspecified morphologicICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-1	N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1 glomerular lesions Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse membranous Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM N07.5 glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with dense deposit disease Diagnosis ICD-10-CM N07.6 glomerulonephritis Diagnosis ICD-10-CM N07.7 glomerulonephritis Diagnosis ICD-10-CM N07.7 glomerulonephritis Diagnosis ICD-10-CM N07.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions Diagnosis ICD-10-CM N07.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N13.1 Hydronephrosis with ureteral stricture, not elsewhere classified Diagnosis ICD-				
Hereditary nephropathy, not elsewhere classified with diffuse membranous Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse endocapillary Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with dense deposit disease Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse crescentic Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with other morphologic lesions Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with unspecified morphologic Diagnosis ICD-10-CM NO7.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N07.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N07.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N13.1 Hydronephrosis ICD-10-CM Nith urberephrosis	N07.1		Diagnosis	ICD-10-CM
N07.2glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangial proliferativeDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse endocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN13.1Hydronephrosis with uretaral and uretaral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.41Nephropathy induced by anspecified drug, medicaments and biological substanceDiagnosisICD-10-CMN14.4Analgesic nephropathyDiagnosisICD-10-CMN14.4Nephropathy induced by nespecified drug, medicament and biological substance<		•		
Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative UD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse endocapillary Diagnosis ICD-10-CM N07.4 proliferative glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary Diagnosis ICD-10-CM N07.5 glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with diffuse crescentc Diagnosis ICD-10-CM N07.7 glomerulonephritis Diagnosis ICD-10-CM Hereditary nephropathy, not elsewhere classified with other morphologic lesions Diagnosis ICD-10-CM N07.7 glomerulane phropathy, not elsewhere classified with uspecified morphologic Diagnosis ICD-10-CM N07.4 Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis Diagnosis ICD-10-CM N08 Glomerular disorders in diseases classified elsewhere classified Diagnosis ICD-10-CM N13.1 Hydronephrosis with renal and ureteral calculous obstruction Diagnosis ICD-10-CM N13.20 Unspecified hydronephrosis I	N07.2		Diagnosis	ICD-10-CM
N07.3glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse endocapillaryDiagnosisICD-10-CMN07.4proliferative glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with other morphologicDiagnosisICD-10-CMN07.7lesionsDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with Off glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.3Unspecified hydronephrosisDiagnosisICD-10-CMN13.3Unspecified hydronephrosisDiagnosisICD-10-CMN13.3Unspecified hydronephrosisDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.4Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.4Nephropathy, not elsewhere classifiedDiagnosisICD-10-CM <tr< td=""><td></td><td></td><td>-</td><td></td></tr<>			-	
Hereditary nephropathy, not elsewhere classified with diffuse endocapillaryDiagnosisICD-10-CMN07.4proliferative glomerulonephritisDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with diffuse crescenticDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN13.1Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.2HydronephrosisDiagnosisICD-10-CMN13.3Other hydronephrosisDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicaments and biological substanceDiagnosisICD-10-CMN14.4Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere	N07.3			ICD-10-CM
N07.4proliferative glomerulonephritisDiagnosisICD-10-CMHereditary nephropathy, not elsewhere classified with diffuse mesangiocapillaryDiagnosisICD-10-CMN07.5glomerulonephritisDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with dense deposit diseaseDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with unspecified morphologicDiagnosisICD-10-CMN07.9lesionsICD-10-CMDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified sewhereDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.4Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.4Nephropathy induced by unspecified drug, medicament or biological substancesDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN14.4Toxic nephropathyDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.4Toxic nephropathyDiagnosisICD-10-CM<			C	
N07.5glomerulonephritisDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with diffuse crescenticDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.9lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with unspecified morphologicDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substanceDiagnosisICD-10-CMN14.2Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classified diseaseDiagnosisICD-10-CMN14.3Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by other drugs, medicament or biological substance <td>N07.4</td> <td></td> <td>Diagnosis</td> <td>ICD-10-CM</td>	N07.4		Diagnosis	ICD-10-CM
N07.5glomerulonephritisDiagnosisICD-10-CMN07.6Hereditary nephropathy, not elsewhere classified with diffuse crescenticDiagnosisICD-10-CMN07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.9lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with unspecified morphologicDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substanceDiagnosisICD-10-CMN14.2Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classified diseaseDiagnosisICD-10-CMN14.3Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by other drugs, medicament or biological substance <td></td> <td>Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary</td> <td>-</td> <td></td>		Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary	-	
Hereditary nephropathy, not elsewhere classified with diffuse crescenticDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with unspecified morphologicDiagnosisICD-10-CMN07.9lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with uretaral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with uretaral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN14.3Nephropathy induced by nespecified drug, medicament or biological substancesDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classified elsewhereDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.4Other specified renal tubulo-interstitial diseaseDiagnosisICD-10-CMN15.7Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17	N07.5		Diagnosis	ICD-10-CM
N07.7glomerulonephritisDiagnosisICD-10-CMN07.8Hereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.9lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with unspecified morphologicDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.3Unspecified hydronephrosisDiagnosisICD-10-CMN13.30Other hydronephrosisDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicament or biological substancesDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.4Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.4Toxic nephropathyDiagnosisICD-10-CMN15.5Balkan nephropathyDiagnosisICD-10-CMN15.4Renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial diseaseDiagnosisICD-10-CMN17.0Acute kidney failure with acute cortical nec	N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.8Hereditary nephropathy, not elsewhere classified with other morphologic lesionsDiagnosisICD-10-CMN07.9lesionsDiagnosisICD-10-CMN07.4Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.40Analgesic nephropathyDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.4Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.4Toxic nephropathy induced by heavy metalsDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.1Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Chronic kidney disease, stage 1DiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.3Acute kidney failure with acute co		Hereditary nephropathy, not elsewhere classified with diffuse crescentic	-	
Hereditary nephropathy, not elsewhere classified with unspecified morphologicN07.9lesionsDiagnosisICD-10-CMN07.AHereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.40Analgesic nephropathyDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by other drugs, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by theavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Othe	N07.7	glomerulonephritis	Diagnosis	ICD-10-CM
N07.9lesionsDiagnosisICD-10-CMN07.AHereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.5Balkan nephropathyDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.4Acute	N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.AHereditary nephropathy, not elsewhere classified with C3 glomerulonephritisDiagnosisICD-10-CMN08Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Onspecified hydronephrosisDiagnosisICD-10-CMN13.30Other hydronephrosisDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by nespecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.0Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.1Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.3Other acute kidney dialure, unspecifiedDiagnosisICD-10-CM		Hereditary nephropathy, not elsewhere classified with unspecified morphologic		
NN88Glomerular disorders in diseases classified elsewhereDiagnosisICD-10-CMN13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.1Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.4Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.4Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CM<	N07.9	lesions	Diagnosis	ICD-10-CM
N13.1Hydronephrosis with ureteral stricture, not elsewhere classifiedDiagnosisICD-10-CMN13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.1Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.8Chronic kidney disease, stage 1DiagnosisICD-10-CMN17.8Chronic kidney failure, unspecifiedDiagnosisICD-10-CM	N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N13.2Hydronephrosis with renal and ureteral calculous obstructionDiagnosisICD-10-CMN13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.4Chter acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Chter kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Chter kidney failure, unspecifiedDiagnosisICD-10-CMN17.4Chter kidney failure, unspecifiedDiagnosisICD-10-CMN17.4Chter kidney failure, unspecifiedDiagnosisICD-10-CMN17.4Chter kidney failure, unspecifiedD	N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.30Unspecified hydronephrosisDiagnosisICD-10-CMN13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.2Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.9Renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Other acute kidney failureDiagnosisICD-10-CMN17.2Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.4Other acute kidney failureDiagnosisICD-10-CMN17.4Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.4Acute kidney failureDiagnosisICD-10-CMN17.5Acute kidney f	N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.39Other hydronephrosisDiagnosisICD-10-CMN14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.3Other acute kidney failureDiagnosisICD-10-CMN17.4Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 unspecifi	N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N14.0Analgesic nephropathyDiagnosisICD-10-CMN14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.4Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 aD	N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N14.1Nephropathy induced by other drugs, medicaments and biological substancesDiagnosisICD-10-CMN14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aD	N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.2Nephropathy induced by unspecified drug, medicament or biological substanceDiagnosisICD-10-CMN14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3a	N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.3Nephropathy induced by heavy metalsDiagnosisICD-10-CMN14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM <td>N14.1</td> <td>Nephropathy induced by other drugs, medicaments and biological substances</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.4Toxic nephropathy, not elsewhere classifiedDiagnosisICD-10-CMN15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.44Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM <td>N14.2</td> <td>Nephropathy induced by unspecified drug, medicament or biological substance</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N15.0Balkan nephropathyDiagnosisICD-10-CMN15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failure, unspecifiedDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N15.8Other specified renal tubulo-interstitial diseasesDiagnosisICD-10-CMN15.9Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.33Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.33Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.34 </td <td>N14.4</td> <td>Toxic nephropathy, not elsewhere classified</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.9Renal tubulo-interstitial disease, unspecifiedDiagnosisICD-10-CMN16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.33Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.44Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N16Renal tubulo-interstitial disorders in diseases classified elsewhereDiagnosisICD-10-CMN17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.3Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.34Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.44Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N17.0Acute kidney failure with tubular necrosisDiagnosisICD-10-CMN17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.34Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N17.1Acute kidney failure with acute cortical necrosisDiagnosisICD-10-CMN17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.34Chronic kidney disease, stage 3 anspecifiedDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3 bnDiagnosisICD-10-CMN18.34Chronic kidney disease, stage 3 bnDiagnosisICD-10-CMN18.44Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.2Acute kidney failure with medullary necrosisDiagnosisICD-10-CMN17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.34Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.8Other acute kidney failureDiagnosisICD-10-CMN17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.9Acute kidney failure, unspecifiedDiagnosisICD-10-CMN18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N18.1Chronic kidney disease, stage 1DiagnosisICD-10-CMN18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N18.2Chronic kidney disease, stage 2 (mild)DiagnosisICD-10-CMN18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.3Chronic kidney disease, stage 3 (moderate)DiagnosisICD-10-CMN18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.30Chronic kidney disease, stage 3 unspecifiedDiagnosisICD-10-CMN18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.31Chronic kidney disease, stage 3aDiagnosisICD-10-CMN18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.32Chronic kidney disease, stage 3bDiagnosisICD-10-CMN18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.4Chronic kidney disease, stage 4 (severe)DiagnosisICD-10-CM	N18.31		-	ICD-10-CM
	N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.5Chronic kidney disease, stage 5DiagnosisICD-10-CM	N18.4		-	ICD-10-CM
	N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
	Chronic obstructive pulmonary disease & bronchiectasis		
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM



Code	Description	Category	Code Type
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
	Depression		
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
	Mood disorder due to known physiological condition with major depressive-like		
F06.32	episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
	Diabetes		
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular		
E10.319	edema	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with		
E10.3211	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with		
E10.3212	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with		
E10.3213	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with		
E10.3219	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E10.3291	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E10.3292	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E10.3293	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E10.3299	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with		
E10.3311	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with		
E10.3312	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with		
E10.3313	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with		
E10.3319	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy		
E10.3391	without macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy		
E10.3392	without macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy		
E10.3393	without macular edema, bilateral	Diagnosis	ICD-10-CM



	·	Code	
Code	Description	Category	Code Type
	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy		
E10.3399	without macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with		
E10.3411	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with		
E10.3412	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with		
E10.3413	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with		
E10.3419	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E10.3491	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E10.3492	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E10.3493	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without	.	
E10.3499	macular edema, unspecified eye	Diagnosis	ICD-10-CM
540 2544	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	.	
E10.3511	right eye	Diagnosis	ICD-10-CM
F10 2F12	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnasia	
E10.3512	left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.5515	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	Diagnosis	
E10.3519	unspecified eye	Diagnosis	ICD-10-CM
L10.3319	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	
E10.3521	detachment involving the macula, right eye	Diagnosis	ICD-10-CM
10.5521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	
E10.3522	detachment involving the macula, left eye	Diagnosis	ICD-10-CM
210.0022	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	
E10.3523		Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal		
E10.3529	detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	U	
E10.3531	detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	-	
E10.3532	detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal		
E10.3533	detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal		
E10.3539	detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined		
E10.3541	traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined		
E10.3542	traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined		···· / ···
E10.3543	traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined	U	
	traction retinal detachment and rhegmatogenous retinal detachment, unspecified		
E10.3549	eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified	-	
E10.3559	eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular	-	
E10.3591	edema, right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular		
E10.3592	edema, left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular	-	
E10.3593	edema, bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular		
E10.3599	edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E10.37X1	right eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E10.37X2	left eye	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E10.37X3	bilateral	Diagnosis	ICD-10-CM
	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E10.37X9	unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-		
E11.00	hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular	_	
E11.319	edema	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with	U	
E11.3211	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with	U	
E11.3212	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with	U	
E11.3213	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with	U	
E11.3219	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E11.3291	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without	U	
E11.3292	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E11.3293	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without		
E11.3299	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with	2.08.0000	
E11.3311	macular edema, right eve	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with		
E11.3312	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with	2.08.0000	
E11.3313	macular edema, bilateral	Diagnosis	ICD-10-CM
211.0010	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with	Bidghosis	
E11.3319	macular edema, unspecified eye	Diagnosis	ICD-10-CM
211.0010	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Bidghosis	
E11.3391		Diagnosis	ICD-10-CM
L11.5551	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	
E11.3392	without macular edema, left eye	Diagnosis	ICD-10-CM
LII.JJJZ	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	
E11.3393	without macular edema, bilateral	Diagnosis	ICD-10-CM
LTT.3333	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	
E11.3399	without macular edema, unspecified eye	Diagnosis	ICD-10-CM
ETT'2222	without matulal edema, dispetilled eye	Diagnosis	



	•	Code	
Code	Description	Category	Code Type
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with	0-1	
E11.3411	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with	J	
E11.3412	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with	-	
E11.3413	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with	-	
E11.3419	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E11.3491	macular edema, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E11.3492	macular edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E11.3493	macular edema, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without		
E11.3499	macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,		
E11.3511	right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,		
E11.3512	left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,		
E11.3513	bilateral	Diagnosis	ICD-10-CM
F44 0546	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema,	D	
E11.3519	unspecified eye	Diagnosis	ICD-10-CM
E44 050 -	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	D	
E11.3521	detachment involving the macula, right eye	Diagnosis	ICD-10-CM
F14 2522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnasis	
E11.3522	detachment involving the macula, left eye	Diagnosis	ICD-10-CM
F14 2522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagrania	
E11.3523	detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11 2E20	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	
ETT.227A	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	ICD-10-CM
E11.3531	detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
LTT.333T	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	
E11.3532	detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
211.3332	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	Diagnosis	
E11.3533	detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal	- 10010010	
E11.3539	detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined	2.2010010	
E11.3541	traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined	0	
E11.3542	traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined	0	
E11.3543	traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
		0	



		Code	
Code	Description	Category	Code Type
	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined		
	traction retinal detachment and rhegmatogenous retinal detachment, unspecified		
E11.3549	eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified		
E11.3559	eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular		
E11.3591	edema, right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular		
E11.3592	edema, left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular		
E11.3593	edema, bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular		
E11.3599	edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E11.37X1	right eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E11.37X2	left eye	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E11.37X3	bilateral	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment,		
E11.37X9	unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CN
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CN
11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CN
	Glaucoma		
40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CN
140.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CN
140.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CN
140.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CN
40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CN
40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CN
40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CN
40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CN
40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CN
40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CN
140.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CN
40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CN
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CN
140.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CN
40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CN
140.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CN
140.041	Steroid responder, right eye	Diagnosis	ICD-10-CN
40.042	Steroid responder, left eye	Diagnosis	ICD-10-CN
140.043	Steroid responder, bilateral	Diagnosis	ICD-10-CN
140.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CN
40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CN
140.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CN
40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CN
140.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CN
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
40.10X1		Diagnosis	ICD-10-CM
40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CN
	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
40.1113		Diagnosis	ICD-10-CN
40.1114		Diagnosis	ICD-10-CN
40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CN
40.1122		Diagnosis	ICD-10-CN
H40.1123		Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CN
	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CN



		Code	
Code	Description	Category	Code Type
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193		Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312		Diagnosis	ICD-10-CM
H40.1313		Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324		Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
	-	-	



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413		Diagnosis	ICD-10-CM
H40.1414		Diagnosis	ICD-10-CM
H40.1420		Diagnosis	ICD-10-CM
H40.1421		Diagnosis	ICD-10-CM
H40.1422		Diagnosis	ICD-10-CM
	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491		Diagnosis	ICD-10-CM
H40.1492		Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate	Diagnosis	ICD-10-CM
H40.1494		Diagnosis	
	-	Diagnosis	ICD-10-CM
H40.151 H40.152	Residual stage of open-angle glaucoma, right eye Residual stage of open-angle glaucoma, left eye	Diagnosis Diagnosis	ICD-10-CM
H40.152 H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM ICD-10-CM
H40.155 H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.2074 H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.211 H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.212 H40.213	Acute angle-closure glaucoma, leit eye	Diagnosis	ICD-10-CM
H40.213 H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.219 H40.2210		Diagnosis	ICD-10-CIM
	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
		Diagnosis	ICD-10-CM
n40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	DIAGHOSIS	



CodeDescriptionCategoryCode TypeH40.2220Chronic angle-closure glaucoma, left eye, mild stageDiagnosisICD-10-CMH40.2221Chronic angle-closure glaucoma, left eye, moderate stageDiagnosisICD-10-CMH40.2222Chronic angle-closure glaucoma, left eye, severe stageDiagnosisICD-10-CMH40.2223Chronic angle-closure glaucoma, left eye, severe stageDiagnosisICD-10-CMH40.2224Chronic angle-closure glaucoma, left eye, indeterminate stageDiagnosisICD-10-CMH40.2231Chronic angle-closure glaucoma, bilateral, mild stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.2231Intermittent angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, hilateralDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, hight eye<			Code	
H40.2220 Chronic angle-closure glaucoma, left eye, mild stage Diagnosis ICD-10-CM H40.2221 Chronic angle-closure glaucoma, left eye, mild stage Diagnosis ICD-10-CM H40.2222 Chronic angle-closure glaucoma, left eye, severe stage Diagnosis ICD-10-CM H40.2222 Chronic angle-closure glaucoma, left eye, severe stage Diagnosis ICD-10-CM H40.2223 Chronic angle-closure glaucoma, bilateral, mild stage Diagnosis ICD-10-CM H40.2232 Chronic angle-closure glaucoma, bilateral, moderate stage Diagnosis ICD-10-CM H40.2232 Chronic angle-closure glaucoma, bilateral, moderate stage Diagnosis ICD-10-CM H40.2232 Chronic angle-closure glaucoma, bilateral, severe stage Diagnosis ICD-10-CM H40.2232 Chronic angle-closure glaucoma, unspecified eye, stage unspecified Diagnosis ICD-10-CM H40.2292 Chronic angle-closure glaucoma, unspecified eye, indeterminate stage Diagnosis ICD-10-CM H40.2292 Chronic angle-closure glaucoma, inspecified eye, indeterminate stage Diagnosis ICD-10-CM H40.2292 Chronic angle-closure glaucoma, inspecified eye, indeterminate stage Diagnosis ICD-10-CM H40	Code	Description		Code Type
H40.222Chronic angle-closure glaucoma, left eye, nderate stageDiagnosisICD-10-CMH40.222Chronic angle-closure glaucoma, left eye, idterminate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CM <t< td=""><td>H40.2220</td><td>Chronic angle-closure glaucoma, left eye, stage unspecified</td><td>Diagnosis</td><td></td></t<>	H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	
H40.222Chronic angle-closure glaucoma, left eye, nderate stageDiagnosisICD-10-CMH40.222Chronic angle-closure glaucoma, left eye, idterminate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.223Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, ingit eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, ingit eyeDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, ingit eyeDiagnosisICD-10-CMH40.232Residual stage of angle-closure glaucoma, ingit eyeDiagnosisICD-10-CMH40.231Residual stage of angle-closure glaucoma, ingit eyeDiagnosisICD-10-CM	H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2224Chronic angle-closure glaucoma, left eye, indeterminate stageDiagnosisICD-10-CMH40.2231Chronic angle-closure glaucoma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, avere stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.2331Intermittent angle-closure glaucoma, glateralDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.232Residual stage of angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, nett eyeDiagnosisICD-10-CMH40.234Resid			Diagnosis	ICD-10-CM
H40.2230Chronic angle-closure glaucoma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.2231Chronic angle-closure glaucoma, bilateral, mild stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2233Chronic angle-closure glaucoma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.2244Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2291Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.2294Chronic angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, plateralDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, plateralDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, plateralDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, inspecified eye, mild stageDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, unspecified eye, mild stageDiagnosisICD-10-CM<	H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2231Chronic angle-closure glaucoma, bilateral, mild stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2234Chronic angle-closure glaucoma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, mild stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.229Chronic angle-closure glaucoma, unspecified eye, severe stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, ingthe eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, ingthe eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, ingthe eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, ingthe eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma	H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2232Chronic angle-closure glaucoma, bilateral, moderate stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, bilateral, severe stageDiagnosisICD-10-CMH40.2232Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2290Chronic angle-closure glaucoma, unspecified eye, mild stageDiagnosisICD-10-CMH40.2291Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, inspecified eye, mild stageDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, inspecified eye, mild stageDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, unspecified eye, mild stageDiagnosis <td>H40.2230</td> <td>Chronic angle-closure glaucoma, bilateral, stage unspecified</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2233Chronic angle-closure glaucoma, bilateral, severe stageDiagnosisICD-10-CMH40.2234Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2290Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2291Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2301Intermittent angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.237Residual stage of angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.248Residual stage of angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.247Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.248Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3403Glaucoma secondary to eye trauma, unspecified eye, indete	H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2234Chronic angle-closure glaucoma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.2290Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2291Chronic angle-closure glaucoma, unspecified eye, mild stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, molerate stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3045Glaucoma secondary to eye trauma, unspecified	H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.229Chronic angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.2291Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, severe stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.2294Chronic angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.305Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.305Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-1	H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2291Chronic angle-closure glaucoma, unspecified eye, mild stageDiagnosisICD-10-CMH40.2292Chronic angle-closure glaucoma, unspecified eye, noderate stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.2294Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, blateralDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, inght eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, unspecified eye, stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.305Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, right eye, win	H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2292Chronic angle-closure glaucoma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.2293Chronic angle-closure glaucoma, unspecified eye, severe stageDiagnosisICD-10-CMH40.2294Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.246Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.247Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.308Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.314Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3140Glaucoma secondary to ey	H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2293Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.2294Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, nepsecified eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.300Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3012Glaucoma secondary to eye trauma, unspecified eye, indetare stageDiagnosisICD-10-CMH40.3024Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3013Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, stageDiagnosisICD-10-CMH40.3131Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10	H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2294Chronic angle-closure glaucoma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.231Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, night eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.245Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.300Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.301Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3022Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3033Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.304Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.311Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-C	H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.231Intermittent angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.234Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, light eyeDiagnosisICD-10-CMH40.244Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.305Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3042Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3052Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3043Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3143Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3143Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CM<	H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.232Intermittent angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.233Intermittent angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.239Intermittent angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3000Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.301Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3023Glaucoma secondary to eye trauma, unspecified eye, noderate stageDiagnosisICD-10-CMH40.3034Glaucoma secondary to eye trauma, unspecified eye, noderate stageDiagnosisICD-10-CMH40.3105Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.3133Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3144Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3134Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosis <td>H40.2294</td> <td>Chronic angle-closure glaucoma, unspecified eye, indeterminate stage</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.233Intermittent angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.239Intermittent angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.300Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.301Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.302Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.303Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3141Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3122Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.3143Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.3143Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.3144Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3143Glaucoma secondary to eye trauma, right eye, severe stageDiagnosis	H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.239Intermittent angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.241Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.300Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.301Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3023Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3033Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3103Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.311Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.3120Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.3131Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3142Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.3132Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.3144Glaucoma secondary to eye trauma, left eye, moderate stage<	H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.241Residual stage of angle-closure glaucoma, right eyeDiagnosisICD-10-CMH40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.300Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.3021Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.3033Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3044Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3053Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.3120Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.3130Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.3141Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.3123Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3144Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.3124Glaucoma secondary to eye trauma, left eye, mode	H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.242Residual stage of angle-closure glaucoma, left eyeDiagnosisICD-10-CMH40.243Residual stage of angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.30X0Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, neght eye, stage unspecifiedDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye traum	H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.243Residual stage of angle-closure glaucoma, bilateralDiagnosisICD-10-CMH40.249Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.30X0Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.30X1Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to	H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.249Residual stage of angle-closure glaucoma, unspecified eyeDiagnosisICD-10-CMH40.30X0Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.30X1Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye	H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.30X0Glaucoma secondary to eye trauma, unspecified eye, stage unspecifiedDiagnosisICD-10-CMH40.30X1Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary t	H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.30X1Glaucoma secondary to eye trauma, unspecified eye, mild stageDiagnosisICD-10-CMH40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to ey	H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X2Glaucoma secondary to eye trauma, unspecified eye, moderate stageDiagnosisICD-10-CMH40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma,	H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X3Glaucoma secondary to eye trauma, unspecified eye, severe stageDiagnosisICD-10-CMH40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, b	H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X4Glaucoma secondary to eye trauma, unspecified eye, indeterminate stageDiagnosisICD-10-CMH40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilat	H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X0Glaucoma secondary to eye trauma, right eye, stage unspecifiedDiagnosisICD-10-CMH40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe st	H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.31X1Glaucoma secondary to eye trauma, right eye, mild stageDiagnosisICD-10-CMH40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stage <t< td=""><td>H40.30X4</td><td>Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X2Glaucoma secondary to eye trauma, right eye, moderate stageDiagnosisICD-10-CMH40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indetermin	H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X3Glaucoma secondary to eye trauma, right eye, severe stageDiagnosisICD-10-CMH40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeter	H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X4Glaucoma secondary to eye trauma, right eye, indeterminate stageDiagnosisICD-10-CMH40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeter	H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X0Glaucoma secondary to eye trauma, left eye, stage unspecifiedDiagnosisICD-10-CMH40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indete	H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.32X1Glaucoma secondary to eye trauma, left eye, mild stageDiagnosisICD-10-CMH40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X2Glaucoma secondary to eye trauma, left eye, moderate stageDiagnosisICD-10-CMH40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X3Glaucoma secondary to eye trauma, left eye, severe stageDiagnosisICD-10-CMH40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X4Glaucoma secondary to eye trauma, left eye, indeterminate stageDiagnosisICD-10-CMH40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.33X0Glaucoma secondary to eye trauma, bilateral, stage unspecifiedDiagnosisICD-10-CMH40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.33X1Glaucoma secondary to eye trauma, bilateral, mild stageDiagnosisICD-10-CMH40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X2Glaucoma secondary to eye trauma, bilateral, moderate stageDiagnosisICD-10-CMH40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X3Glaucoma secondary to eye trauma, bilateral, severe stageDiagnosisICD-10-CMH40.33X4Glaucoma secondary to eye trauma, bilateral, indeterminate stageDiagnosisICD-10-CM	H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X4 Glaucoma secondary to eye trauma, bilateral, indeterminate stage Diagnosis ICD-10-CM	H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
	H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40 40X0 Glaucoma secondary to eve inflammation unspecified evel stage unspecified Diagnosis ICD-10-CM	H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
Hadrone Gradeonia secondary to eye inhamination, unspecinea eye, stage unspecinea Diagnosis ICD-10-CM	H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1 Glaucoma secondary to eye inflammation, unspecified eye, mild stage Diagnosis ICD-10-CM	H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2 Glaucoma secondary to eye inflammation, unspecified eye, moderate stage Diagnosis ICD-10-CM	H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2		Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
	Heart Failure		100 10 01 1
109.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
111.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through		
113.0	stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and with stage 5	.	
113.2	chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
142.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
142.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
142.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
142.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
150.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
150.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart		
150.43	failure	Diagnosis	ICD-10-CM
50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
50.811	Acute right heart failure	Diagnosis	ICD-10-CM
50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
150.82	Biventricular heart failure	Diagnosis	ICD-10-CM
150.83	High output heart failure	Diagnosis	ICD-10-CM
150.84	End stage heart failure	Diagnosis	ICD-10-CM
150.89	Other heart failure	Diagnosis	ICD-10-CM
150.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
	Hip/Pelvic Fracture		
	Age-related osteoporosis with current pathological fracture, right femur, initial	.	
M80.051A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left femur, initial	Diamaria	
IVI80.052A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified femur,	Diamaria	
IVI80.059A	. initial encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right femur, initial encounter	Diagnosis	
IVI80.851A	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, left femur, initial encounter	Diagnasia	
IVI80.852P	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, unspecified femur, initial	Diagnasia	
	encounter for fracture	Diagnosis Diagnosis	ICD-10-CM
	Stress fracture, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
	Stress fracture, right femur, initial encounter for fracture	Diagnosis Diagnosis	ICD-10-CM
	Stress fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
	Stress fracture, unspecified femur, initial encounter for fracture	Diagnosis Diagnosis	ICD-10-CM
	Stress fracture, hip, unspecified, initial encounter for fracture	Diagnosis Dia ang sia	ICD-10-CM
IVI84.451A	Pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture in neoplastic disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.551A	Pathological fracture in neoplastic disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.552A	Pathological fracture in neoplastic disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture in neoplastic disease, unspecified femur, initial encounter for		
M84.553A	fracture	Diagnosis	ICD-10-CM
	Pathological fracture in neoplastic disease, hip, unspecified, initial encounter for		
M84.559A	fracture	Diagnosis	ICD-10-CM
M84.650A	Pathological fracture in other disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture in other disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.652A	Pathological fracture in other disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
	Pathological fracture in other disease, unspecified femur, initial encounter for		
M84.653A	fracture	Diagnosis	ICD-10-CM
M84 659A	Pathological fracture in other disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
	Periprosthetic fracture around internal prosthetic right hip joint, initial encounter	Diagnosis	ICD-10-CM
	Periprosthetic fracture around internal prosthetic left hip joint, initial encounter	Diagnosis	ICD-10-CM
S32.301A	Unspecified fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.301B	Unspecified fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.302A	Unspecified fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.302B	Unspecified fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.309A	Unspecified fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.309B	Unspecified fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.311A	Displaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.311B	Displaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.312A	Displaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.312B	Displaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
		<u>.</u>	
S32.313A	Displaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.313B	Displaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.314A	Nondisplaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.314B	Nondisplaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.315A	Nondisplaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.315B	Nondisplaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
C22 21 CA	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for closed	Diagnasia	
S32.316A	fracture	Diagnosis	ICD-10-CM
C27 2160	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	
S32.316B S32.391A	Other fracture of right ilium, initial encounter for closed fracture	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
S32.391A S32.391B	Other fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.391B	Other fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.392A S32.392B	Other fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CIM ICD-10-CM
	Other fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CIM
S32.399A	סנוובו המננגוב טו מהצףבנוובט וומווז, ווונומו פוונטמוונפו וטו נוטצפט וומנומופ	DIAGUOSIS	



		Code	
Code	Description	Category	Code Type
S32.399B	Other fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.401A	Unspecified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.401B	Unspecified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.402A	Unspecified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.402B	Unspecified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.409A	Unspecified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.409B	Unspecified fracture of unspecified acetabulum, initial encounter for open fracture Displaced fracture of anterior wall of right acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.411A	fracture Displaced fracture of anterior wall of right acetabulum, initial encounter for open	Diagnosis	ICD-10-CM
S32.411B	fracture Displaced fracture of anterior wall of left acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.412A	fracture Displaced fracture of anterior wall of left acetabulum, initial encounter for open	Diagnosis	ICD-10-CM
S32.412B	fracture Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.413A	closed fracture Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.413B	open fracture Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.414A	closed fracture Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for open	Diagnosis	ICD-10-CM
S32.414B	fracture Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.415A	fracture Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for open	Diagnosis	ICD-10-CM
S32.415B	fracture Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter	Diagnosis	ICD-10-CM
S32.416A		Diagnosis	ICD-10-CM
S32.416B	for open fracture Displaced fracture of posterior wall of right acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.421A		Diagnosis	ICD-10-CM
S32.421B	fracture Displaced fracture of posterior wall of left acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.422A		Diagnosis	ICD-10-CM
S32.422B	fracture Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.423A	closed fracture Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.423B	open fracture Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.424A		Diagnosis	ICD-10-CM



	•	Code	
Code	Description	Category	Code Type
	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for	<u> </u>	
S32.424B	open fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for	-	
S32.425A	closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for open		
S32.425B	fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter		
S32.426A	for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter		
S32.426B	for open fracture	Diagnosis	ICD-10-CM
	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial		
S32.431A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial		
S32.431B	encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter		
S32.432A	for closed fracture	Diagnosis	ICD-10-CM
caa	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter	D	
S32.432B	for open fracture	Diagnosis	ICD-10-CM
C22 4224	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial	Diagrania	
S32.433A	encounter for closed fracture	Diagnosis	ICD-10-CM
חרבו רכז	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	
S32.433B		Diagnosis	ICD-10-CM
S32.434A	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
JJZ.434A	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial	Diagnosis	
S32.434B	encounter for open fracture	Diagnosis	ICD-10-CM
JJ2.4J4D	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial	Diagnosis	
S32.435A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial	2.2010010	100 10 000
S32.435B	encounter for open fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum,	0	
S32.436A		Diagnosis	ICD-10-CM
	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum,		
S32.436B	initial encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial		
S32.441A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial		
S32.441B	encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial		
S32.442A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial		
S32.442B	encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial		
S32.443A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial	D	
S32.443B	encounter for open fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
S32.444A	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial		
S32.444B	encounter for open fracture Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial	Diagnosis	ICD-10-CM
S32.445A	encounter for closed fracture	Diagnosis	ICD-10-CM
S32.445B	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
0011102	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum,	2108110010	
S32.446A	initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.446B	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced transverse fracture of right acetabulum, initial encounter for closed		
S32.451A	fracture	Diagnosis	ICD-10-CM
S32.451B	Displaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.452A	Displaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.452B	Displaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.453A	Displaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced transverse fracture of unspecified acetabulum, initial encounter for open	-	
S32.453B	fracture Nondisplaced transverse fracture of right acetabulum, initial encounter for closed	Diagnosis	ICD-10-CM
S32.454A	fracture	Diagnosis	ICD-10-CM
S32.454B	Nondisplaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
552.4546	Nondisplaced transverse fracture of left acetabulum, initial encounter for closed	Diagnosis	
S32.455A	fracture Nondisplaced transverse fracture of left acetabulum, initial encounter for open	Diagnosis	ICD-10-CM
S32.455B	fracture	Diagnosis	ICD-10-CM
532 4564	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
552.450A	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for	Diagnosis	
S32.456B	open fracture Displaced associated transverse-posterior fracture of right acetabulum, initial	Diagnosis	ICD-10-CM
S32.461A	encounter for closed fracture	Diagnosis	ICD-10-CM
C22 4C1D	Displaced associated transverse-posterior fracture of right acetabulum, initial	Diagragia	
S32.461B	encounter for open fracture Displaced associated transverse-posterior fracture of left acetabulum, initial	Diagnosis	ICD-10-CM
S32.462A		Diagnosis	ICD-10-CM
S32.462B	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
600 460 F	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial	-	
S32.463A	encounter for closed fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial	3-1	10.0
S32.463B	encounter for open fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial	-	
S32.464A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial		
S32.464B	encounter for open fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial		
S32.465A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial		
S32.465B	encounter for open fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum,		
S32.466A	initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum,		
S32.466B	initial encounter for open fracture	Diagnosis	ICD-10-CM
606 ·	Displaced fracture of medial wall of right acetabulum, initial encounter for closed	D :	
S32.471A	fracture	Diagnosis	ICD-10-CM
600 1 - 1 -	Displaced fracture of medial wall of right acetabulum, initial encounter for open	Dia i	
S32.471B	fracture	Diagnosis	ICD-10-CM
C22 472 -	Displaced fracture of medial wall of left acetabulum, initial encounter for closed		
S32.472A		Diagnosis	ICD-10-CM
(22 4725	Displaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnasis	
S32.472B	fracture	Diagnosis	ICD-10-CM
527 172 4	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD_10 CM
S32.473A	closed fracture Displaced fracture of medial wall of unspecified acetabulum, initial encounter for	Diagnosis	ICD-10-CM
S32.473B	open fracture	Diagnosis	ICD-10-CM
JJZ.4/JD	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for closed	-	10-T0-CIAI
S32.474A		Diagnosis	ICD-10-CM
JJ2.7/4A	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for open		
S32.474B	fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for closed		J0 CIVI
S32.475A		Diagnosis	ICD-10-CM
	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for open	U	
S32.475B	fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for	-	
S32.476A	closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for	-	
S32.476B	open fracture	Diagnosis	ICD-10-CM
S32.481A	Displaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.481B	Displaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.482A	Displaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.482B	Displaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
	Displaced dome fracture of unspecified acetabulum, initial encounter for closed		
S32.483A	fracture	Diagnosis	ICD-10-CM
	Displaced dome fracture of unspecified acetabulum, initial encounter for open		
S32.483B	fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
S32.484A	Nondisplaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.484B	Nondisplaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.485A	Nondisplaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.485B	Nondisplaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for closed		
S32.486A	fracture	Diagnosis	ICD-10-CM
C22 40CD	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for open	Diagnasia	
S32.486B	fracture Other specified fracture of right asstabulum, initial enseunter for closed fracture	Diagnosis	ICD-10-CM
S32.491A S32.491B	Other specified fracture of right acetabulum, initial encounter for closed fracture Other specified fracture of right acetabulum, initial encounter for open fracture	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
S32.491B	Other specified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CIVI
S32.492A	Other specified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
552.4520	Other specified fracture of unspecified acetabulum, initial encounter for closed	Diagnosis	
S32.499A	fracture	Diagnosis	ICD-10-CM
	Other specified fracture of unspecified acetabulum, initial encounter for open		
S32.499B	fracture	Diagnosis	ICD-10-CM
S32.501A	Unspecified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.501B	Unspecified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.502A	Unspecified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.502B	Unspecified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.509A	Unspecified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.509B	Unspecified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.511A	Fracture of superior rim of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.511B	Fracture of superior rim of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.512A	Fracture of superior rim of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.512B	Fracture of superior rim of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.519A	Fracture of superior rim of unspecified publs, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.519B	Fracture of superior rim of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.591A S32.591B	Other specified fracture of right pubis, initial encounter for closed fracture Other specified fracture of right pubis, initial encounter for open fracture	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
S32.591B	Other specified fracture of left publs, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.592R	Other specified fracture of left publs, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.599A	Other specified fracture of unspecified publs, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.599B	Other specified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.601A	Unspecified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.601B	Unspecified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.602A	Unspecified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.602B	Unspecified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.609A	Unspecified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.609B	Unspecified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.611A	Displaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.611B	Displaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.612A	Displaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.612B	Displaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Displaced avulsion fracture of unspecified ischium, initial encounter for closed		
S32.613A	fracture	Diagnosis	ICD-10-CM
S32.613B	Displaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.614A	Nondisplaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.614B	Nondisplaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.615A	Nondisplaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.615B	Nondisplaced avulsion fracture of left ischium, initial encounter for open fracture Nondisplaced avulsion fracture of unspecified ischium, initial encounter for closed	Diagnosis	ICD-10-CM
S32.616A	fracture Nondisplaced avulsion fracture of unspecified ischium, initial encounter for open	Diagnosis	ICD-10-CM
S32.616B	fracture	Diagnosis	ICD-10-CM
S32.691A	Other specified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.691B	Other specified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.692A	Other specified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.692B	Other specified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.699A	Other specified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.699B	Other specified fracture of unspecified ischium, initial encounter for open fracture Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for	Diagnosis	ICD-10-CM
S32.810A	closed fracture Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for	Diagnosis	ICD-10-CM
S32.810B	open fracture Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter	Diagnosis	ICD-10-CM
S32.811A	for closed fracture Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter	Diagnosis	ICD-10-CM
S32.811B	for open fracture Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for	Diagnosis	ICD-10-CM
S32.82XA	closed fracture Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for	Diagnosis	ICD-10-CM
S32.82XB	open fracture	Diagnosis	ICD-10-CM
S32.82XB	Fracture of other parts of pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.89XB	Fracture of other parts of pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
332.03AD	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for	Diagnosis	
S32.9XXA	closed fracture Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for	Diagnosis	ICD-10-CM
S32.9XXB	open fracture Fracture of unspecified part of neck of right femur, initial encounter for closed	Diagnosis	ICD-10-CM
S72.001A	fracture Fracture of unspecified part of neck of right femur, initial encounter for open	Diagnosis	ICD-10-CM
S72.001B	fracture of unspecified part of neck of right femur, initial encounter for open Fracture of unspecified part of neck of right femur, initial encounter for open	Diagnosis	ICD-10-CM
S72.001C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.002A	Fracture of unspecified part of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Fracture of unspecified part of neck of left femur, initial encounter for open fracture		
S72.002B	type I or II	Diagnosis	ICD-10-CM
\$72.002C	Fracture of unspecified part of neck of left femur, initial encounter for open fracture	Diagnosis	
572.002C	type IIIA, IIIB, or IIIC Fracture of unspecified part of neck of unspecified femur, initial encounter for closed	Diagnosis	ICD-10-CM
S72.009A		Diagnosis	ICD-10-CM
	Fracture of unspecified part of neck of unspecified femur, initial encounter for open		
S72.009B	fracture type I or II	Diagnosis	ICD-10-CM
	Fracture of unspecified part of neck of unspecified femur, initial encounter for open		
\$72.009C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.011A	Unspecified intracapsular fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Unspecified intracapsular fracture of right femur, initial encounter for open fracture		
S72.011B	type I or II	Diagnosis	ICD-10-CM
672 0446	Unspecified intracapsular fracture of right femur, initial encounter for open fracture	Diamaria	
S72.011C S72.012A		Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
372.012A	Unspecified intracapsular fracture of left femur, initial encounter for open fracture	Diagnosis	
S72.012B	type I or II	Diagnosis	ICD-10-CM
	Unspecified intracapsular fracture of left femur, initial encounter for open fracture	-	
S72.012C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Unspecified intracapsular fracture of unspecified femur, initial encounter for closed		
S72.019A		Diagnosis	ICD-10-CM
S72.019B	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
572.0150	Unspecified intracapsular fracture of unspecified femur, initial encounter for open	Diagnosis	
S72.019C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter		
S72.021A		Diagnosis	ICD-10-CM
	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter	.	
S72.021B	for open fracture type I or II Displaced fracture of epiphysis (separation) (upper) of right formula initial encounter	Diagnosis	ICD-10-CM
S72.021C	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
0/10110	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter	2.00.0000	102 20 0
S72.022A	for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter		
S72.022B	for open fracture type I or II	Diagnosis	ICD-10-CM
672 0220	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter	Diagrania	
\$72.022C	for open fracture type IIIA, IIIB, or IIIC Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial	Diagnosis	ICD-10-CM
S72.023A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial		
S72.023B	encounter for open fracture type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial		
\$72.023C	encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial		
S72.024A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial		
S72.024B	encounter for open fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial		
S72.024C	encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial	Diagnosis	
S72.025A	encounter for closed fracture Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial	Diagnosis	ICD-10-CM
S72.025B	encounter for open fracture type I or II	Diagnosis	ICD-10-CM
372.0230	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial	Diagnosis	
S72.025C	encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
572.0250	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial	Diagnosis	
S72.026A	encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial		
S72.026B	encounter for open fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial		
S72.026C	encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.031A	Displaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced midcervical fracture of right femur, initial encounter for open fracture type		
S72.031B	l or ll	Diagnosis	ICD-10-CM
	Displaced midcervical fracture of right femur, initial encounter for open fracture type		
S72.031C	IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.032A	Displaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced midcervical fracture of left femur, initial encounter for open fracture type I	.	
S72.032B	or II Displaced middem incline the of left formula initial encounter for even frontune type.	Diagnosis	ICD-10-CM
572 0220	Displaced midcervical fracture of left femur, initial encounter for open fracture type	Diagnosis	
\$72.032C	IIIA, IIIB, or IIIC Displaced midcervical fracture of unspecified femur, initial encounter for closed	Diagnosis	ICD-10-CM
S72.033A	fracture	Diagnosis	ICD-10-CM
372.033A	Displaced midcervical fracture of unspecified femur, initial encounter for open	Diagnosis	
S72.033B	fracture type I or II	Diagnosis	ICD-10-CM
	Displaced midcervical fracture of unspecified femur, initial encounter for open	8	
S72.033C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
		-	
S72.034A	Nondisplaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture		
S72.034B	type I or II	Diagnosis	ICD-10-CM
	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture		
S72.034C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.035A	Nondisplaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture		
S72.035B	type I or II	Diagnosis	ICD-10-CM
672 6255	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture	D	
S/2.035C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM



	•	Code	
Code	Description	Category	Code Type
	Nondisplaced midcervical fracture of unspecified femur, initial encounter for closed	01	
S72.036A	fracture	Diagnosis	ICD-10-CM
	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open	-	
S72.036B	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open		
S72.036C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
C72 0			
S72.041A	Displaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
572 0440	Displaced fracture of base of neck of right femur, initial encounter for open fracture	Diagnosis	
S72.041B	type I or II Displaced fracture of base of neck of right femur, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.041C		Diagnosis	ICD-10-CM
S72.041C	Displaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
- <i>·</i> =·v-r2M	Displaced fracture of base of neck of left femur, initial encounter for open fracture	~0.10013	10 0141
S72.042B	type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of base of neck of left femur, initial encounter for open fracture	-	
S72.042C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced fracture of base of neck of unspecified femur, initial encounter for closed		
S72.043A	fracture	Diagnosis	ICD-10-CM
	Displaced fracture of base of neck of unspecified femur, initial encounter for open		
S72.043B	fracture type I or II	Diagnosis	ICD-10-CM
0 -	Displaced fracture of base of neck of unspecified femur, initial encounter for open		
S72.043C	fracture type IIIA, IIIB, or IIIC Nandialaged fracture of base of near of right formur, initial encounter for algorid	Diagnosis	ICD-10-CM
572 0444	Nondisplaced fracture of base of neck of right femur, initial encounter for closed	Diagnasic	
S72.044A	fracture Nondisplaced fracture of base of neck of right femur, initial encounter for open	Diagnosis	ICD-10-CM
S72.044B	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
J12.044B	Nondisplaced fracture of base of neck of right femur, initial encounter for open	Diagi10315	
S72 0440	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced fracture of base of neck of left femur, initial encounter for closed	~0.10013	10 0141
S72.045A	fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of base of neck of left femur, initial encounter for open	5	
S72.045B	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced fracture of base of neck of left femur, initial encounter for open		
S72.045C		Diagnosis	ICD-10-CM
	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for		
S72.046A	closed fracture	Diagnosis	ICD-10-CM
0-2	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for		10- ···
S72.046B	open fracture type I or II	Diagnosis	ICD-10-CM
572 0466	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for	Diagnes!-	
S72.046C	open fracture type IIIA, IIIB, or IIIC Unspecified fracture of head of right femur, initial encounter for closed fracture	Diagnosis Diagnosis	ICD-10-CM
S72.051A	Unspecified fracture of head of right femur, initial encounter for closed fracture Unspecified fracture of head of right femur, initial encounter for open fracture type I	Diagnosis	ICD-10-CM
S72.051B	or II	Diagnosis	ICD-10-CM
5, 2.0JID	Unspecified fracture of head of right femur, initial encounter for open fracture type	Pidenosis	
S72.051C	IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
3. 2.00 10	···· , ···-, -· ··· ··		



		Code	
Code	Description	Category	Code Type
\$72.052A	Unspecified fracture of head of left femur, initial encounter for closed fracture Unspecified fracture of head of left femur, initial encounter for open fracture type I	Diagnosis	ICD-10-CM
S72.052B	or II Unspecified fracture of head of left femur, initial encounter for open fracture type	Diagnosis	ICD-10-CM
\$72.052C	IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.059A		Diagnosis	ICD-10-CM
S72.059B	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.059C		Diagnosis	ICD-10-CM
\$72.061A		Diagnosis	ICD-10-CM
\$72.061B	Displaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.061C	Displaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
\$72.062A	Displaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.062B	Displaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.062C	Displaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.063A	Displaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.063B	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.063C	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.064A	Nondisplaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.064B	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.064C	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.065A	Nondisplaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.065B	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
\$72.065C		Diagnosis	ICD-10-CM
\$72.066A	Nondisplaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.066B	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Nondisplaced articular fracture of head of unspecified femur, initial encounter for		
S72.066C	open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.091A	Other fracture of head and neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Other fracture of head and neck of right femur, initial encounter for open fracture	0	
S72.091B	type I or II	Diagnosis	ICD-10-CM
	Other fracture of head and neck of right femur, initial encounter for open fracture	0	
S72.091C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.092A	Other fracture of head and neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Other fracture of head and neck of left femur, initial encounter for open fracture	-	
S72.092B	type I or II	Diagnosis	ICD-10-CM
	Other fracture of head and neck of left femur, initial encounter for open fracture		
S72.092C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Other fracture of head and neck of unspecified femur, initial encounter for closed		
S72.099A	fracture	Diagnosis	ICD-10-CM
	Other fracture of head and neck of unspecified femur, initial encounter for open		
S72.099B	fracture type I or II	Diagnosis	ICD-10-CM
	Other fracture of head and neck of unspecified femur, initial encounter for open		
S72.099C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.101A	Unspecified trochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of right femur, initial encounter for open fracture		
S72.101B	type I or II	Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of right femur, initial encounter for open fracture		
	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.102A	Unspecified trochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of left femur, initial encounter for open fracture		
S72.102B	type I or II	Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of left femur, initial encounter for open fracture		
S72.102C		Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of unspecified femur, initial encounter for closed		
S72.109A	fracture	Diagnosis	ICD-10-CM
	Unspecified trochanteric fracture of unspecified femur, initial encounter for open	<u>.</u>	
S72.109B	fracture type I or II	Diagnosis	ICD-10-CM
672 4000	Unspecified trochanteric fracture of unspecified femur, initial encounter for open	Diamaria	
572.109C	fracture type IIIA, IIIB, or IIIC Displaced fracture of graater trachenter of right formus, initial encounter for glaced	Diagnosis	ICD-10-CM
672 111 4	Displaced fracture of greater trochanter of right femur, initial encounter for closed	Diagnosia	
S72.111A		Diagnosis	ICD-10-CM
672 1110	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	
S72.111B		Diagnosis	ICD-10-CM
\$72 1110	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	
372.1110	Displaced fracture of greater trochanter of left femur, initial encounter for closed	Diagnosis	ICD-10-CM
S72.112A	fracture	Diagnosis	ICD-10-CM
372.112A	Displaced fracture of greater trochanter of left femur, initial encounter for open	agiiusis	
S72.112B	fracture type I or II	Diagnosis	ICD-10-CM
512.1120	Displaced fracture of greater trochanter of left femur, initial encounter for open	agiiusis	
S72 112C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
J/ Z.112C	nucture type may mo, or me	Diagnosis	



		Code	
Code	Description	Category	Code Type
	Displaced fracture of greater trochanter of unspecified femur, initial encounter for		
S72.113A	closed fracture	Diagnosis	ICD-10-CM
	Displaced fracture of greater trochanter of unspecified femur, initial encounter for		
S72.113B	open fracture type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of greater trochanter of unspecified femur, initial encounter for		
S72.113C	open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced fracture of greater trochanter of right femur, initial encounter for		
S72.114A	closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open		
S72.114B	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open		
S72.114C		Diagnosis	ICD-10-CM
	Nondisplaced fracture of greater trochanter of left femur, initial encounter for closed		
S72.115A	fracture	Diagnosis	ICD-10-CM
C72 4455	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open	.	
S72.115B	fracture type I or II	Diagnosis	ICD-10-CM
672 1150	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open	Diagragia	
\$72.115C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.116A	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	
372.110A	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter	Diagnosis	ICD-10-CM
S72.116B	for open fracture type I or II	Diagnosis	ICD-10-CM
572.1100	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter	Diagnosis	
S72.116C	for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
572.1100	Displaced fracture of lesser trochanter of right femur, initial encounter for closed	Diagnosis	
S72.121A	fracture	Diagnosis	ICD-10-CM
0/ =-===	Displaced fracture of lesser trochanter of right femur, initial encounter for open	2.08.0000	
S72.121B	fracture type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of right femur, initial encounter for open		
S72.121C		Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of left femur, initial encounter for closed	-	
S72.122A	fracture	Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of left femur, initial encounter for open		
S72.122B	fracture type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of left femur, initial encounter for open		
S72.122C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for		
S72.123A		Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for		
S72.123B	open fracture type I or II	Diagnosis	ICD-10-CM
	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for		
S72.123C	open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for closed	Diagrantic	
S72.124A	fracture	Diagnosis	ICD-10-CM
C72 1240	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open	Diagnosis	
S72.124B	fracture type I or II	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open		
S72.124C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for closed		
S72.125A	fracture	Diagnosis	ICD-10-CM
	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open		
S72.125B	fracture type I or II	Diagnosis	ICD-10-CM
672 4250	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open	Diamasia	
\$72.125C	fracture type IIIA, IIIB, or IIIC Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for	Diagnosis	ICD-10-CM
S72.126A	closed fracture	Diagnosis	ICD-10-CM
572.120A	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for	Diagnosis	
S72.126B	open fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for	-	
S72.126C	open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.131A	Displaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Displaced apophyseal fracture of right femur, initial encounter for open fracture type		
S72.131B	l or ll Dialacada a subara diferente a fariate forma initial anomator forma a fariate to the	Diagnosis	ICD-10-CM
572 1210	Displaced apophyseal fracture of right femur, initial encounter for open fracture type	Diagnosis	
S72.131C S72.132A	IIIA, IIIB, or IIIC Displaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
572.15ZA	Displaced apophyseal fracture of left femur, initial encounter for open fracture type I	Diagnosis	
S72.132B	or II	Diagnosis	ICD-10-CM
	Displaced apophyseal fracture of left femur, initial encounter for open fracture type	0	
S72.132C	IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced apophyseal fracture of unspecified femur, initial encounter for closed		
S72.133A	fracture	Diagnosis	ICD-10-CM
672 4225	Displaced apophyseal fracture of unspecified femur, initial encounter for open	Diama	
S72.133B	fracture type I or II Displaced apophyseal fracture of unspecified femur, initial encounter for open	Diagnosis	ICD-10-CM
572 1220	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
572.1550		Diagnosis	
S72.134A	Nondisplaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture	-	
S72.134B	type I or II	Diagnosis	ICD-10-CM
	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture		
S72.134C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.135A	Nondisplaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
572 1250	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture	Diagnosia	
S72.135B	type I or II Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.135C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for closed		
S72.136A	fracture	Diagnosis	ICD-10-CM
	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open		
S72.136B	fracture type I or II	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open		
S72.136C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of right femur, initial encounter for closed		
S72.141A	fracture	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of right femur, initial encounter for open		
S72.141B	fracture type I or II	Diagnosis	ICD-10-CM
2	Displaced intertrochanteric fracture of right femur, initial encounter for open		
S72.141C		Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of left femur, initial encounter for closed	<u> </u>	
S72.142A	-	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture		_ · · ·
S72.142B	type I or II	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture		
S72.142C	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of unspecified femur, initial encounter for closed	-	
S72.143A	fracture	Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open		
S72.143B		Diagnosis	ICD-10-CM
	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open		
S72.143C		Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of right femur, initial encounter for closed		
S72.144A		Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open		
S72.144B	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open		
S72.144C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of left femur, initial encounter for closed		
S72.145A		Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open		
S72.145B	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open		
S72.145C	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for		
S72.146A	closed fracture	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for		
S72.146B	open fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for		
S72.146C		Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of right femur, initial encounter for closed		
S72.21XA		Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture		
S72.21XB	type I or II	Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture		
S72.21XC	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.22XA	Displaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture		
S72.22XB	type I or II	Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture		
S72.22XC	type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of unspecified femur, initial encounter for closed		
S72.23XA	fracture	Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open		
S72.23XB	fracture type I or II	Diagnosis	ICD-10-CM
	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open		
S72.23XC		Diagnosis	ICD-10-CM
	Nondisplaced subtrochanteric fracture of right femur, initial encounter for closed		
S72.24XA		Diagnosis	ICD-10-CM
	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open		
S72.24XB	fracture type I or II	Diagnosis	ICD-10-CM
	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open		
S72.24XC	fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
C72 25VA	Nondisplaced subtrochanteric fracture of left femur, initial encounter for closed	Diamania	
S72.25XA		Diagnosis	ICD-10-CM
	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open	Diagnasia	
S72.25XB	fracture type I or II Nandialaged subtrashanteria fracture of laft formus initial ansaunter for onen	Diagnosis	ICD-10-CM
S72.25XC	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open	Diagnosis	
372.2370	fracture type IIIA, IIIB, or IIIC Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for	Diagnosis	ICD-10-CM
S72.26XA	closed fracture	Diagnosis	ICD-10-CM
372.20AA	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for	Diagnosis	ICD-10-CIVI
S72.26XB	open fracture type I or II	Diagnosis	ICD-10-CM
572.2000	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for	Diagnosis	
S72.26XC	open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
0/ ===0/10	Unspecified physeal fracture of upper end of right femur, initial encounter for closed	2.08.0000	
S79.001A	fracture	Diagnosis	ICD-10-CM
	Unspecified physeal fracture of upper end of left femur, initial encounter for closed	0	
S79.002A		Diagnosis	ICD-10-CM
	Unspecified physeal fracture of upper end of unspecified femur, initial encounter for		
S79.009A	closed fracture	Diagnosis	ICD-10-CM
	Salter-Harris Type I physeal fracture of upper end of right femur, initial encounter for		
S79.011A	closed fracture	Diagnosis	ICD-10-CM
	Salter-Harris Type I physeal fracture of upper end of left femur, initial encounter for		
S79.012A	closed fracture	Diagnosis	ICD-10-CM
	Salter-Harris Type I physeal fracture of upper end of unspecified femur, initial		
S79.019A		Diagnosis	ICD-10-CM
	Other physeal fracture of upper end of right femur, initial encounter for closed		
S79.091A	fracture	Diagnosis	ICD-10-CM
	Other physeal fracture of upper end of left femur, initial encounter for closed		
S79.092A		Diagnosis	ICD-10-CM
670 000 -	Other physeal fracture of upper end of unspecified femur, initial encounter for closed	.	
S79.099A	iracture	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Hyperlipidemia		couc type
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Hypertension		
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
110	Essential (primary) hypertension	Diagnosis	ICD-10-CM
111.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
111.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage	-	
112.0	renal disease	Diagnosis	ICD-10-CM
	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney	U	
112.9	disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through	ו	
113.0	stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease without heart failure, with stage 1		
113.10	through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease without heart failure, with stage 5		
113.11	chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and with stage 5		
113.2	chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
115.0	Renovascular hypertension	Diagnosis	ICD-10-CM
115.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
115.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Ischemic Heart Disease		
120.0	Unstable angina	Diagnosis	ICD-10-CM
120.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
120.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
120.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
121.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
	ST elevation (STEMI) myocardial infarction involving left anterior descending		
121.02	coronary artery	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior		
121.09	wall	Diagnosis	ICD-10-CM
121.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior		
121.19	wall	Diagnosis	ICD-10-CM
121.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
121.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
121.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
121.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
122.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
122.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
124.0 124.1	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
124.1	Dressler's syndrome Other forms of acute ischemic heart disease	Diagnosis Diagnosis	ICD-10-CM ICD-10-CM
124.8	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CIM
124.9	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
125.10	Alteroscierotie neart disease of native coronary artery without angina pectoris	Diagnosis	
125.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerotic heart disease of native coronary artery with angina pectoris with	2108.10010	
125.111	documented spasm	Diagnosis	ICD-10-CM
	Atherosclerotic heart disease of native coronary artery with other forms of angina	0	
125.118	pectoris	Diagnosis	ICD-10-CM
	Atherosclerotic heart disease of native coronary artery with unspecified angina	-	
125.119	pectoris	Diagnosis	ICD-10-CM
125.2	Old myocardial infarction	Diagnosis	ICD-10-CM
125.3	Aneurysm of heart	Diagnosis	ICD-10-CM
125.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
125.42	Coronary artery dissection	Diagnosis	ICD-10-CM
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
125.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina		
125.700	pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris		
125.701	with documented spasm	Diagnosis	ICD-10-CM
	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of		
125.708	angina pectoris	Diagnosis	ICD-10-CM
125 700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified	.	
125.709	angina pectoris	Diagnosis	ICD-10-CM
125 740	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable	Diagran	
125.710	angina pectoris	Diagnosis	ICD-10-CM
125 744	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina	Diagnasia	
125.711	pectoris with documented spasm	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

Codo	Description	Code	Codo Turo
Code	Description Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms	Category	Code Type
125.718		Diagnosis	
125.718	of angina pectoris	Diagnosis	ICD-10-CM
125 710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified	Diagnasia	
125.719	angina pectoris	Diagnosis	ICD-10-CM
125 720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable	Diamaria	
125.720	angina pectoris	Diagnosis	ICD-10-CM
125 724	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina	.	
125.721	pectoris with documented spasm	Diagnosis	ICD-10-CM
125 720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms	.	
125.728	of angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified		
125.729	angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with		
125.730	unstable angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with		
125.731	angina pectoris with documented spasm	Diagnosis	ICD-10-CM
	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with		
125.738	other forms of angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with		
125.739	unspecified angina pectoris	Diagnosis	ICD-10-CM
125.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris		
125.751	with documented spasm	Diagnosis	ICD-10-CM
	Atherosclerosis of native coronary artery of transplanted heart with other forms of		
125.758	angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of native coronary artery of transplanted heart with unspecified		
125.759	angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of bypass graft of coronary artery of transplanted heart with		
125.760	unstable angina	Diagnosis	ICD-10-CM
	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina		
125.761	pectoris with documented spasm	Diagnosis	ICD-10-CM
	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other		
125.768	forms of angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of bypass graft of coronary artery of transplanted heart with		
125.769	unspecified angina pectoris	Diagnosis	ICD-10-CM
125.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with		
125.791	documented spasm	Diagnosis	ICD-10-CM
	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina		
125.798	pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina	-	
125.799	pectoris	Diagnosis	ICD-10-CM
125.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
	Atherosclerosis of native coronary artery of transplanted heart without angina	-	
125.811	pectoris	Diagnosis	ICD-10-CM
		5	



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
	Atherosclerosis of bypass graft of coronary artery of transplanted heart without		
125.812	angina pectoris	Diagnosis	ICD-10-CM
125.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
125.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
125.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
125.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
125.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
	Osteoporosis	0	
	Age-related osteoporosis with current pathological fracture, unspecified site, initial		
M80.00XA	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right shoulder, initial		
M80.011A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left shoulder, initial	-	
M80.012A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified shoulder,	U	
M80.019A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right humerus, initial	-	
M80.021A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left humerus, initial	U	
M80.022A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified humerus,	U	
M80.029A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right forearm, initial	U	
M80.031A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left forearm, initial	-	
M80.032A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified forearm,	-	
M80.039A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right hand, initial	-	
M80.041A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left hand, initial	U	
M80.042A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified hand, initial	-	
M80.049A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right femur, initial	-	
M80.051A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left femur, initial	-	
M80.052A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified femur,	U	
M80.059A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, right lower leg, initial	2	
M80.061A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left lower leg, initial	2	
M80.062A	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified lower leg,	0	
M80.069A	initial encounter for fracture	Diagnosis	ICD-10-CM



	•	Code	
Code	Description	Category	Code Type
	Age-related osteoporosis with current pathological fracture, right ankle and foot,		
M80.071A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, left ankle and foot,	0	
M80.072A	initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, unspecified ankle and	U	
M80.079A	foot, initial encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, vertebra(e), initial	-	
M80.08XA	encounter for fracture	Diagnosis	ICD-10-CM
	Age-related osteoporosis with current pathological fracture, other site, initial		
M80.0AXA	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, unspecified site, initial		
M80.80XA	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right shoulder, initial		
M80.811A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, left shoulder, initial encounter		
M80.812A	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, unspecified shoulder, initial		
M80.819A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right humerus, initial		
M80.821A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, left humerus, initial encounter		
M80.822A	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, unspecified humerus, initial	. .	
M80.829A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right forearm, initial	. .	
M80.831A	encounter for fracture	Diagnosis	ICD-10-CM
N400 022A	Other osteoporosis with current pathological fracture, left forearm, initial encounter	Diagnasia	
W180.832A	for fracture	Diagnosis	ICD-10-CM
N100 0201	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	
WI60.659A	Other osteoporosis with current pathological fracture, right hand, initial encounter	Diagnosis	ICD-10-CM
M80 8414	for fracture	Diagnosis	ICD-10-CM
1000.041A	Other osteoporosis with current pathological fracture, left hand, initial encounter for	Diagnosis	
M80.842A		Diagnosis	ICD-10-CM
111001012/1	Other osteoporosis with current pathological fracture, unspecified hand, initial	Biagnosis	
M80.849A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right femur, initial encounter	2108.10010	
M80.851A	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, left femur, initial encounter		
M80.852A	for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, unspecified femur, initial	5	
M80.859A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, right lower leg, initial		
M80.861A	encounter for fracture	Diagnosis	ICD-10-CM
	Other osteoporosis with current pathological fracture, left lower leg, initial		
M80.862A	encounter for fracture	Diagnosis	ICD-10-CM



	Code
le I	Category Code Type
0.869A	Diagnosis ICD-10-CM
0.871A	Diagnosis ICD-10-CM
0.872A	Diagnosis ICD-10-CM
0.879A	Diagnosis ICD-10-CM
0.88XA	Diagnosis ICD-10-CM
0.8AXA	Diagnosis ICD-10-CM
1.0	Diagnosis ICD-10-CM
1.6	Diagnosis ICD-10-CM
1.8	Diagnosis ICD-10-CM
.50	Diagnosis ICD-10-CM
.51	Diagnosis ICD-10-CM
.54	Diagnosis ICD-10-CM
.59	Diagnosis ICD-10-CM
5.00	Diagnosis ICD-10-CM
5.011	Diagnosis ICD-10-CM
5.012	Diagnosis ICD-10-CM
5.019	Diagnosis ICD-10-CM
5.021	Diagnosis ICD-10-CM
5.022	Diagnosis ICD-10-CM
5.029	Diagnosis ICD-10-CM
5.031	Diagnosis ICD-10-CM
5.032	Diagnosis ICD-10-CM
5.039	Diagnosis ICD-10-CM
5.041	Diagnosis ICD-10-CM
5.042	Diagnosis ICD-10-CM
5.049	Diagnosis ICD-10-CM
5.051	Diagnosis ICD-10-CM
5.052	Diagnosis ICD-10-CM
5.059	Diagnosis ICD-10-CM
5.061	Diagnosis ICD-10-CM
5.062	Diagnosis ICD-10-CM
5.069	Diagnosis ICD-10-CM
5.071	Diagnosis ICD-10-CM
5.072	Diagnosis ICD-10-CM
5.079	Diagnosis ICD-10-CM
5.09	Diagnosis ICD-10-CM
5.10	Diagnosis ICD-10-CM
5.111	Diagnosis ICD-10-CM
5.112	Diagnosis ICD-10-CM
5.062 5.069 5.071 5.072 5.079 5.09 5.10 5.111	Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis



		Code	
Code	Description	Category	Code Type
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified site with involvement of other organs and		
M05.60	systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and		
M05.619	systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified elbow with involvement of other organs and		
M05.629	systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified wrist with involvement of other organs and		
M05.639	systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified hand with involvement of other organs and		
M05.649	systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems Rheumatoid arthritis of unspecified hip with involvement of other organs and	Diagnosis	ICD-10-CM
M05.659	systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of unspecified knee with involvement of other organs and		
M05.669	systems	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
	Rheumatoid arthritis of right ankle and foot with involvement of other organs and		
M05.671	systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis of left ankle and foot with involvement of other organs and	. .	
M05.672	systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or	2.08.0000	
M05.70	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or		
M05.711	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or		
M05.712	systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
10105.715	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems	Diagnosis	
M05.721	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems		
M05.722	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or		
M05.729	systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
10105.751	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems	Diagnosis	
M05.732	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or		
M05.739	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems	. .	
M05.741	involvement Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems	Diagnosis	ICD-10-CM
M05.742	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or	2.00.0000	
M05.749	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems		
M05.751	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems	Diagraphia	
M05.752	involvement Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or	Diagnosis	ICD-10-CM
M05.759	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems		•···
M05.761	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems		
M05.762	involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or	Diagnosia	
M05.769	systems involvement	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
couc	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or		couc type
M05.771	systems involvement	Diagnosis	ICD-10-CM
11100.771	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or	2102110313	
M05.772	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without	210210313	
M05.779	organ or systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or	2.0010010	
M05.79	systems involvement	Diagnosis	ICD-10-CM
	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or	0	
M05.7A	systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM



CodeDescriptionCategoryCode TypeM06.331Rheumatoid nodule, right wristDiagnosisICD-10-CMM06.332Rheumatoid nodule, unspecified wristDiagnosisICD-10-CMM06.341Rheumatoid nodule, right handDiagnosisICD-10-CMM06.342Rheumatoid nodule, right handDiagnosisICD-10-CMM06.343Rheumatoid nodule, right handDiagnosisICD-10-CMM06.344Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.351Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.352Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.364Rheumatoid nodule, right haleDiagnosisICD-10-CMM06.371Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified afootDiagnosisICD-10-CMM06.374Rheumatoid nodule, unspecified afootDiagnosisICD-10-CMM06.375Rheumatoid nodule, unspecified steDiagnosisICD-10-CMM06.387Rheumatoid nodule, unspecified steDiagnosisICD-10-CMM06.398Rheumatoid andule, unspecified steDiagnosisICD-10-CMM06.399Rheumatoid andule, unspecified steDiagnosisICD-10-CMM06.391Rheumatoid andule, unspecified shoulderDiagnosisICD-10-CMM06.392<			Code	
NO6.322Rheumatoid nodule, left wristDiagnosisICD-10-CMNO6.331Rheumatoid nodule, right handDiagnosisICD-10-CMNO6.342Rheumatoid nodule, right handDiagnosisICD-10-CMNO6.343Rheumatoid nodule, right handDiagnosisICD-10-CMNO6.351Rheumatoid nodule, right handDiagnosisICD-10-CMNO6.352Rheumatoid nodule, right hipDiagnosisICD-10-CMNO6.353Rheumatoid nodule, right kneeDiagnosisICD-10-CMNO6.364Rheumatoid nodule, right kneeDiagnosisICD-10-CMNO6.365Rheumatoid nodule, right kneeDiagnosisICD-10-CMNO6.366Rheumatoid nodule, uspecified kneeDiagnosisICD-10-CMNO6.371Rheumatoid nodule, uspecified kneeDiagnosisICD-10-CMNO6.372Rheumatoid nodule, uspecified ankle and footDiagnosisICD-10-CMNO6.373Rheumatoid nodule, mutpeistesDiagnosisICD-10-CMNO6.38Nheumatoid nodule, mutpeistesDiagnosisICD-10-CMNO6.39Rheumatoid nodule, mutpeistesDiagnosisICD-10-CMNO6.310Uther specified rheumatoid arthritis, inspecified shulderDiagnosisICD-10-CMNO6.311Other specified rheumatoid arthritis, inspecified shulderDiagnosisICD-10-CMNO6.312Other specified rheumatoid arthritis, inspecified shulderDiagnosisICD-10-CMNO6.313Rheumatoid arthritis, right wristDiagnosisICD-10-CMNO6.321Other specified rheumat	Code	Description	Category	Code Type
M06.339Rheumatoid nodule, unspecified wristDiagnosisICD-10-CMM06.341Rheumatoid nodule, left handDiagnosisICD-10-CMM06.342Rheumatoid nodule, left handDiagnosisICD-10-CMM06.351Rheumatoid nodule, left handDiagnosisICD-10-CMM06.352Rheumatoid nodule, left hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, left hipDiagnosisICD-10-CMM06.354Rheumatoid nodule, left hipDiagnosisICD-10-CMM06.355Rheumatoid nodule, left kneeDiagnosisICD-10-CMM06.366Rheumatoid nodule, left kneeDiagnosisICD-10-CMM06.371Rheumatoid nodule, left anke and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, left anke and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, vertheraeDiagnosisICD-10-CMM06.381Rheumatoid nodule, vertheraeDiagnosisICD-10-CMM06.391Rheumatoid nodule, writhis, singt shoulderDiagnosisICD-10-CMM06.812Other specified heumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.812Other specified heumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.822Other specified heumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.823Other specified heumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.823Other specified heumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.823 <td>M06.331</td> <td>Rheumatoid nodule, right wrist</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.341Rheumatoid nodule, right handDiagnosisICD-10-CMM06.342Rheumatoid nodule, unspecified handDiagnosisICD-10-CMM06.353Rheumatoid nodule, unspecified handDiagnosisICD-10-CMM06.352Rheumatoid nodule, unspecified hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, unspecified hipDiagnosisICD-10-CMM06.354Rheumatoid nodule, unspecified hipDiagnosisICD-10-CMM06.355Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.366Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.377Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.378Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.379Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, unspecified stesDiagnosisICD-10-CMM06.39Rheumatoid nodule, unspecified stesDiagnosisICD-10-CMM06.39Rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.39Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.830Other specified rheumatoid arthritis, right nandDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, right nand	M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.342Rheumatoid nodule, left handDiagnosisICD-10-CMM06.343Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.351Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.352Rheumatoid nodule, right nipDiagnosisICD-10-CMM06.353Rheumatoid nodule, right neeDiagnosisICD-10-CMM06.364Rheumatoid nodule, right neeDiagnosisICD-10-CMM06.365Rheumatoid nodule, right nakle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.374Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified steeDiagnosisICD-10-CMM06.380Other specified rheumatoid arthritis, unspecified steDiagnosisICD-10-CMM06.391Other specified rheumatoid arthritis, unspecified steDiagnosisICD-10-CMM06.800Other specified rheumatoid arthritis, unspecified steDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.8331O	M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.349Rheumatoid nodule, unspecified handDiagnosisICD-10-CMM06.351Rheumatoid nodule, jeft hipDiagnosisICD-10-CMM06.352Rheumatoid nodule, inspecified hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, inspecified hipDiagnosisICD-10-CMM06.364Rheumatoid nodule, inspecified kneeDiagnosisICD-10-CMM06.367Rheumatoid nodule, inspecified kneeDiagnosisICD-10-CMM06.368Rheumatoid nodule, inspecified kneeDiagnosisICD-10-CMM06.371Rheumatoid nodule, inspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, mutple sitesDiagnosisICD-10-CMM06.39Rheumatoid nodule, mutple sitesDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, inght shoulderDiagnosisICD-10-CMM06.810Other specified rheumatoid arthritis, inght shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, inght shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, inght shoulderDiagnosisICD-10-CMM06.823Other	M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.351Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.352Rheumatoid nodule, right hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, right kneeDiagnosisICD-10-CMM06.361Rheumatoid nodule, right kneeDiagnosisICD-10-CMM06.362Rheumatoid nodule, right kneeDiagnosisICD-10-CMM06.363Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.371Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.380Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.391Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.801Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, inght shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, inght elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, inght elbowDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inght wistDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inght wistDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inght wistDiagnosisICD-10-CMM06.834Other specified rheumatoid arthritis, ing	M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.352Rheumatoid nodule, left hipDiagnosisICD-10-CMM06.353Rheumatoid nodule, ingetified hipDiagnosisICD-10-CMM06.361Rheumatoid nodule, left kneeDiagnosisICD-10-CMM06.362Rheumatoid nodule, left kneeDiagnosisICD-10-CMM06.363Rheumatoid nodule, inget nakle and footDiagnosisICD-10-CMM06.371Rheumatoid nodule, left ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, inget nakle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, muspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, muspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.810Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.820Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, nget fied albowDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, nget fied handDiagnosisICD-10-CMM06.832 </td <td>M06.349</td> <td>Rheumatoid nodule, unspecified hand</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.359Rheumatoid nodule, unspecified hipDiagnosisICD-10-CMM06.361Rheumatoid nodule, ight kneeDiagnosisICD-10-CMM06.362Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.371Rheumatoid nodule, ight ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.380Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.391Rheumatoid nodule, unspecified steDiagnosisICD-10-CMM06.800Other specified rheumatoid arthritis, unspecified steDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, ight shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, ight elbowDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, ight vistDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, ight wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inspecified steDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, ight wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, inspecified wristDiagnosi	M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.361Rheumatoid nodule, right kneeDiagnosisICD-10-CMM06.362Rheumatoid nodule, right kneeDiagnosisICD-10-CMM06.362Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.371Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, uspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.38Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.39Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.810Other specified rheumatoid arthritis, inspecified siteDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.813Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.824Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inspecified shoulderDiagnosisICD-10-CMM06.844Other specified rheumatoid arthritis, inspec	M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.362Rheumatoid nodule, left kneeDiagnosisICD-10-CMM06.369Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.371Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.381Rheumatoid nodule, mutiple sitesDiagnosisICD-10-CMM06.800Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, right wistDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, right wistDiagnosisICD-10-CMM06.834Other specified rheumatoid arthritis, right wistDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.850Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hand <td>M06.359</td> <td>Rheumatoid nodule, unspecified hip</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.369Rheumatoid nodule, unspecified kneeDiagnosisICD-10-CMM06.371Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.39Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.30Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.81Other specified rheumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.82Other specified rheumatoid arthritis, night shoulderDiagnosisICD-10-CMM06.82Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.82Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.830Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.830Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.844Other specified rheumatoid arthritis, night handDiagnosisICD-10-CMM06.845Other specifi	M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.371Rheumatoid nodule, right ankle and footDiagnosisICD-10-CMM06.372Rheumatoid nodule, left ankle and footDiagnosisICD-10-CMM06.373Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, wertebraeDiagnosisICD-10-CMM06.30Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.810Other specified rheumatoid arthritis, inspecified siteDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.820Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, left elbowDiagnosisICD-10-CMM06.824Other specified rheumatoid arthritis, inght wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, inght wristDiagnosisICD-10-CMM06.844Other specified rheumatoid arthritis, inght findDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, inspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, inspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, inght hipDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis,	M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.372Rheumatoid nodule, left ankle and footDiagnosisICD-10-CMM06.377Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, wertebraeDiagnosisICD-10-CMM06.30Rheumatoid nodule, wertebraeDiagnosisICD-10-CMM06.30Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.810Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.820Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.834Other specified rheumatoid arthritis, unspecified wirstDiagnosisICD-10-CMM06.835Other specified rheumatoid arthritis, inght handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, inght handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, inght hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, inght hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, inght hipDiagnosisICD-10-CMM06.852Othe	M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.379Rheumatoid nodule, unspecified ankle and footDiagnosisICD-10-CMM06.38Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.39Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, ieft elbowDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, ieft wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, ieft wristDiagnosisICD-10-CMM06.834Other specified rheumatoid arthritis, ieft wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, unspecified havitDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, unspecified havitDiagnosisICD-10-CMM06.855Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.850Other specified rheumatoid arthritis, unspecified havitDiagnosisICD-10-CMM06.85	M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.38Rheumatoid nodule, vertebraeDiagnosisICD-10-CMM06.39Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.813Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.820Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.855Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.856Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.	M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.39Rheumatoid nodule, multiple sitesDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.813Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, left knee	M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.80Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.811Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.813Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.829Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.864Other specified rheumatoid arthritis, right ankle and foo	M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.811Other specified rheumatoid arthritis, right shoulderDiagnosisICD-10-CMM06.812Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.819Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, left elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.863Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.864Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.865Other specified rheumatoid arthritis, unspecified hip	M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.812Other specified rheumatoid arthritis, left shoulderDiagnosisICD-10-CMM06.819Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, left elbowDiagnosisICD-10-CMM06.823Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, right haneDiagnosisICD-10-CMM06.855Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, unspecified knee	M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.819Other specified rheumatoid arthritis, unspecified shoulderDiagnosisICD-10-CMM06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.829Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.839Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosis <t< td=""><td>M06.811</td><td>Other specified rheumatoid arthritis, right shoulder</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.821Other specified rheumatoid arthritis, right elbowDiagnosisICD-10-CMM06.822Other specified rheumatoid arthritis, left elbowDiagnosisICD-10-CMM06.829Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, inght wristDiagnosisICD-10-CMM06.833Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.844Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.855Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, wright ankle and footDiagnosisIC	M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.822Other specified rheumatoid arthritis, left elbowDiagnosisICD-10-CMM06.829Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.839Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.873Other specified rheumatoid arthritis, wretebraeDiagnosisICD-10-CMM06.874Other specified rheumatoid arthritis, unspecified ankl	M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.829Other specified rheumatoid arthritis, unspecified elbowDiagnosisICD-10-CMM06.831Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.839Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.843Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.853Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.854Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.855Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.873Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, unspecified ankle and footDiagnosi	M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.831Other specified rheumatoid arthritis, right wristDiagnosisICD-10-CMM06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.839Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.863Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.890Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.890Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.890Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-C	M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.832Other specified rheumatoid arthritis, left wristDiagnosisICD-10-CMM06.839Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.863Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.884Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.895Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.896Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.897Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CM <t< td=""><td>M06.829</td><td>Other specified rheumatoid arthritis, unspecified elbow</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.839Other specified rheumatoid arthritis, unspecified wristDiagnosisICD-10-CMM06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.840Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.80Unspecified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.80Unspecified juvenile rheumatoid arthritis of unspe	M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.841Other specified rheumatoid arthritis, right handDiagnosisICD-10-CMM06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, nultiple sitesDiagnosisICD-10-CMM06.80Unspecified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.80Unspecified rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM06.81Unspecified juvenile rheumatoid arthritis of unspecified site </td <td>M06.832</td> <td>Other specified rheumatoid arthritis, left wrist</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.842Other specified rheumatoid arthritis, left handDiagnosisICD-10-CMM06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.863Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.864Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.85Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, of unspecifie	M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.849Other specified rheumatoid arthritis, unspecified handDiagnosisICD-10-CMM06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.870Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.890Other specified rheumatoid arthritis, nultiple sitesDiagnosisICD-10-CMM06.840Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.89Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, right shoulderDi	M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.851Other specified rheumatoid arthritis, right hipDiagnosisICD-10-CMM06.852Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.863Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.852Other specified rheumatoid arthritis, left hipDiagnosisICD-10-CMM06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.9Rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.859Other specified rheumatoid arthritis, unspecified hipDiagnosisICD-10-CMM06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, nultiple sitesDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM06.9Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.861Other specified rheumatoid arthritis, right kneeDiagnosisICD-10-CMM06.862Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, wiltiple sitesDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.862Other specified rheumatoid arthritis, left kneeDiagnosisICD-10-CMM06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.880Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.90Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.869Other specified rheumatoid arthritis, unspecified kneeDiagnosisICD-10-CMM06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, wertebraeDiagnosisICD-10-CMM06.80Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.871Other specified rheumatoid arthritis, right ankle and footDiagnosisICD-10-CMM06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.90Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.872Other specified rheumatoid arthritis, left ankle and footDiagnosisICD-10-CMM06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.84Other specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecified siteDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.879Other specified rheumatoid arthritis, unspecified ankle and footDiagnosisICD-10-CMM06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.8AOther specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecifiedDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.88Other specified rheumatoid arthritis, vertebraeDiagnosisICD-10-CMM06.89Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.8AOther specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecifiedDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.89Other specified rheumatoid arthritis, multiple sitesDiagnosisICD-10-CMM06.8AOther specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecifiedDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM	M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.8AOther specified rheumatoid arthritis, other specified siteDiagnosisICD-10-CMM06.9Rheumatoid arthritis, unspecifiedDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM		-	-	
M06.9Rheumatoid arthritis, unspecifiedDiagnosisICD-10-CMM08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM				ICD-10-CM
M08.00Unspecified juvenile rheumatoid arthritis of unspecified siteDiagnosisICD-10-CMM08.011Unspecified juvenile rheumatoid arthritis, right shoulderDiagnosisICD-10-CM				
M08.011 Unspecified juvenile rheumatoid arthritis, right shoulder Diagnosis ICD-10-CM		-	-	
			-	
M08.012 Unspecified juvenile rheumatoid arthritis, left shoulder Diagnosis ICD-10-CM			-	
	M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM



M16.50 Unilateral post-traumatic osteoarthritis, right hip Diagnosis IC M16.51 Unilateral post-traumatic osteoarthritis, right hip Diagnosis IC M16.52 Unilateral post-traumatic osteoarthritis of hip Diagnosis IC M16.6 Other bilateral secondary osteoarthritis of hip Diagnosis IC M16.7 Other unilateral secondary osteoarthritis of hip Diagnosis IC M16.9 Osteoarthritis of hip, unspecified Diagnosis IC M17.00 Bilateral primary osteoarthritis, right knee Diagnosis IC M17.10 Unilateral primary osteoarthritis, right knee Diagnosis IC M17.10 Unilateral primary osteoarthritis, right knee Diagnosis IC M17.11 Unilateral post-traumatic osteoarthritis, right knee Diagnosis IC M17.30 Unilateral post-traumatic osteoarthritis, right knee Diagnosis IC M17.31 Unilateral post-traumatic osteoarthritis, right knee Diagnosis IC M17.32 Unilateral post-traumatic osteoarthritis, right knee Diagnosis IC M17.32 Unilateral post-traumatic osteoarthritis of knee Diagnosis <th>Code Type CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM</th>	Code Type CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M16.51Unilateral post-traumatic osteoarthritis, right hipDiagnosis <thdiagnosis< t<="" th=""><th>CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM</th></thdiagnosis<>	CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M16.52Unilateral post-traumatic osteoarthritis, left hipDiagnosis <td>CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM</td>	CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M16.6Other bilateral secondary osteoarthritis of hipDiagnosis <t< td=""><td>CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM</td></t<>	CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M16.7Other unilateral secondary osteoarthritis of hipDiagnosis<	CD-10-CM CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M16.9Osteoarthritis of hip, unspecifiedDiagnosis </td <td>CD-10-CM CD-10-CM CD-10-CM CD-10-CM</td>	CD-10-CM CD-10-CM CD-10-CM CD-10-CM
M17.0Bilateral primary osteoarthritis of kneeDiagnosisICM17.10Unilateral primary osteoarthritis, unspecified kneeDiagnosisICM17.11Unilateral primary osteoarthritis, ight kneeDiagnosisICM17.12Unilateral primary osteoarthritis, left kneeDiagnosisICM17.20Bilateral post-traumatic osteoarthritis of kneeDiagnosisICM17.31Unilateral post-traumatic osteoarthritis, inght kneeDiagnosisICM17.32Unilateral post-traumatic osteoarthritis, right kneeDiagnosisICM17.32Unilateral post-traumatic osteoarthritis of kneeDiagnosisICM17.4Other bilateral secondary osteoarthritis of kneeDiagnosisICM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal jointsDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.12Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.20Inilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM	CD-10-CM CD-10-CM CD-10-CM
M17.10Unilateral primary osteoarthritis, unspecified kneeDiagnosisDiagnosisM17.11Unilateral primary osteoarthritis, right kneeDiagnosisDiagnosisDiagnosisM17.12Unilateral primary osteoarthritis, left kneeDiagnosisDiagnosisDiagnosisM17.20Bilateral post-traumatic osteoarthritis, left kneeDiagnosisDiagnosisDiagnosisM17.30Unilateral post-traumatic osteoarthritis, unspecified kneeDiagnosisDiagnosisDiagnosisM17.31Unilateral post-traumatic osteoarthritis, left kneeDiagnosisDiagnosisDiagnosisM17.42Uther bilateral secondary osteoarthritis of kneeDiagnosisDiagnosisDiagnosisDiagnosisM17.5Other unilateral secondary osteoarthritis of kneeDiagnosis <td>CD-10-CM CD-10-CM</td>	CD-10-CM CD-10-CM
M17.11Unilateral primary osteoarthritis, right kneeDiagnosisDiagnosisM17.12Unilateral primary osteoarthritis, left kneeDiagnosisDiagnosisDiagnosisM17.2Bilateral post-traumatic osteoarthritis, unspecified kneeDiagnosisDiagnosisDiagnosisM17.30Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagnosisDiagnosisDiagnosisM17.31Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagn	CD-10-CM
M17.12Unilateral primary osteoarthritis, left kneeDiagnosisDiagnosisM17.2Bilateral post-traumatic osteoarthritis of kneeDiagnosisDiagnosisM17.30Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagnosisM17.31Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagnosisM17.32Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagnosisM17.40Other bilateral secondary osteoarthritis of kneeDiagnosisDiagnosisM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisDiagnosisM17.5Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisDiagnosisM18.0Bilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisDiagnosisM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisDiagnosisM18.2Bilateral primary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.2Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.30handDiagnosisDiagnosisDiagnosisDiagnosisM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisDiagnosisM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.32Unilateral post-traumatic osteoarth	
M17.2Bilateral post-traumatic osteoarthritis of kneeDiagnosisDiagnosisM17.30Unilateral post-traumatic osteoarthritis, unspecified kneeDiagnosisDiagnosisM17.31Unilateral post-traumatic osteoarthritis, right kneeDiagnosisDiagnosisM17.32Unilateral post-traumatic osteoarthritis, left kneeDiagnosisDiagnosisM17.4Other bilateral secondary osteoarthritis of kneeDiagnosisDiagnosisM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisDiagnosisM17.9Osteoarthritis of knee, unspecifiedDiagnosisDiagnosisM18.0Bilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisDiagnosisM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisDiagnosisM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisDiagnosisM18.12Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.30handDiagnosisDiagnosisDiagnosisDiagnosisM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisDiagnosisM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisDiagnosisM18.32Unilateral post-traumatic osteoarthriti	CD-10-CM
M17.30Unilateral post-traumatic osteoarthritis, unspecified kneeDiagnosisICM17.31Unilateral post-traumatic osteoarthritis, right kneeDiagnosisICM17.32Unilateral post-traumatic osteoarthritis, left kneeDiagnosisICM17.4Other bilateral secondary osteoarthritis of kneeDiagnosisICM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.30handDiagnosisICICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.	
M17.31Unilateral post-traumatic osteoarthritis, right kneeDiagnosisICM17.32Unilateral post-traumatic osteoarthritis, left kneeDiagnosisICM17.4Other bilateral secondary osteoarthritis of kneeDiagnosisICM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint,DiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.2Bilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedM18.32DiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedM18.32DiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.33Unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedM18.32DiagnosisIC<	CD-10-CM
M17.32Unilateral post-traumatic osteoarthritis, left kneeDiagnosisICM17.4Other bilateral secondary osteoarthritis of kneeDiagnosisICM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint,Unspecified handDiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.2Bilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.33Unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.40Cher unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDi	CD-10-CM
M17.4Other bilateral secondary osteoarthritis of kneeDiagnosisICM17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICMiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosis of first carpometacarpal joint, unspecifiedDiagnosisICM18.51Other unilateral secondary osteoarthritis of first	CD-10-CM
M17.5Other unilateral secondary osteoarthritis of kneeDiagnosisICM17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint,DiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.33Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.43Other unilateral secondary osteoarth	CD-10-CM
M17.9Osteoarthritis of knee, unspecifiedDiagnosisICM18.0Bilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.10Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.12Unilateral post-traumatic osteoarthritis of first carpometacarpal jointsDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, nuspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right ha	CD-10-CM
M18.0Bilateral primary osteoarthritis of first carpometacarpal jointsDiagnosisICM18.0Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.41Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosis	CD-10-CM
M18.10Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified handDiagnosisICM18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of fir	CD-10-CM
M18.11Unilateral primary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal jointsDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.32unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.32Unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.4Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	CD-10-CM
M18.12Unilateral primary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal jointsDiagnosisICM18.2Nullateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.53Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.54Other unilateral secondary osteoarthritis	CD-10-CM
M18.2Bilateral post-traumatic osteoarthritis of first carpometacarpal joints Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisICM19.012Primary osteoarthritis, left shoul	CD-10-CM
Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecifiedM18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.30handDiagnosisICM18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.59Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.31Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal jointsDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	
M18.32Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.4Other bilateral secondary osteoarthritis of first carpometacarpal jointsDiagnosisICOther unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.4Other bilateral secondary osteoarthritis of first carpometacarpal joints Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecifiedM18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.50handDiagnosisICM18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.51Other unilateral secondary osteoarthritis of first carpometacarpal joint, right handDiagnosisICM18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	
M18.52Other unilateral secondary osteoarthritis of first carpometacarpal joint, left handDiagnosisICM18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M18.9Osteoarthritis of first carpometacarpal joint, unspecifiedDiagnosisICM19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M19.011Primary osteoarthritis, right shoulderDiagnosisICM19.012Primary osteoarthritis, left shoulderDiagnosisIC	CD-10-CM
M19.012 Primary osteoarthritis, left shoulder Diagnosis IC	CD-10-CM
	CD-10-CM
M19.019 Primary osteoarthritis, unspecified shoulder Diagnosis IC	CD-10-CM
	CD-10-CM
M19.072 Primary osteoarthritis, left ankle and foot Diagnosis IC	CD-10-CM



W19.079 Primary osteoarthritis, unspecified ankle and foot Diagnosis ICD-10-CM W19.079 Primary osteoarthritis, other specified site Diagnosis ICD-10-CM W19.111 Post-traumatic osteoarthritis, ight shoulder Diagnosis ICD-10-CM W19.112 Post-traumatic osteoarthritis, ight shoulder Diagnosis ICD-10-CM W19.122 Post-traumatic osteoarthritis, ight elbow Diagnosis ICD-10-CM W19.122 Post-traumatic osteoarthritis, ight wist Diagnosis ICD-10-CM W19.132 Post-traumatic osteoarthritis, inght wist Diagnosis ICD-10-CM W19.132 Post-traumatic osteoarthritis, inght wist Diagnosis ICD-10-CM W19.141 Post-traumatic osteoarthritis, inght mist Diagnosis ICD-10-CM W19.142 Post-traumatic osteoarthritis, inght ankle Diagnosis ICD-10-CM W19.141 Post-traumatic osteoarthritis, inght ankle and foot Diagnosis ICD-10-CM W19.142 Post-traumatic osteoarthritis, inght ankle and foot Diagnosis ICD-10-CM W19.147 Post-traumatic osteoarthritis, inght ankle and foot Diagnosis ICD-10-CM W19.147 Post-traumatic osteoarthritis, inght ankle and foot Diagnosis ICD-10-CM W19.147 Post-traumatic osteoarthritis, i			Code	
M19.09Primary osteoarthritis, right shoulderDiagnosisICD-10-CMM19.111Post-traumatic osteoarthritis, left shoulderDiagnosisICD-10-CMM19.112Post-traumatic osteoarthritis, left shoulderDiagnosisICD-10-CMM19.121Post-traumatic osteoarthritis, right elbowDiagnosisICD-10-CMM19.122Post-traumatic osteoarthritis, left elbowDiagnosisICD-10-CMM19.123Post-traumatic osteoarthritis, left wistDiagnosisICD-10-CMM19.131Post-traumatic osteoarthritis, left wistDiagnosisICD-10-CMM19.132Post-traumatic osteoarthritis, inght andDiagnosisICD-10-CMM19.134Post-traumatic osteoarthritis, inght andDiagnosisICD-10-CMM19.141Post-traumatic osteoarthritis, inght and and footDiagnosisICD-10-CMM19.142Post-traumatic osteoarthritis, inght ankle and footDiagnosisICD-10-CMM19.174Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.175Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.174Post-traumatic osteoarthritis, inght shoulderDiagnosisICD-10-CMM19.175Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.174Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.175Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.174Post-traumatic osteoarthritis, inght elbowDiagnosisICD-10-CMM19.1	Code	Description	Category	Code Type
VI19.111 Post-traumatic osteoarthritis, right shoulder Diagnosis ICD-10-CM VI19.119 Post-traumatic osteoarthritis, nepecified shoulder Diagnosis ICD-10-CM VI19.121 Post-traumatic osteoarthritis, nepecified aboulder Diagnosis ICD-10-CM VI19.122 Post-traumatic osteoarthritis, inght elbow Diagnosis ICD-10-CM VI19.123 Post-traumatic osteoarthritis, inght wrist Diagnosis ICD-10-CM VI19.131 Post-traumatic osteoarthritis, inght wrist Diagnosis ICD-10-CM VI19.132 Post-traumatic osteoarthritis, inght wrist Diagnosis ICD-10-CM VI19.132 Post-traumatic osteoarthritis, inght hand Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght ande Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght ande Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght ankle and foot Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght shoulder Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght shoulder Diagnosis ICD-10-CM VI19.142 Post-traumatic osteoarthritis, inght shoulder Diagnosis ICD-10-CM VI19.142 Secondary osteoarthritis, i	M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
V19.112 Post-traumatic osteoarthritis, left shoulder Diagnosis ICD-10-CM V19.112 Post-traumatic osteoarthritis, ingle elbow Diagnosis ICD-10-CM V19.122 Post-traumatic osteoarthritis, ingle elbow Diagnosis ICD-10-CM V19.123 Post-traumatic osteoarthritis, ingle elbow Diagnosis ICD-10-CM V19.124 Post-traumatic osteoarthritis, ingle wist Diagnosis ICD-10-CM V19.131 Post-traumatic osteoarthritis, ingle wist Diagnosis ICD-10-CM V19.132 Post-traumatic osteoarthritis, ingle diwist Diagnosis ICD-10-CM V19.142 Secondary osteoarthritis, ingle diwist Diagnosis	M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
VI19.119Post-traumatic osteoarthritis, right elbowDiagnosisICD-10-CMVI19.122Post-traumatic osteoarthritis, right elbowDiagnosisICD-10-CMVI19.122Post-traumatic osteoarthritis, right wristDiagnosisICD-10-CMVI19.131Post-traumatic osteoarthritis, right wristDiagnosisICD-10-CMVI19.132Post-traumatic osteoarthritis, right wristDiagnosisICD-10-CMVI19.133Post-traumatic osteoarthritis, right handDiagnosisICD-10-CMVI19.141Post-traumatic osteoarthritis, right handDiagnosisICD-10-CMVI19.142Post-traumatic osteoarthritis, right ankle and footDiagnosisICD-10-CMVI19.171Post-traumatic osteoarthritis, right ankle and footDiagnosisICD-10-CMVI19.172Post-traumatic osteoarthritis, inspecified ankle and footDiagnosisICD-10-CMVI19.173Post-traumatic osteoarthritis, onspecified siteDiagnosisICD-10-CMVI19.174Post-traumatic osteoarthritis, onter specified siteDiagnosisICD-10-CMVI19.175Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMVI19.121Secondary osteoarthritis, right wristDiagnosisICD-10-CMVI19.222Secondary osteoarthritis, right wristDiagnosisICD-10-CMVI19.223Secondary osteoarthritis, right wristDiagnosisICD-10-CMVI19.224Secondary osteoarthritis, right wristDiagnosisICD-10-CMVI19.225Secondary osteoarthritis, right wristDiagnosisICD-1	M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
V19.121Post-traumatic osteoarthritis, right elbowDiagnosisICD-10-CMV19.122Post-traumatic osteoarthritis, unspecified elbowDiagnosisICD-10-CMV19.131Post-traumatic osteoarthritis, unspecified elbowDiagnosisICD-10-CMV19.132Post-traumatic osteoarthritis, unspecified wistDiagnosisICD-10-CMV19.139Post-traumatic osteoarthritis, unspecified wistDiagnosisICD-10-CMV19.141Post-traumatic osteoarthritis, unspecified hardDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, unspecified hardDiagnosisICD-10-CMV19.149Post-traumatic osteoarthritis, unspecified hardDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, unspecified hardDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, unspecified steeDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, unspecified steeDiagnosisICD-10-CMV19.172Secondary osteoarthritis, unspecified steeDiagnosisICD-10-CMV19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMV19.221Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMV19.222Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMV19.223Secondary osteoarthritis, unspecified wistDiagnosisICD-10-CMV19.224Secondary osteoarthritis, unspecified wistDiagnosisICD-10-CMV19.225Secondary osteoarthritis, unspecified wist <t< td=""><td>M19.112</td><td>Post-traumatic osteoarthritis, left shoulder</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
V19.122Post-traumatic osteoarthritis, left elbowDiagnosisICD-10-CMV19.129Post-traumatic osteoarthritis, right vristDiagnosisICD-10-CMV19.131Post-traumatic osteoarthritis, right vristDiagnosisICD-10-CMV19.132Post-traumatic osteoarthritis, left wristDiagnosisICD-10-CMV19.134Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.141Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, left shoulderDiagnosisICD-10-CMV19.172Secondary osteoarthritis, ight shoulderDiagnosisICD-10-CMV19.212Secondary osteoarthritis, ight elbowDiagnosisICD-10-CMV19.223Secondary osteoarthritis, ight elbowDiagnosisICD-10-CMV19.232Secondary osteoarthritis, ight handDiagnosisICD-10-CMV19.243Secondary osteoarthritis, ight handDiagnosisICD-10-CMV19.243Secondary osteoarthritis, ight handDiagnosisICD-10-CMV19.243Secondary osteoarthritis, ight handDiagnosisICD-10-CMV19.243Secondary ost	M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.129Post-traumatic osteoarthritis, inght wristDiagnosisICD-10-CMM19.131Post-traumatic osteoarthritis, inght wristDiagnosisICD-10-CMM19.132Post-traumatic osteoarthritis, inght mristDiagnosisICD-10-CMM19.139Post-traumatic osteoarthritis, inght handDiagnosisICD-10-CMM19.141Post-traumatic osteoarthritis, inght handDiagnosisICD-10-CMM19.142Post-traumatic osteoarthritis, inght handDiagnosisICD-10-CMM19.147Post-traumatic osteoarthritis, inght ankle and footDiagnosisICD-10-CMM19.179Post-traumatic osteoarthritis, inght ankle and footDiagnosisICD-10-CMM19.171Post-traumatic osteoarthritis, inght ankle and footDiagnosisICD-10-CMM19.172Post-traumatic osteoarthritis, inght shoulderDiagnosisICD-10-CMM19.171Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMM19.212Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMM19.223Secondary osteoarthritis, inght wristDiagnosisICD-10-CMM19.231Secondary osteoarthritis, inght wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, inght wristDiagnosisICD-10-CMM19.233Secondary osteoarthritis, inght wristDiagnosisICD-10-CMM19.243Secondary osteoarthritis, inght maiDiagnosisICD-10-CMM19.243Secondary osteoarthritis, inght andDiagnosisICD-10-CMM19.243Secondary	M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
V19.131Post-traumatic osteoarthritis, right wristDiagnosisICD-10-CMV19.132Post-traumatic osteoarthritis, left wristDiagnosisICD-10-CMV19.141Post-traumatic osteoarthritis, right handDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.149Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.149Post-traumatic osteoarthritis, inght ankle and footDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMV19.211Secondary osteoarthritis, unspecified shulderDiagnosisICD-10-CMV19.212Secondary osteoarthritis, right shoulderDiagnosisICD-10-CMV19.223Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMV19.224Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.232Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.243Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.243Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.245 </td <td>M19.122</td> <td>Post-traumatic osteoarthritis, left elbow</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
V19.132Post-traumatic osteoarthritis, left wristDiagnosisICD-10-CMV19.134Post-traumatic osteoarthritis, unspecified wristDiagnosisICD-10-CMV19.141Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.149Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, left shoulderDiagnosisICD-10-CMV19.211Secondary osteoarthritis, left shoulderDiagnosisICD-10-CMV19.212Secondary osteoarthritis, left shoulderDiagnosisICD-10-CMV19.213Secondary osteoarthritis, right elbowDiagnosisICD-10-CMV19.224Secondary osteoarthritis, right wristDiagnosisICD-10-CMV19.225Secondary osteoarthritis, right wristDiagnosisICD-10-CMV19.231Secondary osteoarthritis, right wristDiagnosisICD-10-CMV19.242Secondary osteoarthritis, right handDiagnosisICD-10-CMV19.241Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMV19.242Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMV19.243Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMV19.244	M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
V19.139Post-traumatic osteoarthritis, unspecified wristDiagnosisICD-10-CMV19.141Post-traumatic osteoarthritis, right handDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, unspecified handDiagnosisICD-10-CMV19.147Post-traumatic osteoarthritis, unspecified handDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMV19.172Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMV19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMV19.221Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMV19.222Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMV19.231Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMV19.242Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.232Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV19.245Secondary osteoarthritis	M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
V19.141Post-traumatic osteoarthritis, right handDiagnosisICD-10-CMV19.142Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.149Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV19.171Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV19.179Post-traumatic osteoarthritis, other specified ankle and footDiagnosisICD-10-CMV19.191Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMV19.211Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMV19.221Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMV19.221Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMV19.221Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.223Secondary osteoarthritis, inspecified elbowDiagnosisICD-10-CMV19.233Secondary osteoarthritis, inght wristDiagnosisICD-10-CMV19.242Secondary osteoarthritis, inght handDiagnosisICD-10-CMV19.242Secondary osteoarthritis, inght andDiagnosisICD-10-CMV19.242Secondary osteoarthritis, inght and footDiagnosisICD-10-CMV19.242Secondary osteoarthritis, inght andDiagnosisICD-10-CMV19.242Secondary osteoarthritis, inght andDiagnosisICD-10-CMV19.242Secondary	M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
V119.142Post-traumatic osteoarthritis, left handDiagnosisICD-10-CMV119.149Post-traumatic osteoarthritis, unspecified handDiagnosisICD-10-CMV119.171Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV119.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMV119.179Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMV119.171Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMV119.121Secondary osteoarthritis, ight shoulderDiagnosisICD-10-CMV119.212Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMV119.212Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMV119.222Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMV119.223Secondary osteoarthritis, inght wirstDiagnosisICD-10-CMV119.224Secondary osteoarthritis, inght wirstDiagnosisICD-10-CMV119.231Secondary osteoarthritis, inght wirstDiagnosisICD-10-CMV119.242Secondary osteoarthritis, inght andDiagnosisICD-10-CMV119.243Secondary osteoarthritis, inght andDiagnosisICD-10-CMV119.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMV119.245Secondary osteoarthritis, inght ankle and footDiagnosisICD-10-CMV119.247Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CM <td< td=""><td>M19.139</td><td>Post-traumatic osteoarthritis, unspecified wrist</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.149Post-traumatic osteoarthritis, unspecified handDiagnosisICD-10-CMW19.171Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMW19.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMW19.179Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMW19.19Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMW19.219Secondary osteoarthritis, inght shoulderDiagnosisICD-10-CMW19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.223Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.224Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.225Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMW19.232Secondary osteoarthritis, inght wristDiagnosisICD-10-CMW19.233Secondary osteoarthritis, inght wristDiagnosisICD-10-CMW19.241Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMW19.242Secondary osteoarthritis, inght nandDiagnosisICD-10-CMW19.243Secondary osteoarthritis, inght ankle and footDiagnosisICD-10-CMW19.244Secondary osteoarthritis, inght ankle and footDiagnosisICD-10-CMW19.245Secondary osteoarthritis, inght ankle and footDiagnosisICD-10-CMW19.249Secondary osteoarthritis, unspecified ankle and foot<	M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.171Post-traumatic osteoarthritis, right ankle and footDiagnosisICD-10-CMW19.172Post-traumatic osteoarthritis, utf ankle and footDiagnosisICD-10-CMW19.179Post-traumatic osteoarthritis, other specified ankle and footDiagnosisICD-10-CMW19.19Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMW19.211Secondary osteoarthritis, right shoulderDiagnosisICD-10-CMW19.212Secondary osteoarthritis, right shoulderDiagnosisICD-10-CMW19.223Secondary osteoarthritis, left elbowDiagnosisICD-10-CMW19.224Secondary osteoarthritis, left elbowDiagnosisICD-10-CMW19.225Secondary osteoarthritis, left elbowDiagnosisICD-10-CMW19.226Secondary osteoarthritis, left wristDiagnosisICD-10-CMW19.227Secondary osteoarthritis, left wristDiagnosisICD-10-CMW19.238Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMW19.241Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMW19.242Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMW19.274Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMW19.275Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.271Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CM <t< td=""><td>M19.142</td><td>Post-traumatic osteoarthritis, left hand</td><td>Diagnosis</td><td>ICD-10-CM</td></t<>	M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.172Post-traumatic osteoarthritis, left ankle and footDiagnosisICD-10-CMW19.179Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMW19.19Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMW19.211Secondary osteoarthritis, right shoulderDiagnosisICD-10-CMW19.212Secondary osteoarthritis, right elbowDiagnosisICD-10-CMW19.212Secondary osteoarthritis, right elbowDiagnosisICD-10-CMW19.222Secondary osteoarthritis, inght elbowDiagnosisICD-10-CMW19.223Secondary osteoarthritis, inght wristDiagnosisICD-10-CMW19.224Secondary osteoarthritis, right wristDiagnosisICD-10-CMW19.233Secondary osteoarthritis, right wristDiagnosisICD-10-CMW19.243Secondary osteoarthritis, right handDiagnosisICD-10-CMW19.244Secondary osteoarthritis, right handDiagnosisICD-10-CMW19.245Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMW19.247Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMW19.278Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary ost	M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.179Post-traumatic osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMW19.19Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMW19.211Secondary osteoarthritis, irght shoulderDiagnosisICD-10-CMW19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.213Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.224Secondary osteoarthritis, right elbowDiagnosisICD-10-CMW19.225Secondary osteoarthritis, right elbowDiagnosisICD-10-CMW19.226Secondary osteoarthritis, right wristDiagnosisICD-10-CMW19.237Secondary osteoarthritis, right wristDiagnosisICD-10-CMW19.238Secondary osteoarthritis, right wristDiagnosisICD-10-CMW19.249Secondary osteoarthritis, right handDiagnosisICD-10-CMW19.241Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMW19.242Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMW19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMW19.244Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.275Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.276Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.277Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.278 <td< td=""><td>M19.171</td><td>Post-traumatic osteoarthritis, right ankle and foot</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.19Post-traumatic osteoarthritis, other specified siteDiagnosisICD-10-CMM19.211Secondary osteoarthritis, left shoulderDiagnosisICD-10-CMM19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMM19.213Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.224Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.225Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.226Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.237Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.248Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.249Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.241Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.242Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.245Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.271Secondary osteoarthritis, onspecified siteDiagnosisICD-10-CMM19.292Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.293Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.294Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.295Secondary oste	M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.211Secondary osteoarthritis, right shoulderDiagnosisICD-10-CMW19.212Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.213Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.214Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMW19.225Secondary osteoarthritis, left elbowDiagnosisICD-10-CMW19.229Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMW19.231Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMW19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMW19.233Secondary osteoarthritis, left wristDiagnosisICD-10-CMW19.243Secondary osteoarthritis, left wristDiagnosisICD-10-CMW19.243Secondary osteoarthritis, right handDiagnosisICD-10-CMW19.244Secondary osteoarthritis, inght ankle and footDiagnosisICD-10-CMW19.275Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMW19.276Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.277Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.278Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.271Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW19.292Secondary os	M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.212Secondary osteoarthritis, left shoulderDiagnosisICD-10-CMM19.219Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMM19.221Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.222Secondary osteoarthritis, left elbowDiagnosisICD-10-CMM19.223Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.233Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.233Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.234Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.245Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.247Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.248Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.271Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.291Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.292Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.293Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.294Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.295Secondary osteoarthritis	M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.219Secondary osteoarthritis, unspecified shoulderDiagnosisICD-10-CMM19.221Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.222Secondary osteoarthritis, left elbowDiagnosisICD-10-CMM19.223Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.231Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.233Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.243Secondary osteoarthritis, right andDiagnosisICD-10-CMM19.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.275Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.290Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.291Peimary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.292Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.293Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.294Post-traumati	M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.221Secondary osteoarthritis, right elbowDiagnosisICD-10-CMM19.222Secondary osteoarthritis, left elbowDiagnosisICD-10-CMM19.223Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.231Secondary osteoarthritis, inght wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.233Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.243Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.244Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.245Secondary osteoarthritis, inght andDiagnosisICD-10-CMM19.247Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.273Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.274Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.275Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.29Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylos	M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.222Secondary osteoarthritis, left elbowDiagnosisICD-10-CMM19.229Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.231Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.233Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.242Secondary osteoarthritis, ight handDiagnosisICD-10-CMM19.243Secondary osteoarthritis, ight andDiagnosisICD-10-CMM19.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.274Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.275Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.95Secondary osteoarthriti	M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.229Secondary osteoarthritis, unspecified elbowDiagnosisICD-10-CMM19.231Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.239Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.244Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.95Secondary os	M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.231Secondary osteoarthritis, right wristDiagnosisICD-10-CMM19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.239Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.243Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.271Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.273Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.0Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Anky	M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.232Secondary osteoarthritis, left wristDiagnosisICD-10-CMM19.239Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.299Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.95Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.2	M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.239Secondary osteoarthritis, unspecified wristDiagnosisICD-10-CMM19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.273Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6<	M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.241Secondary osteoarthritis, right handDiagnosisICD-10-CMM19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.273Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CM<	M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.242Secondary osteoarthritis, left handDiagnosisICD-10-CMM19.249Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicathracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis umbar regionDiagnosisICD-10-CMM45.6A	M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.249Secondary osteoarthritis, unspecified handDiagnosisICD-10-CMM19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, other specified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CMM45	M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.271Secondary osteoarthritis, right ankle and footDiagnosisICD-10-CMM19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.0Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.272Secondary osteoarthritis, left ankle and footDiagnosisICD-10-CMM19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, other specified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.94Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.0Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.279Secondary osteoarthritis, unspecified ankle and footDiagnosisICD-10-CMM19.29Secondary osteoarthritis, other specified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.29Secondary osteoarthritis, other specified siteDiagnosisICD-10-CMM19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.90Unspecified osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.91Primary osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.92Post-traumatic osteoarthritis, unspecified siteDiagnosisICD-10-CMM19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMM45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93Secondary osteoarthritis, unspecified siteDiagnosisICD-10-CMW45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMW45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMW45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMW45.3Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMW45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMW45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMW45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMW45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0Ankylosing spondylitis of multiple sites in spineDiagnosisICD-10-CMM45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.1Ankylosing spondylitis of occipito-atlanto-axial regionDiagnosisICD-10-CMM45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.2Ankylosing spondylitis of cervical regionDiagnosisICD-10-CMM45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CMM45.6DiagnosisICD-10-CMDiagnosisM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.3Ankylosing spondylitis of cervicothoracic regionDiagnosisICD-10-CMM45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.4Ankylosing spondylitis of thoracic regionDiagnosisICD-10-CMM45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M45.2			ICD-10-CM
M45.5Ankylosing spondylitis of thoracolumbar regionDiagnosisICD-10-CMM45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M45.3		Diagnosis	ICD-10-CM
M45.6Ankylosing spondylitis lumbar regionDiagnosisICD-10-CM	M45.4		Diagnosis	
	M45.5		-	
M45.7Ankylosing spondylitis of lumbosacral regionDiagnosisICD-10-CM	M45.6		-	
	M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM



		Code	
Code D	Description	Category	Code Type
M45.8 A	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9 A	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0 N	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1 N	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2 N	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3 N	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4 N	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5 N	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6 N	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7 N	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80 C	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96 L	Jnspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
	Inspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
	Jnspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011 A	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012 A	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013 A	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014 A	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015 A	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016 A	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019 A	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021 \	/ertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022 \	/ertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029 \	/ertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10 C	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11 C	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.12 C	stile spondylosis with myclopatity, certical region	0	



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified Stroke or Transient Ischemic Attack	Diagnosis	ICD-10-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1 G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.1 G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.2 G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
040.0	Amaurosis rugan	Diagnosis	



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

G45.8 Other transient cerebral ischemic attacks and related syndromes Diagnosis ICD-10-CM G45.9 Transient cerebral ischemic attack, unspecified Diagnosis ICD-10-CM G46.0 Midle cerebral artery syndrome Diagnosis ICD-10-CM G46.1 Anterior cerebral artery syndrome Diagnosis ICD-10-CM G46.3 Brain stem stroke syndrome Diagnosis ICD-10-CM G46.4 Cerebellar stroke syndrome Diagnosis ICD-10-CM G46.5 Pure motor lacunar syndrome Diagnosis ICD-10-CM G46.6 Pure sensory lacunar syndrome Diagnosis ICD-10-CM G46.7 Other lacunar syndromes do train in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage from right carotid siphon and bifurcation Diagnosis ICD-10-CM Intraoperative hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM Intraoperati			Code	
G45.9 Transient cerebral ischemic attack, unspecified Diagnosis ICD-10-CM G46.0 Middle cerebral attery syndrome Diagnosis ICD-10-CM G46.1 Anterior cerebral attery syndrome Diagnosis ICD-10-CM G46.2 Posterior cerebral attery syndrome Diagnosis ICD-10-CM G46.3 Brain stare syndrome Diagnosis ICD-10-CM G46.4 Cerebellar stroke syndrome Diagnosis ICD-10-CM G46.5 Pure motor lacunar syndromes Diagnosis ICD-10-CM G46.6 Pure motor lacunar syndromes Diagnosis ICD-10-CM G46.7 Other vascular syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure G97.31 Complicating other procedure Diagnosis ICD-10-CM Intraoperative hemorrhage from unspecified carotid siphon and Diagnosis ICD-10-CM Intraoperative hemorrhage from right carotid siphon and bifurcation Diagnosis ICD-10-CM I060.0 Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral attery Diagnosis	Code	Description	Category	Code Type
G46.0 Middle cerebral artery syndrome Diagnosis ICD-10-CM G46.1 Anterior cerebral artery syndrome Diagnosis ICD-10-CM G46.2 Posterior cerebral artery syndrome Diagnosis ICD-10-CM G46.3 Brain stem stroke syndrome Diagnosis ICD-10-CM G46.4 Cerebellar stroke syndrome Diagnosis ICD-10-CM G46.5 Pure motor lacunar syndrome Diagnosis ICD-10-CM G46.6 Pure sensory lacunar syndrome Diagnosis ICD-10-CM G46.7 Other vascular syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM G97.31 complicating antervous system procedure Diagnosis ICD-10-CM Intraoperative hemorrhage from right carotid siphon and bifurcation Diagnosis ICD-10-CM I60.01 Nontraumatic subarachnoid hemorrhage from inght carotid siphon and bifurcation Diagnosis ICD-10-CM I60.11 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM <tr< td=""><td>G45.8</td><td>Other transient cerebral ischemic attacks and related syndromes</td><td>Diagnosis</td><td>ICD-10-CM</td></tr<>	G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G46.1Anterior cerebral artery syndromeDiagnosisICD-10-CMG46.2Posterior cerebral artery syndromeDiagnosisICD-10-CMG46.3Briar stem stroke syndromeDiagnosisICD-10-CMG46.4Cerebellar stroke syndromeDiagnosisICD-10-CMG46.5Pure motor lacunar syndromeDiagnosisICD-10-CMG46.6Pure sensory lacunar syndromeDiagnosisICD-10-CMG46.7Other lacunar syndromesDiagnosisICD-10-CMG46.8Other vascular syndromes of brain in cerebrovascular diseasesDiagnosisICD-10-CMIntraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.31complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from unspecified carotid siphon andDiagnosisICD-10-CMI60.00bifurcationDiagnosisICD-10-CMI60.11Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CMI60.21Nontraumatic subarachnoid hemorrhage from nespecified middle cerebral arteryDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating arteryDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from sight anterior communicating arteryDiagnosisICD-10-CMI60.24Nontraumatic subarachnoid hemorrhage from sight anterior communicating arteryDiagnosisICD-10-CMI60.24Nontraumatic subarachnoid hemorrhage from	G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.2 Posterior cerebral artery syndrome Diagnosis ICD-10-CM G46.3 Brain stem stroke syndrome Diagnosis ICD-10-CM G46.4 Cerebellar stroke syndrome Diagnosis ICD-10-CM G46.5 Pure motor lacunar syndrome Diagnosis ICD-10-CM G46.6 Pure sensory lacunar syndrome Diagnosis ICD-10-CM G46.7 Other vascular syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage from unspecified carotid siphon and bifurcation Diagnosis ICD-10-CM I60.00 bifurcation Diagnosis ICD-10-CM I60.01 Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation Diagnosis ICD-10-CM I60.11 Nontraumatic subarachnoid hemorrhage from left middle cerebral artery Diagnosis ICD-10-CM I60.12 Nontraumatic subarachnoid hemorrhage from right naterior communicating artery Diagnosis	G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3 Brain stem stroke syndrome Diagnosis ICD-10-CM G46.4 Cerebellar stroke syndrome Diagnosis ICD-10-CM G46.5 Pure motor lacunar syndrome Diagnosis ICD-10-CM G46.6 Pure sensory lacunar syndromes Diagnosis ICD-10-CM G46.7 Other lacunar syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM 697.32 complicating other procedure Diagnosis ICD-10-CM 160.00 Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation Diagnosis ICD-10-CM 160.11 Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery Diagnosis ICD-10-CM 160.12 Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery Diagnosis ICD-10-CM 160.21 Nontraumatic subarachnoid hemorr	G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.4Cerebellar stroke syndromeDiagnosisICD-10-CMG46.5Pure motor lacunar syndromeDiagnosisICD-10-CMG46.6Pure sensory lacunar syndromeDiagnosisICD-10-CMG46.7Other usensory lacunar syndromes of brain in cerebrovascular diseasesDiagnosisICD-10-CMIntraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.31complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from unspecified carotid siphon andDiagnosisICD-10-CM160.00bifurcationDiagnosisICD-10-CM160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcationDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CMDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from left posterior	G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.5Pure motor lacunar syndromeDiagnosisICD-10-CMG46.6Pure sensory lacunar syndromesDiagnosisICD-10-CMG46.7Other lacunar syndromes of brain in cerebrovascular diseasesDiagnosisICD-10-CMIntraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.31complicating a nervous system procedureDiagnosisICD-10-CMIntraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.32complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CMI60.00Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CMI60.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from left anterior communicatingDiagnosisICD-10-CMI60.21Nontraumatic subarachnoid hemorrhage from left anterior communicatingDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CMI60.21Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from laft posterior communicating arteryDiagnosis <td< td=""><td>G46.3</td><td>Brain stem stroke syndrome</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.6 Pure sensory lacunar syndrome Diagnosis ICD-10-CM G46.7 Other lacunar syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM G46.8 Other vascular syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM G97.32 complicating other procedure Diagnosis ICD-10-CM Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and Diagnosis ICD-10-CM I60.00 bifurcation Diagnosis ICD-10-CM I60.01 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM I60.12 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM I60.12 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM I60.20 artery Diagnosis ICD-10-CM I60.21 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery Diagnosis ICD-10-CM I60.21 Nontraumatic subarachnoid hemorrhage from righ	G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.7 Other lacunar syndromes Diagnosis ICD-10-CM G46.8 Other vascular syndromes of brain in cerebrovascular diseases Diagnosis ICD-10-CM Intraoperative hemorrhage and hematoma of a nervous system organ or structure Diagnosis ICD-10-CM G97.31 complicating a nervous system procedure Diagnosis ICD-10-CM Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation Diagnosis ICD-10-CM I60.00 bifurcation Diagnosis ICD-10-CM I60.01 Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation Diagnosis ICD-10-CM I60.01 Nontraumatic subarachnoid hemorrhage from inght carotid siphon and bifurcation Diagnosis ICD-10-CM I60.11 Nontraumatic subarachnoid hemorrhage from inght middle cerebral artery Diagnosis ICD-10-CM I60.22 Nontraumatic subarachnoid hemorrhage from right anterior communicating artery Diagnosis ICD-10-CM I60.21 Nontraumatic subarachnoid hemorrhage from inght anterior communicating artery Diagnosis ICD-10-CM I60.22 Nontraumatic subarachnoid hemorrhage from inght posterior communicating artery Diagnosis <td>G46.5</td> <td>Pure motor lacunar syndrome</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.8Other vascular syndromes of brain in cerebrovascular diseasesDiagnosisICD-10-CMIntraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.31complicating a nervous system procedureDiagnosisICD-10-CMMitraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.32complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcationDiagnosisICD-10-CMI60.00Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CMI60.10Nontraumatic subarachnoid hemorrhage from neter carotid siphon and bifurcationDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from neter indidle cerebral arteryDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from neterior communicating arteryDiagnosisICD-10-CMI60.21Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating arteryDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating arteryDiagnosisICD-10-CMI60.23Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating arteryDiagnosisICD-10-CMI60.24Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating arteryDiagnosisICD-10-CMI60.25Nontraumatic subarachnoid hemorrhage from sight arterior communicating arteryDiagnosis<	G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
Intraoperative hemorrhage and hematoma of a nervous system organ or structureDiagnosisICD-10-CMG97.31complicating a nervous system procedureDiagnosisICD-10-CMG97.32complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from unspecified carotid siphon andDiagnosisICD-10-CMI60.00bifurcationDiagnosisICD-10-CMI60.01Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcationDiagnosisICD-10-CMI60.02Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcationDiagnosisICD-10-CMI60.11Nontraumatic subarachnoid hemorrhage from inght middle cerebral arteryDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CMI60.21Nontraumatic subarachnoid hemorrhage from inght anterior communicating arteryDiagnosisICD-10-CMI60.22AnteryDiagnosisICD-10-CMDiagnosisICD-10-CMI60.23Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CMI60.24Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CMI60.25Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.31Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.41Nontraumatic subarachnoid hemorrhage from left posterior commun	G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G97.31complicating a nervous system procedure Intraoperative hemorrhage and hematoma of a nervous system organ or structure G97.32DiagnosisICD-10-CMG97.32complicating other procedure Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcationDiagnosisICD-10-CMI60.00bifurcationDiagnosisICD-10-CMI60.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CMI60.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CMI60.22Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating arteryDiagnosisICD-10-CMI60.23Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CMI60.24Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CMI60.25Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CMI60.30arteryDiagnosisICD-10-CMDiagnosisICD-10-CMI60.31Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.33Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CMI60.34 <td< td=""><td>G46.8</td><td>Other vascular syndromes of brain in cerebrovascular diseases</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
Intraoperative hemorrhage and hematoma of a nervous system organ or structureG97.32complicating other procedureDiagnosisICD-10-CMNontraumatic subarachnoid hemorrhage from unspecified carotid siphon andDiagnosisICD-10-CM160.00bifurcationDiagnosisICD-10-CM160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.02Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.20Nontraumatic subarachnoid hemorrhage from septified anterior communicatingDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicatingDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from septified posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from septified posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hem		Intraoperative hemorrhage and hematoma of a nervous system organ or structure		
G97.32complicating other procedure Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcationICD-10-CM160.00bifurcationDiagnosisICD-10-CM160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.02Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from efft middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from efft middle cerebral arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.33Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage	G97.31	complicating a nervous system procedure	Diagnosis	ICD-10-CM
Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcationDiagnosisICD-10-CM160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.02Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from night anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.23Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.33Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.34Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.45Nontraumatic subarachnoid hemorrhage from night vertebral artery		Intraoperative hemorrhage and hematoma of a nervous system organ or structure		
160.00bifurcationDiagnosisICD-10-CM160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.02Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcationDiagnosisICD-10-CM160.10Nontraumatic subarachnoid hemorrhage from uspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.20Nontraumatic subarachnoid hemorrhage from uspecified anterior communicating arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.23Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CMDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.35Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-C	G97.32	complicating other procedure	Diagnosis	ICD-10-CM
160.01Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcationDiagnosisICD-10-CM160.02Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.33Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosis <td< td=""><td></td><td>Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and</td><td></td><td></td></td<>		Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and		
160.02Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcationDiagnosisICD-10-CM160.10Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.2Nontraumatic subarachnoid hemorrhage from unspecified anterior communicatingICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.23nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from splt posterior communicating arteryDiagnosisICD-10-CM160.34Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.35Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.36Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.35Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosis <td< td=""><td>160.00</td><td>bifurcation</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	160.00	bifurcation	Diagnosis	ICD-10-CM
160.10Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral arteryDiagnosisICD-10-CM160.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.20Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.33Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.51Nontrauma	160.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.11Nontraumatic subarachnoid hemorrhage from right middle cerebral arteryDiagnosisICD-10-CM160.12Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.2Nontraumatic subarachnoid hemorrhage from unspecified anterior communicatingDiagnosisICD-10-CM160.2arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicatingDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.23Nontraumatic subarachnoid hemorrhage from unspecified posterior communicatingDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CMDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.33Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.55Nontrau	160.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
160.12Nontraumatic subarachnoid hemorrhage from left middle cerebral arteryDiagnosisICD-10-CM160.2Nontraumatic subarachnoid hemorrhage from anterior communicating arteryDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.23Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.35Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.6Nontraumatic sub	160.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
160.2Nontraumatic subarachnoid hemorrhage from anterior communicating artery Nontraumatic subarachnoid hemorrhage from unspecified anterior communicatingDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating artery Nontraumatic subarachnoid hemorrhage from left anterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from right posterior communicating artery Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from left posterior communicating artery DiagnosisDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating artery DiagnosisDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery DiagnosisDiagnosisICD-10-CM160.35Nontraumatic subarachnoid hemorrhage from right vertebral artery DiagnosisDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from left vertebral artery DiagnosisDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery DiagnosisDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteries DiagnosisDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from un	160.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
Nontraumatic subarachnoid hemorrhage from unspecified anterior communicatingDiagnosisICD-10-CM160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from unspecified posterior communicatingDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from their intracranial arteriesDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage in musp	160.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
160.20arteryDiagnosisICD-10-CM160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating arteryDiagnosisICD-10-CM160.22Nontraumatic subarachnoid hemorrhage from unspecified posterior communicatingDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage	160.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
160.21Nontraumatic subarachnoid hemorrhage from right anterior communicating artery Nontraumatic subarachnoid hemorrhage from left anterior communicating artery Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating arteryDiagnosis DiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating artery Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating artery DiagnosisDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from basilar artery Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.53Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhage in bemisphere, subcorticalDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, cortical <td></td> <td>Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating</td> <td></td> <td></td>		Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating		
160.22Nontraumatic subarachnoid hemorrhage from left anterior communicating artery Nontraumatic subarachnoid hemorrhage from unspecified posterior communicatingDiagnosisICD-10-CM160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating artery Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating artery DiagnosisDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery I60.50DiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral artery I60.52DiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral artery I60.66DiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from other intracranial arteries I60.67DiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery I60.8DiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhage I60.9DiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcortical I61.1DiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in hemisphere, cortical	160.20	artery	Diagnosis	ICD-10-CM
Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from basilar arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.54Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.55Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM <td>160.21</td> <td>Nontraumatic subarachnoid hemorrhage from right anterior communicating artery</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	160.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
160.30arteryDiagnosisICD-10-CM160.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CM160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from basilar arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.54Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.55Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.56Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDia	160.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.31Nontraumatic subarachnoid hemorrhage from right posterior communicating arteryDiagnosisICD-10-CMI60.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CMI60.4Nontraumatic subarachnoid hemorrhage from basilar arteryDiagnosisICD-10-CMI60.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CMI60.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CMI60.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CMI60.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CMI60.6Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CMI60.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CMI60.8Other nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CMI60.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CMI60.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CMI60.9Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CMI61.0Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CMI61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontrau		Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating		
160.32Nontraumatic subarachnoid hemorrhage from left posterior communicating arteryDiagnosisICD-10-CM160.4Nontraumatic subarachnoid hemorrhage from basilar arteryDiagnosisICD-10-CM160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteriesDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosis <td>160.30</td> <td>artery</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	160.30	artery	Diagnosis	ICD-10-CM
I60.4Nontraumatic subarachnoid hemorrhage from basilar arteryDiagnosisICD-10-CMI60.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CMI60.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CMI60.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CMI60.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CMI60.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CMI60.8Other nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CMI60.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CMI61.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CMI61.1Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
160.50Nontraumatic subarachnoid hemorrhage from unspecified vertebral arteryDiagnosisICD-10-CM160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
160.51Nontraumatic subarachnoid hemorrhage from right vertebral arteryDiagnosisICD-10-CM160.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CM160.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.52Nontraumatic subarachnoid hemorrhage from left vertebral arteryDiagnosisICD-10-CMI60.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CMI60.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CMI60.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CMI60.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CMI61.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CMI61.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CMI61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
160.6Nontraumatic subarachnoid hemorrhage from other intracranial arteriesDiagnosisICD-10-CM160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
160.7Nontraumatic subarachnoid hemorrhage from unspecified intracranial arteryDiagnosisICD-10-CM160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
160.8Other nontraumatic subarachnoid hemorrhageDiagnosisICD-10-CM160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
160.9Nontraumatic subarachnoid hemorrhage, unspecifiedDiagnosisICD-10-CM161.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CM161.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CM161.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CM161.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CM161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I61.0Nontraumatic intracerebral hemorrhage in hemisphere, subcorticalDiagnosisICD-10-CMI61.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CMI61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I61.1Nontraumatic intracerebral hemorrhage in hemisphere, corticalDiagnosisICD-10-CMI61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	160.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.2Nontraumatic intracerebral hemorrhage in hemisphere, unspecifiedDiagnosisICD-10-CMI61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	161.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.3Nontraumatic intracerebral hemorrhage in brain stemDiagnosisICD-10-CMI61.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	161.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
161.4Nontraumatic intracerebral hemorrhage in cerebellumDiagnosisICD-10-CM	161.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
	161.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.5Nontraumatic intracerebral hemorrhage, intraventricularDiagnosisICD-10-CM	161.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
	161.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6Nontraumatic intracerebral hemorrhage, multiple localizedDiagnosisICD-10-CM	161.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM



		Code	
Code	Description	Category	Code Type
161.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
162.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
162.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
162.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
162.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
163.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
163.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
163.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
163.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
163.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
163.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
163.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
163.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
163.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
163.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
163.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
163.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
163.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
163.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of unspecified		
163.20	precerebral arteries	Diagnosis	ICD-10-CM
63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
163.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral		
163.213	arteries	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral		
163.219	artery	Diagnosis	ICD-10-CM
63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
163.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
163.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid	Diagnosis	ICD-10-CM
163.233	arteries Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid	Diagnosis	ICD-10-CM
163.239	artery	Diagnosis	ICD-10-CM
.00.200	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral	Diagnosis	
63.29	arteries	Diagnosis	ICD-10-CM
163.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
103.30	Cerebral initiation due to unombosis of dispectied terebral aftery	Diagnosis	



		Code	
Code	Description	Category	Code Type
163.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
163.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
163.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
163.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis Diagnosis	ICD-10-CM
163.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis Diagnosis	ICD-10-CM
l63.341 l63.342	Cerebral infarction due to thrombosis of right cerebellar artery Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM ICD-10-CM
163.342	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis Diagnosis	ICD-10-CIM
163.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.345	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
163.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
163.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
163.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
163.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
163.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
163.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral		
163.50	artery	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral		
163.511	artery	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral		
163.512	artery	Diagnosis	ICD-10-CM
100 510	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle	D	
163.513	cerebral arteries	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle	Dia i	
163.519	cerebral artery	Diagnosis	ICD-10-CM



CodeCodeCodeCategoryCode TypCerebral infarction due to unspecified occlusion or stenosis of right anterior cerebralI63.521arteryDiagnosisCerebral infarction due to unspecified occlusion or stenosis of left anterior cerebralI63.522arteryDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of bilateral anteriorI63.523cerebral infarction due to unspecified occlusion or stenosis of bilateral anteriorI63.523cerebral arteriesDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorI63.529cerebral arteryDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of right posterior
Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral163.521arteryDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of left anterior cerebralDiagnosisICD-10-CN163.522arteryDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of bilateral anteriorDiagnosisICD-10-CN163.523cerebral arteriesDiagnosisICD-10-CNCerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorDiagnosisICD-10-CN163.529cerebral arteryDiagnosisICD-10-CN163.529cerebral arteryDiagnosisICD-10-CN
163.521artery Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebralDiagnosisICD-10-CM163.522artery Cerebral infarction due to unspecified occlusion or stenosis of bilateral anteriorDiagnosisICD-10-CM163.523cerebral arteries Cerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorDiagnosisICD-10-CM163.529cerebral arteryDiagnosis of unspecified anteriorDiagnosisICD-10-CM
163.522artery Cerebral infarction due to unspecified occlusion or stenosis of bilateral anteriorDiagnosisICD-10-CN163.523cerebral arteries Cerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorDiagnosisICD-10-CN163.529cerebral arteryDiagnosis of unspecified anteriorDiagnosisICD-10-CN
Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior163.523cerebral arteries Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior163.529cerebral artery163.529Diagnosis
I63.523cerebral arteries Cerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorDiagnosisICD-10-CMI63.529cerebral arteryDiagnosisICD-10-CM
Cerebral infarction due to unspecified occlusion or stenosis of unspecified anteriorI63.529cerebral arteryDiagnosisICD-10-CN
163.529 cerebral artery Diagnosis ICD-10-CM
,
Cerebral infarction due to unspecified occlusion or stenosis of right posterior
I63.531 cerebral artery Diagnosis ICD-10-CN
Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral
I63.532 artery Diagnosis ICD-10-CN
Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior
I63.533 cerebral arteries Diagnosis ICD-10-CN
Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior
I63.539 cerebral artery Diagnosis ICD-10-CN
I63.541 Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery Diagnosis ICD-10-CM
I63.542 Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery Diagnosis ICD-10-CM
Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar
I63.543 arteries Diagnosis ICD-10-CN
Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar
I63.549 artery Diagnosis ICD-10-CM
I63.59 Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery Diagnosis ICD-10-CN
I63.6Cerebral infarction due to cerebral venous thrombosis, nonpyogenicDiagnosisICD-10-CN
I63.8Other cerebral infarctionDiagnosisICD-10-CN
I63.81Other cerebral infarction due to occlusion or stenosis of small arteryDiagnosisICD-10-CN
I63.89Other cerebral infarctionDiagnosisICD-10-CN
I63.9Cerebral infarction, unspecifiedDiagnosisICD-10-CN
I66.01Occlusion and stenosis of right middle cerebral arteryDiagnosisICD-10-CN
I66.02Occlusion and stenosis of left middle cerebral arteryDiagnosisICD-10-CN
I66.03Occlusion and stenosis of bilateral middle cerebral arteriesDiagnosisICD-10-CN
I66.09Occlusion and stenosis of unspecified middle cerebral arteryDiagnosisICD-10-CN
I66.11Occlusion and stenosis of right anterior cerebral arteryDiagnosisICD-10-CN
I66.12Occlusion and stenosis of left anterior cerebral arteryDiagnosisICD-10-CN
I66.13Occlusion and stenosis of bilateral anterior cerebral arteriesDiagnosisICD-10-CN
I66.19Occlusion and stenosis of unspecified anterior cerebral arteryDiagnosisICD-10-CN
I66.21Occlusion and stenosis of right posterior cerebral arteryDiagnosisICD-10-CN
I66.22Occlusion and stenosis of left posterior cerebral arteryDiagnosisICD-10-CN
I66.23Occlusion and stenosis of bilateral posterior cerebral arteriesDiagnosisICD-10-CN
I66.29Occlusion and stenosis of unspecified posterior cerebral arteryDiagnosisICD-10-CN
I66.3Occlusion and stenosis of cerebellar arteriesDiagnosisICD-10-CN
I66.8Occlusion and stenosis of other cerebral arteriesDiagnosisICD-10-CN
I66.9Occlusion and stenosis of unspecified cerebral arteryDiagnosisICD-10-CN
I67.841Reversible cerebrovascular vasoconstriction syndromeDiagnosisICD-10-CN
I67.848Other cerebrovascular vasospasm and vasoconstrictionDiagnosisICD-10-CN



		Code	
Code	Description	Category	Code Type
167.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
197.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
197.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
197.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
197.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
	Breast Cancer		
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
550.021	manonant neoplashi or annary tan or right male breast	Diagnosis	



		Code	
Code	Description	Category	Code Type
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CN
50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CN
50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CN
50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CN
50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CN
50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CN
50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CN
05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CN
05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CN
05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CN
05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CN
05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CN
05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CN
05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CN
05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CN
05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CN
05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CN
05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CN
17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CN
17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CN
19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CN
19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CN
85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CN
86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CN
	Colorectal Cancer		
18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CN
18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CN
18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CN
18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CN
18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CN
18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CN
18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CN
18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CN
218.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CN
219	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CN
20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CN
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CN



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and		
Z85.048	anus	Diagnosis	ICD-10-CM
	Prostate Cancer		
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
	Lung Cancer		
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
	Endometrial Cancer		
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Urologic Cancer			
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM



Appendix G. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used
to Define Covariates in this Request

		Code	
Code	Description	Category	Code Type
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D09.10	Carcinoma in situ of unspecified urinary organ	Diagnosis	ICD-10-CM
D09.19	Carcinoma in situ of other urinary organs	Diagnosis	ICD-10-CM
Z85.520	Personal history of malignant carcinoid tumor of kidney	Diagnosis	ICD-10-CM
Z85.528	Personal history of other malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.53	Personal history of malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
Z85.54	Personal history of malignant neoplasm of ureter	Diagnosis	ICD-10-CM
Z85.59	Personal history of malignant neoplasm of other urinary tract organ	Diagnosis	ICD-10-CM



	Query Period	: 5/22/2018-12/11/2019 (P	re-Pandemic)		
	Coverage Requirement	: Medical & Drug Coverage			
Pre-index	Pre-index enrollment requirement: Varies; see below				
Post-index	enrollment requirement:	N/A			
Post-episode req	uirement for T2 analyses	: N/A			
	Enrollment gap	: 45			
Restrictions: Demographic: M/F sex					
	Age groups:	18-44, 45-64, and ≥ 65			
	Stratifications	: Year			
Cen	sor output categorization	: N/A			
	=	Reclassify encounters			
	Never-exposed cohort:				
Distribution	n of index-defining codes:	N/A			
	Freeze data:	Yes			
	SCENARIO 1.1	PRE-PANDEMIC)	SCENARIO 1.2	(PRE-PANDEMIC)	
	short l	ookback	long le	ookback	
Pre-index enrollment requirement:	1	.83		365	
Pre-index enrollment requirement: Group	111 r1_acei	83 r1_bb	r4_acei	865 r4_bb	
Group Drug/Exposure				r4_bb	
Group Drug/Exposure Index Exposure/Comparator	r1_acei ACEi	r1_bb Beta Blockers	r4_acei ACEi	r4_bb Beta Blockers	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition	r1_acei ACEi First valid exposure epis	r1_bb Beta Blockers odes during query period	r4_acei ACEi First valid exposure epis	r4_bb Beta Blockers sodes during query perio	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab	r4_acei ACEi First valid exposure epis See stoo	r4_bb Beta Blockers sodes during query perio kpiling tab	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure?	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers odes during query period kpiling tab No	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio kpiling tab No	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio kpiling tab No 14	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap Exposure episode extension	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14 14	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio kpiling tab No 14 14	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap Exposure episode extension Minimum days supplied	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14 14 1	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio kpiling tab No 14 14 1	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap Exposure episode extension Minimum days supplied Incidence Criteria Care Setting	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14 14 14	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio kpiling tab No 14 14 14 1 N/A	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap Exposure episode extension Minimum days supplied Incidence Criteria Care Setting Principal Diagnosis Position	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14 14 14 1 1 /A	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query perio sodes during query perio kpiling tab No 14 14 14 1 N/A N/A	
Group Drug/Exposure Index Exposure/Comparator Cohort Definition Stockpiling Build Episodes on Point Exposure? Treatment Episode Gap Exposure episode extension Minimum days supplied Incidence Criteria Care Setting	r1_acei ACEi First valid exposure epis See stoc	r1_bb Beta Blockers codes during query period kpiling tab No 14 14 14	r4_acei ACEi First valid exposure epis See stoc	r4_bb Beta Blockers sodes during query peri kpiling tab No 14 14 1 N/A	



	SCENARIO 1.1 (PRE-PANDEMIC)	SCENARIO 1.2 (PRE-PANDEMIC)
	short lookback	long lookback
Inclusion/Exclusion Criteria		
Inclusion/Exclusion group	Aliskiren, ARBs, ACEi, beta Aliskiren, ARBs, ACEi, beta	Aliskiren, ARBs, ACEi, Aliskiren, ARBs, ACEi,
Type of criteria	Exclusion	Exclusion
Evaluation Period Start	-183	-365
Evaluation Period End	-1	-1
Care Setting/PDX	N/A	N/A
Principal Diagnosis Position	N/A	N/A
Exclude evidence of days supply if inclusion/exclusion	Evaluation period should search for evidence of days	Evaluation period should search for evidence of
evaluation period includes dispensings	supply	days supply
Number of instances the criteria should be found in the	1	1
evaluation period		
Minimum Days Supplied	1	1
Minimum cumulative dose	N/A	N/A
Minimum average filled daily dose	N/A	N/A
Maximum average filled daily dose	N/A	N/A
Minimum current filled daily dose	N/A	N/A
Maximum current filled daily dose	N/A	N/A
Forced supply to attach to dispensings	N/A	N/A
Inclusion/Exclusion group	Angioedema DX	Angioedema DX
Type of criteria	Exclusion	Exclusion
Evaluation Period Start	-183	-365
Evaluation Period End	-1	-1
Care Setting/PDX	Any	Any
Principal Diagnosis Position	Any	Any
Exclude evidence of days supply if inclusion/exclusion		N/A
evaluation period includes dispensings		
Number of instances the criteria should be found in the	1	1
evaluation period		
At Risk Time		
Minimum exposure episode duration	0	0
Maximum exposure episode duration	90	90




	SCENARIO 1.1 (PRE-PANDEMIC)	SCENARIO 1.2 (PRE-PANDEMIC)	
	short lookback	long lookback	
Risk window interval start	0	0	
Censor treatment episode at evidence	DP end date; death; DP end date; death;	DP end date; death; DP end date; death;	
Blackout Period	·		
Event/Outcome			
Event/Outcome	Angioedema DX	Angioedema DX	
Care Setting	IP, ED, AV	IP, ED, AV	
Principal Diagnosis Position	Any	Any	
Exclude evidence of days supply if event washout	N/A	N/A	
includes dispensings			
Event de-duplication	De-duplicates occurrences of the same event code	De-duplicates occurrences of the same event	
Forced supply to attach to dispensings	N/A	N/A	
Propensity Score Model Parameters			
PS Model Label	ps_r1_base, ps_r1_adj (includes YEAR)	ps_r4_base, ps_r4_adj (includes YEAR)	
Covariates	Age; sex; see also Covariates, Utilization, &	Age; sex; see also Covariates, Utilization, &	
	Comorbidity tabs	Comorbidity tabs	
Firth Logistic Intercept Correct (FLIC)	No	No	
High-dimensional Propensity Score	No	No	
Output Kaplan Meier Plot	Yes	Yes	
PS Stratification			
Stratif. Comparison Identifier	r1_strat_base, r1_strat_adj	r4_strat_base, r4_strat_adj	
Percentiles	5	5	
PS Trimming Indicator	0 (Trim Non-Overlap)	0 (Trim Non-Overlap)	
Percentile Distribution Indicator	O (Overall)	O (Overall)	
PS Matching			
PS Comparison Identifier	r1_fixed_base, r1_fixed_adj	r4_fixed_base, r4_fixed_adj	
Ratio Type	Fixed ratio matching	Fixed ratio matching	
Matching Ratio	1:1	1:1	
Matching Caliper Settings	0.025	0.025	
Analysis Type	Conditional and unconditional	Conditional and unconditional	
Subgroup Analyses			
Stratifying variable	Calendar year	Calendar year	
Subgroup Categories	Year	Year	



	SCENARIO 1.1 (PRE-PANDEMIC) short lookback	SCENARIO 1.2 (PRE-PANDEMIC) long lookback		
Firth Logistic Intercept Correct (FLIC) Method	No	No		
Re-estimate Propensity Score within subgroup level	No	No		
Should subgroup re-matching be restricted to the	Yes	Yes		
ICD-9-CM, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."				






* Exclusion Criteria: Aliskiren, ARBs, ACE inhibitors/beta blockers; angioedema

^ The follow up period begins on the day of the index date and ends at the earliest occurrence of the end of at-risk time; angioedema; comparator drug, aliskiren, or ARBs; disenrollment; Data Partner end date; or death.

~ Covariates: Window I: Age, sex, year, race

Window II: History of: allergic reaction, diabetes, heart failure, ischemic heart disease, NSAID use; Comorbidity Score; Drug Utilization (dispensings, unique generics); Medical Utilization (IP hospital stays, non-acute institutional stays, ED visits, AV visits, OA visits), CCW conditions (acquired hypothyroidism, acute myocardial infarction, Alzheimer's disease & related disorders or senile dementia, anemia, asthma, atrial fibrillation, benign prostatic hyperplasia, cancer (breast, colorectal, endometrial, lung, prostate), cataract, chronic kidney disease, chronic obstructive pulmonary disease & bronchiectasis, depression, glaucoma, hip/pelvic fracture, hyperlipidemia, hypertension, osteoporosis, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack)





* Exclusion Criteria: Aliskiren, ARBs, ACE inhibitors/beta blockers; angioedema

• The follow up period begins on the day of the index date and ends at the earliest occurrence of the end of at-risk time; angioedema; comparator drug, aliskiren, or ARBs; disenrollment; Data Partner end date; or death.

~ Covariates: Window I: Age, sex, year, race

<u>Window II</u>: History of: allergic reaction, diabetes, heart failure, ischemic heart disease, NSAID use; Comorbidity Score; Drug Utilization (dispensings, unique generics); Medical Utilization (IP hospital stays, non-acute institutional stays, ED visits, AV visits, OA visits), CCW conditions (acquired hypothyroidism, acute myocardial infarction, Alzheimer's disease & related disorders or senile dementia, anemia, asthma, atrial fibrillation, benign prostatic hyperplasia, cancer (breast, colorectal, endometrial, lung, prostate), cataract, chronic kidney disease, chronic obstructive pulmonary disease & bronchiectasis, depression, glaucoma, hip/pelvic fracture, hyperlipidemia, hypertension, osteoporosis, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack)